Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators

ABSTRACT

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

This application is a U.S. National Phase filing of InternationalApplication No. PCT/IB2015/055006 filed 2 Jul. 2015, which claimspriority to U.S. Application No. 62/020,166 filed 2 Jul. 2014, and alsoclaims priority to U.S. Application No. 62/168,627, filed 29 May 2015,the contents' of which are incorporated herein by reference in theirentirety.

FIELD OF THE INVENTION

The present invention is related generally to compounds which activatesoluble guanylate cyclase (sGC). The invention further relates to theuse of said sGC activators in the treatment of glaucoma and in thelowering intraocular pressure (IOP) such as that associated withglaucoma and ocular hypertension.

BACKGROUND OF THE INVENTION

The eye disease glaucoma is characterized by a permanent loss of visualfunction due to irreversible damage to the optic nerve. The severalmorphologically or functionally distinct types of glaucoma are typicallycharacterized by an undesirable elevation of IOP, which is considered tobe causally related to the pathological course of the disease.Continuously elevated IOP has been associated with the progressive lossof retinal ganglion cells and optic nerve damage ultimately resulting inthe loss of visual function. In some cases, ocular hypertension, acondition in which IOP is elevated, can present without apparent loss ofvisual function. However, patients with ocular hypertension areconsidered to be at a high risk for eventually developing the visualloss associated with glaucoma. Therefore, lowering IOP is the currenttreatment objective for the of glaucoma patients and for patients withocular hypertension in order to decrease the potential for, or severityof, glaucomatous retinopathy. Unfortunately, many individuals do notachieve or maintain desired level of IOP reduction when treated withexisting glaucoma therapies.

Patients known as normotensive or low-tension glaucoma patients haverelatively low IOP, yet present with glaucomatous visual field loss.These patients may benefit from agents that lower and control IOP,because glaucoma that is detected early and treated promptly may havereduced or delayed loss of visual function. Conventional therapeuticagents that have proven to be effective for the reduction of IOP includeboth agents that decrease aqueous humor production and agents thatincrease the outflow facility. Such agents are in general administeredby one of two routes; topically by direct application to the eye, ororally. However, many of these agents have associated side effects whichmay render them undesirable as ocular therapeutic agents.

Soluble guanylate cyclase (sGC) is a receptor enzyme for the secondmessenger, nitric oxide (NO) in several cell types including muscle,epithelial, neuronal, and endothelial cells. In humans, functional sGCis a heterodimer composed of either an alpha 1 or alpha 2 subunitcombined with the beta 1 subunit which has a heme prosthetic group.Under physiological conditions, NO binds to the prosthetic heme of sGCwhich activates the enzyme to catalyze the conversion ofguanosine-5′-triphosphate (GTP) to cyclic guanosine monophosphate(cGMP). cGMP is a second messenger which in turn exerts its effects byactivating cGMP dependent protein kinase (PKG) isoforms,phosphodiesterases, and cGMP gated ion channels. In doing so, sGC canthus modulate numerous pathways associated with diseases includinghypertension (arterial and pulmonary), heart failure, atherosclerosis,erectile dysfunction, liver cirrhosis, and renal fibrosis. Underaforementioned pathologic conditions, prolonged oxidative stress cancause the oxidation of the heme group of sGC (from ferrous to ferricstate) which is incapable of being activated by NO and can contribute toexacerbation of disease processes. As a consequence of sGC oxidation andunresponsiveness to NO, endothelial dysfunction, atherosclerosis,hypertension, stable or unstable angina pectoris, thromboses, myocardialinfarction, strokes or erectile dysfunction are worsened. Therefore,pharmacological stimulation or activation of sGC offers a possibility tonormalize cGMP production and therefore makes possible the treatmentand/or prevention of such disorders.

To this effort, there are two classes of compounds have been identified,including NO-independent/reduced heme-dependent sGC stimulators andNO-independent/heme-independent sGC activators. sGC stimulators aredependent on heme, but they are not active once sGC become oxidized. sGCactivators on the other hand can still activate the enzyme to generatecGMP even in the absence of nitric oxide (NO) and/or under oxidativestress induced oxidation of sGC in disease tissue. Thus, the activity ofsGC in these situations will be corrected by sGC activators, but not bysGC stimulators, and will have the potential to provide benefit in manydiseases caused by defective signaling in the NO pathway especiallyfollowing oxidative stress.

SUMMARY OF THE INVENTION

The present invention in part relates to new activators of sGC and theuse thereof in the treatment of disease. In one aspect the sGCactivators provided herein are suitable for use in methods of treatingglaucoma in human patients or other mammals. The present invention alsorelates to methods of lowering or controlling normal or elevated IOP ina human patient or other mammals. In particular, the invention providesmethods of treating and/or preventing glaucoma by administration of asGC activator compound described infra.

In the eye, the trabecular outflow pathway by which 70-80% of aqueoushumor would normally leave the anterior chamber of the eye and lowerintraocular pressure (IOP), is pathologically compromised in primaryopen angle glaucoma (POAG). Oxidative stress is thought to be anunderlying factor that can adversely affect trabecular meshworkfunction, resulting from/in IOP elevation in POAG. Reactive oxygenspecies (ROS) not only decrease the bioavailability of nitric oxide (NO)but also shift the sGC redox equilibrium to its oxidized form, which asmentioned before is unresponsive to NO. Selective activation of theoxidized form of sGC should target only the diseased state of the targetenzyme in the putative target tissue, trabecular meshwork/Schlemm'scanal tissue, thus offering a highly innovative therapy for glaucomathat should work adjunctively with current therapies.

In one aspect of the invention, sGC activators, and salts thereof, areprovided which have the structure of formula (I):

or a pharmaceutically acceptable salt thereof, wherein the variables aredefined infra.

Certain embodiments of the present invention comprise compositions ormethods which include or use compounds capable of activating sGC therebymodulating intraocular pressure in the eye. By activating sGC receptoractivity, subject compounds according to certain embodiments of thepresent invention are accordingly useful for lowering and/or controllingIOP associated with normal-tension glaucoma, ocular hypertension, andglaucoma, including primary open-angle glaucoma in humans and otherwarm-blooded animals. When used in such applications, the compounds maybe formulated in pharmaceutical compositions suitable for topicaldelivery to the eye.

The foregoing brief summary broadly describes the features and technicaladvantages of certain embodiments of the present invention. Additionalfeatures and technical advantages will be described in the detaileddescription of the invention that follows.

DESCRIPTION OF THE INVENTION

As the term is used herein, a “sGC activator” is a compound capable ofmodulating sGC activity to generate cGMP signaling which would otherwisebe unresponsive to nitric oxide. In contrast, “sGC stimulators” refersto compounds that are capable of synergizing with nitric oxide and candirectly stimulate cGMP production so long as the reduced heme domain ispresent in the enzyme.

In a first embodiment, the invention provides a compound according toFormula (I)

Or a pharmaceutically acceptable salt thereof, wherein

-   -   X is N or CH;    -   Y is CH or N;    -   A is CH₂, O or N(H) when Y is CH, or    -   A is CH₂ when Y is N;    -   B is O or CR⁷R⁸;    -   Z¹ is CR⁴ or N    -   R is hydrogen, C₁-C₄alkyl, monofluoromethyl, difluoromethyl or        trifluoromethyl;    -   R¹ is hydrogen, halogen, C₁-C₄alkyl or trifluoromethyl    -   R² is piperidinyl which is N-substituted with C₁-C₄alkyl,        C₃-C₆cycloalkyl, haloC₁-C₄alkyl, C(O)C₁-C₄alkyl,        S(O)₂C₁-C₄alkyl, C(O)C₃-C₆cycloalkyl, C(O)haloC₁-C₄alkyl,        C(O)C₁-C₄alkoxy, C(O)C₁-C₄alkenoxy, heteroaryl or CO(O)₂benzyl,        wherein each cycloalkyl is optionally substituted by hydroxy and        each alkyl or alkoxy is optionally substituted by hydroxyl,        C₁-C₄alkoxy or C₃-C₆cycloalkyl and wherein each heteroaryl has 5        or 6 ring atoms, 1, 2 or 3 ring heteroatoms independently        selected from N, O and S and is optionally substituted with 1 or        2 C₁-C₄alkyl substituents.    -   R³ is hydrogen, halogen or C₁-C₄alkyl; or    -   R² and R³, taken in combination, form a 5 or 6 member fused        saturated azacyclic ring optionally substituted with benzyl or 5        or 6 member heteroarylmethyl, which heteroaryl has 1 or 2 ring        heteroatoms independently selected from N, O and S;    -   R⁴ is hydrogen or C₁-C₄alkyl;    -   R⁵ is hydrogen, halogen, C₁-C₄alkyl or C₃-C₆cycloalkyl;    -   R⁷ is hydrogen or C₁-C₄alkyl; or    -   R⁷ and R⁹, taken in combination with the ring atoms to which        they are attached form a carbon-carbon double bond;    -   R⁸ is hydrogen or C₁-C₄alkyl; and    -   R⁹ is hydrogen or C₁-C₄alkyl.

In a second embodiment, the invention provides a compound according toFormula (Ia)

or a pharmaceutically acceptable salt thereof, wherein

X is N or CH;

Y is CH or N;

A is CH₂, O or N(H) when Y is CH, or

A is CH₂ when Y is N;

R is hydrogen, C₁-C₄alkyl or trifluoromethyl;

R¹ is hydrogen, halogen or C₁-C₄alkyl;

R² is piperidinyl which is N-substituted with C₁-C₄alkyl,C₃-C₆cycloalkyl, haloC₁-C₄alkyl, C(O)C₁-C₄alkyl, C(O)C₃-C₆cycloalkyl,C(O)haloC₁-C₄alkyl or C(O)C₁-C₄alkoxy;

R³ is hydrogen or C₁-C₄alkyl; or

R² and R³, taken in combination, form a 5 or 6 member fused saturatedazacyclic ring optionally substituted with benzyl or 5 or 6 memberheteroarylmethyl, which heteroaryl has 1 or 2 ring heteroatomsindependently selected from N, O and S;

R⁴ is hydrogen or C₁-C₄alkyl and

R⁵ is hydrogen, halogen, C₁-C₄alkyl or C₃-C₆cycloalkyl.

In a third embodiment, the invention provides compounds according toembodiment which are represented by the formula (Ib):

In a fourth embodiment, compounds of any one of embodiments 1 through 3are provided in which Y is CH and A is O.

In a fifth embodiment, compounds of any one of embodiments 1 through 3are provided in which Y is CH and A is N(H).

In a sixth embodiment, compounds of any one of embodiments 1 through 3are provided in which Y is N and A is CH₂.

In a seventh embodiment, compounds of any one embodiments 1 to 6 areprovided in which R² is N-substituted piperidin-4-yl wherein theN-substituent is 2,2,2-trifluoroethyl, C(O)cyclopropyl orC(O)C₁-C₄alkyl.

In an eighth embodiment, compounds of any one embodiments 1 to 7 areprovided in which R¹ is hydrogen or methyl;

R³ is hydrogen, methyl or ethyl, wherein at least one of R¹ or R³ ishydrogen; and

R⁴ is hydrogen.

In a ninth embodiment, compounds of any one embodiments 1 to 8 areprovided in which R¹ is methyl; and R³ and R⁴ are hydrogen.

In a tenth embodiment, compounds of any one embodiments 1 to 8 areprovided in which R¹ and R⁴ are hydrogen and R³ is ethyl.

In an eleventh embodiment, compounds of any one embodiments 1 to 10 areprovided in which R is trifluoromethyl, methyl or ethyl.

In a twelfth embodiment, compounds of any one embodiments 1 to 11 areprovided in which R is trifluoromethyl.

In a thirteenth embodiment, compounds of any one embodiments 1 to 12 areprovided in which R is methyl or ethyl.

In a fourteenth embodiment, compounds of the first and second embodimentare provided in which the compound of Formula (I) is a compoundaccording to Formula (II):

WhereinA is O, CH₂ or NH;R is methyl, ethyl or trifluoromethyl;R⁶ is 2,2,2-trifluoroethyl, C(O)cyclopropyl or C(O)C₁-C₄alkyl.

In a fifteenth embodiment, compounds of the first or second embodimentare provided in which the compound of Formula (I) is a compoundaccording to Formula (III):

-   -   Wherein    -   A is O, CH₂ or NH;    -   R is methyl, ethyl or trifluoromethyl;

R⁶ is 2,2,2-trifluoroethyl, C(O)cyclopropyl or C(O)C₁-C₄alkyl.

In a sixteenth embodiment, compounds of the fourteenth or fifteenthembodiment are provided in which A is NH; R is methyl or ethyl; and R⁶is C(O)cyclopropyl or C(O)C₁-C₄alkyl.

In another aspect of the thirteenth and fifteenth embodiment, compoundsare provided in which A is O.

In yet another aspect of the fourteenth or fifteenth embodiment,compounds are provided in which A is NH.

In still another aspect of the fourteenth or fifteenth embodiment,compounds are provided in which A is CH₂.

In a seventeenth embodiment, compounds of the first or second embodimentare provided in which the compound of Formula (I) is a compoundaccording to Formula (IV):

-   -   Wherein    -   R is methyl, ethyl or trifluoromethyl;    -   R⁶ is 2,2,2-trifluoroethyl, C(O)cyclopropyl or C(O)C₁-C₄alkyl;        and    -   Each of R⁷, R⁸ and R⁹ is independently selected from hydrogen        and methyl.

In an eighteenth embodiment, compounds of the first or second embodimentare provided in which the compound of Formula (I) is a compoundaccording to Formula (V):

-   -   Wherein    -   R is methyl, ethyl or trifluoromethyl;    -   R⁶ is 2,2,2-trifluoroethyl, C(O)cyclopropyl or C(O)C₁-C₄alkyl;        and    -   each of R⁷, R⁸ and R⁹ is independently selected from hydrogen        and methyl.

In a nineteenth embodiment, compounds of the seventeenth or eighteenthembodiment are provided in which R is methyl or ethyl; and R⁶ is2,2,2-trifluoroethyl.

In another aspect of any one of the seventeenth to nineteenthembodiments, compounds are provided in which R⁷ and R⁸ are hydrogen andR⁹ is methyl. In certain other compounds of the sixteenth to eighteenthembodiments, R⁷ is hydrogen or methyl, R⁸ is methyl and R⁹ is hydrogen.

In a twentieth embodiment, compounds of the first embodiment areprovided in which the compound of Formula (I) is a compound according toFormula (VI):

-   -   Wherein    -   R is methyl, ethyl or trifluoromethyl;    -   R⁶ is 2,2,2-trifluoroethyl, C(O)cyclopropyl or C(O)C₁-C₄alkyl;        and    -   R⁸ is independently selected from hydrogen and methyl.

In a twenty-first embodiment, compounds of the first embodiment areprovided in which the compound of Formula (I) is a compound according toFormula (VII):

-   -   Wherein    -   R is methyl, ethyl or trifluoromethyl;    -   R³ is hydrogen, methyl or ethyl;    -   R⁴ is hydrogen or methyl; and    -   R⁶ is 2,2,2-trifluoroethyl, C(O)cyclopropyl or C(O)C₁-C₄alkyl        optionally substituted with hydroxy.

In a twentieth second embodiment of the invention, compounds of thefirst and second embodiment are provided which are selected from thegroup consisting of:

-   (−)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)    piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-(S)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)    piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (±)-1-(6-(6-methyl-3-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (±)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-(S)-1-(6-(3-(2-methyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-(S)-5-ethyl-1-(6-(3-(2-methyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (±)-5-ethyl-1-(6-(3-((2-methyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (±)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(4-(1-(cyclopropanecarbonyl)    piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(4-(1-(cyclopropanecarbonyl)    piperidin-4-yl)-3-ethylbenzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(4-(1-(cyclopropanecarbonyl)    piperidin-4-yl)-3-ethylbenzyl)indolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(3-ethyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   5-ethyl-1-(6-(1-(3-ethyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (+)-(S)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   5-Ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-1);-   5-Ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-2);-   (S)-5-Ethyl-1-(6-(1-(4-(1-(2-hydroxypropanoyl)piperidin-4-yl)-2-methylbenzyl)indolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)indolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)indolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3,3-dimethylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(4-(1-Cyclopropylpiperidin-4-yl)-2-methylbenzyl)indolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-((2-(Pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(4-(1-(Cyclopropane    carbonyl)piperidin-4-yl)benzyl)-1H-indol-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-1H-indol-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methyl-1H-indol-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (S)-1-(6-(3-(4-(1-(Ethoxycarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   5-Ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   5-Ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   5-Ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   5-Ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-3-hydroxy-2-methylpropanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(1-hydroxycyclobutanecarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   5-Ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-1);-   5-Ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-2);-   (S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(1-hydroxycyclopropanecarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-((S)-2-Hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-((S)-2-Hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (−)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-1);-   (+)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-2);-   (−)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-1);-   (+)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-2);-   (−)-5-Ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-1);-   (+)-5-Ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-2);-   (−)-5-Ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypentanoyl)    piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-1);-   (+)-5-Ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-2);-   (+)-Ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (−)-Ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (+)-5-Ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (−)-5-Ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-(6-(3-((4-(1-(Cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-5-methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (−)-5-Methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)- or    (−)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-5-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-5-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-((S)-2-Hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid (diastereomer-1);-   (−)-1-(6-(3-((4-(1-((S)-2-Hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid (diastereomer-2);-   (+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-2);-   (−)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-1);-   (+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-2);-   (−)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-1);-   (+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-2);-   (−)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid (diastereomer-1);-   (+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-(isopropoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (−)-Ethyl-1-(6-(3-((3-ethyl-4-(1-(isopropoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(Ethoxycarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(Ethoxycarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (−)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-((Allyloxy)carbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-((Allyloxy)carbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(3-((4-(1-(Ethoxycarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(3-((4-(1-((2-methoxyethoxy)carbonyl)-piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   5-Methyl-1-(6-(3-((2-methyl-4-(1-((prop-1-en-2-yloxy)carbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-2-fluoro-6-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-2-fluoro-6-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(difluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(difluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)    piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(3-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(difluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(3-(3-((4-(1-(2-Hydroxyacetyl)piperidin-4-yl)-2-methyl    phenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxylic    acid;-   (−)-5-Methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (+)-5-Methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (±)-5-Methyl-1-(6-(3-((2-methyl-4-(1-(pyridin-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (±)-1-(6-(3-((4-(1-Cyclopropylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-(trifluoromethyl)    phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid (enantiomer-1);-   1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic    acid (enantiomer-2);-   (±)-1-(6-(3-((5-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-methylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic    acid;-   (+)-1-(6-(3-((5-(1-(Cyclopropanecarbonyl)    piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (−)-1-(6-(3-((5-(1-(Cyclopropanecarbonyl)    piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (S)-1-(6-(3-(4-(1-((Benzyloxy)carbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(isobutoxycarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(isopropoxycarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(propoxycarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (S)-1-(6-(3-(4-(1-((Allyloxy)carbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (S)-1-(6-(3-(4-(1-((Cyclopropylmethoxy)carbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic    acid;-   (S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid;-   (S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic    acid; and pharmaceutically acceptable salts thereof.

In another aspect of the invention, synthetic intermediates which aresuitable for use in the preparation of compounds of embodiments one totwenty two of the invention are provided. In one aspect, intermediatesare provided according to the formula:

Where X is either CH or N;R is C1-C4 alkyl, monofluoromethyl, difluoromethyl or trifluoromethyl;And W is OH or C1-C4alkoxy.

Certain particularly preferred indanone intermediates suitable for usein the preparation of some of the compounds of the invention include,

-   Ethyl    5-methyl-1-(6-(3-oxo-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate;-   Ethyl    5-ethyl-1-(6-(3-oxo-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate;-   Ethyl    1-(6-(3-oxo-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate;-   Ethyl    5-(difluoromethyl)-1-(6-(3-oxo-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate;-   Ethyl    5-methyl-1-(3-(3-oxo-2,3-dihydro-1H-inden-4-yl)phenyl)-1H-pyrazole-4-carboxylate.

In another aspect, synthetic intermediates suitable for use in preparingthe compounds of the invention include compounds of the formula:

Where A, B, Z¹, R¹, R², R³ and R⁵ are substituents as defined inembodiment one. LG is a moiety suitable for transition metal mediatedcross coupling reactions. In preferred intermediates, LG is a sulfonicacid ester (such as triflate (OSO₂CF₃), mesylate (OSO₂CH₃), or tosylate(OSO₂CH₂C₆H₄Me)) or LG is a halide (chloro, bromo or iodo).

Certain preferred synthetic intermediates include those compounds of theformula:

Where A, B, Z¹, R¹, R³ and R⁵ are substituents as defined inembodiment 1. Q is C(O)R⁷ or —C(O)OR⁷ where R⁷ is C₁-C₄alkyl orcyclopropyl. LG is a moiety suitable for transition metal mediated crosscoupling reactions. In preferred intermediates, LG is a sulfonic acidester (such as triflate (OSO₂CF₃), mesylate (OSO₂CH₃), or tosylate(OSO₂CH₂C₆H₄Me)) or LG is a halide (chloro, bromo or iodo).Certain particularly preferred synthetic intermediates suitable formaking compounds of the instant invention include those compounds of theformula:

Where A, Z¹, R¹, and R³ are substituents as defined in embodiment 1. Qis C(O)R⁷ or —C(O)OR⁷ where R⁷ is C₁-C₄alkyl or cyclopropyl. LG is amoiety suitable for transition metal mediated cross coupling reactions.In preferred intermediates, LG is a sulfonic acid ester (such astriflate (OSO₂CF₃), mesylate (OSO₂CH₃), or tosylate (OSO₂CH₂C₆H₄Me)) orLG is a halide (chloro, bromo or iodo).

Certain particularly preferred intermediates suitable for use in thepreparation of some of the compounds of the invention include,

-   (+)-(S)-(4-(4-((7-Bromo-2,3-dihydro-1H-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)    (cyclopropyl)methanone-   (+)-(S)-(4-(4-((7-Bromo-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidin-1-yl)(cyclopropyl)methanone-   (S)-tert-Butyl    4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidine-1-carboxylate-   (±)-(4-(4-((7-Bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidin-1-yl)    (cyclopropyl)methanone-   (+)-(4-(4-((7-Bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidin-1-yl)    (cyclopropyl)methanone-   (±)-(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)phenyl)piperidin-1-yl)    (cyclopropyl)methanone-   (±)-tert-Butyl    4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidine-1-carboxylate-   (±)-tert-Butyl    4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate-   (±)-tert-Butyl    4-(4-((4-bromo-2,3-dihydrobenzofuran-3-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate-   (±)-tert-Butyl    4-(4-((4-bromo-2,3-dihydrobenzofuran-3-yl)amino)-3-methylphenyl)piperidine-1-carboxylate-   (±)-tert-Butyl    4-(6-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylpyridin-3-yl)piperidine-1-carboxylate-   (±)-3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl    trifluoromethanesulfonate-   (±)-3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl    trifluoromethanesulfonate-   (±)-tert-Butyl    4-(2-ethyl-4-((7-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate-   (±)-tert-Butyl    4-(3-methyl-4-((7-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate

In a twenty third embodiment, the present invention relates to a methodof treating or preventing glaucoma or reducing intraocular pressurecomprising administering to a subject in need thereof a sGC activatorselected from the compounds of any one of embodiments one to sixteen.The invention has surprisingly shown that administration of sGCactivators to a patient in need of therapy has desirable sustainedefficacy in reducing IOP and in the treatment of glaucoma.

Unless specified otherwise, the term “compounds of the presentinvention” refers to compounds of formula (I) and subformulae thereof,and salts thereof, as well as all stereoisomers (includingdiastereoisomers and enantiomers), rotamers, tautomers and isotopicallylabeled compounds (including deuterium substitutions), as well asinherently formed moieties.

Depending on the choice of the starting materials and procedures, thecompounds can be present in the form of one of the possible isomers oras mixtures thereof, for example as pure optical isomers, or as isomermixtures, such as racemates and diastereoisomer mixtures, depending onthe number of asymmetric carbon atoms. The present invention is meant toinclude all such possible isomers, including racemic mixtures,diasteriomeric mixtures and optically pure forms. Optically active (R)-and (S)-isomers may be prepared using chiral synthons or chiralreagents, or resolved using conventional techniques. If the compoundcontains a double bond, the substituent may be E or Z configuration. Ifthe compound contains a disubstituted cycloalkyl, the cycloalkylsubstituent may have a cis- or trans-configuration. All tautomeric formsare also intended to be included.

As used herein, the terms “salt” or “salts” refers to an acid additionor base addition salt of a compound of the invention. “Salts” include inparticular “pharmaceutical acceptable salts”. The term “pharmaceuticallyacceptable salts” refers to salts that retain the biologicaleffectiveness and properties of the compounds of this invention and,which typically are not biologically or otherwise undesirable. In manycases, the compounds of the present invention are capable of formingacid and/or base salts by virtue of the presence of amino and/orcarboxyl groups or groups similar thereto.

Pharmaceutically acceptable acid addition salts can be formed withinorganic acids and organic acids.

Inorganic acids from which salts can be derived include, for example,hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like.

Organic acids from which salts can be derived include, for example,acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid,malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid,benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid,toluenesulfonic acid, sulfosalicylic acid, and the like.

Pharmaceutically acceptable base addition salts can be formed withinorganic and organic bases.

Inorganic bases from which salts can be derived include, for example,ammonium salts and metals from columns I to XII of the periodic table.In certain embodiments, the salts are derived from sodium, potassium,ammonium, calcium, magnesium, iron, silver, zinc, and copper;particularly suitable salts include ammonium, potassium, sodium, calciumand magnesium salts.

Organic bases from which salts can be derived include, for example,primary, secondary, and tertiary amines, substituted amines includingnaturally occurring substituted amines, cyclic amines, basic ionexchange resins, and the like. Certain organic amines includeisopropylamine, benzathine, cholinate, diethanolamine, diethylamine,lysine, meglumine, piperazine and tromethamine.

In another aspect, the present invention provides compounds of formula Iin acetate, ascorbate, adipate, aspartate, benzoate, besylate,bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate,camphorsulfonate, caprate, chloride/hydrochloride, chlortheophyllonate,citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate,glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide,isethionate, lactate, lactobionate, laurylsulfate, malate, maleate,malonate, mandelate, mesylate, methylsulphate, mucate, naphthoate,napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate,palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate,polygalacturonate, propionate, sebacate, stearate, succinate,sulfosalicylate, sulfate, tartrate, tosylate trifenatate,trifluoroacetate or xinafoate salt form.

In another aspect, the present invention provides(+)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid in sodium, potassium, ammonium, calcium, magnesium, iron, silver,zinc, and copper salt form; particularly suitable inorganic saltsinclude ammonium, potassium, sodium, calcium and magnesium salts. Theinvention further provides(+)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid in isopropylamine, benzathine, cholinate, diethanolamine,diethylamine, lysine, meglumine, piperazine and tromethamine salt forms.The compound of this embodiment is provided in salt form in racemic orenantiomerically enriched form.

In another aspect, the present invention provides(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid in sodium, potassium, ammonium, calcium, magnesium, iron, silver,zinc, and copper salt form; particularly suitable inorganic saltsinclude ammonium, potassium, sodium, calcium and magnesium salts. Theinvention further provides(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid in isopropylamine, benzathine, cholinate, diethanolamine,diethylamine, lysine, meglumine, piperazine and tromethamine salt forms.The compound of this embodiment is provided in salt form in racemic orenantiomerically enriched form.

In another aspect, the present invention provides(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid in sodium, potassium, ammonium, calcium, magnesium, iron, silver,zinc, and copper salt form; particularly suitable inorganic saltsinclude ammonium, potassium, sodium, calcium and magnesium salts. Theinvention further provides(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid in isopropylamine, benzathine, cholinate, diethanolamine,diethylamine, lysine, meglumine, piperazine and tromethamine salt forms.The compound of this embodiment is provided in salt form in racemic orenantiomerically enriched form.

In another aspect, the present invention provides(+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid in sodium, potassium, ammonium, calcium, magnesium, iron, silver,zinc, and copper salt form; particularly suitable inorganic saltsinclude ammonium, potassium, sodium, calcium and magnesium salts. Theinvention further provides(+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid in isopropylamine, benzathine, cholinate, diethanolamine,diethylamine, lysine, meglumine, piperazine and tromethamine salt forms.The compound of this embodiment is provided in salt form in racemic orenantiomerically enriched form.

In another aspect, the present invention provides(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid in sodium, potassium, ammonium, calcium, magnesium, iron, silver,zinc, and copper salt form; particularly suitable inorganic saltsinclude ammonium, potassium, sodium, calcium and magnesium salts. Theinvention further provides(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid in isopropylamine, benzathine, cholinate, diethanolamine,diethylamine, lysine, meglumine, piperazine and tromethamine salt forms.The compound of this embodiment is provided in salt form in racemic orenantiomerically enriched form.

In another aspect, the present invention provides5-Ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid in sodium, potassium, ammonium, calcium, magnesium, iron, silver,zinc, and copper salt form; particularly suitable inorganic saltsinclude ammonium, potassium, sodium, calcium and magnesium salts. Theinvention further provides5-Ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid in isopropylamine, benzathine, cholinate, diethanolamine,diethylamine, lysine, meglumine, piperazine and tromethamine salt forms.The compound of this embodiment is provided in salt form in racemic orenantiomerically enriched form.

In another aspect, the present invention provides(+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid in sodium, potassium, ammonium, calcium, magnesium, iron, silver,zinc, and copper salt form; particularly suitable inorganic saltsinclude ammonium, potassium, sodium, calcium and magnesium salts. Theinvention further provides(+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid in isopropylamine, benzathine, cholinate, diethanolamine,diethylamine, lysine, meglumine, piperazine and tromethamine salt forms.The compound of this embodiment is provided in salt form in racemic orenantiomerically enriched form.

In another aspect, the present invention provides(+)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid in sodium, potassium, ammonium, calcium, magnesium, iron, silver,zinc, and copper salt form; particularly suitable inorganic saltsinclude ammonium, potassium, sodium, calcium and magnesium salts. Theinvention further provides(+)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid in isopropylamine, benzathine, cholinate, diethanolamine,diethylamine, lysine, meglumine, piperazine and tromethamine salt forms.The compound of this embodiment is provided in salt form in racemic orenantiomerically enriched form.

In another aspect, the present invention provides5-Ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (diastereomer-1) in sodium, potassium, ammonium, calcium,magnesium, iron, silver, zinc, and copper salt form; particularlysuitable inorganic salts include ammonium, potassium, sodium, calciumand magnesium salts. The invention further provides5-Ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (diastereomer-1) in isopropylamine, benzathine, cholinate,diethanolamine, diethylamine, lysine, meglumine, piperazine andtromethamine salt forms. The compound of this embodiment is provided insalt form in racemic or enantiomerically enriched form.

Any formula given herein is also intended to represent unlabeled formsas well as isotopically labeled forms of the compounds. Isotopicallylabeled compounds have structures depicted by the formulas given hereinexcept that one or more atoms are replaced by an atom having a selectedatomic mass or mass number. Examples of isotopes that can beincorporated into compounds of the invention include isotopes ofhydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine,such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸F ³¹P, ³²P, ³⁵S, ³⁶C, ¹²³I, ¹²⁴I,¹²⁵I respectively. The invention includes various isotopically labeledcompounds as defined herein, for example those into which radioactiveisotopes, such as ³H and ¹⁴C, or those into which non-radioactiveisotopes, such as ²H and ¹³C are present. Such isotopically labelledcompounds are useful in metabolic studies (with ¹⁴C), reaction kineticstudies (with, for example ²H or ³H), detection or imaging techniques,such as positron emission tomography (PET) or single-photon emissioncomputed tomography (SPECT) including drug or substrate tissuedistribution assays, or in radioactive treatment of patients. Inparticular, an ¹⁸F or labeled compound may be particularly desirable forPET or SPECT studies. Isotopically-labeled compounds of formula (I) cangenerally be prepared by conventional techniques known to those skilledin the art or by processes analogous to those described in theaccompanying Examples and Preparations using an appropriateisotopically-labeled reagents in place of the non-labeled reagentpreviously employed.

Further, substitution with heavier isotopes, particularly deuterium(i.e., ²H or D) may afford certain therapeutic advantages resulting fromgreater metabolic stability, for example increased in vivo half-life orreduced dosage requirements or an improvement in therapeutic index. Itis understood that deuterium in this context is regarded as asubstituent of a compound of the formula (I). The concentration of sucha heavier isotope, specifically deuterium, may be defined by theisotopic enrichment factor. The term “isotopic enrichment factor” asused herein means the ratio between the isotopic abundance and thenatural abundance of a specified isotope. If a substituent in a compoundof this invention is denoted deuterium, such compound has an isotopicenrichment factor for each designated deuterium atom of at least 3500(52.5% deuterium incorporation at each designated deuterium atom), atleast 4000 (60% deuterium incorporation), at least 4500 (67.5% deuteriumincorporation), at least 5000 (75% deuterium incorporation), at least5500 (82.5% deuterium incorporation), at least 6000 (90% deuteriumincorporation), at least 6333.3 (95% deuterium incorporation), at least6466.7 (97% deuterium incorporation), at least 6600 (99% deuteriumincorporation), or at least 6633.3 (99.5% deuterium incorporation).

Pharmaceutically acceptable solvates in accordance with the inventioninclude those wherein the solvent of crystallization may be isotopicallysubstituted, e.g. D₂O, d₆-acetone, d₆-DMSO.

Compounds of the invention, i.e. compounds of formula (I) that containgroups capable of acting as donors and/or acceptors for hydrogen bondsmay be capable of forming co-crystals with suitable co-crystal formers.These co-crystals may be prepared from compounds of formula (I) by knownco-crystal forming procedures. Such procedures include grinding,heating, co-subliming, co-melting, or contacting in solution compoundsof formula (I) with the co-crystal former under crystallizationconditions and isolating co-crystals thereby formed. Suitable co-crystalformers include those described in WO 2004/078163. Hence the inventionfurther provides co-crystals comprising a compound of formula (I).

As used herein, the term “pharmaceutically acceptable carrier” includesany and all solvents, dispersion media, coatings, surfactants,antioxidants, preservatives (e.g., antibacterial agents, antifungalagents), isotonic agents, absorption delaying agents, salts,preservatives, drug stabilizers, binders, excipients, disintegrationagents, lubricants, sweetening agents, flavoring agents, dyes, and thelike and combinations thereof, as would be known to those skilled in theart (see, for example, Remington's Pharmaceutical Sciences, 18th Ed.Mack Printing Company, 1990, pp. 1289-1329). Except insofar as anyconventional carrier is incompatible with the active ingredient, its usein the therapeutic or pharmaceutical compositions is contemplated.

The term “a therapeutically effective amount” of a compound of thepresent invention refers to an amount of the compound of the presentinvention that will elicit the biological or medical response of asubject, for example, activation of soluble guanylate cyclase activity,or ameliorate symptoms, alleviate conditions, slow or delay diseaseprogression, or prevent a disease, etc. In one non-limiting embodiment,the term “a therapeutically effective amount” refers to the amount ofthe compound of the present invention that, when administered to asubject, is effective to (1) at least partially alleviate, inhibit,prevent and/or ameliorate a condition, or a disorder or a disease (i)mediated by activation of sGC, or (ii) associated with decreased sGCactivity, or (iii) characterized by activity (normal or abnormal) ofsGC. In another non-limiting embodiment, the term “a therapeuticallyeffective amount” refers to the amount of the compound of the presentinvention that, when administered to a cell, or a tissue, or anon-cellular biological material, or a medium, is effective to at leastpartially increasing the activity of sGC.

As used herein, the term “subject” refers to an animal. Typically theanimal is a mammal. A subject also refers to for example, primates(e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats,rabbits, rats, mice and the like. In certain embodiments, the subject isa primate. In yet other embodiments, the subject is a human. In yetother embodiments, the subject is a human. In certain other embodiments,the compounds of the invention may be suitable for use in the treatmentof glaucoma or reduction of IOP in dogs.

As used herein, the term “inhibit”, “inhibition” or “inhibiting” refersto the reduction or suppression of a given condition, symptom, ordisorder, or disease, or a significant decrease in the baseline activityof a biological activity or process.

As used herein, the term “activate”, “activation” or “activating” refersto the significant increase in the baseline activity of a biologicalactivity or process.

As used herein, the term “treat”, “treating” or “treatment” of anydisease or disorder refers in one embodiment, to ameliorating thedisease or disorder (i.e., slowing or arresting or reducing thedevelopment of the disease or at least one of the clinical symptomsthereof). In another embodiment “treat”, “treating” or “treatment”refers to alleviating or ameliorating at least one physical parameterincluding those which may not be discernible by the patient. In yetanother embodiment, “treat”, “treating” or “treatment” refers tomodulating the disease or disorder, either physically, (e.g.,stabilization of a discernible symptom), physiologically, (e.g.,stabilization of a physical parameter), or both. In yet anotherembodiment, “treat”, “treating” or “treatment” refers to preventing ordelaying the onset or development or progression of the disease ordisorder.

As used herein, a subject is “in need of” a treatment if such subjectwould benefit biologically, medically or in quality of life from suchtreatment.

As used herein, the term “a,” “an,” “the” and similar terms used in thecontext of the present invention (especially in the context of theclaims) are to be construed to cover both the singular and plural unlessotherwise indicated herein or clearly contradicted by the context.

All methods described herein can be performed in any suitable orderunless otherwise indicated herein or otherwise clearly contradicted bycontext. The use of any and all examples, or exemplary language (e.g.“such as”) provided herein is intended merely to better illuminate theinvention and does not pose a limitation on the scope of the inventionotherwise claimed.

Any asymmetric atom (e.g., carbon or the like) of the compound(s) of thepresent invention can be present in racemic or enantiomericallyenriched, for example the (R)-, (S)- or (R,S)-configuration. In certainembodiments, each asymmetric atom has at least 50% enantiomeric excess,at least 60% enantiomeric excess, at least 70% enantiomeric excess, atleast 80% enantiomeric excess, at least 90% enantiomeric excess, atleast 95% enantiomeric excess, or at least 99% enantiomeric excess inthe (R)- or (S)-configuration. Substituents at atoms with unsaturateddouble bonds may, if possible, be present in cis-(Z)- or trans-(E)-form.

Accordingly, as used herein a compound of the present invention can bein the form of one of the possible isomers, rotamers, atropisomers,tautomers or mixtures thereof, for example, as substantially puregeometric (cis or trans) isomers, diastereomers, optical isomers(antipodes), racemates or mixtures thereof.

Any resulting mixtures of isomers can be separated on the basis of thephysicochemical differences of the constituents, into the pure orsubstantially pure geometric or optical isomers, diastereomers,racemates, for example, by chromatography and/or fractionalcrystallization.

Any resulting racemates of final products or intermediates can beresolved into the optical antipodes by known methods, e.g., byseparation of the diastereomeric salts thereof, obtained with anoptically active acid or base, and liberating the optically activeacidic or basic compound. In particular, a basic moiety may thus beemployed to resolve the compounds of the present invention into theiroptical antipodes, e.g., by fractional crystallization of a salt formedwith an optically active acid, e.g., tartaric acid, dibenzoyl tartaricacid, diacetyl tartaric acid, di-O, O′-p-toluoyl tartaric acid, mandelicacid, malic acid or camphor-10-sulfonic acid. Racemic products can alsobe resolved by chiral chromatography, e.g., high pressure liquidchromatography (HPLC) using a chiral adsorbent.

Furthermore, the compounds of the present invention, including theirsalts, can also be obtained in the form of their hydrates, or includeother solvents used for their crystallization. The compounds of thepresent invention may inherently or by design form solvates withpharmaceutically acceptable solvents (including water); therefore, it isintended that the invention embrace both solvated and unsolvated forms.The term “solvate” refers to a molecular complex of a compound of thepresent invention (including pharmaceutically acceptable salts thereof)with one or more solvent molecules. Such solvent molecules are thosecommonly used in the pharmaceutical art, which are known to be innocuousto the recipient, e.g., water, ethanol, and the like. The term “hydrate”refers to the complex where the solvent molecule is water.

The compounds of the present invention, including salts, hydrates andsolvates thereof, may inherently or by design form polymorphs.

Typically, the compounds of formula (I) can be prepared according to theSchemes provided infra

General Synthetic Aspects

Typically, the compounds of Formula (I) can be prepared according to theSchemes provided below. The following Examples serve to illustrate theinvention without limiting the scope thereof.

Compounds such as 1-3; wherein R^(a) is C₁-C₄ alkyl (preferably methylor ethyl), R^(b) is R^(a) or trifluoromethyl, W^(a) is CH or N, andX^(a) is Cl or Br; can be prepared according to Scheme 1.

Aryl hydrazines 1-1 and beta-ketoester derivatives 1-2 can be reacted inan alcoholic solvent such as EtOH at temperatures between roomtemperature and at reflux to provide the pyrazole derivatives 1-3.Alternatively, the beta-ketoester derivatives 1-5 can be prepared by areaction of the corresponding beta-ketoesters 1-4 with dimethylformamidedimethyl acetal at room temperature. Reaction of 1-1 with 1-5 to afford1-3 can be achieved by applying similar conditions described above forthe reaction with 1-2.

Compounds such as 2a-4 or 2b-2; wherein R^(c-1) is H, F, R^(a), C₁-C₄alkoxy, or hydroxymethyl; R^(c-2) is R^(b), hydrogen, C₁-C₄ alkoxy, orfluorine; and R^(d) is hydrogen or methyl; R^(e) is Boc, C(O)-Et,—C(O)-cPr, or CH₂CF₃; R^(w) is C(O)-Et, —C(O)-cPr, or CH₂CF₃, and R^(f)is benzyl or 5 or 6 membered heteroarylmethyl can be synthesizedaccording to Scheme 2a and Scheme 2b.

2a-1 can be transformed to 2a-3 utilizing a Suzuki-type coupling withboronate 2a-2. 2a-3, when R^(d)=Me, can be transformed into 2a-4 viahydrogenation over catalysts such as Pd/C or platinum oxide, followed bytreating with an acid such as TFA in an appropriate solvent such asCH₂Cl₂ and subsequent reaction with an acid anhydride such as propionicanhydride or an acid chloride such as cyclopropylcarbonyl chloride alongwith a trialkylamine base (e.g., trimethylamine), or reacted with alkylhalides or reagents such as 2,2,2-trifluoroethyltrifluoromethanesulfonate in an appropriate solvent such as DMF in thepresence of K₂CO₃. 2a-4 can be transformed into 2a-5 via treatment withboron tribromide in the appropriate solvent such as dichloromethane atlow temperatures. Alternatively 2a-3 when R^(d)═H can be directlyconverted to 2a-5 (R^(e)=Boc) by hydrogenation over catalysts such asPd/C or platinum oxide, or 2a-3 when R^(d)═H can be directly convertedto 2a-5 (R^(e)═R^(w)) by treating with an acid such as TFA in anappropriate solvent such as CH₂Cl₂ and subsequent reaction with an acidanhydride such as propionic anhydride or an acid chloride such ascyclopropylcarbonyl chloride along with a trialkylamine base (e.g.,trimethylamine) followed by treatment with MeOH in the presence ofK₂CO₃.

Treatment of 2b-1a with acid such as TFA in an appropriate solvent suchas CH₂Cl₂ affords 2b-1 b. 2b-1 b can then be reacted with arylmethylhalide such as benzyl bromide or (2-bromomethyl)pyridine in the presenceof a suitable base such as triethylamine in an acceptable solvent suchas DCM can provide 2b-2.

Compounds such as 3-3 can be prepared according to Scheme 3.

Transformation of 3-1 to 3-2 can be accomplished employing similarmethods as described in Scheme 2a (i.e., 2a-1→2a-3). When necessary 3-2ato 3-2c can be accomplished by treating with an acid such as TFA in anappropriate solvent such as CH₂Cl₂ and subsequent reaction with an acidanhydride such as propionic anhydride or an acid chloride such ascyclopropylcarbonyl chloride along with a trialkylamine base (e.g.,trimethylamine), or reacted with alkyl halides or reagents such as2,2,2-trifluoroethyl trifluoromethanesulfonate in an appropriate solventsuch as DMF in the presence of K₂CO₃. Subsequent catalytic hydrogenationof 3-2 over Pd/C in appropriate solvents such as EtOH can furnish 3-3.

Compounds such as 4a-4 and 4a-5 wherein R⁹ is H or C₁-C₄ alkyl,preferably H or Me; wherein X^(b) is —OTf, or —Br can be preparedaccording to Scheme 4a.

Heating an intimate mixture of 4a-1 and AlCl₃ at temperatures between100° C. and 180° C. can afford 4a-2 (as in Heterocycles, 407-421, 1988).4a-2 can then be converted to trifluoromethanesulfonate 4a-3 bytreatment with a triflating agent such as trifluoromethanesulfonicanhydride in an appropriate solvent such as CH₂Cl₂ in the presence of anappropriate base such as pyridine. The ketone 4a-3 can then be reducedby a reducing agent such as NaBH₄ in a suitable solvent such as MeOH attemperatures between 0° C. and room temperature to generate alcohol 4a-4where X^(b) is OTf. Alternatively, alcohol 4a-4 where X^(b) is Br, canbe generated by reduction of ketone 4a-3a under similar reducingconditions (ie. 4a-3-4a-4). The alcohol 4a-4 can then be reacted with awide variety of phenol derivatives such as 2a-5 or 2b-2 by employingtriaryl- or trialkyl-phosphines such as triphenylphosphine and anazodicarboxylate such as DIAD in suitable solvents such as THF attemperatures between 0° C. to room temperature to afford 4a-5 or 4a-6respectively.

Compounds such as 4b-1 can be prepared according to Scheme 4b.

Ketones of type 4a-3 can be reacted with and the anilines such as 3-3 inthe presence of suitable reducing agent such as NaB(OAc)₃H in solventssuch as AcOH at temperatures between room temperature and 50° C. canfurnish 4b-1. Alternatively, reaction of Ketones of type 4a-3 withanilines such as 3-3 in the presence of acid such as TsOH, in solventssuch as toluene or a solvent mixture of toluene and dimethylacetamindeunder the reflux conditions with a Dean-Stark trap can providecorresponding imine. The subsequent imine reduction can be achieved byreagents such as NaB(OAc)₃H the presence of an appropriate acid such asAcOH in solvents such as CH₂Cl₂ or mixture of CH₂Cl₂ and alcoholicsolvents at temperatures between 0° C. and room temperature.

Compounds such as 5-1 and 5-2 can be prepared according to Scheme 5.

A Miyaura-type borylation of 1-3 with bis(pinacolato)diboron employingconditions such as Pd(OAc)₂,2,2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl and potassiumacetate in dioxane at temperatures between 60° C. and 120° C. canprovide the corresponding boronic ester, which can then be reacteddirectly with 4a-3 or 4a-3a by a Suzuki-type reaction utilizingconditions such as Pd(dppf)Cl₂ in the presence of a suitable aqueousbase such as aqueous sodium carbonate in dioxane at temperatures between80° C. to 110° C. to afford 5-1. The ketone 5-1 can then be reducedusing a reductive agent such as NaBH₄ in a suitable solvent such as EtOHto provide 5-2.

Compounds such as 6a-1, 6a-2, 6b-1, and 6b-2 can be prepared accordingto Scheme 6a and Scheme 6b.

A Miyaura-type borylation of 1-3 with bis(pinacolato)diboron employingconditions such as Pd(OAc)₂,2,2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl and potassiumacetate in dioxane at temperatures between 60° C. and 120° C. canprovide corresponding boronic ester, which can then be reacted directlywith 4a-5 or 4a-6 by a Suzuki-type reaction utilizing conditions such asPd(dppf)Cl₂ in the presence of a suitable aqueous base such as aqueoussodium carbonate in dioxane at temperatures between 80° C. to 110° C. toafford 6a-1.

Alternatively, 5-2 can be reacted with a wide variety of phenolderivatives such as 2a-5 by employing triaryl- or trialkyl-phosphinessuch as triphenylphosphine and an azodicarboxylate such as DIAD insuitable solvent such as THF at temperatures between 0° C. to roomtemperature to afford 6a-1.

Saponification of 6a-1 can be accomplished employing conditions such asaqueous LiOH in a solvent mixture of MeOH and THF at temperaturesbetween room temperature to 70° C. to afford 6a-2.

A Miyaura-type borylation of 1-3 with bis(pinacolato)diboron employingconditions such as Pd(OAc)₂,2,2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl and potassiumacetate in dioxane at temperatures between 60° C. and 120° C. canprovide corresponding boronic ester, which can then be reacted directlywith one of 4b-1 by a Suzuki-type reaction utilizing conditions such asPd(dppf)Cl₂ in the presence of a suitable aqueous base such as aqueoussodium carbonate in dioxane at temperatures between 80° C. to 110° C. toafford 6b-1.

Alternatively compounds such as 6b can be accessed via ketone 5-1 bytreatment with anilines such as 3-3 in refluxing toluene in the presenceof catalytic acid such as TsOH, followed by treatment with a reducingagent such as NaBH₄ in a suitable solvent such as EtOH to afford 6b-1.Saponification of 6b-1 can be accomplished employing conditions such asaqueous LiOH in a solvent mixture of MeOH and THF at temperaturesbetween room temperature to 70° C. to afford 6b-2.

Compounds such as 6c-3, wherein R^(e-1)═C(O)—C₁-C₄ alkyl orC(O)-cycloalkyl, can be prepared according to Scheme 6c.

Treatment of 6b-1 (R^(e)=Boc) with suitable acids such as anhydrous HCl(e.g., a solution of HCl in 1,4-dioxane or in THF) in solvents such asCH₂Cl₂ at temperatures between 0° C. to room temperature can provide6c-1 which can then be transformed to compounds of type 6c-2(R^(e-1)═C(O)—C₁-C₄ alkyl or C(O)-cycloalkyl) by reactions with acylchlorides such as cyclopropanecarbonyl chloride, or acid anhydrides suchas propionic anhydride, or carboxylic acids, such as 2-cyclopropylaceticacid, under peptide coupling conditions (e.g., HATU and DIPEA).

Saponification of 6c-2 can be accomplished employing conditions such asaqueous LiOH in a solvent mixture of MeOH and THF at temperaturesbetween room temperature to 70° C. to afford 6c-3.

Compound such as 7-6 can be prepared according to scheme 7.

Transformation of 7-1 to 7-3 can be accomplished in accordance with theroute described in Scheme 2a. (i.e. 2a-1-2a-3). 7-3 can undergohydrogenation over catalysts such as Pd/C or platinum oxide to furnish7-4. The ester 7-4 can then be reduced by reagents such as LiAlH₄ insolvent such as THF preferably at 0° C. to afford 7-5. Lastly, treatmentof 7-5 with reagents such as triphenylphosphine and carbon tetrabromidein solvents such as dichloromethane at temperatures between 0° C. androom temperature can afford 7-6.

Compound such as 8-4, where R^(f-1) and R^(f-2) are independentlyselected from hydrogen or C₁-C₄ alkyl, can be synthesized according toScheme 8.

Transformation of 1-3 (W^(a)═N) to 8-3 can be achieved utilizing aSuzuki-type coupling with an appropriate boronate such as7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole, 8-2.Reduction of the indole 8-3 to corresponding indoline 8-4 can them beaccomplished by reaction with triethylsilane in the presence of TFA indichloromethane at room temperature.

Compound such as 9-2b, 9-3b, and 9-4b can be synthesized according toScheme 9 where R^(e-2)═R^(e-3)═C₁-C₄alkyl or cylcloalkyl, andR^(e-4)═C₁-C₄alkyl, C₃-C₆cycloalkyl, haloC₁-C₄alkyl

Reaction of compound 7-6 with indoline 8-4 can be achieved by employingbases such as potassium carbonate in solvents such as DMF attemperatures between 0° C. to 80° C. to afford 9-1a. Treatment of 9-1awith suitable acids such as TFA in CH₂Cl₂ or HCl in dioxane attemperatures between 0° C. to room temperature can provide 9-1b, whichcan then be further functionalized to 9-2a 9-3a in accordance withScheme 6c (i.e. 6c-1→6c-2). Alternatively, the amine 9-1b can bealkylated with electrophiles such as 2,2,2-trifluoroethyltrifluoromethanesulfonate in the presence of bases such as K₂CO₃ insolvents such as DMF at temperatures between room temperature to 100° C.to furnish 9-4a.

Lastly, saponification of 9-2a, 9-3a or 9-4a can be accomplishedemploying conditions such as aqueous LiOH in a solvent mixture of MeOHand THF at temperatures between room temperature to 70° C. to afford9-2b, 9-3b or 9-4b respectively.

Compound such as 10-1b, could be synthesized according to Scheme 10.

Treatment of compounds type 9-2a, 9-2b, 9-3a, and 9-3b with oxidizingreagents such as o-chloranil in suitable solvents such ascyclopentylmethyl ether at room temperature could afford compounds type10-1a and 10-1b. For compound type 10-1a, saponification by methods asoutlined above can furnish Compound type 10-1b.

Compound such as 11c-3, 11d-3, 11d-5, and 11d-7, could be synthesizedaccording to Scheme 11.

Scheme 11.

Compounds such as 11a-5 can be prepared starting from7-methoxy-2,3-dihydro-1H-inden-1-ol (CAS#34985-44-9), 11a-1. 11a-1 canbe reacted with triphenylphosphine hydrobromide in toluene at elevatedtemperatures, preferably 90° C., to afford salt 11a-2. Salt 11a-2 canundergo a Wittig-like coupling with aldehydes of type 11a-3 (preparedvia oxidation of 7-5) by reacting with a strong base, such as potassiumtert-butoxide, in solvents such as THF at elevated temperatures,preferably at 70° C. to furnish olefins of type 11a-4. Compounds of type11a-4 can undergo palladium mediated hydrogenation to provide compoundssuch as type 11a-5.

Compounds such as 11a-5 when R^(e)=Boc can be treated with a strongLewis acid such as BBr₃ at low temperatures, preferably 0° C., to affordphenols of type 11 b-1. 11 b-1 can then be converted into 11b-2, byreaction with acyl chlorides such as cyclopropanecarbonyl chloride, oracid anhydrides such as propionic anhydride, or carboxylic acids underpeptide coupling conditions. 11b-1 can also be reacted withdi-tert-butyl dicarbonate to furnish 11b-2, where R^(e)=Boc.Alternatively when 11a-5 employs R^(e) as an Lewis acid stable moietythese compounds can be treated with BBr₃ at low temperatures, preferably−78° C. to furnish 11 b-2 directly.

Phenols of type 11 b-2 can be converted to trifluoromethanesulfonates oftype 11c-1 by treatment with a triflating agent such astrifluoromethanesulfonic anhydride in an appropriate solvent such asCH₂Cl₂ in the presence of an appropriate base such as pyridine. AMiyaura-type borylation of 1-3 with bis(pinacolato)diboron employingconditions such as Pd(OAc)₂,2,2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl and potassiumacetate in dioxane at temperatures between 60° C. and 120° C. canprovide corresponding boronic ester, which can then be reacted directlywith compounds of type 11c-1 by a Suzuki-type reaction utilizingconditions such as Pd(dppf)Cl₂ in the presence of a suitable aqueousbase such as aqueous sodium carbonate in dioxane at temperatures between80° C. to 110° C. to afford esters of type 11c-2. Saponification ofesters of type 11c-2 can then be accomplished by employing conditionssuch as aqueous LiOH in a solvent mixture of MeOH and THF attemperatures between room temperature to 70° C. to furnish acids of type11c-3

Alternatively, compounds of type 11c-2 where R^(e)=Boc can be treatedwith suitable acids such as TFA in CH₂Cl₂ or HCl in dioxane attemperatures between 0° C. to room temperature to provide 11d-1, whichcan then be further functionalized to 11d-2 and 11d-4, in accordancewith Scheme 6c (i.e. 6c-1-6c-2). Alternatively, the amine 11d-2 can bealkylated with electrophiles such as 2,2,2-trifluoroethyltrifluoromethanesulfonate in the presence of bases such as K₂CO₃ insolvents such as DMF at temperatures between room temperature to 100° C.to furnish compounds of type 11d-6.Lastly, saponification of 11d-2, 11d-4 and 11d-6 can be accomplishedemploying conditions such as aqueous LiOH in a solvent mixture of MeOHand THF at temperatures between room temperature to 70° C. to afford11d-3, 11d-5 and 11d-7 respectively.

The invention further includes any variant of the present processes, inwhich an intermediate product obtainable at any stage thereof is used asstarting material and the remaining steps are carried out, or in whichthe starting materials are formed in situ under the reaction conditions,or in which the reaction components are used in the form of their saltsor optically pure material.

Compounds of the invention and intermediates can also be converted intoeach other according to methods generally known to those skilled in theart.

In another aspect, the present invention provides a pharmaceuticalcomposition comprising a compound of the present invention, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier. In a further embodiment, the composition comprisesat least two pharmaceutically acceptable carriers, such as thosedescribed herein. For purposes of the present invention, unlessdesignated otherwise, solvates and hydrates are generally consideredcompositions. Preferably, pharmaceutically acceptable carriers aresterile. The pharmaceutical composition can be formulated for particularroutes of administration such as oral administration, parenteraladministration, and rectal administration, etc. In addition, thepharmaceutical compositions of the present invention can be made up in asolid form (including without limitation capsules, tablets, pills,granules, powders or suppositories), or in a liquid form (includingwithout limitation solutions, suspensions or emulsions). Thepharmaceutical compositions can be subjected to conventionalpharmaceutical operations such as sterilization and/or can containconventional inert diluents, lubricating agents, or buffering agents, aswell as adjuvants, such as preservatives, stabilizers, wetting agents,emulsifiers and buffers, etc. Typically, the pharmaceutical compositionsare tablets or gelatin capsules comprising the active ingredienttogether with one or more of:

-   -   a) diluents, e.g., lactose, dextrose, sucrose, mannitol,        sorbitol, cellulose and/or glycine;    -   b) lubricants, e.g., silica, talcum, stearic acid, its magnesium        or calcium salt and/or polyethyleneglycol; for tablets also    -   c) binders, e.g., magnesium aluminum silicate, starch paste,        gelatin, tragacanth, methylcellulose, sodium        carboxymethylcellulose and/or polyvinylpyrrolidone; if desired    -   d) disintegrants, e.g., starches, agar, alginic acid or its        sodium salt, or effervescent mixtures; and    -   e) absorbents, colorants, flavors and sweeteners.

Tablets may be either film coated or enteric coated according to methodsknown in the art.

Suitable compositions for oral administration include an effectiveamount of a compound of the invention in the form of tablets, lozenges,aqueous or oily suspensions, dispersible powders or granules, emulsion,hard or soft capsules, or syrups or elixirs. Compositions intended fororal use are prepared according to any method known in the art for themanufacture of pharmaceutical compositions and such compositions cancontain one or more agents selected from the group consisting ofsweetening agents, flavoring agents, coloring agents and preservingagents in order to provide pharmaceutically elegant and palatablepreparations. Tablets may contain the active ingredient in admixturewith nontoxic pharmaceutically acceptable excipients which are suitablefor the manufacture of tablets. These excipients are, for example, inertdiluents, such as calcium carbonate, sodium carbonate, lactose, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, corn starch, or alginic acid; binding agents, for example,starch, gelatin or acacia; and lubricating agents, for example magnesiumstearate, stearic acid or talc. The tablets are uncoated or coated byknown techniques to delay disintegration and absorption in thegastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonostearate or glyceryl distearate can be employed. Formulations fororal use can be presented as hard gelatin capsules wherein the activeingredient is mixed with an inert solid diluent, for example, calciumcarbonate, calcium phosphate or kaolin, or as soft gelatin capsuleswherein the active ingredient is mixed with water or an oil medium, forexample, peanut oil, liquid paraffin or olive oil.

Certain injectable compositions are aqueous isotonic solutions orsuspensions, and suppositories are advantageously prepared from fattyemulsions or suspensions. Said compositions may be sterilized and/orcontain adjuvants, such as preserving, stabilizing, wetting oremulsifying agents, solution promoters, salts for regulating the osmoticpressure and/or buffers. In addition, they may also contain othertherapeutically valuable substances. Said compositions are preparedaccording to conventional mixing, granulating or coating methods,respectively, and contain about 0.1-75%, or contain about 1-50%, of theactive ingredient.

Suitable compositions for transdermal application include an effectiveamount of a compound of the invention with a suitable carrier. Carrierssuitable for transdermal delivery include absorbable pharmacologicallyacceptable solvents to assist passage through the skin of the host. Forexample, transdermal devices are in the form of a bandage comprising abacking member, a reservoir containing the compound optionally withcarriers, optionally a rate controlling barrier to deliver the compoundof the skin of the host at a controlled and predetermined rate over aprolonged period of time, and means to secure the device to the skin.

Suitable compositions for topical application, e.g., to the skin andeyes, include aqueous solutions, suspensions, ointments, creams, gels orsprayable formulations, e.g., for delivery by aerosol or the like. Suchtopical delivery systems will in particular be appropriate for dermalapplication, e.g., for the treatment of skin cancer, e.g., forprophylactic use in sun creams, lotions, sprays and the like. They arethus particularly suited for use in topical, including cosmetic,formulations well-known in the art. Such may contain solubilizers,stabilizers, tonicity enhancing agents, buffers and preservatives.

As used herein a topical application may also pertain to an inhalationor to an intranasal application. They may be conveniently delivered inthe form of a dry powder (either alone, as a mixture, for example a dryblend with lactose, or a mixed component particle, for example withphospholipids) from a dry powder inhaler or an aerosol spraypresentation from a pressurised container, pump, spray, atomizer ornebuliser, with or without the use of a suitable propellant.

Compositions of the present invention may be utilized in various dosageregimens known to those of skill in the art. Such dosing frequency ismaintained for a varying duration of time depending on the therapeuticregimen. The duration of a particular therapeutic regimen may vary fromone-time dosing to a maintenance regimen that extends for a month, yearor more. One of ordinary skill in the art would be familiar withdetermining a therapeutic regimen for a specific indication. Preferreddosage regimens of the present invention include, but are not limitedto, once a day dosing and twice a day dosing.

In the methods for the treatment of ocular disease and particularly forthe treatment of glaucoma, set forth herein, administration to a subjectof a composition of the present invention may be by various methodsknown to those of skill in the art, including, but not limited to,topical, subconjunctival, periocular, retrobulbar, subtenon,intraocular, subretinal, posterior juxtascleral, or suprachoroidaladministration. In preferred embodiments, administration of acomposition of the present invention is by topical administration to theocular surface.

It is contemplated that the concentration of the sGC activator in thecompositions of the present invention can vary, but is preferably 0.01to 3.0 w/v % and more preferably 0.05-1.0 w/v %. The most preferredconcentration range is from 0.05-0.5 w/v % and the most preferredconcentration is about 0.1 w/v %. The sGC activators of the presentinvention comprise the pharmaceutically useful hydrates and salts ofsuch compounds and stereoisomers (where applicable), and may beformulated with a pharmaceutically acceptable vehicle.

The methods of treating glaucoma may include administering the sGCactivator compound by a technique selected from the group consisting of:topical ocular administration, periocular injection, sub-conjunctivalinjection, sub-tenon injection, intracameral injection, intravitrealinjection, intracanalicular injection, implanting delivery device in thecul-de-sac, implanting delivery device adjacent to the sclera,implanting delivery device within the eye, oral administration,intravenous administration, subcutaneous administration, intramuscularadministration, parenteral administration, dermal administration, andnasal administration.

In certain aspects of the invention, compounds of the invention may beformulated in either fixed and unfixed combinations of two therapeuticagents effective in the treatment of glaucoma wherein one therapeuticagent is sGC activator disclosed supra and the second therapeutic agentis an efficacious glaucoma drug. In other embodiments, a pharmaceuticalcomposition of the invention comprising a sGC activator can beadministered to a patient alone or in combination with otherIOP-lowering agents to increase the potency, efficacy and/or duration ofthe IOP reduction. In certain preferred combinations, the secondIOP-lowering agent is selected from carbonic anhydrase inhibitors,beta-blockers, prostaglandins, alpha-2 agonists, serotonin-2 agonists,alpha-1 antagonists, dopamine agonists, Rho kinase inhibitors, myosin-IICa2+ATPase, inhibitors, matrix metalloproteinase activators, activatorprotein-1 (AP-1) activators, natriuretic peptide receptor-B agonists,phosphodiesterase inhibitors, K+-channel blockers and maxi-K-channelactivators. The combination therapy of the invention provides thebenefit of lowering IOP by two mechanisms, including inducinguveoscleral outflow of aqueous humor and inhibiting aqueous humorinflow, which can allow for reduced dosages of the compounds therebylowering the risk of side effects.

Pharmaceutical compositions of the invention can also be advantageouslycombined with suitable neuroprotective agents such as memantine,eliprodil, Ca2+-channel blockers, and betaxolol.

In a further aspect of the invention, the sGC activator may beadministered alone or in combination with a second therapeutic agentwhich is suitable for the treatment of glaucoma. Certain preferredsecond therapeutic agents include beta-blockers, prostaglandin analogs,carbonic anhydrase inhibitors, α2 agonists, miotics, PDE-V inhibitors,Rho kinase inhibitors and neuroprotectants. In one preferredcombination, a prostaglandin F2α analogue selected from the groupconsisting of Latanaprost and Travoprost is administered in combinationwith sGC activator of Formula (I) or subformulae thereof. In anotherpreferred combination, a PDE-V inhibitor selected from the groupconsisting of Sildenafil, Tadalafil, Vardenafil, Udenafil, Avanafil,Lodenafil and Mirodenafil is administered in combination with a sGCactivator of Formula (I) or subformulae thereof. In yet anotherpreferred combination, a sGC activator of Formula (I) or subformulaethereof is administered in combination with a sGC stimulator (such asRiociguat) or a NO precursor (such as sodium nitroprusside ornitroglycerine). In another preferred combination, a sGC activator ofFormula (I) or subformulae thereof is administered in combination with aRho-kinase inhibitor (such as AR-13324 alone or combination of AR-13324and Latanaprost).

In a further embodiment of the invention, a sGC activator of Formula (I)is administered in combination with a carbonic anhydrase inhibitor (suchas Brinzolamide) for the treatment of glaucoma or to reduce IOP. Inanother embodiment, a sGC activator of Formula (I) is administered incombination with a α2 adrenergic agonist (such as Brimonidine) for thetreatment of glaucoma or to reduce IOP. In a particularly preferredcombination therapy, a sGC activator of Formula (I) is administered incombination with a fixed combination of Brimonidine and Brinzolamide(such as SIMBRINZA™ from by Alcon, Fort Worth, Tex.) for the treatmentof glaucoma or to reduce IOP.

In certain embodiments, a sGC activator and the second pharmaceuticalagent are administered concurrently in separate pharmaceuticalcompositions. In other embodiments, a sGC activator and the secondpharmaceutical agent are administered formulated together in apharmaceutical composition. In yet other embodiments, the sGC activatorand the second pharmaceutical agent are administered sequentially inseparate pharmaceutical compositions.

In the combination therapies of the invention, the compound of theinvention and the other therapeutic agent may be manufactured and/orformulated by the same or different manufacturers. Moreover, thecompound of the invention and the other therapeutic may be broughttogether into a combination therapy: (i) prior to release of thecombination product to physicians (e.g. in the case of a kit comprisingthe compound of the invention and the other therapeutic agent); (ii) bythe physician themselves (or under the guidance of the physician)shortly before administration; (iii) in the patient themselves, e.g.during sequential administration of the compound of the invention andthe other therapeutic agent.

In addition to a sGC activator, the compositions of the presentinvention optionally comprise one or more excipients. Excipientscommonly used in pharmaceutical compositions include, but are notlimited to, tonicity agents, preservatives, chelating agents, bufferingagents, surfactants and antioxidants. Other excipients comprisesolubilizing agents, stabilizing agents, comfort-enhancing agents,polymers, emollients, pH-adjusting agents and/or lubricants. Any of avariety of excipients may be used in compositions of the presentinvention including water, mixtures of water and water-misciblesolvents, such as C1-C7-alkanols, vegetable oils or mineral oilscomprising from 0.5 to 5% non-toxic water-soluble polymers, naturalproducts, such as alginates, pectins, tragacanth, karaya gum, xanthangum, carrageenin, agar and acacia, starch derivatives, such as starchacetate and hydroxypropyl cellulose or starch, and also other syntheticproducts such as polyvinyl alcohol, polyvinylpyrrolidone, polyvinylmethyl ether, polyethylene oxide, preferably cross-linked polyacrylicacid and mixtures of those products. The concentration of the excipientis, typically, from 1 to 100,000 times the concentration of the sGCactivator. In preferred embodiments, excipients are selected on thebasis of their inertness towards the sGC activator.

Relative to ophthalmic formulations, suitable tonicity-adjusting agentsinclude, but are not limited to, mannitol, sodium chloride, glycerin,sorbitol and the like. Suitable buffering agents include, but are notlimited to, phosphates, borates, acetates and the like. Suitablesurfactants include, but are not limited to, ionic and nonionicsurfactants (though nonionic surfactants are preferred), RLM 100, POE 20cetylstearyl ethers such as Procol® CS20 and poloxamers such asPluronic® F68. Suitable antioxidants include, but are not limited to,sulfites, ascorbates, butylated hydroxyanisole (BHA) and butylatedhydroxytoluene (BHT).

The compositions set forth herein may comprise one or morepreservatives. Examples of such preservatives include p-hydroxybenzoicacid ester, sodium chlorite, benzalkonium chloride, parabens such asmethylparaben or propylparaben, alcohols such as chlorobutanol, benzylalcohol or phenyl ethanol, guanidine derivatives such aspolyhexamethylene biguanide, polymeric quaternary ammonium compoundssuch as Onamer M and Polyquaterium-1 (POLYQUAD® from Alcon), sodiumperborate, or sorbic acid. In certain embodiments, the composition maybe self-preserved that no preservation agent is required.

In preferred compositions a sGC activator of the present invention willbe formulated for topical application to the eye in aqueous solution inthe form of drops. The term “aqueous” typically denotes an aqueouscomposition wherein the composition is >50%, more preferably >75% and inparticular >90% by weight water. These drops may be delivered from asingle dose ampoule which may preferably be sterile and thus renderbacteriostatic components of the composition unnecessary. Alternatively,the drops may be delivered from a multi-dose bottle which may preferablycomprise a device which extracts any preservative from the compositionas it is delivered, such devices being known in the art.

In other aspects, components of the invention may be delivered to theeye as a concentrated gel or a similar vehicle, or as dissolvableinserts that are placed beneath the eyelids. In yet other aspects,components of the invention may be delivered to the eye as ointments,water-in-oil and oil-in-water emulsions, solutions, or suspensions.

The compositions of the present invention, and particularly the topicalcompositions, are preferably isotonic or slightly hypotonic in order tocombat any hypertonicity of tears caused by evaporation and/or disease.This may require a tonicity agent to bring the osmolality of thecomposition to a level at or near 210-320 milliosmoles per kilogram(mOsm/kg). The compositions of the present invention generally have anosmolality in the range of 220-320 mOsm/kg, and preferably have anosmolality in the range of 235-300 mOsm/kg. The ophthalmic compositionswill generally be formulated as sterile aqueous solutions.

In certain embodiments, a sGC activator of the present invention isformulated in a composition that comprises one or more tear substitutes.A variety of tear substitutes are known in the art and include, but arenot limited to: monomeric polyols, such as, glycerol, propylene glycol,and ethylene glycol; polymeric polyols such as polyethylene glycol;cellulose esters such hydroxypropylmethyl cellulose, carboxymethylcellulose sodium and hydroxy propylcellulose; dextrans such asdextran 70; vinyl polymers, such as polyvinyl alcohol; guars, such asHP-guar and other guar derivatives, and carbomers, such as carbomer934P, carbomer 941, carbomer 940 and carbomer 974P. Certain compositionsof the present invention may be used with contact lenses or otherophthalmic products.

In certain embodiments, the compositions set forth herein have aviscosity of 0.5-100 cps, preferably 0.5-50 cps, and most preferably1-20 cps. These viscosities insure that the product is comfortable, doesnot cause blurring, and is easily processed during manufacturing,transfer and filling operations.

Preferred compositions are prepared using a buffering system thatmaintains the composition at a pH of about 3 to a pH of about 8.0,preferably 5.5-7.5, and most preferably 6.0-7.4. Topical compositions(particularly topical ophthalmic compositions) are preferred which havea physiological pH matching the tissue to which the composition will beapplied or dispensed.

The following examples are presented to further illustrate selectedembodiments of the present invention.

TOPICAL OCULAR FORMULATION EXAMPLE Concentration Ingredient (w/v %) sGCactivator 0.1% Dibasic Sodium Phosphate 0.2% Sodium Chloride 0.75%Disodium EDTA 0.01% Polysorbate 80 0.05% Benzalkonium Chloride Solution0.01% Hydroxypropyl Methylcellulose 0.5%

The compounds of formula I in free form or in pharmaceuticallyacceptable salt form, exhibit valuable pharmacological properties, e.g.sGC modulating properties, e.g. as indicated in vitro and in vivo testsas provided in the next sections, and are therefore indicated fortherapy or for use as research chemicals, e.g. as tool compounds. Moreparticularly, the compounds of formula I, in free form or inpharmaceutically acceptable salt form, activate sGC which is suitablefor use in treatment of disease.

In one preferred use, the compounds of Formula I are suitable for use inlowering intra-ocular pressure (IOP) and in the treatment of glaucoma.The compounds of the invention may be used alone or in combination witha second therapeutic agent for the treatment of glaucoma. The embodimentfurther provides methods of treating glaucoma or reducing intraocularpressure in a subject, the method comprising administering a compound ofFormula I alone or in combination with a second therapeutic agent. Incertain aspects, the method contemplates to topical ocularadministration of the compound of Formula I to the subject in need ofsuch therapy. In preferred aspects, the method comprises administrationof the compound of Formula I as a mono-therapy. In certain otheraspects, the method comprises the co-administration (eitherconcomitantly or sequentially) of a compound of Formula I and a PDE-Vinhibitor.

Compounds of the invention may also be useful in the treatment of anindication selected from: kidney disease, urologic disordershypertension, atherosclerosis, peripheral artery disease, restenosis,stroke, heart failure, coronary vasospasm, cerebral vasospasm,ischemia/reperfusion injury, thromboembolic pulmonary hypertension,pulmonary arterial hypertension, stable and unstable angina,thromboembolic disorders. In addition, the compounds of the inventionhave the potential to treat renal disease, diabetes, fibrotic disorders(including those of the liver, kidney and lungs), urologic disorders(including overactive bladder), benign prostatic hyperplasia, erectiledysfunction, neuropathic pain and neurological disorders (IncludingAlzheimer's disease and Parkinson's disease). Treatment with an sGCactivator of the invention may further provide benefit in the treatmentof inflammatory disorder such as psoriasis, multiple sclerosis,arthritis, asthma and chronic obstructive pulmonary disease.

Thus, as a further embodiment, the present invention provides the use ofa compound of formula (I) in therapy. In a further embodiment, thetherapy is selected from a disease which may be treated by activation ofsGC. In a preferred application, the disease is selected from theafore-mentioned list, suitably glaucoma.

In another embodiment, the invention provides a method of treating adisease which is treated by activation of sGC comprising administrationof a therapeutically acceptable amount of a compound of formula (I) or asalt thereof. In a further embodiment, the disease is selected from theafore-mentioned list, suitably glaucoma.

In a particularly preferred use,(+)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid,(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid,(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid or(+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid or a pharmaceutically acceptable salt thereof are suitable for usein lowering intra-ocular pressure (IOP) and in the treatment ofglaucoma.(+)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid,(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid,(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid or(+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid or a pharmaceutically acceptable salt thereof may be used alone orin combination with a second therapeutic agent for the treatment ofglaucoma. The embodiment further provides methods of treating glaucomaor reducing intraocular pressure in a subject, the method comprisingadministering one of the specific compounds listed supra alone or incombination with a second therapeutic agent. In certain aspects, themethod contemplates topical ocular administration of one of the specificcompounds listed supra to the subject in need of such therapy. Inpreferred aspects, the method comprises administration of one of thesespecific compounds as a mono-therapy. In certain other aspects, themethod comprises the co-administration (either concomitantly orsequentially) of a compound of Formula I and a PDE-V inhibitor.(+)-1-(3-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid,(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid,(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid or(+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid may be used in the treatment of glaucoma or reducing intraocularpressure in racemic or enantiomerically enriched form.

Thus, as a further embodiment, the present invention provides the use ofa compound of formula (I) or subformulae thereof for the manufacture ofa medicament. In a further embodiment, the medicament is for treatmentof a disease which may be treated by activation of sGC. In anotherembodiment, the disease is selected from the afore-mentioned list,suitably glaucoma.

For systemic administration, the administered pharmaceutical compositionor combination of the present invention can be in unit dosage of about1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, orabout 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg,or about 1-50 mg of active ingredients. The therapeutically effectivedosage of a compound, the pharmaceutical composition, or thecombinations thereof, is dependent on the species of the subject, thebody weight, age and individual condition, the disorder or disease orthe severity thereof being treated. A physician, clinician orveterinarian of ordinary skill can readily determine the effectiveamount of each of the active ingredients necessary to prevent, treat orinhibit the progress of the disorder or disease.

The above-cited dosage properties are demonstrable in vitro and in vivotests using advantageously mammals, e.g., mice, rats, dogs, monkeys orisolated organs, tissues and preparations thereof. The compounds of thepresent invention can be applied in vitro in the form of solutions,e.g., aqueous solutions, and in vivo either enterally, parenterally,advantageously intravenously, e.g., as a suspension or in aqueoussolution. The dosage in vitro may range between about 10⁻³ molar and10⁻⁹ molar concentrations. A therapeutically effective amount in vivomay range depending on the route of administration, between about0.1-500 mg/kg, or between about 1-100 mg/kg.

The activity of a compound according to the present invention can beassessed by the following in vitro & in vivo methods.

The following examples are intended to illustrate the invention and arenot to be construed as being limitations thereon. Temperatures are givenin degrees Celsius. If not mentioned otherwise, all evaporations areperformed under reduced pressure, typically between about 15 mm Hg and100 mm Hg (=20-133 mbar). The structure of final products, intermediatesand starting materials is confirmed by standard analytical methods,e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR,NMR. Abbreviations used are those conventional in the art.

All starting materials, building blocks, reagents, acids, bases,dehydrating agents, solvents, and catalysts utilized to synthesis thecompounds of the present invention are either commercially available orcan be produced by organic synthesis methods known to one of ordinaryskill in the art. Further, the compounds of the present invention can beproduced by organic synthesis methods known to one of ordinary skill inthe art as shown in the following examples.

Abbreviations

-   Ac acetyl-   AcOH acetic acid-   AIBN azobisisobutyronitrile-   App apparent-   aq. aqueous-   atm atmosphere-   Bis(pinacolato)diboron    4,4,4′,4′,5,5,5′,5′-Octamethyl-2,2′-bi-1,3,2-dioxaborolane-   Boc tertiary butyl carboxy-   Boc-anhydride di-tert-butyl dicarbonate-   (Boc)₂O di-tert-butyl dicarbonate-   br. broad-   BSA bovine serum albumin-   BuOH butanol-   calcd. calculated-   CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate-   CH₃CN acetonitrile-   Cs₂CO₃ cesium carbonate-   d doublet-   DBU 1,8-diazabicyclo[5.4.0]undec-7-ene-   dd doublet of doublets-   DCE 1,2-dichloroethane-   DCM dichloromethane-   DEA diethylamine-   DEAD diethyl azodicarboxylate-   DIAD diisopropyl azodicarboxylate-   DIPEA N,N-diisopropylethylamine-   DIBAL-H diisobutylaluminium hydride-   DIPEA N,N-diisopropylethylamine-   DMAP 4,4-dimethylaminopyridine-   DME 1,4-dimethoxyethane-   DMF N,N-dimethylformamide-   Dess-Martin Periodinane Dess-Martin reagent;    1,1,1-Triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one    (CAS#87413-09-0)-   DMSO dimethylsulfoxide-   EDCl N¹-((ethylimino)methylene)-N²,N²-dimethylethane-1,2-diamine-   ESI electrospray ionization-   EtOAc, AcOEt ethyl acetate-   Et ethyl-   EtOH ethanol-   FCC flash column chromatography-   g grams-   h hour(s)-   HATU 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium    hexafluorophosphate methanaminium-   HBSS Hank's Balanced Salt Solution-   HBTU    O-benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate-   HC HPLC condition-   HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-   HFlP 1,1,1,3,3,3-hexafluoro-2-propanol-   HPLC high performance liquid chromatography-   IBMX 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione-   IPA 2-propanol-   IR infrared spectroscopy-   L liter(s)-   LDA lithium diisopropyl amide-   LHMDS lithium bis(trimethylsilyl)amide-   M molar-   MHz mega Hertz-   m multiplet-   m-CPBA meta-chloroperoxybenzoic acid-   Me methyl-   MeCN acetonitrile-   MeI iodomethane-   MeOH methanol-   mg milligram(s)-   mm millimeter(s)-   min minutes-   mL milliliter(s)-   mmol millimoles-   MP melting point-   MS mass spectrometry-   MsCl methanesulfonyl chloride-   Ms₂O methanesulfonyl anhydride-   MsOH methanesulfonic acid-   MTBE methyl tert-butylether-   m/z mass to charge ratio-   N normal-   NaBH₄ sodium borohydride-   Na(AcO)₃BH sodium triacetoxyborohydride-   NBS N-bromosuccinimide-   NCS N-chlorosuccinimide-   NH₄Cl ammonium chloride-   NMR nuclear magnetic resonance-   PBS phosphate buffered saline-   ODQ 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (CAS#41443-28-1)-   Pd/C palladium on carbon-   Pd(dppf)Cl₂    1,1′-bis(diphenylphosphino)ferrocene-palladium(II)dichloride-   Pd(dppf)Cl₂.CH₂Cl₂ adduct    1,1′-bis(diphenylphosphino)ferrocene-palladium(II)dichloride    dichloromethane complex-   Pd(PPh₃)₄ tetrakis(triphenylphosphine)palladium(0)-   Ph phenyl-   ppm parts per million-   PyBOP benzotriazol-1-yloxytripyrrolidinophosphonium-   hexafluorophosphate-   rac racemic-   RP reverse phase-   rt room temperature-   s singlet-   sat. saturated-   SFC Supercritical Fluid Chromatography-   t triplet-   t_(r) retention time-   T3P propylphosphonic anhydride-   TBAF tetra-n-butylammonium fluoride-   TBAT tetrabutylammonium difluorotriphenylsilicate-   TBSCl tert-butyldimethylsilyl chloride-   TEA, Et₃N triethylamine-   tert-tertiary-   TFA trifluoroacetic acid-   THF tetrahydrofuran-   TLC Thin Layer Chromatography-   TMP 2,2′,6,6′-tetramethylpiperidine, 2,2′,6,6′-tetramethylpiperidyl-   TMSCF₃ trifluoromethyltrimethylsilane-   TMS trimethylsilyl-   TMSOTf trimethylsilyl trifluoromethanesulfonate-   Ts p-toluenesulfonyl-   Tsdpen N-(2-amino-1,2-diphenylethyl)-4-methylbenzenesulfonamide-   TsOH p-toluenesulfonic acid-   UPLC ultra performance liquid chromatography-   v/v volume per volume-   w/v weight per volume-   w/w weight per weight

The following examples are intended to illustrate the invention and arenot to be construed as being limitations thereon. Unless otherwisestated, one or more tautomeric forms of compounds of the examplesdescribed hereinafter may be prepared in situ and/or isolated. Alltautomeric forms of compounds of the examples described hereafter shouldbe considered to be disclosed. Temperatures are given in degreescentigrade. If not mentioned otherwise, all evaporations are performedunder reduced pressure, preferably between about 15 mm Hg and 100 mm Hg(=20-133 mbar). The structure of final products, intermediates andstarting materials is confirmed by standard analytical methods, e.g.,microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR.Abbreviations used are those conventional in the art.

All starting materials, building blocks, reagents, acids, bases,dehydrating agents, solvents, and catalysts utilized to synthesis thecompounds of the present invention are either commercially available orcan be produced by organic synthesis methods known to one of ordinaryskill in the art (Houben-Weyl 4th Ed. 1952, Methods of OrganicSynthesis, Thieme, Volume 21). Further, the compounds of the presentinvention can be produced by organic synthesis methods known to one ofordinary skill in the art as shown in the following examples.

All reactions are carried out under nitrogen or argon unless otherwisestated. Optical rotations were measured in MeOH, using D line of asodium lamp.

Proton NMR (¹H NMR) is conducted in deuterated solvent. In certaincompounds disclosed herein, one or more ¹H shifts overlap with residualproteo solvent signals; these signals have not been reported in theexperimental provided hereinafter.

Multiple parent ion masses are reported for mass spectroscopy data whenthe compound of the invention contains one or more bromine atoms.Bromine exists as an approximately 1:1 molar ratio of ⁷⁹Br:⁸¹Br. Thus, acompound with a single bromine atom will exhibit two parent mass ionshaving a difference of 2 amu. The smaller mass is reported in theExperimental infra.

Following preparation methods were used for reverse phase HPLC(RP-HPLC).

HC-A:

-   -   Stationary phase: Waters SunFire™ Prep C18 OBD™ 5 μm, 30×100 mm    -   Mobile phase: gradient, water with 0.1% TFA/acetonitrile

HC-B

-   -   Stationary phase: Gemini® NX 5μ C18 110A 100×30 mm    -   Mobile phase: gradient, water with 0.1% (28% ammonium        hydroxide)/acetonitrile

HC-C

-   -   Stationary phase: X-bridge® BEH C18 OBD Prep 5 μm, 30 mm×50 mm    -   Mobile phase: gradient, water with 0.1% (28% ammonium        hydroxide)/acetonitrile

Absolute stereochemistry and/or optical rotations are provided for theembodiments of the invention where applicable. The inventioncontemplates all stereochemical forms of the compounds provided herein.Where absolute stereochemistry is provided the assessment was made viaX-ray diffraction, and/or chemical correlation, and/or at least onechiral center was from a purchased commercial enantiopure (>15:1 er)starting material

In the case of racemic samples, including intermediates, enantiomers areseparated by chromatography using a chiral stationary phase and areidentified/differentiated either by HPLC retention time employing achiral stationary phase and the monikers “enantiomer-1” or“enantiomer-2”, and/or by a specific “+” or “−” sign referring to therotation of polarized light when this data is available.

In some instances examples possess an acidic functional group as suchduring final purification procedures samples may contain an undeterminedmixture of the free acid along with potassium and/or lithium salts ofthe titled compound. Small changes in the amount of salt present maychange the observed chemical shift or intensity for some peaks in the ¹HNMR spectra.

Intermediate 1-1. Ethyl1-(6-bromopyridin-2-yl)-5-(trifliuoromethyl)-1H-pyrazole-4-carboxylate

A solution of 2-bromo-6-hydrazinylpyridine (CAS#26944-71-8; 12.63 g, 67mmol) in THF (350 mL) was cooled in an acetone/dry ice bath, and thenethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutyrate (CAS#571-55-1,13.72 mL, 71 mmol) was added dropwise. Once the addition was complete,the reaction mixture was gradually allowed to warm to room temperatureover 2 h. The reaction mixture was then concentrated, and dissolved inEtOAc. The organic layer was then washed successively with sat. aq.NaHCO₃ and brine, dried over MgSO₄, filtered, and then concentrated. Theresulting residue was purified by silica gel flash column chromatography(10% EtOAc in hexane) to afford the title compound. ¹H NMR (400 MHz,Methanol-d₄) δ 8.19 (s, 1H), 7.96 (t, J=7.82 Hz, 1H), 7.74-7.80 (m, 2H),4.37 (q, J=7.13 Hz, 2H), 1.38 (t, J=7.15 Hz, 3H).

Intermediate 1-2

The following compounds were prepared using similar methods as describedabove for Intermediate 1-1 using the appropriate hydrazines denotedbelow as starting materials.

intermediate Structure/Chemical Name Starting materials Analytical data1-2-1

  Ethyl 1-(6-chloropyridin-2- yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 2-chloro-6- hydrazinylpyridine (CAS# 5193-03-3)and ethyl 2- (ethoxymethylene)- 4,4,4-trifluoro-3- oxobutyrate (CAS#571-55-1) ¹H NMR (400 MHz, DMSO-d₆) δ 8.38 (s, 1H), 8.22 (dd, J = 7.8,7.9 Hz, 1H), 7.86 (dd, J = 0.63, 8.0 Hz, 1H), 7.81 (dd, J = 0.63, 8.0Hz, 1H), 4.33 (q, J = 7.15 Hz, 2H), 1.31 (t, J = 7.15 Hz, 3H) 1-2-2

  Ethyl 1-(3-bromophenyl)- 5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (3-bromophenyl) hydrazine hydrochloride (CAS#27246-81-7) and ethyl 2-(ethoxymethylene)- 4,4,4-trifluoro-3-oxobutyrate (the reaction was carried in the presence of 1 equivalent ofEt₃N) MS (ESI+) m/z 362.9 (M + H)

Intermediate 1-3. Ethyl1-(6-bromopyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

A mixture of 2-bromo-6-hydrazinylpyridine (5.04 g, 26.8 mmol) and ethyl2-acetyl-3-(dimethylamino)acrylate (CAS#51145-57-4; 4.96 g, 26.8 mmol)in EtOH (81 ml) was heated to 70° C. for 1.5 h. The reaction mixture wasthen allowed to cool to room temperature and a precipitate formed. Water(80 mL) was then added to the mixture and the resulting heterogeneousmixture was filtered. The filter cake was washed with water and driedunder reduced pressure to yield the title compound. MS (ESI+) m/z 310.1(M+H).

Intermediate 1-4

The following compounds were prepared using similar methods as describedabove for Intermediate 1-3 using the appropriate starting materials asdenoted below.

Intermediate Structure/Chemical Name Starting materials Analytical data1-4-1

  Ethyl 1-(6-chloropyridin-2- yl)-5-methyl-1H-pyrazole- 4-carboxylate2-Chloro-6- hydrazinylpyridine (CAS# 5193-03-3) and ethyl 2-((dimethylamino) methylene)-3-oxobutanoate (CAS#; 51145-57-4) ¹H NMR(400 MHz, CDCl₃) δ 8.02 (s, 1H), 7.86-7.76 (m, 2H), 7.30 (dd, J = 6.4,2.1 Hz, 1H), 4.33 (q, J = 7.1 Hz, 2H), 2.97 (s, 3H), 1.38 (t, J = 7.1Hz, 3H). 1-4-2

  Ethyl 1-(6-bromopyridin-2- yl)-5-ethyl-1H-pyrazole-4- carboxylate2-Bromo-6- hydrazinylpyridine and ethyl 2- ((dimethylamino)methylene)-3-oxopentanoate (CAS# 89193-23-7) MS (ESI+) m/z 324.1 (M + H)1-4-3

  Ethyl 1-(3-bromophenyl)- 5-methyl-1H-pyrazole-4- carboxylate(3-Bromophenyl) hydrazine hydrochloride (CAS# 27246-81-7) and ethyl2-acetyl-3- (dimethylamino) acrylate (CAS# 51145-57-4). (the reactionwas carried in the presence of 1 equivalent of Et₃N) MS (ESI+) m/z 309.3(M + H) 1-4-4

  Ethyl 1-(6-bromopyridin-2- yl)-1H-pyrazole-4- carboxylate 2-Bromo-6-hydrazinylpyridine and ethyl 3- (dimethylamino)-2- formylacrylate (CAS #92385-43-8) MS (ESI+) m/z 296.1 (M + H) 1-4-5

  Ethyl 1-(6-bromopyridin-2- yl)-5-(difluoromethyl)-1H-pyrazole-4-carboxylate 2-Bromo-6- hydrazinylpyridine and ethyl 2-(ethoxymethylene)-4,4- difluoro-3- oxobutanoate (CAS# 176969-33-8) MS(ESI+) m/z 346.1 (M + H) 1-4-6

  Ethyl 1-(3-bromophenyl)- 5-(difluoromethyl)-1H- pyrazole-4-carboxylate(3-Bromophenyl) hydrazine hydrochloride (CAS# 27246-81-7) and ethyl2-(ethoxymethylene)- 4,4-difluoro-3- oxobutanoate (CAS# 176969-33-8)(the reaction was carried in the presence of 1 equivalent of Et₃N) MS(ESI+) m/z 345.1 (M + H) 1-4-7

  Ethyl 1-(6-bromopyridin-2- yl)-5-isopropyl-1H- pyrazole-4-carboxylate2-Bromo-6- hydrazinylpyridine and ethyl 2- ((dimethylamino)methylene)-4-methyl-3- oxopentanoate (CAS# 116344-09-3) MS (ESI+) m/z338.1 (M + H)

Intermediate 1-5. Ethyl5-methyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole-4-carboxylate

Chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)-methyl-t-butylether adduct (CAS #1028206-58-7; 0.125 g, 0.186 mmol) was added to asolution of Intermediate 1-4-3 (1.15 g, 3.72 mmol),bis(pinacolato)diboron (1.039 g, 4.09 mmol), KOAc (0.730 g, 7.44 mmol)in dioxane (19 mL) and the head space purged with nitrogen. The reactionmixture was heated at 100° C. for 90 minutes. After the reaction mixturewas cooled to room temperature, Celite® was added and the mixture wasconcentrated. The residue was purified by flash column chromatography toprovide the title compound. ¹H NMR (400 MHz, Chloroform-d) δ 8.02 (s,1H), 7.89-7.84 (m, 2H), 7.51-7.48 (m, 2H), 4.33 (q, J=7.1 Hz, 2H), 2.56(s, 3H), 1.38 (t, J=7.1 Hz, 3H), 1.34 (s, 12H).

Intermediate 1-6

The following compound was prepared using similar methods as describedabove for Intermediate 1-5 using the appropriate starting materials.

intermediate Structure/Chemical Name Starting materials Analytical data1-6-1

  Ethyl 1-(3-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)-5-(trifluoromethyl)-1H- pyrazole-4-carboxylate Intermediate 1-2-2 ¹H NMR(400 MHz, Chloroform-d) δ 8.13 (d, J = 0.8 Hz, 1H), 7.98- 7.93 (m, 1H),7.90-7.87 (m, 1H), 7.58-7.45 (m, 2H), 4.40 (q, J = 7.1 Hz, 2H), 1.41 (t,J = 7.1 Hz, 3H), 1.37 (s, 12H).

Intermediate 1-8 Intermediate 1-8-A. Ethyl2-((dimethylamino)methylene)-5,5,5-trifluoro-3-oxopentanoate

A mixture of 1,1-dimethoxy-N,N-dimethylmethanamine (0.713 mL, 5.05 mmol)and ethyl 5,5,5-trifluoro-3-oxopentanoate (CAS#127146-29-6; 1 g, 5.05mmol) was stirred at room temperature for 18 hr. The reaction mixturewas concentrated to furnish the title compound. ¹H NMR (400 MHz,Chloroform-d) δ 7.84 (s, 1H), 4.24 (q, J=7.1 Hz, 2H), 3.72 (q, J=10.9Hz, 2H), 3.38-3.28 (m, 3H), 2.92-2.82 (m, 3H), 1.34 (t, J=7.1 Hz, 3H).

Intermediate 1-8. Ethyl1-(6-bromopyridin-2-yl)-5-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxylate

2-Bromo-6-hydrazinylpyridine (0.933 g, 4.96 mmol) was added toIntermediate 1-8-A (1.256 g, 4.96 mmol) in EtOH (17 mL) and the reactionmixture was heated to 75° C. for 3 h. The reaction mixture was cooled toroom temperature and poured into water (150 mL) to afford a precipitate.The mixture was filtered and the solid was washed with water to providethe title compound. MS (ESI+) m/z 378.1 (M+H).

Intermediate 2-1 Intermediate 2-1-A. tert-Butyl4-(4-hydroxy-3-methylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate

To a suspension of 4-bromo-2-methyl phenol (CAS#2362-12-1, 5 g, 26.7mmol), tert-butyl4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (CAS#286961-14-6, 8.27 g, 26.7 mmol), and K₃PO₄ (2M inH₂O, 26.7 mL, 53.5 mmol) in acetonitrile (54 mL) was addedPd(dppf)Cl₂.CH₂Cl₂ adduct (1.09 g, 1.33 mmol). The mixture was thenstirred at 80° C. for 3 h, and then cooled to room temperature. Thereaction mixture was added to Celite®, and then concentrated. Theresulting residue was purified by silica gel flash column chromatography(heptane/EtOAc=1/0 to 1/1) to afford the title compound. MS (ESI+) m/z290.1 (M+H).

Intermediate 2-1. tert-Butyl4-(4-hydroxy-3-methylphenyl)piperidine-1-carboxylate

A mixture of Intermediate 2-1-A (4.4 g, 15.21 mmol) and Pd/C (5%, 0.8 g)in MeOH (50 mL) was stirred under H₂ atmosphere at room temperature for2 h. The reaction mixture was then filtered through a plug of Celite®.The filtrate was then concentrated to furnish the title compounddirectly. MS (ESI−) m/z 290.2 (M−H).

Intermediate 2-2 Intermediate 2-2-A. tert-Butyl4-(2-ethyl-4-hydroxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate

To a mixture of 4-chloro-3-ethylphenol (3 g, 19.16 mmol), tert-butyl4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (CAS#286961-14-6, 7.70 g, 24.90 mmol),chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)methyl-t-butylether adduct (CAS#1028206-58-7, 0.644 g, 0.958 mmol) inDMF (96 mL) was added 2 M aq. potassium phosphate (28.7 mL, 57.5 mmol).The mixture was stirred at 110° C. for 1 h, and then cooled to roomtemperature. The reaction mixture was diluted with EtOAc and H₂O. Theorganic layer was then separated, and dried over Na₂SO₄, filtered, andthen concentrated. The resulting residue was purified by silica gelflash column chromatography (heptane/EtOAc=1/0 to 6/4) to afford thetitle compounds. MS (ESI+) m/z 248.2 (M-tBu+2H).

Intermediate 2-2. tert-Butyl4-(2-ethyl-4-hydroxyphenyl)piperidine-1-carboxylate

A mixture of Intermediate 2-2-A (5.4 g, 17.80 mmol) and 10% Pd/C (1.894g) in MeOH (250 mL) was stirred under an H₂ atmosphere at roomtemperature for 1 h. The reaction mixture was then filtered through aplug of Celite® which was then washed with MeOH. The filtrate was thenconcentrated to furnish the title compound directly. MS (ESI−) m/z 304.1(M−H).

Intermediate 2-3 Intermediate 2-3-A. 2-Methyl-4-(piperidin-4-yl)phenol

To a solution of Intermediate 2-1 (3.98 g, 13.66 mmol) in CH₂Cl₂ (137mL) at 0° C. was added TFA (12.63 mL, 164 mmol). The mixture was thenstirred for 1.5 h, and then concentrated to furnish the title compoundas the TFA salt. MS (ESI+) m/z 192.1 (M+H).

Intermediate 2-3.Cyclopropyl(4-(4-hydroxy-3-methylphenyl)piperidin-1-yl)methanone

To a solution of Intermediate 2-3-A (2.6 g, 13.59 mmol) in CH₂Cl₂ (68mL) at 0° C. was added DIPEA (9.5 mL, 54.4 mmol), followed bycyclopropanecarbonyl chloride (2.47 mL, 27.2 mmol). The mixture was thenstirred at 0° C. for 1 h, and then quenched with H₂O. The mixture wasthen extracted with CH₂Cl₂. The organic layer was then concentrated. Theresulting residue was diluted with MeOH (68 mL) and charged with K₂CO₃(9.39 g, 68 mmol) and placed at room temperature. The mixture wasstirred for 2 h, and then diluted with CH₂Cl₂ and H₂O. The mixture wasthen passed through an ISOLUTE® Phase Separator. The resulting organiclayer was then concentrated to furnish the title compound. MS (ESI+) m/z260.1 (M+H).

Intermediate 2-4

The following compounds were prepared using similar methods as describedabove for Intermediate 2-3 using the appropriate starting materials asdenoted below.

Interme- MS or NMR diate Structure/Chemical Name Starting material(s)data 2-4-1

tert-Butyl 4-(4- hydroxyphenyl)piperidine-1- carboxylate (CAS# 149377-19-5) and propionyl chloride MS (ESI+) m/z 234.0 2-4-2

4-bromo-2- (trifluoromethyl)phenol (CAS# 50824-04-9) andcyclopropanecarbonyl chloride MS (ESI+) m/z 314.3 2-4-5

Intermediate 2-2 and cyclopropanecarbonyl chloride MS (ESI+) m/z 274.3(M + H)

Intermediate 2-5 Intermediate 2-5-A.1-Benzyl-4-(4-methoxy-3-methylphenyl)piperidin-4-ol

Magnesium turnings (3.63 g, 149.2 mmol) and a catalytic amount of iodinewere suspended in THF (20 mL), 4-bromo-1-methoxy-2-methylbenzene(CAS#14804-31-0, 30.0 g, 149.2 mmol) in THF (140 mL) was added dropwiseover 60 min. The mixture was refluxed for 1 h. After the reactionmixture was cooled to room temperature a solution ofN-benzyl-4-piperidone (CAS#3612-20-2, 31.06 g, 164 mmol) in THF (100 mL)was then added dropwise over 50 min and then the mixture was stirred atreflux for 20 min. The mixture was cooled to room temperature andquenched with sat. aq. NH₄Cl and diluted with EtOAc. The organic layerwas then separated. The aqueous phase was extracted twice with EtOAc.The combined organic layers were dried over MgSO₄, filtered andconcentrated. The resulting residue was purified by silica gel flashcolumn chromatography (hexane/EtOAc=5/1 to 3/1) to afford the titlecompound. MS (ESI+) m/z 312.3 (M+H).

Intermediate 2-5-B.1-Benzyl-4-(4-methoxy-3-methylphenyl)-1,2,3,6-tetrahydropyridine

A mixture of Intermediate 2-5-A (29.3 g, 94.1 mmol) and 6M aq. HCl (100mL) in dioxane (50 mL) was stirred under the reflux conditions for 3.5h, and then concentrated. The resulting residue was triturated withdiethyl ether. The resulting solid was collected by filtration to affordthe title compound as an HCl salt. MS (ESI+) m/z 294.3 (M+H).

Intermediate 2-5-C. 4-(4-Methoxy-3-methylphenyl)piperidine

To a degassed solution of Intermediate 2-5-B (32.0 g, 97.1 mmol) inMeOH/H₂O (80 mL/40 mL) was added Pd/C (10%, 30 mg), and then the mixturewas then stirred under H₂ atmosphere at 50° C. for 16 h. The H₂atmosphere was then replaced with N₂, and then the additional Pd/C (10%,30 mg) was added to the mixture. The mixture was then placed back undera H₂ atmosphere and stirred at 50° C. for 16 h. The mixture was thenfiltered through a plug of Celite® which was rinsed with MeOH. Thefiltrate was then concentrated and the resulting residue was suspendedin diethyl ether, and then the resulting precipitate was collected byfiltration to afford the title compound as the HCl salt. MS (ESI+) m/z206.0 (M+H).

Intermediate 2-5-D.1-(4-(4-Methoxy-3-methylphenyl)piperidin-1-yl)propan-1-one

To a solution of Intermediate 2-5-C (6.3 g, 26 mmol) and triethylamine(9.09 mL, 65 mmol) in CH₂Cl₂ (63 mL) at 0° C. was added propionicanhydride (3.67 mL, 29 mmol) dropwise.

The mixture was stirred at room temperature for 2 h and then quenchedwith H₂O. The mixture was then washed with H₂O, dried over MgSO₄,filtered and concentrated to furnish the title compound. MS (ESI+) m/z261.9 (M+H).

Intermediate 2-5.1-(4-(4-Hydroxy-3-methylphenyl)piperidin-1-yl)propan-1-one

To a solution of Intermediate 2-5-D (6.4 g, 25 mmol) in CH₂Cl₂ (32 mL)at −78° C. was added a solution of boron tribromide (1M in CH₂Cl₂, 61mL, 61 mmol). The mixture was stirred at −78° C. for 1.5 h, and thenstirred at room temperature for 16 h. The reaction was then quenchedwith 1M solution of NaHCO₃ until the pH=˜9. Then the mixture was washedwith H₂O, dried over Na₂SO₄, filtered, and concentrated. The resultingsolid was triturated with i-PrOH to afford the title compound. MS (ESI+)m/z 248.1 (M+H).

Intermediate 2-6.2-(Pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-ol

2-(Bromomethyl)pyridine hydrobromide (CAS#31106-82-8) (2.42 g, 9.56mmol) was added to a mixture of 1,2,3,4-tetrahydroisoquinolin-6-olhydrobromide (CAS #59839-23-5; 2 g, 8.69 mmol) and TEA (4.85 mL, 34.8mmol) in DCM (87 mL) at 0° C. in four portions (30 min apart). Thereaction mixture was allowed to warm to room temperature over 1 h. Thereaction mixture was then partitioned between half saturated aq. NaHCO₃and DCM. The mixture was passed through an ISOLUTE® Phase Separator andthe organic phase was concentrated. The resulting residue was purifiedby silica gel flash column chromatography (acetone/heptane, 0-50%gradient) to give the title compound. MS (ESI+) m/z 241.1 (M+H).

Intermediate 2-7 Intermediate 2-7-A. tert-Butyl4-(4-(benzyloxy)-3-methylphenyl)piperidine-1-carboxylate

To a suspension of Intermediate 2-1 (10 g, 34.3 mmol) and K₂CO₃ (10 g,72.4 mmol) in DMF (100 mL) was added benzyl bromide (5 mL, 42.1 mmol).The mixture was then stirred at room temperature for 67 h. The reactionwas then quenched with N,N-dimethylaminoethylenediamine. The mixture wasthen stirred for 3 h, and then diluted with H₂O/sat.aq. KHSO₄ (ca. 3/1).The mixture was then extracted with EtOAc. The organic layer was thenwashed successively with H₂O and brine, dried over Na₂SO₄, filtered, andthen concentrated to furnish the title compound. MS (ESI+) m/z 326.3(M-tBu+2H)

Intermediate 2-7-B. 4-(4-(Benzyloxy)-3-methylphenyl)piperidine

The title compound was synthesized analogously to the preparation ofIntermediate 2-3-A using tert-butyl4-(4-(benzyloxy)-3-methylphenyl)piperidine-1-carboxylate. MS (ESI+) m/z282.0 (M+H).

Intermediate 2-7-C.4-(4-(Benzyloxy)-3-methylphenyl)-1-(2,2,2-trifluoroethyl)piperidine

To a suspension of Intermediate 2-7-B (5 g, 17.77 mmol) and K₂CO₃ (5 g,36.2 mmol) in DMF (40 mL) was added 2,2,2-trifluoroethyltrifluoromethanesulfonate (CAS#6226-25-1) (4 mL, 27.8 mmol). The mixturewas then stirred at 40° C. for 23 h. The reaction was then quenched withH₂O. The mixture was then stirred at room temperature for 3 h. Themixture was then extracted with EtOAc. The organic layer was then washedsuccessively with H₂O and brine, dried over Na₂SO₄, filtered, and thenconcentrated. The resulting residue was purified by silica gel flashcolumn chromatography (heptane/EtOAc=1/0 to 4/1) to afford the titlecompound. MS (ESI+) m/z 364.0 (M+H).

Intermediate 2-7.2-Methyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)phenol

A mixture of Intermediate 2-7-C (4.9 g, 13.48 mmol) and Pd/C (10%) (500mg, 13.48 mmol) in MeOH (100 mL) was stirred under H₂ atmosphere for 12h. The mixture was then filtered through a plug of Celite®, which wasrinsed with a mixture of EtOAc/MeOH (ca. 2/1). The filtrate was thenconcentrated to furnish the title compound. MS (ESI+) m/z 274.3 (M+H).

Intermediate 2-8 Intermediate 2-8-A. tert-Butyl4-(3-methyl-4-nitrophenyl)-5,6-dihydropyridine-1(2H)-carboxylate

The title compound was synthesized analogously to the preparation ofIntermediate 2-1-A using 4-bromo-2-methyl-1-nitrobenzene(CAS#52414-98-9) and tert-butyl4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate.MS (ESI−) m/z 317.2 (M−H).

Intermediate 2-8-B.Cyclopropyl(4-(3-methyl-4-nitrophenyl)-5,6-dihydropyridin-1(2H)-yl)methanone

The title compound was synthesized from Intermediate 2-8-A in a similarmanner as described for the synthesis of Intermediate 2-3. MS (ESI+) m/z287.2 (M+H).

Intermediate 2-8.(4-(4-Amino-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone

A mixture of Intermediate 2-8-B (5.98 g, 20.89 mmol) and Pd/C (10%)(1.11 g) in EtOH (104 mL) was stirred under H₂ atmosphere at roomtemperature for 8 h. The mixture was filtered through a plug of Celite®,which was rinsed with EtOH. The filtrate was concentrated. The resultingresidue was resubjected to the same reaction conditions for 8 h, and themixture was filtered through a plug of Celite®, which was rinsed withEtOH. The filtrate was concentrated and the resulting residue waspurified by silica gel flash column chromatography (0.2% Et₃N inheptane/EtOAc=1/0 to 0/1) to afford the title compound. MS (ESI+) m/z259.3 (M+H).

Intermediate 2-9.(4-(4-Aminophenyl)piperidin-1-yl)(cyclopropyl)methanone

The title compound was synthesized starting from 4-bromo-1-nitrobenzene(CAS#586-78-7). Reaction of 4-bromo-1-nitrobenzene with tert-butyl4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (CAS#286961-14-6), in a fashion analogous toIntermediate 2-1-A, afforded the Boc protected amine which wasdeprotected analogous to the transformation outlined in Intermediate2-3-A. The resulting TFA salt of the amine was then reacted withcyclopropanecarbonyl chloride analogously to the procedure as describedin Intermediate 2-5-D. The resulting product underwent concomitanthydrogenation and nitro reduction in a similar manner as described forthe synthesis of Intermediate 2-1 to furnish(4-(4-aminophenyl)piperidin-1-yl)(cyclopropyl)methanone. MS (ESI+) m/z245.1 (M+H).

Intermediate 2-10 Intermediate 2-10-A. tert-Butyl4-(4-amino-2-ethylphenyl)-5,6-dihydropyridine-1(2H)-carboxylate

To a mixture of 4-bromo-3-ethylaniline (CAS#52121-42-3, 5 g, 24.99mmol),2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(9.66 g, 31.2 mmol), and Pd(dppf)Cl₂.CH₂Cl₂ adduct (1.02 g, 1.25 mmol)in DMF (100 mL) was added 2 M aq. potassium phosphate (37.5 mL, 75.0mmol). The mixture was then stirred at 110° C. for 50 minutes, cooled toroom temperature, and diluted with EtOAc. The organic layer was thenseparated from the aqueous layer, dried over Na₂SO₄, filtered, and thenconcentrated. The resulting residue was purified by silica gel flashcolumn chromatography (heptane/EtOAc=1/0 to 4/6) to afford the titlecompound. MS (ESI+) m/z 303.1 (M+H).

Intermediate 2-10. tert-Butyl4-(4-amino-2-ethylphenyl)piperidine-1-carboxylate

To a solution of Intermediate 2-10-A (8.34 g, 27.6 mmol) in MeOH (276ml) was added Pd/C (10% wet; 2.93 g, 2.76 mmol) and the mixture wasdegassed and back filled with hydrogen from a balloon (3 times). Thereaction mixture was filtered after 2 hours and the filtrate wasconcentrated to obtain the title compound. MS (ESI+) m/z 249.3(M-tBu+2H).

Intermediate 2-11.2-methyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)aniline

The title compound was synthesized starting from Intermediate 2-8-A.Deprotection of Intermediate 2-8-A with TFA, in a fashion analogous tothe procedure described for Intermediate 2-3-A, afforded the TFA salt ofthe amine which was reacted with 2,2,2-trifluoroethyltrifluoromethanesulfonate analogously to the procedure described inIntermediate 2-7-C. The resulting product was hydrogenated analogous tothe transformation outlined in Intermediate 2-8 to furnish the titlecompound. MS (ESI+) m/z 273.3 (M+H).

Intermediate 2-12

The following compounds were prepared by coupling the appropriate bromoaniline starting material as denoted in the table and2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane asdescribed in Intermediate 2-10-A, followed by palladium catalyzedhydrogenation analogous to Intermediate 2-10.

Interme- MS or NMR diate Structure/Chemical Name Starting material data2-12-1

4-bromo-3-fluoro-2- methylaniline (CAS# 127408- 03-01) MS (ESI+) m/z309.3 (M + 1) 2-12-2

4-bromo-5-fluoro-2- methylaniline (CAS# 52723- 82-7) MS (ESI+) m/z 253.2(M-t-Bu + 2H) 2-12-3

4-bromo-2-fluoro-6- methylaniline (CAS# 429683- 46-5) MS (ESI+) m/z253.2 (M-t-Bu + 2H)

Intermediate 2-13. tert-Butyl4-(4-amino-3-methylphenyl)piperidine-1-carboxylate

Pd/C (10% wet) (0.251 g, 2.356 mmol) was added to a solution ofIntermediate 2-8-A (1.5 g, 4.71 mmol) in EtOH (23.5 mL). The atmosphereof the flask was purged and backfilled with H₂ and the reaction mixturewas stirred under an H₂ atmosphere at room temperature for 3 h. About 5g of Celite® and 20 μL of saturated aqueous NH₄Cl were added to thereaction mixture. The mixture was filtered through a plug of Celite®,which was rinsed with MeOH. The filtrate was concentrated to provide thetitle compound, which was used without further purification. ¹H NMR (400MHz, Methanol-d₄) δ 6.87-6.85 (m, 1H), 6.82 (dd, J=8.0, 2.1 Hz, 1H),6.66 (d, J=8.0 Hz, 1H), 4.16 (dt, J=13.4, 2.4 Hz, 2H), 2.82 (br.s, 2H),2.54 (tt, J=12.1, 3.6 Hz, 1H), 2.14 (s, 3H), 1.74 (ddd, J=14.0, 3.2, 1.8Hz, 2H), 1.56-1.51 (m, 2H), 1.47 (s, 9H).

Intermediate 3-1 Intermediate 3-1-A.7-Hydroxy-2,3-dihydro-1H-inden-1-one

As described in Heterocycles, 27(2), 407-21; 1988, a mixture of phenyl3-chloropropanoate (CAS #24552-27-0, 7 g, 37.9 mmol) and AlCl₃ (20.22 g,152 mmol) was heated at 100° C. for 1 h, then at 180° C. for 2 h, andsubsequently cooled to room temperature. The excess AlCl₃ was thenquenched with 1N HCl. The resulting mixture was extracted with DCM. Thecombined organic layers were washed with water, passed through anISOLUTE® phase separator. The filtrate was concentrated to give7-hydroxy-2,3-dihydro-1H-inden-1-one. ¹H NMR (400 MHz, Chloroform-d) δ9.07 (s, 1H), 7.47 (t, J=7.8 Hz, 1H), 6.97-6.92 (m, 1H), 6.78-6.74 (m,1H), 3.16-3.06 (m, 2H), 2.78-2.68 (m, 2H).

Intermediate 3-1-B. 3-Oxo-2,3-dihydro-1H-inden-4-yltrifluoromethanesulfonate

Trifluoromethanesulfonic anhydride (800 μl, 4.74 mmol) was addeddropwise to a solution of Intermediate 3-1-A (500 mg, 3.37 mmol) andpyridine (820 μl, 10.14 mmol) in DCM (7 mL) at 0° C. The resultingsuspension was stirred at 0° C. for 60 min. The reaction mixture wasquenched with water, followed by 1N HCl (5 mL). The resulting mixturewas passed through an ISOLUTE® Phase Separator and the organic phase wasconcentrated to provide the title compound. MS (ESI+) m/z 281.0 (M+H).

Intermediate 3-1-C. (±)-3-Hydroxy-2,3-dihydro-1H-inden-4-yltrifluoromethanesulfonate

Sodium borohydride (126 mg, 3.33 mmol) was added to a solution ofIntermediate 3-1-B (932.1 mg, 3.33 mmol) in MeOH (20 mL) at 0° C. Themixture was stirred at 0° C. for 1 h and was then partitioned betweenwater and DCM. The mixture was passed through an ISOLUTE® PhaseSeparator. The organic layer was concentrated to furnish the titlecompound. ¹H NMR (400 MHz, Chloroform-d) δ 7.34 (t, J=7.8 Hz, 1H), 7.28(dd, J=7.5, 1.1 Hz, 1H), 7.10 (d, J=8.0 Hz, 1H), 5.57-5.45 (m, 1H),3.26-3.13 (m, 1H), 2.96-2.84 (m, 1H), 2.45-2.32 (m, 1H), 2.18 (d, J=5.1Hz, 1H), 2.17-2.07 (m, 1H).

Intermediate 3-1.(±)-3-((2-(Pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yltrifluoromethanesulfonate

DIAD (150 μl, 0.771 mmol) was added to a mixture of Intermediate 3-1-C(164 mg, 0.581 mmol), Intermediate 2-6 (130 mg, 0.541 mmol), andtri-n-butylphosphine (200 μl, 0.770 mmol) in DCM (6 mL) at roomtemperature under nitrogen. The reaction mixture was stirred for 1 h,and then was partitioned between DCM and half saturated brine. Themixture was passed through an ISOLUTE® Phase Separator and the organiclayer was concentrated. The resulting residue was purified by flashcolumn chromatography to provide title compound. MS (ESI+) m/z 505.1(M+H).

Intermediate 3-1-D. 7-hydroxy-5-methyl-2,3-dihydro-1H-inden-1-one

Intermediate 3-1-D was synthesized using the same procedure asIntermediate 3-1-A, starting with m-tolyl 3-chloropropanoate (CAS#158304-80-4). ¹H NMR (400 MHz, Chloroform-d) δ 8.95 (s, 1H), 6.80-6.72(m, 1H), 6.64-6.52 (m, 1H), 3.08-3.03 (m, 2H), 2.71-2.67 (m, 2H), 2.38(s, 3H).

Intermediate 3-1-E. 6-methyl-3-oxo-2,3-dihydro-1H-inden-4-yltrifluoromethanesulfonate

Intermediate 3-1-E was synthesized using the same procedure asIntermediate 3-1-B starting with Intermediate 3-1-D. ¹H NMR (400 MHz,Chloroform-d) δ 7.25-7.21 (m, 1H), 6.90 (s, 1H), 3.11-3.02 (m, 2H),2.70-2.63 (m, 2H), 2.41 (s, 3H).

Intermediate 3-1-F. 3-hydroxy-6-methyl-2,3-dihydro-1H-inden-4-yltrifluoromethanesulfonate

Intermediate 3-1-F was reduced using the same procedure as Intermediate3-1-C, starting with Intermediate 3-1-E. ¹H NMR (400 MHz, Chloroform-d)δ 7.09 (s, 1H), 6.89 (s, 1H), 5.47-5.42 (m, 1H), 3.22-3.11 (m, 1H),2.89-2.78 (m, 1H), 2.50-2.40 (m, 1H), 2.38 (s, 3H), 2.15-2.06 (m, 1H).

Intermediate 3-2

The following compounds were prepared using similar methods as describedabove for Intermediate 3-1 using the appropriate starting materials asdenoted below.

Inter- medi- ate Structure/Chemical Name Starting material(s) MS or NMRdata 3-2-1

Intermediate 3-1-F and Intermediate 2-6 MS (ESI+) m/z 518.5 (M + H)3-2-2

Intermediate 3-1-F and Intermediate 2-3 MS (ESI+) m/z 538.3 (M + H)3-2-3

Intermediate 3-1-C and Intermediate 2-3 MS (ESI+) m/z 524.2 (M + H)

Intermediate 3-3 Intermediate 3-3-A.(±)-7-Bromo-2,3-dihydro-1H-inden-1-ol

Sodium borohydride (0.090 g, 2.369 mmol) was added to a solution of7-bromo-2,3-dihydro-1H-inden-1-one (CAS #125114-77-4; 0.5 g, 2.37 mmol)in MeOH (24 mL) at 0° C. The mixture was stirred at 0° C. for 1 h thenlet warm to room temperature. After 2 h the reaction mixture was dilutedwith water and DCM, and then saturated aqueous ammonium chloride wasadded. The mixture was then passed through an ISOLUTE® Phase Separatorand the organic phase was concentrated to give(±)-7-bromo-2,3-dihydro-1H-inden-1-ol. ¹H NMR (400 MHz, Chloroform-d) δ7.41-7.33 (m, 1H), 7.25-7.20 (m, 1H), 7.15 (t, J=7.6 Hz, 1H), 5.41-5.34(m, 1H), 3.30-3.17 (m, 1H), 2.97-2.84 (m, 1H), 2.51-2.35 (m, 1H),2.20-2.09 (m, 1H).

Intermediate 3-3-B. (−)-R-7-bromo-2,3-dihydro-1H-inden-1-ol

Triethylamine (1.45 mL, 10.42 mmol) was added dropwise to a 40 mL vialwith formic acid (1.018 mL, 26.5 mmol) and a stir bar at roomtemperature. The temperature of the reaction mixture was maintainedunder 45° C. by controlling the rate of the addition. After the additionwas completed, the reaction mixture was cooled to 0° C. in an ice bathand stirred for 30 min. The mixture was then warmed to room temperatureand stirred for 1 h. To this solution was added DMF (7 mL) followed by7-bromo-2,3-dihydro-1H-inden-1-one (4 g, 18.95 mmol) andRuCl[(R,R)-Tsdpen](p-cymene) (CAS#192139-92-7) (0.013 g, 0.021 mmol).The reaction mixture was stirred at room temperature for 40 h beforebeing heated to 60° C. for a further 24 h. The reaction mixture wascooled to room temperature and partitioned between EtOAc and halfsaturated brine. The layers were separated and the aqueous layer wasextracted with EtOAc. The combined organic layers were concentrated. Theresidue was absorbed onto silica and purified by flash columnchromatography with 100% DCM to provide(−)-7-bromo-2,3-dihydro-1H-inden-1-ol (>98% e.e.). ¹H NMR (400 MHz,Chloroform-d) δ 7.41-7.33 (m, 1H), 7.25-7.20 (m, 1H), 7.15 (t, J=7.6 Hz,1H), 5.41-5.34 (m, 1H), 3.30-3.17 (m, 1H), 2.97-2.84 (m, 1H), 2.51-2.35(m, 1H), 2.20-2.09 (m, 1H). Absolute stereochemistry of(−)-R-7-bromo-2,3-dihydro-1H-inden-1-ol was confirmed by X-ray singlecrystal diffraction.

Enantiomeric excess of 7-bromo-2,3-dihydro-1H-inden-1-ol was determinedby chiral SFC using CHIRALPAK® OD-H, 10% IPA in CO₂;(−)-7-bromo-2,3-dihydro-1H-inden-1-ol (t_(r)=4.87 min) and(+)-7-bromo-2,3-dihydro-1H-inden-1-ol (t_(r)=5.58 min).

Intermediate 3-3. a).(±)-(4-(4-((7-Bromo-2,3-dihydro-1H-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone

Azodicarboxylic dimorpholide (CAS #10465-82-4; 502 mg, 1.960 mmol) wasadded to a solution of Intermediate 3-3-A (348 mg, 1.633 mmol),Intermediate 2-3 (508 mg, 1.960 mmol), and tri-n-butylphosphine (509 μl,1.960 mmol) in THF (6.5 mL) at room temperature. The mixture was stirredat room temperature for 16 h. The reaction mixture was partitionedbetween DCM and water, and then passed through an ISOLUTE® PhaseSeparator. Celite® was added to the organic layer and the resultingmixture was concentrated. The resulting residue was purified by silicaflash column chromatography to provide the title compound. MS (ESI+) m/z454.2 (M+H).

Intermediate 3-3. b).(+)-(S)-(4-(4-((7-Bromo-2,3-dihydro-1H-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone

Intermediate 3-3-B underwent reaction with Intermediate 2-3 under theconditions described for Intermediate 3-3. a) to provide the titlecompound in >97% e.e. MS (ESI+) m/z 454.3 (M+H).

Enantiomeric excess of(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanonewas determined by chiral SFC using CHIRALPAK® OJ-H 5-55% IPA gradient inCO₂, 5 mL/min;(+)-(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone(t_(r)=2.38 min) and(−)-(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)oxy)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone(t_(r)=2.70 min).

Intermediate 3-4

The following compounds were prepared using either Intermediate 3-3-A(racemate) or Intermediate 3-3-B (>98% e.e.) employing similar methodsas described above for Intermediate 3-3. a) using the appropriatestarting materials as denoted below.

Interme- diate Structure/Chemical Name Starting material(s) MS or NMRdata 3-4-1

Intermediate 2-6 and Intermediate 3- 3-A MS (ESI+) m/z 435.2 (M + H)3-4-2

Intermediate 2-6 and Intermediate 3- 3-B MS (ESI) m/z 435.1 (M + H)3-4-3

Intermediate 2-4-5 and Intermediate 3- 3-B MS (ESI+) m/z 468.2 (M + H)3-4-4

Intermediate 2-7 and Intermediate 3- 3-B MS (ESI+) m/z 468.6 (M + H)3-4-5

Intermediate 2-2 and Intermediate 3- 3-B MS (ESI+) m/z 500.2 (M + H)3-4-6

Intermediate 2-4-2 and Intermediate 3- 3-A MS (ESI+) m/z 508.2 (M + H)

Intermediate 3-5-A. a).(±)-(4-(4-((7-Bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone

A solution of 7-bromo-2,3-dihydro-1H-inden-1-one (160 mg, 0.759 mmol)and Intermediate 2-8 (196 mg, 0.759 mmol) in glacial acetic acid (3 mL)was stirred at room temperature for 30 min. Sodium triacetoxyborohydride(161 mg, 0.759 mmol) was then added at room temperature and the reactionmixture was stirred at room temperature for 1 h. Another portion ofsodium triacetoxyborohydride (161 mg, 0.759 mmol) was added and themixture was stirred for 16 h. Another portion of sodiumtriacetoxyborohydride (161 mg, 0.759 mmol) was added, and then themixture was stirred for an additional 2 h. The reaction mixture waspoured into water (10 mL) and the pH of the mixture was adjusted byaddition of 33% NH₄OH to ˜11. The resulting mixture was then extractedtwice with EtOAc. The combined organic layers were concentrated. Theresulting residue was purified by flash column chromatography (0-40%EtOAc/heptane gradient) to give title compound. MS (ESI+) m/z 453.2(M+H).

Intermediate 3-5-A. b).(+)-(4-(4-((7-Bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanoneand(−)-(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone

Resolution of the enantiomers of(±)-(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanonewas achieved by chiral SFC using CHIRALCEL® OJ-H column with 25% MeOH inCO₂ to give(+)-(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone(t_(r)=2.93 min) and(−)-(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone(t_(r)=3.58 min).

Intermediate 3-5-B.(±)-(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)phenyl)piperidin-1-yl)(cyclopropyl)methanone

The title compound was prepared using a similar procedure to thatdescribed in Intermediate 3-5-A. a) starting with Intermediate 2-9. MS(ESI+) m/z 439.2 (M+H).

Intermediate 3-5-C. (±)-tert-Butyl4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidine-1-carboxylate

A mixture of 7-bromo-2,3-dihydro-1H-inden-1-one (400 mg, 2.00 mmol),tert-butyl 4-(4-amino-3-methylphenyl)piperidine-1-carboxylate(Intermediate 2-13) (600 mg, 2.07 mmol), and TsOH.H₂O (50 mg, 0.263mmol) in toluene/dimethylacetamide (20 mL/5 mL) was stirred under thereflux condition for 19 h, and then cooled to 0° C., and then dilutedwith CH₂Cl₂ (10 mL). To the reaction mixture was then added NaB(OAc)₃H(1 g, 4.72 mmol), followed by AcOH (2 mL). The mixture was then stirredat 0° C. for 2 h, and then poured into H₂O. The mixture was thenextracted with EtOAc. The organic extracts were washed successively with5% aq. NaHCO₃, H₂O, and brine, dried over Na₂SO₄, filtered, and thenconcentrated. The resulting residue was purified by silica gel flashcolumn chromatography (heptane/EtOAc=1/0 to 85/15) to afford the titlecompound. MS (ESI+) m/z 485.3 (M+H).

Intermediate 3-5-D. (±)-tert-Butyl4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate

The title compound was prepared by a reaction of7-bromo-2,3-dihydro-1H-inden-1-one with tert-butyl4-(4-amino-2-ethylphenyl)piperidine-1-carboxylate (Intermediate 2-10) bythe similar procedure as described in the synthesis of Intermediate3-5-C. MS (ESI+) m/z 499.3 (M+H).

Intermediate 3-6. Ethyl1-(3-(3-oxo-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

Pd(dppf)Cl₂.CH₂Cl₂ adduct (87 mg, 0.107 mmol) was added to a mixture of7-bromo-2,3-dihydro-1H-inden-1-one (225 mg, 1.066 mmol) and Intermediate1-6-1 (481 mg, 1.173 mmol) in dioxane (5 mL) and 2M aqueous K₃PO₄ (1.1mL, 2.132 mmol). The reaction mixture was stirred at 80° C. under anitrogen atmosphere for 3 hour. The reaction mixture was then cooled toroom temperature and Celite® was added. The resulting mixture wasconcentrated and the residue was purified by flash column chromatographyusing silica gel with a gradient of 0-50% EtOAc/heptane to provide thetitle compound. ¹H NMR (400 MHz, Methanol-d4) δ 8.16 (d, J=0.8 Hz, 1H),7.69 (t, J=7.6 Hz, 1H), 7.66-7.62 (m, 1H), 7.61-7.55 (m, 2H), 7.53-7.50(m, 1H), 7.50-7.45 (m, 1H), 7.33-7.29 (m, 1H), 4.36 (q, J=7.1 Hz, 2H),3.23-3.17 (m, 2H), 2.72-2.66 (m, 2H), 1.37 (t, J=7.1 Hz, 3H).

Intermediate 3-7. Ethyl5-methyl-1-(6-(3-oxo-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

To a mixture of Intermediate 1-3 (1.03 g, 3.31 mmol),bis(pinacolato)diboron (0.84 g, 3.31 mmol), KOAc (0.65 g, 6.61 mmol) indioxane (11 mL) was addedchloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)-methyl-t-butylether adduct (CAS #1028206-58-7; 0.11 g, 0.165 mmol). The mixture wasthen stirred at 120° C. under the microwave irradiation for 45 minutes.To the mixture was then added a solution of7-bromo-2,3-dihydro-1H-inden-1-one (0.66 g, 3.14 mmol) in dioxane (11mL), followed by sodium carbonate (1M in water; 8.3 mL, 8.27 mmol) andPd(dppf)Cl₂.CH₂Cl₂ adduct (CAS #95464-05-4; 0.14 g, 0.165 mmol). Thewhole mixture was then stirred under microwave irradiation for 30 min at110° c. Celite® was added to the reaction mixture and the mixture wasconcentrated. The residue was purified by flash column chromatography(0-50% EtOAc/heptane) to yield the title compound. MS (ESI+) m/z 362.3(M+H).

Intermediate 3-8

The following compounds were prepared using similar methods as describedabove for Intermediate 3-7 using the appropriate starting materials.

Interme- diate Structure/Chemical Name Starting material(s) MS or NMRdata 3-8-1

Intermediate 1-4-2 and 7-bromo-2,3-dihydro- 1H-inden-1-one MS (ESI+) m/z376.3 (M + H). 3-8-2

Intermediate 1-2-1 and 7-bromo-2,3-dihydro- 1H-inden-1-one MS (ESI+) m/z416.2 (M + H). 3-8-3

Intermediate 1-2-1 and Intermediate 3-1-E MS (ESI+) m/z 430.3 (M + H).3-8-4

Intermediate 1-4-6 and 7-bromo-2,3-dihydro- 1H-inden-1-one MS (ESI+) m/z398.3 (M + H). 3-8-5

Intermediate 1-5 and 7- bromo-2,3-dihydro-1H- inden-1-one MS (ESI+) m/z361.3 (M + H).

Intermediate 3-9.(±)-(4-(4-((4-bromo-2,3-dihydrobenzofuran-3-yl)amino)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone

Sodium cyanoborohydride (377 mg, 6.00 mmol) was added to a solution ofIntermediate 2-8 (776 mg, 3.00 mmol), 4-bromobenzofuran-3(2H)-one(CAS#1020966-78-2; 640 mg, 3.00 mmol), and AcOH (860 μl, 15.00 mmol) inMeOH (15 mL) at room temperature. The reaction mixture was stirred atroom temperature for 6 hours before another portion of sodiumcyanoborohydride (377 mg, 6.00 mmol) was added. After a total of 24hours stirring, the reaction mixture was partitioned between CH₂Cl₂ andsaturated aq. sodium bicarbonate. The organic layer was passed through aphase separator and the filtrate was concentrated onto Celite®. Theresidue was purified by silica gel flash chromatography to afford thetitle compound. MS (ESI+) m/z 457.3 (M+H).

Intermediate 3-10. (±)-tert-Butyl4-(4-((4-bromo-2,3-dihydrobenzofuran-3-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate

The title compound was synthesized starting from4-bromo-benzofuran-1-one and tert-butyl4-(4-amino-2-ethylphenyl)piperidine-1-carboxylate (Intermediate 2-10) bya similar method described for the synthesis of Intermediate 3-5-C butusing NaCNBH₃ in the place of NaB(OAc)₃H. ¹H NMR (400 MHz, CDCl₃): δ7.15-7.03 (m, 3H), 6.82 (d, J=8.4 Hz, 1H), 6.46-6.44 (m, 2H), 5.07-5.06(m, 1H), 4.67-4.63 (m, 1H), 4.58-4.55 (m, 1H), 4.24 (br.s, 2H), 3.93(br.s, 1H), 2.78-2.70 (m, 3H), 2.62 (q, J=7.6, 15.2 Hz, 2H), 1.72-1.58(m, 4H), 1.49 (s, 9H), 1.26 (t, J=7.2 Hz, 3H).

Intermediate 3-11. (±)-tert-Butyl4-(4-((4-bromo-2,3-dihydrobenzofuran-3-yl)amino)-3-methylphenyl)piperidine-1-carboxylate

The title compound was synthesized starting from4-bromo-benzofuran-1-one and tert-butyl4-(4-amino-3-methylphenyl)piperidine-1-carboxylate (Intermediate 2-13)by a similar method described for the synthesis of Intermediate 3-5-Cbut using NaCNBH₃ in the place of NaB(OAc)₃H. ¹H NMR (400 MHz, CDCl₃): δ7.17-7.08 (m, 2H), 6.99-6.95 (m, 2H), 6.84 (d, J=7.6 Hz, 1H), 6.45 (d,J=8.4 Hz, 1H), 5.07 (d, J=3.2 Hz, 1H), 4.71 (dd, J=6.8, 9.2 Hz, 1H),4.55 (dd, J=2.8, 9.6 Hz, 1H), 4.22 (br.s, 2H), 3.85 (s, 1H), 2.78 (br.s,2H), 2.57-2.51 (m, 1H), 2.12 (s, 3H), 1.79 (d, J=12.8 Hz, 2H), 1.63-1.59(m, 2H), 1.48 (s, 9H).

Intermediate 3-12 Intermediate 3-12-A. tert-Butyl2-chloro-5′,6′-dihydro-[3,4′-bipyridine]-1′(2′H)-carboxylate

To a solution of 3-bromo-2-chloropyridine (CAS#52200-48-3, 2.89 g, 15mmol) and tert-butyl4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (CAS#286961-14-6, 4.87 g, 15.75 mmol) in toluene (100mL)/ethanol (15 mL) were added 2N Na₂CO₃ solution (22.5 mL, 45.0 mmol)and Pd(PPh₃)₄(0.87 g, 0.75 mmol). The mixture was then stirred at 120°C. for 2 h and then cooled to room temperature. The reaction mixture wasdiluted with brine and extracted three times with EtOAc. The combinedorganic layers were washed with brine and dried over Na₂SO₄, filtered,and then concentrated. The resulting residue was purified by silica gelflash column chromatography (heptane/EtOAc=1/0 to 1/2) to afford thetitle compound. MS (ESI+) m/z 295.1, 297.1 (M+H).

Intermediate 3-12-B. tert-Butyl2-ethyl-5′,6′-dihydro-[3,4′-bipyridine]-1′(2′H)-carboxylate

To a solution of tert-butyl2-chloro-5′,6′-dihydro-[3,4′-bipyridine]-1′(2′H)-carboxylate (1 g, 3.39mmol) in THF (20 mL) were added Pd(dppf)Cl₂.CH₂Cl₂ adduct (0.208 g,0.254 mmol) and K₂CO₃ solid (1.407 g, 10.18 mmol), followed bydiethylzinc (15% w/w in toluene, 10.68 mL). The mixture was then stirredat room temperature for 1 h, and then at 50° C. for 3 h. The reaction at0° C. was quenched with sat. aq. NH₄Cl. The mixture was then extractedthree times with EtOAc. The combined organic layers were dried overNa₂SO₄, filtered, and then concentrated. The resulting residue waspurified by silica gel flash column chromatography (heptane/EtOAc=1/0 to0/1) to afford the title compound. MS (ESI+) m/z 289.6 (M+H).

Intermediate 3-12-C. tert-Butyl4-(2-ethylpyridin-3-yl)piperidine-1-carboxylate

A mixture of tert-butyl2-ethyl-5′,6′-dihydro-[3,4′-bipyridine]-1′(2′H)-carboxylate (810 mg,2.81 mmol) and Pd/C 10% wet (299 mg, 0.281 mmol) in MeOH (20 mL) wasstirred at room temperature under hydrogen atmosphere for 0.5 h. Thereaction mixture was then filtered through a plug of Celite®, which wasrinsed with MeOH. The filtrate was concentrated to afford the titlecompound. MS (ESI+) m/z 291.4 (M+H).

Intermediate 3-12-D.3-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-2-ethylpyridine 1-oxide

To a solution of tert-butyl4-(2-ethylpyridin-3-yl)piperidine-1-carboxylate (350 mg, 1.2 mmol) inchloroform (15 mL) was added m-CPBA (77% purity, 520 mg, 3.0 mmol). Thereaction mixture was then stirred at room temperature for 0.5 h. Thereaction was then quenched with 1N Na₂S₂O₃, and a saturated NaHCO₃aqueous solution. To the mixture was then added sat. aq. NaHCO₃. Thereaction mixture was then extracted three times with EtOAc. The combinedorganic layers were washed with brine and dried over Na₂SO₄, filtered,and then concentrated. The resulting residue was absorbed onto silicagel, which was purified by silica gel flash column chromatography (0 to15% MeOH in CH₂Cl₂) to afford the title compound. MS (ESI+) m/z 307.2(M+H).

Intermediate 3-12. (±)-tert-Butyl4-(6-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylpyridin-3-yl)piperidine-1-carboxylate

To a solution of 7-bromo-2,3-dihydro-1H-inden-1-amine (ACS Med. Chem.Lett. 2011, 2, 565-570) (346 mg, 1.63 mmol) and3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-2-ethylpyridine 1-oxide (250mg, 0.816 mmol) and DIPEA (143 μL, 0.816 mmol) in CH₂Cl₂ (5 mL), wasadded PyBrOP (761 mg, 1.632 mmol). The reaction was stirred at roomtemperature for 76 h. The reaction was quenched with 1N citric acidsolution. The bi-layer was then separated. The aqueous layer wasextracted twice with CH₂Cl₂. The combined organic layers were washedwith brine and dried over Na₂SO₄, filtered, and then concentrated. Theresulting residue was absorbed onto silica gel, and purified by silicagel flash column chromatography (0 to 60% EtOAc in CH₂Cl₂) to afford thetitle compound. MS (ESI+) m/z 499.9 (M+H).

Intermediate 4-1 Intermediate 4-1-A. Ethyl1-(6-(1H-indol-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

Bis(triphenylphosphine) palladium(II) dichloride (CAS #13965-03-2, 46.2mg, 0.066 mmol) was added to a solution of7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole (CAS#642494-37-9; 448 mg, 1.842 mmol) and Intermediate 1-1 (600 mg, 1.648mmol) in acetonitrile (8.0 mL) and 1.0 M Na₂CO₃ (5.27 mL, 5.27 mmol).The reaction mixture was sealed and stirred at 70° C. for 16 h, afterwhich it was cooled to room temperature. The reaction mixture was thenfiltered through a plug of Celite®. The filtrate was diluted with EtOAcand the organic layer was washed successively with H₂O and brine. Theorganic layer was dried over Na₂SO₄, filtered, and then concentrated.The resulting residue was purified by flash column chromatography onsilica gel (heptane/EtOAc=100/0 to 50/50) to afford the title compound.MS (ESI+) m/z 401.1 (M+H).

Intermediate 4-1. Ethyl1-(6-(indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

Triethylsilane (CAS #617-86-7; 1.08 g, 9.24 mmol) and TFA (1.05 g, 9.24mmol) were added to a solution of Intermediate 4-1-A (370 mg, 0.924mmol) in dichloromethane (5 mL). The reaction mixture was stirred atroom temperature for 24 h, and then concentrated. The resulting residuewas partitioned between EtOAc and saturated NaHCO₃. The isolated organiclayer was washed with brine, dried over Na₂SO₄, filtered, and thenconcentrated. The resulting residue was purified by flash columnchromatography on silica gel (heptane/EtOAc=100/0 to 50/50) to affordthe title compound. ¹H NMR (400 MHz, CDCl₃) δ 8.15 (s, 1H) 7.80-8.02 (m,2H) 7.51 (d, J=8.08 Hz, 1H) 7.40 (d, J=7.45 Hz, 1H) 7.14 (d, J=7.20 Hz,1H) 6.71 (t, J=7.58 Hz, 1H) 4.40 (q, J=7.07 Hz, 2H) 3.67 (t, J=8.46 Hz,2H) 3.07 (t, J=8.40 Hz, 2H) 1.40 (t, J=7.14 Hz, 3H).

Intermediate 4-2 Intermediate 4-2-A. Ethyl1-(6-(1H-indol-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate

Bis(triphenylphosphine)palladium(II) dichloride (0.11 g, 0.154 mmol) wasadded to a solution of7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole (0.84 g, 3.45mmol) and Intermediate 1-4-2 (1 g, 3.08 mmol) in acetonitrile (16 mL)and 1.0 M Na₂CO₃ (9.25 mL, 9.25 mmol). The reaction mixture was sealedand stirred at 70° C. for 16 h. The mixture was then cooled to roomtemperature, and then filtered through a plug of Celite®. The filtratewas diluted with EtOAc and the organic layer was washed successivelywith H₂O and brine. The organic layer was dried over Na₂SO₄, filtered,and then concentrated. The resulting residue was purified by flashcolumn chromatography on silica gel (0-50% EtOAc/heptane gradient) toafford the title compound. MS (ESI+) m/z 361.3 (M+H).

Intermediate 4-2. Ethyl5-ethyl-1-(6-(indolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

Triethylsilane (2.7 mL, 17 mmol) and TFA (1.3 mL, 17 mmol) were added toa solution of Intermediate 4-2-A (611 mg, 1.7 mmol) in dichloromethane(10 mL). The mixture was stirred at room temperature for 24 h, and thenconcentrated. The resulting residue was partitioned between EtOAc andsaturated NaHCO₃. The isolated organic layer was washed with brine,dried over Na₂SO₄, filtered, and then concentrated. The resultingresidue was purified by silica gel flash column chromatography (0-50%EtOAc/heptane gradient) to afford the title compound. MS (ESI+) m/z363.3 (M+H).

Intermediate 5-1 Intermediate 5-1-A. tert-Butyl4-(2-ethyl-4-(methoxycarbonyl)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate

To a mixture of methyl 4-bromo-3-ethylbenzoate (CAS #1008769-90-1) (1.4g, 5.76 mmol) and tert-butyl4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (CAS#286961-14-6, 2.32 g, 7.49 mmol) in DMF (20 mL) wasadded 2.0 M aq. potassium phosphate (8.64 mL, 17.28 mmol), followed byPd(dppf)Cl₂.CH₂Cl₂ adduct (260 mg, 0.317 mmol). The mixture was stirredat 110° C. for 2.0 h, and then cooled to room temperature. The reactionmixture was filtered through a plug of Celite®. The filtrate was dilutedwith EtOAc. The organic layer was then washed with H₂O, dried overNa₂SO₄, filtered, and then concentrated. The resulting residue waspurified by silica gel flash column chromatography (0-50% EtOAc/heptanegradient) to afford the title compound. ¹H NMR (400 MHz, Chloroform-d) b7.90 (s, 1H) 7.81 (dd, J=7.96, 1.52 Hz, 1H) 7.12 (d, J=7.96 Hz, 1H) 5.57(br. s., 1H) 4.04 (br. s, 2H) 3.91 (s, 3H) 3.63 (t, J=5.49 Hz, 2H) 2.65(q, J=7.58 Hz, 2H) 2.34 (br. s., 2H) 1.51 (s, 9H) 1.22 (t, J=7.58 Hz,3H).

Intermediate 5-1-B. tert-Butyl4-(2-ethyl-4-(methoxycarbonyl)phenyl)piperidine-1-carboxylate

A mixture of Intermediate 5-1-A (1.75 g, 5.07 mmol) and 10% Pd/C (175mg) in EtOH (200 mL) was stirred under H₂ atmosphere at room temperaturefor 2 h. The reaction mixture was then filtered through a plug ofCelite® which was then rinsed with EtOH. The filtrate was thenconcentrated to furnish the title compound directly. ¹H NMR (400 MHz,Chloroform-d) δ 7.81-7.88 (m, 2H) 7.23-7.26 (m, 1H) 4.27 (br. s., 2H)3.90 (s, 3H) 2.88-2.99 (m, 1H) 2.82 (t, J=11.75 Hz, 2H) 2.73 (q, J=7.49Hz, 2H) 1.59-1.78 (m, 4H) 1.49 (s, 9H) 1.23-1.27 (t, J=8.0 Hz, 3H).

Intermediate 5-1. tert-Butyl4-(2-ethyl-4-(hydroxymethyl)phenyl)piperidine-1-carboxylate

To a solution of Intermediate 5-1-B (1.3 g, 3.74 mmol) in THF (16 mL)was added a solution of 1.0M lithium aluminum hydride in THF (4.5 mL,4.5 mmol) dropwise. The mixture was then stirred at 0° C. for 1 h. Thereaction was quenched with 0.5 M NaOH solution, and then diluted withH₂O and EtOAc. The mixture was then filtered through a plug of Celite®.The organic phase was then separated. The organic phase was washed withbrine, dried over Na₂SO₄ and concentrated. The resulting residue waspurified by silica gel flash column chromatography (0-50% EtOAc/heptanegradient) to afford the title compound. ¹H NMR (400 MHz, DMSO-d₆) b6.98-7.19 (m, 3H) 5.02 (t, J=5.68 Hz, 1H) 4.41 (d, J=5.68 Hz, 2H) 4.07(d, J=12.00 Hz, 2H) 2.77-2.96 (m, 3H) 2.64 (q, J=7.49 Hz, 2H) 1.58-1.68(m, 2H) 1.45-1.55 (m, 2H) 1.37-1.44 (m, 9H) 1.15 (t, J=7.52 Hz, 3H).

Intermediate 5-2. tert-Butyl4-(4-(bromomethyl)-2-ethylphenyl)piperidine-1-carboxylate

Triphenylphosphine (723 mg, 2.76 mmol) and CBr₄ (916 mg, 2.76 mmol) wereadded to a solution of Intermediate 5-1 (840 mg, 2.63 mmol) indichloromethane (14 mL). The mixture was then stirred at roomtemperature for 16 h, and then concentrated. The resulting residue waspurified by flash column chromatography (0-20% EtOAc/heptane gradient)to afford the title compound. MS (ESI+) m/z 326.2 (M-tBu+2H).

Intermediate 5-3 Intermediate 5-3-A. Methyl3-ethyl-4-(piperidin-4-yl)benzoate

A mixture of Intermediate 5-1-B (3.5 g, 10.1 mmol) and TFA (10 mL) inCH₂Cl₂ (100 mL) was stirred at room temperature for 0.5 h, and thenconcentrated. The resulting residue was dissolved in CH₂Cl₂, which wasthen washed successively with satd. NaHCO₃ and brine, dried over Na₂SO₄,filtered, and then concentrated to furnish the title compound. MS (ESI+)m/z 248.3 (M+H).

Intermediate 5-3-B. Methyl4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzoate

To a solution of Intermediate 5-3-A (2.23 g, 9.02 mmol) andtriethylamine (1.89 mL, 13.5 mmol) in CH₂Cl₂ (50 mL) at 0° C. was addedcyclopropanecarbonyl chloride (1.13 g, 10.8 mmol). The mixture was thenstirred at room temperature for 1.5 h. The reaction was quenched withsat. aq. NaHCO₃. The mixture was then extracted twice with CH₂Cl₂. Thecombined organic layers were then dried over Na₂SO₄, filtered, and thenconcentrated. The resulting residue was purified by silica gel flashcolumn chromatography (heptane/EtOAc=I/O to 0/1) to afford the titlecompound. MS (ESI+) m/z 316.4 (M+H).

Intermediate 5-3-C.Cyclopropyl(4-(2-ethyl-4-(hydroxymethyl)phenyl)piperidin-1-yl)methanone

To a solution of Intermediate 5-3-B (4.2 g, 13.3 mmol) in THF (50 mL) at0° C. was added LiBH₄ (2M in THF, 20 ml, 40 mmol), followed by MeOH (3.2mL). The mixture was then stirred at room temperature for 2 h and then60° C. for 2 h. The reaction was quenched with sat. aq. NH₄Cl at 0° C.The mixture was concentrated, and then diluted with brine, and thenextracted three times with EtOAc. The combined organic extracts weredried over Na₂SO₄, filtered, and then concentrated. The resultingresidue was purified by silica gel flash column chromatography(heptane/EtOAc=1/0 to 0/1) to afford the title compound. MS (ESI+) m/z288.3 (M+H).

Intermediate 5-3.(4-(4-(Bromomethyl)-2-ethylphenyl)piperidin-1-yl)(cyclopropyl)methanone

To a solution of Intermediate 5-3-C (600 mg, 2.09 mmol) in CH₂Cl₂ (20mL) was added CBr₄ (1.04 g, 3.13 mmol), followed by PPh₃ (0.82 g, 3.13mmol). The mixture was then stirred at room temperature for 24 h. Themixture was diluted with CH₂Cl₂, and then washed twice with brine, driedover MgSO₄, filtered, and then concentrated. The resulting residue waspurified by silica gel flash column chromatography (heptane/EtOAc) toafford the title compound. MS (ESI+) m/z 350.3, 352.1 (M+H).

Intermediate 5-4. tert-Butyl4-(4-(hydroxymethyl)-3-methylphenyl)piperidine-1-carboxylate

The title compound was synthesized starting from methyl4-bromo-2-methylbenzoate (CAS#148547-19-7) as outlined in the synthesisof Intermediate 5-1. MS (ESI+) m/z 306.2 (M+H).

Intermediate 5-5. tert-Butyl4-(4-(bromomethyl)-3-methylphenyl)piperidine-1-carboxylate

The title compound was synthesized starting from Intermediate 5-4 by themethod described for the synthesis of Intermediate 5-2. MS (ESI+) m/z368.3 (M+H).

Intermediate 5-6.(4-(4-(Bromomethyl)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone

The title compound was synthesized starting from methyl4-bromo-2-methylbenzoate as outlined in the synthesis of Intermediate5-3. MS (ESI+) m/z 336.1 (M+H).

Intermediate 6-1 Intermediate 6-1-A. tert-Butyl4-(4-formyl-3-methylphenyl)piperidine-1-carboxylate

To a mixture of tert-butyl4-(4-(hydroxymethyl)-3-methylphenyl)piperidine-1-carboxylate,Intermediate 5-4, (1.04 g, 3.41 mmol) and H₂O (0.06 mL, 3.41 mmol) inCH₂Cl₂ (34 mL) was added Dess-Martin periodinane (1.59 g, 3.75 mmol).The mixture was then stirred at room temperature for 1.5 h. The reactionmixture was diluted with 1N NaOH (15 mL), and then extracted withCH₂Cl₂. The organic layer was passed through an ISOLUTE® phaseseparator, and then concentrated. The resulting residue was purified bysilica gel flash chromatography to afford the title compound. ¹H NMR(400 MHz, CDCl₃) δ 10.24 (s, 1H), 7.77 (d, J=7.9 Hz, 1H), 7.22 (dd,J=7.9, 1.7 Hz, 1H), 7.15-7.08 (m, 1H), 4.36-4.22 (m, 2H), 2.89-2.76 (m,2H), 2.76-2.62 (m, 4H), 1.89-1.78 (m, 2H), 1.71-1.60 (m, 2H), 1.51 (s,9H).

Intermediate 6-1-B.(7-Methoxy-2,3-dihydro-1H-inden-1-yl)triphenylphosphonium bromide

A mixture of 7-methoxyindan-1-ol (CAS#34985-44-9) (0.86 g, 5.23 mmol)and triphenylphosphine hydrobromide (1.85 g, 5.23 mmol) in toluene (10.5ml) was stirred at 90° C. for 16 h, and then cooled to room temperature.The solvent from the resulting heterogeneous mixture was decanted, andthen diethyl ether was added to the mixture, which was then stirred for0.5 h at room temperature. The resulting solid was collected byfiltration, and then washed with diethyl ether to furnish the titlecompound. MS (ESI+) m/z 409.3 (M-Br).

Intermediate 6-1-C. tert-Butyl4-(4-((7-methoxy-2,3-dihydro-1H-inden-1-ylidene)methyl)-3-methylphenyl)piperidine-1-carboxylate

To a solution of(7-methoxy-2,3-dihydro-1H-inden-1-yl)triphenylphosphonium bromide (1.22g, 2.50 mmol) in THF (12.5 mL) at room temperature was added potassiumtert-butoxide (1M in THF) (2.74 mL, 2.74 mmol). The mixture was stirredat room temperature for 0.5 h. To the reaction mixture was then added asolution of tert-butyl4-(4-formyl-3-methylphenyl)piperidine-1-carboxylate (0.75 g, 2.49 mmol)in THF (12.5 mL). The mixture was then stirred at 70° C. for 16 h. Thereaction mixture was then diluted with CH₂Cl₂, and then washed with halfsaturated NH₄Cl. The organic layer was passed through an ISOLUTE® phaseseparator, and then concentrated. The resulting residue was purified bysilica gel flash chromatography to afford the title compound. MS (ESI+)m/z 434.3 (M+H).

Intermediate 6-1-D. (±)-tert-Butyl4-(4-((7-methoxy-2,3-dihydro-1H-inden-1-yl)methyl)-3-methylphenyl)piperidine-1-carboxylate

A mixture of tert-butyl4-(4-((7-methoxy-2,3-dihydro-1H-inden-1-ylidene)methyl)-3-methylphenyl)piperidine-1-carboxylate(0.72 g, 1.67 mmol) and Pd/C (10%, 0.09 g, 0.83 mmol) in MeOH/EtOAc (20mL/2 mL) was stirred at room temperature under H₂ atmosphere for 3 h.The reaction mixture was filtered through a plug of Celite®, which wasrinsed with MeOH. The filtrate was concentrated to afford the titlecompound. MS (ESI+) m/z 380.3 (M-tBu+2H).

Intermediate 6-1-E.(±)-4-(4-((7-Methoxy-2,3-dihydro-1H-inden-1-yl)methyl)-3-methylphenyl)piperidine

To a solution of tert-butyl4-(4-((7-methoxy-2,3-dihydro-1H-inden-1-yl)methyl)-3-methylphenyl)piperidine-1-carboxylate(0.3 mg, 0.68 mmol) in MeOH (2 mL) at 0° C. was added 4M HCl in dioxane)(0.34 mL, 1.37 mmol). The mixture was then stirred at room temperaturefor h. The reaction was quenched with 1M aq. Na₂CO₃ (ca. 1.5 mL). Themixture was then extracted twice with CH₂Cl₂. The combine organic layerswere passed through an ISOLUTE® phase separator, and then concentratedto furnish the title compound. MS (ESI+) m/z 336.3 (M+H).

Intermediate 6-1-F.(±)-Cyclopropyl(4-(4-((7-methoxy-2,3-dihydro-1H-inden-1-yl)methyl)-3-methylphenyl)piperidin-1-yl)methanone

To a solution of4-(4-((7-methoxy-2,3-dihydro-1H-inden-1-yl)methyl)-3-methylphenyl)piperidine(79 mg, 0.235 mmol) and DIPEA (82 μL, 0.471 mmol) in CH₂Cl₂ (2.4 mL) at0° C. was added cyclopropanecarbonyl chloride (23.5 μL, 0.259 mmol). Themixture was stirred at 0° C. for 2 h, and then diluted with CH₂Cl₂. Theorganic layer was then washed with H₂O, and passed through a phaseseparator, and then concentrated to furnish the title compound. MS(ESI+) m/z 404.3 (M+H).

Intermediate 6-1-G.(±)-Cyclopropyl(4-(4-((7-hydroxy-2,3-dihydro-1H-inden-1-yl)methyl)-3-methylphenyl)piperidin-1-yl)methanone

To a solution ofcyclopropyl(4-(4-((7-methoxy-2,3-dihydro-1H-inden-1-yl)methyl)-3-methylphenyl)piperidin-1-yl)methanone(270 mg, 0.67 mmol) in CH₂Cl₂ (6.7 mL) at −78° C. was added a solutionof BBr₃ in CH₂Cl₂ (1.34 mL, 1.34 mmol). The mixture was then stirred at0° C. for 1 h. The reaction was quenched with a mixture of CH₂Cl₂ andsatd. aq. NaHCO₃. The organic layer was passed through an ISOLUTE® phaseseparator, and then concentrated to furnish the title compound. MS(ESI+) m/z 390.3 (M+H).

Intermediate 6-1.(±)-3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yltrifluoromethanesulfonate

To an solution ofcyclopropyl(4-(4-((7-hydroxy-2,3-dihydro-1H-inden-1-yl)methyl)-3-methylphenyl)piperidin-1-yl)methanone(156 mg, 0.40 mmol) and pyridine (97 μL, 1.20 mmol) in CH₂Cl₂ (4.0 mL)at 0° C. was added Tf₂O (95 μL, 0.56 mmol). The mixture was then stirredat 0° C. for 1.5 h. The reaction was quenched with a mixture of 1N HCland CH₂Cl₂. The organic layer was washed with satd. aq. NaHCO₃, and thenpassed through an ISOLUTE® phase separator, and concentrated to furnishthe title compound. MS (ESI+) m/z 522.3 (M+H).

Intermediate 6-2 Intermediate 6-2-A (±)-tert-Butyl4-(2-ethyl-4-((7-methoxy-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate

The title compound was synthesized by the similar method as outlined inthe synthesis of Intermediate 6-1 (i.e. 6-1-A→6-1-B→6-1-C→6-1-D) butusing tert-butyl4-(2-ethyl-4-(hydroxymethyl)phenyl)piperidine-1-carboxylate(Intermediate 5-1) in the place of Intermediate 5-4. MS (ESI+) m/z 450.3(M+H).

Intermediate 6-2(±)-3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yltrifluoromethanesulfonate

The title compound was synthesized by the similar method as outlined forthe synthesis of Intermediate 6-1 (i.e. 6-1-D→6-1-E→6-1-F→6-1-G→6-1)starting with (±)-tert-Butyl4-(2-ethyl-4-((7-methoxy-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate,Intermediate 6-2-A. MS (ESI+) m/z 536.2 (M+H).

Intermediate 6-3 Intermediate 6-3-A.(±)-3-(3-Ethyl-4-(piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-ol

To a solution of tert-butyl4-(2-ethyl-4-((7-methoxy-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate,Intermediate 6-2-A, (1.52 g, 3.38 mmol) in CH₂Cl₂ (34 mL) at −78° C. wasadded a solution of BBr₃ in CH₂Cl₂ (1 M, 10 mL, 10 mmol). The mixturewas stirred at 0° C. for 1 h, and then diluted with CH₂Cl₂. The reactionwas then carefully quenched with satd. aq. NaHCO₃. The organic layer waswashed successively with H₂O and brine, and then was passed through anISOLUTE® Phase Separator. The organic layer was concentrated to furnishthe title compound. MS (ESI+) m/z 336.5 (M+H).

Intermediate 6-3-B. (±)-tert-Butyl4-(2-ethyl-4-((7-hydroxy-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate

To a solution of(±)-3-(3-ethyl-4-(piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-ol (1.14g, 3.40 mmol) and Boc₂O (0.89 g, 4.08 mmol) in THF (17 mL) at 0° C. wasadded triethylamine (0.71 mL, 5.1 mmol). The mixture was stirred for 0.5h, and then diluted with EtOAc. The mixture was then washed with satd.aq. NaHCO₃. The aqueous layer was extracted with EtOAc. The combinedorganic layers were washed with brine, and then passed through a phaseseparator and concentrated. The resulting residue was purified by silicagel flash column chromatography to afford the title compound. MS (ESI+)m/z 380.2 (M-tBu+2H).

Intermediate 6-3. (±)-tert-Butyl4-(2-ethyl-4-((7-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate

To a solution of (±)-tert-butyl4-(2-ethyl-4-((7-hydroxy-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate(540 mg, 1.24 mmol) and pyridine (0.30 mL, 3.72 mmol) in CH₂Cl₂ (12.4mL) at 0° C. was added Tf₂O (0.29 mL, 1.73 mmol) dropwise. The mixturewas stirring at the same temperature for 1 h. The reaction mixture wasdiluted with CH₂Cl₂, and then washed successively with 1N HCl, and satd.NaHCO₃. The organic layer was then passed through an ISOLUTE® PhaseSeparator and concentrated to furnish the title compound. MS (ESI+) m/z512.2 (M-tBu+2H).

Intermediate 6-4. (±)-tert-Butyl4-(3-methyl-4-((7-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate

The title compound was synthesized by the similar method as outlined inthe synthesis of Intermediate 6-3 but using (±)-tert-Butyl4-(4-((7-methoxy-2,3-dihydro-1H-inden-1-yl)methyl)-3-methylphenyl)piperidine-1-carboxylate(Intermediate 6-1-D). MS (ESI+) m/z 554.2 (M+H).

Example 1 Example 1-A. (±)-Ethyl1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

Pd(dppf)Cl₂.CH₂Cl₂ adduct (17.79 mg, 0.022 mmol) was added to a mixtureof Intermediate 3-3. a) (99 mg, 0.218 mmol) and Intermediate 1-6-1 (98mg, 0.240 mmol) in dioxane (1.0 mL) and K₃PO₄ (2M in water; 218 μl,0.436 mmol). The reaction mixture was stirred at 80° C. under a nitrogenatmosphere for 1 h and then cooled to room temperature. Celite® wasadded and the resulting mixture was concentrated. The residue waspurified by flash column chromatography using silica gel with a gradientof 0-50% EtOAc/heptane to provide the title compound. MS (ESI+) m/z658.4 (M+H).

Example 1. a).(±)-1-(3-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

LiOH (1M in water; 0.785 mL, 0.785 mmol) was added dropwise to asolution of Example 1-A (103.2 mg, 0.157 mmol) in MeOH (0.78 mL) and THF(0.78 mL) and the resulting mixture was stirred for 3 h at roomtemperature. 1N HCl (0.79 mL) was added to quench the excess base andthe resulting mixture was then partitioned between water and EtOAc. Theaqueous layer was extracted with EtOAc. The combined organic layers wereconcentrated. The resulting residue was purified by reverse phase HPLC(HC-B) to provide the title compound. ¹H NMR (400 MHz, Methanol-d4) δ7.95 (s, 1H), 7.73-7.67 (m, 2H), 7.52 (t, J=7.8 Hz, 1H), 7.49-7.43 (m,1H), 7.42-7.32 (m, 3H), 6.92-6.86 (m, 1H), 6.86-6.82 (m, 1H), 6.74 (d,J=8.4 Hz, 1H), 5.59 (d, J=4.9 Hz, 1H), 4.64 (d, J=13.1 Hz, 1H), 4.45 (d,J=13.5 Hz, 1H), 3.25-3.16 (m, 2H), 3.00-2.91 (m, 1H), 2.78-2.63 (m, 2H),2.34-2.21 (m, 2H), 2.05-1.96 (m, 1H), 1.96-1.88 (m, 4H), 1.88-1.79 (m,1H), 1.67-1.41 (m, 2H), 0.94-0.86 (m, 2H), 0.86-0.79 (m, 2H). HRMS;calcd. for C₃₆H₃₅F₃N₃O₄(M+H) 630.2580, found 630.2615.

Example 1. b).(+)-1-(3-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid and(−)-1-(3-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

Resolution of the enantiomers of(±)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALPAK® AD-H column with 20% (5mM NH₄OH in 2-propanol) in CO₂ to afford(+)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (t_(r)=5.85 min) and(−)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (t_(r)=6.95 min).

Example 2 Example 2-A.(+)-(S)-Ethyl-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylate

Example 2-A was prepared as described in Example 1-A using Intermediate3-3. b) and Intermediate 1-5 to provide(+)-ethyl-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylate.MS (ESI+) m/z 604.4 (M+H).

Example 2.(+)-(S)-1-(3-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid

LiOH (2M in water; 760 μl, 1.52 mmol) was added dropwise to a solutionof Example 2-A (92 mg, 0.152 mmol) in MeOH (1.5 mL) and THF (1.5 mL) atroom temperature and then heated to 50° C. for 6 h. The reaction mixturewas cooled to room temperature and 1.55 mL 1N HCl was added and themixture was partitioned between EtOAc and water. The aqueous layer wasextracted with EtOAc and the combined organic layers were concentrated.The residue was purified by reverse phase HPLC (HC-B) to provide thetitle compound. ¹H NMR (400 MHz, Methanol-d4) δ 7.85 (s, 1H), 7.64-7.59(m, 2H), 7.52 (t, J=7.8 Hz, 1H), 7.45 (t, J=7.5 Hz, 1H), 7.41-7.37 (m,1H), 7.36-7.30 (m, 2H), 6.91-6.86 (m, 1H), 6.85-6.83 (m, 1H), 6.75 (d,J=8.4 Hz, 1H), 5.72-5.67 (m, 1H), 4.64 (d, J=12.1 Hz, 1H), 4.45 (d,J=13.3 Hz, 1H), 3.23 (d, J=8.6 Hz, 2H), 3.01-2.92 (m, 1H), 2.79-2.64 (m,2H), 2.44-2.33 (m, 1H), 2.23-2.16 (m, 1H), 2.15 (s, 3H), 2.05-1.97 (m,1H), 1.97-1.77 (m, 5H), 1.67-1.43 (m, 2H), 0.93-0.85 (m, 2H), 0.85-0.79(m, 2H). HRMS; calcd. for C₃₆H₃₈N₃O₄ (M+H) 576.2862, found 576.2864.

Example 3 Example 3-A. a). (±)-Ethyl1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

Chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)-methyl-t-butylether adduct (CAS #1028206-58-7; 4.37 mg, 6.49 μmol) was added toIntermediate 1-2-1 (62.3 mg, 0.195 mmol), bis(pinacolato)diboron (49.5mg, 0.195 mmol), and KOAc (38.2 mg, 0.390 mmol) in dioxane (0.65 mL) andthe head space was purged with N₂. The reaction mixture was heated at120° C. under microwave irradiation for 45 minutes. The reaction mixturewas cooled to room temperature and a solution of Intermediate 3-3. a)(59 mg, 0.130 mmol) in dioxane (0.65 mL) was added, followed by sodiumcarbonate (1M in water; 195 μl, 0.195 mmol) andchloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)-methyl-t-butylether adduct (CAS #1028206-58-7; 4.37 mg, 6.49 μmol). The reactionmixture was heated to 110° C. under microwave irradiation for 30 min.Celite® was added to the reaction mixture and the mixture wasconcentrated. The resulting residue was purified with flash columnchromatography (0-50% EtOAc/heptane gradient) to yield the titlecompound. MS (ESI+) m/z 659.4 (M+H).

Example 3-A. b). (+)-Ethyl1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylateand (−)-Ethyl1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

Resolution of the enantiomers of (±)-ethyl1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylatewas achieved by chiral SFC using CHIRALPAK® OJ-H column with 5% to 55%MeOH gradient in CO₂ to give (+)-ethyl1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(t_(r)=2.02 min) and (−)-ethyl1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(t_(r)=2.19 min).

Example 3a.(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

LiOH (1M aq, 660 μL, 0.660 mmol) was added to a solution of Example 3-A.b) ((+)-isomer, t_(r)=2.02 min)(87 mg, 0.132 mmol) in MeOH (1.3 mL) andTHF (1.3 mL) at room temperature and the reaction mixture was stirredfor 4 h at room temperature. HCl (1M aq, 660 μL, 0.66 mmol) was added tothe reaction mixture, and the resulting suspension was extracted twicewith EtOAc. The combined organic layers were concentrated. The resultingresidue was purified by RP-HPLC (HC-B) to afford the title compound. ¹HNMR (400 MHz, Methanol-d4) δ 7.97 (s, 1H), 7.93 (t, J=7.9 Hz, 1H),7.82-7.78 (m, 1H), 7.68-7.63 (m, 1H), 7.55-7.51 (m, 1H), 7.47 (t, J=7.5Hz, 1H), 7.45-7.41 (m, 1H), 6.82-6.75 (m, 2H), 6.69 (d, J=8.2 Hz, 1H),6.39-6.34 (m, 1H), 4.64 (d, J=13.0 Hz, 1H), 4.45 (d, J=13.6 Hz, 1H),3.24-3.16 (m, 2H), 3.05-2.95 (m, 1H), 2.78-2.64 (m, 2H), 2.59-2.47 (m,1H), 2.18-2.08 (m, 1H), 2.05-1.97 (m, 1H), 1.92 (d, J=13.1 Hz, 1H), 1.84(d, J=13.5 Hz, 1H), 1.63 (s, 3H), 1.61-1.44 (m, 2H), 0.93-0.86 (m, 2H),0.86-0.78 (m, 2H). HRMS; calcd. for C₃₅H₃₄F₃N₄O₄(M+H) 631.2532, found631.2572.

Example 3b.(−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

(−)-Isomer in Example 3-A. b) (t_(r)=2.19 min) was saponified asdescribed in Example 1. a) and then purified by reverse phase HPLC(HC-B) to afford the title compound. ¹H NMR and HRMS data weresubstantially identical to Example 3a.

Example 4 Example 4-A. a). (±)-Ethyl1-(6-(3-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

Example 4-A. a) was prepared as described in Example 3-A usingIntermediate 1-2-1 and Intermediate 3-1 to provide the title compound.MS (ESI+) m/z 640.2 (M+H).

Example 4-A. b). (+)-Ethyl1-(6-(3-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylateand (−)-Ethyl1-(6-(3-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

Resolution of the enantiomers of (±)-ethyl1-(6-(3-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylatewas achieved by chiral SFC using CHIRALPAK® AD-H column with 5% to 55%IPA gradient in CO₂ to give (−)-ethyl1-(6-(3-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(t_(r)=3.01 min) and (+)-ethyl1-(6-(3-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(t_(r)=3.42 min).

Example 4a.(+)-1-(6-(3-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

LiOH (aq) (457 μL, 0.915 mmol) was added dropwise to a solution ofExample 4-A. b) ((+)-isomer, t_(r)=3.42 min) (117 mg, 0.183 mmol) in THF(0.9 mL) at 0° C. The mixture was stirred for 1 h at 0° C. MeOH (0.9 mL)was added to the mixture, and then the mixture was warmed to roomtemperature and stirred for 1 h. 1N HCl (0.92 mL) was added to thereaction mixture and the resulting suspension was extracted twice withEtOAc. The combined organic layers were concentrated. The resultingresidue was purified by RP-HPLC (HC-B) to afford the title compound. ¹HNMR (400 MHz, Methanol-d4) δ 8.61-8.54 (m, 1H), 7.96-7.85 (m, 2H),7.82-7.77 (m, 2H), 7.70-7.60 (m, 2H), 7.52-7.37 (m, 4H), 6.76 (d, J=8.4Hz, 1H), 6.46 (d, J=2.5 Hz, 1H), 6.45-6.40 (m, 1H), 6.37-6.32 (m, 1H),4.12 (s, 2H), 3.86 (s, 2H), 3.19 (dd, J=16.0, 8.0 Hz, 1H), 3.10-3.02 (m,2H), 3.02-2.93 (m, 1H), 2.93-2.86 (m, 2H), 2.52-2.38 (m, 1H), 2.22-2.12(m, 1H). HRMS; calcd. for C₃₄H₂₉F₃N₅O₃(M+H) 612.2222, found 612.2199.

Example 4b.(−)-1-(6-(3-((2-(Pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

The (−)-isomer in Example 4-A. b) (t_(r)=3.01 min) was saponified asdescribed in Example 4a and purified by reverse phase HPLC (HC-B) toafford the title compound. ¹H NMR and HRMS data were substantiallyidentical to Example 4a.

Example 5

The following compounds were prepared using similar methods as describedabove in Example 3 and/or Example 4 using the appropriate startingmaterials.

Exam- ple Structure/Chemical Name Starting material(s) MS or NMR data5-1

Intermediate 1-2-1 and Intermediate 3-2-1 ¹H NMR (400 MHz, DMSO-d₆) δ8.49-8.54 (m, 1H), 7.93-8.05 (m, 2H), 7.83 (d, J = 7.7 Hz, 1H),7.75-7.81 (m, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.46-7.52 (m, 2H),7.24-7.30 (m, 2H), 6.77 (d, J = 8.2 Hz, 1H), 6.40- 6.48 (m, 2H),6.13-6.18 (m, 1H), 3.76 (s, 2H), 3.50 (s, 2H), 3.03-3.11 (m, 1H),2.83-2.94 (m, 1H), 2.64-2.74 (m, 4H), 2.44-2.57 (m, 1H), 2.40 (s, 3H),2.30-2.38 (m, 1H), 2.01- 2.11 (m, 1H). HRMS; calcd. for C₃₅H₃₁F₃N₅O₃(M + H) 626.2379, found 626.2415. 5-2

Intermediate 1-2-1 and Intermediate 3-2-2 ¹H NMR (400 MHz, Methanol- d₄)δ 7.92 (s, 1H), 7.88 (t, J = 7.9 Hz, 1H), 7.77-7.73 (m, 1H), 7.53-7.48(m, 2H), 7.25 (s, 1H), 6.82-6.78 (m, 2H), 6.70 (d, J = 9.0 Hz, 1H),6.30- 6.27 (m, 1H), 4.64 (d, J = 12.7 Hz, 1H), 4.45 (d, J = 13.3 Hz,1H), 3.23-3.14 (m, 2H), 2.99- 2.89 (m, 1H), 2.78-2.64 (m, 2H), 2.54-2.46(m, 1H), 2.45 (s, 3H), 2.18-2.09 (m, 1H), 2.05-1.97 (m, 1H), 1.92 (d, J= 13.1 Hz, 1H), 1.83 (d, J = 13.1 Hz, 1H), 1.67 (s, 3H), 1.64-1.43 (m,2H), 0.93- 0.79 (m, 4H). HRMS; calcd. for C₃₆H₃₆F₃N₄O₄ (M + H) 645.2689,found 645.2698. 5-3

Intermediate 1-2-1 and Intermediate 3-4-3 ¹H NMR (400 MHz, Methanol- d₄)δ 7.92-7.86 (m, 2H), 7.81- 7.76 (m, 1H), 7.67-7.63 (m, 1H), 7.56-7.52(m, 1H), 7.46 (t, J = 7.5 Hz, 1H), 7.44-7.41 (m, 1H), 6.96 (d, J = 8.5Hz, 1H), 6.59-6.51 (m, 1H), 6.48 (d, J = 9.5 Hz, 1H), 6.27 (d, J = 6.0Hz, 1H), 4.71-4.61 (m, 1H), 4.52-4.42 (m, 1H), 3.24- 3.15 (m, 2H),3.05-2.92 (m, 2H), 2.75 (t, J = 12.7 Hz, 1H), 2.67-2.54 (m, 2H), 2.48-2.36 (m, 1H), 2.25-2.16 (m, 1H), 2.07-1.97 (m, 1H), 1.89- 1.80 (m, 1H),1.78-1.49 (m, 3H), 1.15 (t, J = 7.5 Hz, 3H), 0.95-0.78 (m, 4H). HRMScalculated for C₃₆H₃₆F₃N₄O₄ (M + H) 645.2689, found 645.2744. 5-4

Intermediate 1-2-1 and Intermediate 3-4-4 ¹H NMR (400 MHz, Methanol- d₄)δ 7.92 (s, 1H), 7.89 (dd, J = 7.8, 8.0 Hz, 1H), 7.76 (d, J = 7.8 Hz,1H), 7.63-7.67 (m, 1H), 7.53 (dd, J = 0.7, 8.0 Hz, 1H), 7.41-7.50 (m,2H), 6.78- 6.82 (m, 2H), 6.68-6.72 (m, 1H), 6.34 (dd, J = 2.8, 6.4 Hz,1H), 3.16-3.25 (m, 1H), 3.04- 3.14 (m, 4H), 2.95-3.04 (m, 1H), 2.42-2.56(m, 3H), 2.31- 2.41 (m, 1H), 2.08-2.18 (m, 1H), 1.67-1.80 (m, 4H), 1.65(s, 3H). HRMS; calcd for C₃₃H₃₁F₆N₄O₃ (M + H) 645.2300, found 645.2324.5-5

Intermediate 1-4-4 and Intermediate 3-3. b) ¹H NMR (400 MHz, Methanol-d₄) δ 8.60 (d, J = 0.6 Hz, 1H), 7.87-7.94 (m, 2H), 7.74 (d, J = 7.6 Hz,1H), 7.57-7.63 (m, 2H), 7.41-7.51 (m, 2H), 6.92 (d, J = 8.4 Hz, 1H),6.77 (dd, J = 1.7, 8.2 Hz, 1H), 6.56-6.62 (m, 2H), 4.54-4.63 (m, 1H),4.36-4.44 (m, 1H), 3.17-3.26 (m, 2H), 3.02-3.12 (m, 1H), 2.79-2.90 (m,1H), 2.62-2.72 (m, 1H), 2.47-2.58 (m, 1H), 2.12-2.23 (m, 1H), 1.95-2.03(m, 1H), 1.64-1.82 (m, 2H). 1.33-1.54 (m, 5H), 0.77-0.94 (m, 4H). HRMS;calcd. for C₃₄H₃₅N₄O₄ (M + H) 563.2658, found 563.2669. 5-6

Intermediate 1-3 and Intermediate 3-3. b) ¹H NMR (400 MHz, Methanol- d₄)δ 7.91-7.85 (m, 2H), 7.68- 7.64 (m, 1H), 7.63-7.56 (m, 2H), 7.47 (t, J =7.5 Hz, 1H), 7.45-7.41 (m, 1H), 6.80- 6.72 (m, 3H), 6.36-6.31 (m, 1H),4.62 (d, J = 13.1 Hz, 1H), 4.42 (d, J = 12.1 Hz, 1H), 3.27- 3.17 (m,2H), 3.06-2.96 (m, 1H), 2.76-2.66 (m, 4H), 2.66- 2.53 (m, 2H), 2.19-2.09(m, 1H), 2.04-1.96 (m, 1H), 1.88 (d, J = 13.4 Hz, 1H), 1.80 (d, J = 13.6Hz, 1H), 1.62 (s, 3H), 1.60-1.39 (m, 2H), 0.92- 0.78 (m, 4H). HRMS;calcd. for C₃₅H₃₇N₄O₄ (M + H) 577.2815, found 577.2859. 5-7

Intermediate 1-4-2 and Intermediate 3-3. b) ¹H NMR (400 MHz, Methanol-d₄) δ 7.93 (s, 1H), 7.84 (t, J = 7.9 Hz, 1H), 7.66-7.62 (m, 1H),7.61-7.55 (m, 2H), 7.47 (t, J = 7.4 Hz, 1H), 7.45-7.41 (m, 1H),6.85-6.81 (m, 2H), 6.76 (d, J = 9.0 Hz, 1H), 6.28- 6.23 (m, 1H), 4.62(d, J = 13.3 Hz, 1H), 4.44 (d, J = 13.7 Hz, 1H), 3.40-3.34 (m, 2H),3.25- 3.19 (m, 2H), 3.05-2.96 (m, 1H), 2.77-2.62 (m, 2H), 2.58- 2.47 (m,1H), 2.24-2.14 (m, 1H), 2.05-1.96 (m, 1H), 1.88 (d, J = 13.0 Hz, 1H),1.80 (d, J = 13.5 Hz, 1H), 1.71 (s, 3H), 1.66-1.41 (m, 2H), 1.12 (t, J =7.3 Hz, 3H), 0.93-0.79 (m, 4H). HRMS; calcd. for C₃₆H₃₉N₄O₄ (M + H)591.2971, found 591.2981. 5-8

Intermediate 1-3 and Intermediate 3-4-4 ¹H NMR (400 MHz, Chloroform-d) δ7.98 (s, 1H), 7.68-7.53 (m, 4H), 7.41- 7.28 (m, 2H), 6.87-6.78 (m, 2H),6.74-6.65 (m, 1H), 5.95- 5.86 (m, 1H), 3.45-3.26 (m, 2H), 3.18 (dt, J =15.8, 7.8 Hz, 1H), 3.02-2.97 (m, 2H), 2.97 (s, 2H), 2.89-2.82 (m, 1H),2.43-2.35 (m, 2H), 2.33- 2.25 (m, 2H), 2.23-2.14 (m, 1H), 1.78 (s, 3H),1.73-1.64 (m, 4H), 1.17 (t, J = 7.3 Hz, 4H). HRMS; calcd. for C₃₇H₄₁N₄O₄(M + H) 605.2661, found 605.2735. 5-9

Intermediate 1-4-2 and Intermediate 3-4-3 ¹H NMR (400 MHz, Methanol- d₄)δ 7.93 (s, 1H), 7.89 (t, J = 7.9 Hz, 1H), 7.72 (dd, J = 7.7, 0.9 Hz,1H), 7.62-7.57 (m, 2H), 7.47 (t, J = 7.5 Hz, 1H), 7.43 (dd, J = 7.5, 1.3Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 6.58- 6.51 (m, 1H), 6.51-6.46 (m,1H), 6.18 (dd, J = 6.2, 2.4 Hz, 1H), 4.65 (d, J = 13.2 Hz, 1H), 4.46 (d,J = 13.4 Hz, 1H), 3.29- 3.15 (m, 4H), 3.04-2.93 (m, 2H), 2.74 (t, J =12.6 Hz, 1H), 2.63-2.54 (m, 2H), 2.50-2.39 (m, 1H), 2.26-2.17 (m, 1H),2.05-1.96 (m, 1H), 1.81 (d, J = 13.4 Hz, 1H), 1.72 (d, J = 13.6 Hz, 1H),1.68-1.48 (m, 2H), 1.16-1.08 (m, 6H), 0.94-0.86 (m, 2H), 0.86-0.78 (m,2H). HRMS; calcd. for C₃₇H₄₀N₄O₄ (M + H) 605.3050, found 605.3146. 5-10

Intermediate 1-3 and Intermediate 3-4-3 ¹H NMR (400 MHz, Methanol- d₄) δ7.94-7.86 (m, 2H), 7.68 (dd, J = 7.8, 0.8 Hz, 1H), 7.62- 7.56 (m, 2H),7.47 (t, J = 7.5 Hz, 1H), 7.42 (dd, J = 7.6, 1.2 Hz, 1H), 6.92 (d, J =8.8 Hz, 1H), 6.54-6.41 (m, 2H), 6.25 (dd, J = 6.4, 2.8 Hz, 1H), 4.65 (d,J = 13.1 Hz, 1H), 4.46 (d, J = 13.4 Hz, 1H), 3.27-3.15 (m, 2H),3.05-2.90 (m, 2H), 2.78- 2.67 (m, 4H), 2.61-2.52 (m, 2H), 2.52-2.44 (m,1H), 2.24- 2.14 (m, 1H), 2.06-1.96 (m, 1H), 1.80 (d, J = 13.1 Hz, 1H),1.72 (d, J = 13.4 Hz, 1H), 1.66- 1.45 (m, 2H), 1.12 (t, J = 7.5 Hz, 3H),0.95-0.86 (m, 2H), 0.86-0.77 (m, 2H). HRMS; calcd. for C36H39N4O4 (M +H) 591.2971, found 591.2953.

Example 6 Example 6-A. (±)-Ethyl1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

A mixture of Intermediate 3-5-A. a) (150 mg, 0.232 mmol) andIntermediate 1-6-1 (95 mg, 0.232 mmol) in CH₃CN (1.2 mL) and aqueousK₃PO₄ (2M in water; 232 μl, 0.463 mmol) was degassed using a slow streamof nitrogen gas for 5 minutes. Pd(dppf)Cl₂CH₂Cl₂ adduct (18.9 mg, 0.023mmol) was then added to the solution and the reaction mixture was heatedat 80° C. under a nitrogen atmosphere for 3 hours. The reaction mixturewas filtered and the eluent was directly purified by reverse phase HPLCto provide the title compound. MS (ESI+) m/z 657.3 (M+H).

Example 6. a).(±)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

Example 6-A (195 mg, 0.297 mmol) was dissolved in MeOH (3.0 mL) and THF(3.0 mL) and then LiOH (2M aq) (1.485 mL, 1.485 mmol) was added dropwiseat room temperature and stirred at room temperature for 3 hrs. 1N HCl(1.5 mL) was added and the mixture was partitioned between EtOAc andwater. The aqueous layer was extracted with EtOAc and the combinedorganic layers were concentrated to provide the title compound, whichwas purified by reverse phase HPLC (HC-B). ¹H NMR (400 MHz, Methanol-d₄)δ 7.97 (d, J=0.8 Hz, 1H), 7.76 (t, J=1.9 Hz, 1H), 7.72-7.67 (m, 1H),7.47 (t, J=7.9 Hz, 1H), 7.43-7.38 (m, 1H), 7.38-7.30 (m, 3H), 6.84-6.79(m, 1H), 6.75-6.73 (m, 1H), 6.50 (d, J=8.2 Hz, 1H), 5.05-4.99 (m, 1H),4.62 (d, J=12.9 Hz, 1H), 4.43 (d, J=13.5 Hz, 1H), 3.26-3.18 (m, 2H),2.99-2.88 (m, 1H), 2.77-2.58 (m, 2H), 2.40-2.28 (m, 1H), 2.14-2.05 (m,1H), 2.04-1.96 (m, 1H), 1.89 (d, J=13.3 Hz, 1H), 1.84-1.76 (m, 4H),1.65-1.40 (m, 2H), 0.94-0.77 (m, 4H). HRMS; calcd. for C₃₆H₃₆F₃N₄O₃(M+H)629.2740, found 629.2668.

Example 6. b).(+)-1-(3-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid and(−)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

Resolution of enantiomers of(±)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALPAK® AD-H column with 25%MeOH in CO₂ to give(−)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (t_(r)=2.30 min) and(+)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (t_(r)=3.05 min).

Example 7 Example 7-A. a). (±)-Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

A Dean-Stark trap was fitted to a flask containing a solution ofIntermediate 2-8 (286 mg, 1.107 mmol), Intermediate 3-7 (400 mg, 1.107mmol), and TsOH (21 mg, 0.111 mmol) in anhydrous toluene (12 mL). Thereaction mixture was heated at 130° C. for 22 hours, at which point themixture was concentrated. The crude residue was re-dissolved inanhydrous EtOH (12 mL) and cooled to 0° C. Sodium borohydride (42 mg,1.107 mmol) was added to the cooled solution and the reaction mixturewas stirred at 0° C. for 1.5 h. The reaction mixture was quenched withwater and saturated aq. ammonium chloride. The aqueous layer wasextracted twice with CH₂Cl₂. Celite® was added to the combined organiclayers and the mixture was concentrated. The resulting residue waspurified by flash column chromatography (0-50% EtOAc/heptane gradient)to give the title compound. MS (ESI+) m/z 604.4 (M+H).

Example 7-A. b). (+)-Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylateand (−)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

Resolution of enantiomers of (±)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylatewas achieved by chiral SFC using CHIRALPAK® AD-H column with 5% to 55%IPA gradient in CO₂ to give (+)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(t_(r)=4.24 min) and (−)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(t_(r)=4.55 min).

Example 7a.(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

LiOH (1M aq; 2.8 mL, 2.8 mmol) was added dropwise to a solution ofExample 7-A. b) ((+)-isomer, t_(r)=4.24 min) (168 mg, 0.278 mmol) inMeOH (2.8 mL) and THF (2.8 mL) at room temperature and the reactionmixture was heated to 50° C. for 2 h. Upon completion, the reactionmixture was cooled to room temperature and 2.9 mL 1M HCl was added. Theresulting mixture was extracted with EtOAc and the combined organiclayers were concentrated to provide the title compound afterpurification by reverse phase HPLC (HC-B). ¹H NMR (400 MHz, Methanol-d₄)δ 7.89 (s, 1H), 7.82 (t, J=7.9 Hz, 1H), 7.69-7.65 (m, 1H), 7.58-7.54 (m,1H), 7.53-7.50 (m, 1H), 7.44-7.37 (m, 2H), 6.83-6.79 (m, 1H), 6.74-6.71(m, 1H), 6.56 (d, J=8.2 Hz, 1H), 5.38 (s, 1H), 4.61 (d, J=12.9 Hz, 1H),4.43 (d, J=13.2 Hz, 1H), 3.24-3.15 (m, 2H), 3.02-2.93 (m, 1H), 2.75-2.59(m, 5H), 2.54-2.43 (m, 1H), 2.13-2.04 (m, 1H), 2.03-1.96 (m, 1H), 1.90(d, J=13.1 Hz, 1H), 1.80 (d, J=13.4 Hz, 1H), 1.67 (s, 3H), 1.64-1.41 (m,2H), 0.92-0.78 (m, 4H). HRMS; calcd. for C₃₅H₃₈N₅O₃ (M+H) 576.2975,found 576.3015. Absolute stereochemistry of(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid was confirmed by X-ray single crystal diffraction

Example 7b.(−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

Example 7-A. b) ((−)-isomer, t_(r)=4.55 min) was saponified as describedin Example 7a to provide the title compound after purification byreverse phase HPLC (HC-B). ¹H NMR and HRMS data were substantiallyidentical to Example 7a.

Example 8 Example 8-A. (±)-Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

The reductive amination between Intermediate 2-8 and Intermediate 3-8-2was performed as described in Example 7-A. a) to provide the titlecompound. MS (ESI+) m/z 658.5 (M+H).

Example 8. a).(±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

Example 8-A was saponified as described in Example 1. a) to provide thetitle compound after purification by reverse phase HPLC (HC-B). ¹H NMR(400 MHz, Methanol-d₄) b 7.98-7.91 (m, 2H), 7.91-7.87 (m, 1H), 7.67-7.61(m, 1H), 7.51-7.47 (m, 1H), 7.43 (d, J=5.9 Hz, 2H), 6.85-6.80 (m, 1H),6.74-6.71 (m, 1H), 6.55 (d, J=8.2 Hz, 1H), 5.24 (s, 1H), 4.63 (d, J=13.0Hz, 1H), 4.45 (d, J=13.3 Hz, 1H), 3.26-3.16 (m, 2H), 2.98-2.89 (m, 1H),2.79-2.61 (m, 2H), 2.42-2.31 (m, 1H), 2.16-2.07 (m, 1H), 2.05-1.97 (m,1H), 1.93 (d, J=13.2 Hz, 1H), 1.84 (d, J=12.9 Hz, 1H), 1.70 (s, 3H),1.67-1.45 (m, 2H), 0.93-0.78 (m, 4H). HRMS; calcd. for C₃₅H₃₅F₃N₅O₃(M+H)630.2692, found 630.2451.

Example 8. b).(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid and(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

Resolution of the enantiomers of(±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALPAK® OJ-H column with 20% (5mM NH₄OH in MeOH) in CO₂ to give(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (t_(r)=3.10 min) and(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (t_(r)=4.40 min).

Example 9 Example 9-A. (±)-Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

The reductive amination between Intermediate 3-7 and Intermediate 2-9was performed as described in Example 7-A to provide the title compound.MS (ESI+) m/z 590.5 (M+H).

Example 9. a).(±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

Example 9-A was saponified as described in Example 2 to provide thetitle compound after purification by reverse phase HPLC. ¹H NMR (400MHz, Methanol-d₄) δ 7.94 (s, 1H), 7.91 (t, J=7.9 Hz, 1H), 7.85-7.80 (m,1H), 7.60-7.54 (m, 2H), 7.43-7.38 (m, 2H), 6.87-6.82 (m, 2H), 6.44-6.38(m, 2H), 5.25-5.21 (m, 1H), 4.62 (d, J=13.2 Hz, 1H), 4.43 (d, J=13.2 Hz,1H), 3.23-3.15 (m, 2H), 2.97-2.88 (m, 1H), 2.77-2.59 (m, 5H), 2.38-2.26(m, 1H), 2.17-2.08 (m, 1H), 2.04-1.96 (m, 1H), 1.89 (d, J=13.3 Hz, 1H),1.80 (d, J=13.3 Hz, 1H), 1.64-1.41 (m, 2H), 0.93-0.78 (m, 4H). HRMS;calcd. for C₃₄H₃₆N₅O₃ (M+H) 562.2818, found 562.2833.

Example 9. b).(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid and(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

Resolution of the enantiomers of(±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALPAK® AD-H column with 5-55%(5 mM NH₄OH in MeOH) gradient in CO₂ to give(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r)=3.68 min) and(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r)=4.10 min).

Example 10 Example 10-A. a). (±)-Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate

The reductive amination between Intermediate 2-8 and Intermediate 3-8-1was performed as described in Example 7-A. a) to provide the titlecompound. MS (ESI+) m/z 618.4 (M+H).

Example 10-A. b). (+)-Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylateand (−)-Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate

Resolution of the enantiomers of (±)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylatewas achieved by chiral SFC using CHIRALPAK® OJ-H column with 30% to 45%IPA gradient in CO₂ to give (+)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(t_(r)=3.77 min) and (−)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(t_(r)=5.85 min).

Example 10a.(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

LiOH (1 M aq.) (1.20 mL, 1.20 mmol) was added dropwise at roomtemperature to a solution of Example 10-A. b) ((+)-isomer, t_(r)=3.77min) (74.6 mg, 0.121 mmol) in MeOH (1.2 mL) and THF (1.2 mL). Themixture was stirred at 50° C. for 5 h. The reaction mixture was cooledto room temperature and 1N HCl (aq. 1.3 mL) was added. The resultingsuspension was extract twice with EtOAc. The combined organic layerswere concentrated. The resulting residue was purified by reverse phaseHPLC (HC-B) to afford the title compound. ¹H NMR (400 MHz, Methanol-d₄)δ 7.92 (s, 1H), 7.88 (t, J=7.9 Hz, 1H), 7.78-7.74 (m, 1H), 7.58-7.52 (m,2H), 7.43-7.40 (m, 2H), 6.84-6.80 (m, 1H), 6.74-6.72 (m, 1H), 6.56 (d,J=8.2 Hz, 1H), 5.33-5.28 (m, 1H), 4.62 (d, J=12.9 Hz, 1H), 4.43 (d,J=13.5 Hz, 1H), 3.21-3.15 (m, 3H), 3.11-3.04 (m, 1H), 3.01-2.92 (m, 1H),2.77-2.58 (m, 2H), 2.50-2.40 (m, 1H), 2.16-2.06 (m, 1H), 2.04-1.96 (m,1H), 1.88 (d, J=13.6 Hz, 1H), 1.81 (d, J=13.6 Hz, 1H), 1.69 (s, 3H),1.64-1.42 (m, 2H), 1.08 (t, J=7.4 Hz, 3H), 0.91-0.80 (m, 4H). HRMS;calcd. for C₃₆H₄₀N₅O₃ (M+H) 590.3131, found 590.3145.

Example 10b.(−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

The (−)-isomer in Example 10-A. b) (t_(r)=5.85 min) was saponified asdescribed in Example 10a and then purified by reverse phase HPLC (HC-B)to afford the title compound. ¹H NMR and HRMS data were substantiallyidentical to Example 10a.

Example 11

The following compounds were prepared using similar methods as describedabove for Example 7-A. a) using the appropriate starting

Exam- Starting ple Structure/Chemical Name material(s) HRMS and NMR data11-1

Intermediate 2-8 and Intermediate 3-8- 3 ¹H NMR (400 MHz, Methanol- d₄)δ 7.94-7.89 (m, 2H), 7.89- 7.85 (m, 1H), 7.49-7.45 (m, 2H), 7.25-7.23(m, 1H), 6.84- 6.81 (m, 1H), 6.75-6.71 (m, 1H), 6.55 (d, J = 8.2 Hz,1H), 5.20-5.16 (m, 1H), 4.63 (d, J = 13.1 Hz, 1H), 4.43 (d, J = 13.1 Hz,1H), 3.28-3.21 (m, 1H), 3.19-3.12 (m, 1H), 2.93- 2.84 (m, 1H), 2.77-2.61(m, 2H), 2.43 (s, 3H), 2.39-2.28 (m, 1H), 2.15-2.06 (m, 1H), 2.05-1.96(m, 1H), 1.96- 1.89 (m, 1H), 1.87-1.80 (m, 1H), 1.70 (s, 3H), 1.67-1.44(m, 2H), 0.92-0.79 (m, 4H). HRMS; calcd. for C₃₆H₃₇F₃N₅O₃ (M + H)644.2848, found 644.2841. 11-2

Intermediate 3-4- B and Intermediate 1-2- 1 ¹H NMR (400 MHz, Methanol-d₄) δ 7.96-7.91 (m, 3H), 7.64 (dd, J = 5.5, 3.3 Hz, 1H), 7.52 (dd, J =5.8, 2.9 Hz, 1H), 7.42- 7.38 (m, 2H), 6.89 (d, J = 8.5 Hz, 2H), 6.46 (d,J = 8.5 Hz, 2H), 5.15 (d, J = 6.4 Hz, 1H), 4.63 (d, J = 11.7 Hz, 1H),4.45 (d, J = 13.5 Hz, 1H), 3.24- 3.16 (m, 2H), 2.95-2.86 (m, 1H),2.78-2.63 (m, 2H), 2.30- 2.20 (m, 1H), 2.19-2.10 (m, 1H), 2.05-1.96 (m,1H), 1.90 (d, J = 13.1 Hz, 1H), 1.83 (d, J = 13.1 Hz, 1H), 1.69-1.44 (m,2H), 0.93-0.78 (m, 4H). HRMS; calcd. for C₃₄H₃₃F₃N₅O₃ (M + H) 616.2535,found 616.2557. 11-3

Intermediate 3-8- 1 and Intermediate 2-11 ¹H NMR (400 MHz, Methanol- d₄)δ 7.92 (s, 1H), 7.87 (t, J = 7.9 Hz, 1H), 7.78-7.74 (m, 1H), 7.58-7.53(m, 2H), 7.44- 7.40 (m, 2H), 6.83 (dd, J = 8.2, 2.2 Hz, 1H), 6.75-6.72(m, 1H), 6.56 (d, J = 8.2 Hz, 1H), 5.32-5.28 (m, 1H), 3.23- 3.15 (m,3H), 3.10-3.02 (m, 4H), 3.01-2.92 (m, 1H), 2.51- 2.40 (m, 3H), 2.37-2.28(m, 1H), 2.15-2.06 (m, 1H), 1.76- 1.71 (m, 3H), 1.69 (s, 3H), 1.09 (t, J= 7.4 Hz, 3H). HRMS; calcd. for C₃₄H₃₇F₃N₅O₂ (M + H) 604.2899, found604.2890. 11-4

Intermediate 3-5- A, a) and Intermediate 1-5 ¹H NMR (400 MHz, Methanol-d₄) δ 7.87 (s, 1H), 7.62-7.58 (m, 2H), 7.49 (t, J = 8.1 Hz, 1H),7.41-7.36 (m, 1H), 7.36- 7.25 (m, 3H), 6.84-6.79 (m, 1H), 6.74-6.71 (m,1H), 6.51 (d, J = 8.2 Hz, 1H), 5.15-5.11 (m, 1H), 4.61 (d, J = 12.7 Hz,1H), 4.43 (d, J = 13.4 Hz, 1H), 3.23-3.15 (m, 2H), 3.01- 2.92 (m, 1H),2.76-2.67 (m, 1H), 2.67-2.57 (m, 1H), 2.54- 2.43 (m, 1H), 2.18 (s, 3H),2.09-1.96 (m, 2H), 1.88 (d, J = 13.3 Hz, 1H), 1.79 (d, J = 13.3 Hz, 1H),1.69 (s, 3H), 1.63-1.41 (m, 2H), 0.92- 0.78 (m, 4H). HRMS; calcd. forC₃₆H₃₉N₄O₃ (M + H) 575.3022, found 575.3071.

Example 12 Example 12-A. tert-Butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)indolin-1-yl)methyl)phenyl)piperidine-1-carboxylate

Triphenylphosphine (117 mg, 0.446 mmol) and CBr₄ (CAS#558-13-4, 148 mg,0.446 mmol) were added to a solution of tert-butyl4-(4-(hydroxymethyl)phenyl)piperidine-1-carboxylate (CAS #864359-18-2;130 mg, 0.446 mmol) in dichloromethane (3.0 mL). The mixture was thenstirred at room temperature for 16 h, at which point the reactionmixture was concentrated. The resulting residue was dissolved in DMF(1.0 mL). The DMF solution was then added dropwise to a suspension ofIntermediate 4-1 (125 mg, 0.311 mmol) and K₂CO₃ (119 mg, 0.932 mmol) inDMF (1.0 mL). The mixture was stirred at 65° C. for 3 h, and then cooledto room temperature. The reaction mixture was partitioned between EtOAcand H₂O. The organic layer was then separated. The organic layer wasthen washed three times with brine, dried over Na₂SO₄, filtered, andconcentrated. The resulting residue was purified by flash columnchromatography on silica gel (heptane/EtOAc=100/0 to 60/40) to affordthe title compound. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (s, 1H) 7.79 (d,J=7.20 Hz, 1H) 7.68 (t, J=7.83 Hz, 1H) 7.39 (d, J=7.07 Hz, 2H) 7.16 (dd,J=7.14, 1.07 Hz, 1H) 7.03-7.12 (m, 4H) 6.87 (t, J=7.45 Hz, 1H) 4.38 (q,J=7.07 Hz, 2H) 4.22 (br. s., 2H) 3.94 (s, 2H) 3.39 (t, J=8.59 Hz, 2H)3.03 (t, J=8.53 Hz, 2H) 2.79 (t, J=12.44 Hz, 2H) 2.51-2.67 (m, 1H) 1.79(d, J=13.14 Hz, 2H) 1.55-1.67 (m, 2H) 1.45-1.51 (m, 9H) 1.39 (t, J=7.14Hz, 3H).

Example 12-B. Ethyl1-(6-(1-(4-(piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

A solution of Example 12-A (230 mg, 0.34 mmol) and TFA (1 mL) in CH₂Cl₂(5 mL) was stirred at room temperature for 1 h. The reaction mixture wasthen concentrated. The resulting residue was partitioned between EtOAcand saturated NaHCO₃. The isolated organic layer was washed with brine,dried over Na₂SO₄, filtered, and then concentrated to furnish the titlecompound. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (s, 1H) 7.77-7.83 (m, 1H) 7.68(t, J=7.77 Hz, 1H) 7.39 (dd, J=7.83, 0.76 Hz, 2H) 7.16 (dd, J=7.20, 1.14Hz, 1H) 7.10 (s, 4H) 6.87 (t, J=7.45 Hz, 2H) 4.38 (q, J=7.20 Hz, 2H)3.94 (s, 2H) 3.39 (t, J=8.59 Hz, 2H) 3.19 (d, J=12.00 Hz, 2H) 3.03 (t,J=8.59 Hz, 2H) 2.74 (td, J=12.16, 2.34 Hz, 2H) 2.51-2.65 (m, 1H) 1.81(d, J=12.88 Hz, 2H) 1.71 (br. s, 1H) 1.54-1.68 (m, 2H) 1.39 (t, J=7.14Hz, 2H).

Example 12-C. Ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

Cyclopropanecarbonyl chloride (0.032 mL, 0.354 mmol) was added to asolution of Example 12-B (170 mg, 0.295 mmol) in CH₂Cl₂ (2 mL) and TEA(0.21 mL) at room temperature. The mixture was then stirred at roomtemperature for 3 h, after which the reaction mixture was concentrated.The resulting residue was partitioned between EtOAc and H₂O. Theisolated organic layer was washed with brine, dried over Na₂SO₄,filtered, and then concentrated. The resulting residue was purified byflash column chromatography on silica gel (heptane/EtOAc=100/0 to 20/80)to afford the title compound. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (s, 1H)7.79 (d, J=7.71 Hz, 1H) 7.65-7.73 (m, 1H) 7.39 (d, J=7.83 Hz, 2H) 7.17(d, J=7.20 Hz, 1H) 7.09 (q, J=8.29 Hz, 4H) 6.88 (t, J=7.45 Hz, 1H) 4.76(br. s., 1H) 4.38 (q, J=7.12 Hz, 3H) 3.88-4.00 (m, 2H) 3.39 (t, J=8.59Hz, 2H) 3.19 (br. s., 1H) 3.03 (t, J=8.53 Hz, 2H) 2.56-2.81 (m, 2H) 1.89(br. s., 2H) 1.79 (m, 1H) 1.63 (br. s., 2H) 1.39 (t, J=7.14 Hz, 3H) 1.01(br. s., 2H) 0.77 (dd, J=7.89, 2.72 Hz, 2H).

Example 12.1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

LiOH (2M in water; 185 μl, 0.37 mmol) was added dropwise to a solutionof Example 12-C (80 mg, 0.124 mmol) in MeOH (1 mL) and THF (1 mL) atroom temperature and the mixture was stirred for 3 h. 1N HCl was addedto adjust pH˜2. The mixture was then concentrated. The residue waspurified by reverse phase HPLC (HC-B) to provide the title compound. ¹HNMR (400 MHz, Methanol-d₄) δ 7.88 (s, 1H) 7.73-7.85 (m, 2H) 7.48 (dd,J=7.71, 1.01 Hz, 1H) 7.30 (d, J=7.83 Hz, 1H) 7.14 (dd, J=7.20, 1.14 Hz,1H) 7.09 (s, 4H) 6.79-6.87 (m, 1H) 4.64 (d, J=13.64 Hz, 1H) 4.46 (d,J=11.87 Hz, 1H) 3.92 (s, 2H) 3.58-3.64 (m, 1H) 3.55 (t, J=5.62 Hz, 1H)3.36-3.42 (m, 1H) 3.00 (t, J=8.65 Hz, 2H) 2.72-2.84 (m, 1H) 2.63-2.69(m, 1H) 1.98-2.08 (m, 1H) 1.68-1.83 (m, 4H) 0.85-0.92 (m, 2H) 0.81 (d,J=7.96 Hz, 2H). HRMS; calcd. for C₃₄H₃₃F₃N₅O₃(M+H) 616.2535, found616.2536.

Example 13 Example 13-A. tert-Butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)indolin-1-yl)methyl)-2-ethylphenyl)piperidine-1-carboxylate

Triphenylphosphine (723 mg, 2.76 mmol) and CBr₄ (916 mg, 2.76 mmol) wereadded to a solution of Intermediate 5-1 (840 mg, 2.63 mmol) indichloromethane (14 mL). The mixture was then stirred at roomtemperature for 16 h, and then concentrated. The resulting residue wasdissolved in DMF (6 mL). The DMF solution was then added dropwise to asuspension of Intermediate 4-1 (325 mg, 0.808 mmol) and K₂CO₃ (311 mg,3.423 mmol) in DMF (2.0 mL). The mixture was stirred at 65° C. for 3 h,and then cooled to room temperature. The reaction mixture waspartitioned between EtOAc and H₂O. The organic layer was then separated.The organic layer was then washed three times with brine, dried overNa₂SO₄, filtered, and concentrated. The resulting residue was purifiedby flash column chromatography (0-40% EtOAc/heptane gradient) to affordthe title compound. MS (ESI+) m/z 704.6 (M+H)

Example 13-B. Ethyl1-(6-(1-(3-ethyl-4-(piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

A solution of Example 13-A (517 mg, 0.735 mmol) and 4 N HCl in dioxanesolution (2 mL) in CH₂Cl₂ (5 mL) was stirred at room temperature for 1h. The reaction mixture was then concentrated. The resulting residue waspartitioned between EtOAc and saturated NaHCO₃. The isolated organiclayer was washed with brine, dried over Na₂SO₄, filtered, and thenconcentrated to furnish the title compound. MS (ESI+) m/z 604.4 (M+H).

Example 13-C. Ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

Cyclopropanecarbonyl chloride (0.028 mL, 0.309 mmol) was added to asolution of Example 13-B (143 mg, 0.237 mmol) in CH₂Cl₂ (2.0 mL) and TEA(0.165 mL, 1.187 mmol) at room temperature. The mixture was then stirredat room temperature for 3 h, and then concentrated. The resultingresidue was partitioned between EtOAc and H₂O. The isolated organiclayer was washed with brine, dried over Na₂SO₄, filtered, and thenconcentrated. The resulting residue was purified by flash columnchromatography (0-80% EtOAc/heptane gradient) to afford the titlecompound. MS (ESI+) m/z 672.5 (M+H).

Example 13.1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

LiOH (2.0M in H₂O; 167 μl, 0.335 mmol) was added dropwise to a solutionof Example 13-C (75 mg, 0.112 mmol) in EtOH (1 mL) and THF (1 mL). Themixture was then stirred at room temperature for 3 h. The pH of themixture was adjusted by addition of 1N aqueous HCl to ˜2. The mixturewas then concentrated. The residue was purified by RP-HPLC (HC-B) toprovide the title compound. ¹H NMR (400 MHz, Methanol-d₄) δ 7.94 (s, 1H)7.73-7.86 (m, 2H) 7.48 (dd, J=7.64, 1.07 Hz, 1H) 7.30 (d, J=6.82 Hz, 1H)7.14 (dd, J=7.20, 1.14 Hz, 1H) 7.02-7.07 (m, 1H) 6.92-6.98 (m, 1H) 6.88(d, J=1.52 Hz, 1H) 6.83 (t, J=7.52 Hz, 1H) 4.66 (d, J=12.76 Hz, 1H) 4.47(d, J=13.64 Hz, 1H) 3.91 (s, 2H) 3.41 (t, J=8.65 Hz, 2H) 3.22-3.28 (m,1H) 3.03-3.09 (m, 1H) 2.95-3.02 (m, 2H) 2.75 (t, J=12.32 Hz, 1H) 2.63(q, J=7.45 Hz, 2H) 1.95-2.06 (m, 1H) 1.51-1.86 (m, 4H) 1.13 (t, J=7.52Hz, 3H) 0.76-0.94 (m, 4H). HRMS; calcd. for C₃₆H₃₇F₃N₅O₃(M+H) 644.2849,found 644.2842.

Example 14 Example 14-A. tert-Butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)indolin-1-yl)methyl)-2-ethylphenyl)piperidine-1-carboxylate

A solution of Intermediate 5-2 (348 mg, 0.911 mmol) was added to asuspension of Intermediate 4-2 (300 mg, 0.828 mmol) and K₂CO₃ (318 mg,2.483 mmol) in DMF (6 mL). The mixture was stirred at 65° C. for 3 h,and then cooled to room temperature. The reaction mixture waspartitioned between EtOAc and H₂O. The organic layer was then separated.The organic layer was then washed three times with brine, dried overNa₂SO₄, filtered, and concentrated. The resulting residue was purifiedby flash column chromatography (0-40% EtOAc/heptane gradient) to affordthe title compound. MS (ESI+) m/z 664.6 (M+H).

Example 14-B. Ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

A solution of Example 14-A (487 mg, 0.734 mmol) and 4 N HCl in dioxanesolution (5 mL) in CH₂Cl₂ (2 mL) was stirred at room temperature for 16h. The reaction mixture was then concentrated to furnish the titlecompound as the HCl salt. MS (ESI+) m/z 564.3 (M+H).

Example 14-C. Ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)indolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate

Cyclopropanecarbonyl chloride (0.031 mL, 0.338 mmol) was added to asolution of Example 14-B (156 mg, 0.245 mmol) in CH₂Cl₂ (2.0 mL) and TEA(0.181 mL, 1.30 mmol) at room temperature. The mixture was then stirredat room temperature for 3 h. The resulting residue was partitionedbetween EtOAc and H₂O. The isolated organic layer was washed with brine,dried over Na₂SO₄, filtered, and then concentrated. The resultingresidue was purified by flash column chromatography (0-80% EtOAc/heptanegradient) to afford the title compound. MS (ESI+) m/z 632.5 (M+H).

Example 14.1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)indolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

LiOH (2.0M in water; 178 μl, 0.356 mmol) was added dropwise to asolution of Example 14-C (75 mg, 0.119 mmol) in EtOH (1 mL) and THF (1mL). The mixture was then stirred at 60° C. for 3 h. The pH of themixture was adjusted by addition of 1N aqueous HCl to ˜2. The mixturewas then concentrated. The residue was purified by RP-HPLC (HC-B) toprovide the title compound. ¹H NMR (400 MHz, Methanol-d₄) δ 7.95 (s, 1H)7.80-7.87 (m, 1H) 7.64 (dd, J=7.71, 0.76 Hz, 1H) 7.56 (dd, J=8.02, 0.69Hz, 1H) 7.24 (d, J=7.33 Hz, 1H) 7.14 (dd, J=7.14, 1.07 Hz, 1H) 7.00 (d,J=8.08 Hz, 1H) 6.89 (d, J=8.08 Hz, 1H) 6.79-6.86 (m, 2H) 4.64 (d,J=12.00 Hz, 1H) 4.45 (d, J=12.38 Hz, 1H) 3.91 (s, 2H) 3.37-3.44 (m, 4H)3.20-3.27 (m, 1H) 2.96-3.04 (m, 3H) 2.69-2.79 (m, 1H) 2.59 (q, J=7.58Hz, 2H) 1.96-2.06 (m, 1H) 1.49-1.84 (m, 4H) 1.17 (t, J=7.33 Hz, 3H) 1.10(t, J=7.58 Hz, 3H) 0.79-0.94 (m, 4H). HRMS; calcd. for C₃₇H₄₂N₅O₃ (M+H)604.3288, found 604.3279.

Example 15 Example 15-A. Ethyl1-(6-(1-(3-ethyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

To a solution of Example 13-B (121 mg, 0.200 mmol) in DMF (2 mL) wasadded potassium carbonate (77 mg, 0.600 mmol), followed by2,2,2-trifluoroethyl trifluoromethanesulfonate (84 mg, 0.360 mmol). Themixture was then stirred at 70° C. for 3 h. The reaction mixture wasdiluted with EtOAc. The organic phase was washed successively with H₂Oand brine, dried over Na₂SO₄ and concentrated. The resulting residue waspurified by flash column chromatography (0-50% EtOAc/heptane gradient)to afford the title compound. MS (ESI+) m/z 686.5 (M+H).

Example 15.1-(6-(1-(3-Ethyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

LiOH (2.0M in water; 0.18 mL, 0.36 mmol) was added dropwise to asolution of Example 15-A (83 mg, 0.121 mmol) in EtOH (1 mL) and THF (1mL). The mixture was then stirred at room temperature for 3 h. The pH ofthe mixture was adjusted by addition of 1N aqueous HCl to ˜2. Themixture was then concentrated. The residue was purified by RP-HPLC(HC-B) to provide the title compound. ¹H NMR (400 MHz, Methanol-d₄) δ8.09 (s, 1H) 7.83-7.89 (m, 1H) 7.77-7.82 (m, 1H) 7.49 (dd, J=7.71, 1.01Hz, 1H) 7.27 (d, J=6.69 Hz, 1H) 7.15 (dd, J=7.20, 1.14 Hz, 1H) 7.09 (d,J=7.96 Hz, 1H) 6.94 (dd, J=7.89, 1.71 Hz, 1H) 6.78-6.87 (m, 2H) 3.90 (s,2H) 3.41 (t, J=8.59 Hz, 2H) 3.09 (q, J=9.81 Hz, 4H) 2.99 (t, J=8.59 Hz,2H) 2.66-2.77 (m, 1H) 2.57 (q, J=7.58 Hz, 2H) 2.45-2.53 (m, 2H)1.72-1.87 (m, 2H) 1.60-1.69 (m, 2H) 1.10 (t, J=7.58 Hz, 3H) HRMS; calcd.for C₃₄H₃₄F₆N₅O₂(M+H) 658.2617, found 658.2590.

Example 16 Example 16-A. Ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

To a solution of Example 14-B (126 mg, 0.189 mmol) in DMF (2 mL) wasadded potassium carbonate (81 mg, 0.63 mmol), followed by2,2,2-trifluoroethyl trifluoromethanesulfonate (88 mg, 0.378 mmol). Themixture was then stirred at 70° C. for 3 h. The reaction mixture wasdiluted with EtOAc. The organic phase was washed successively with H₂Oand brine, dried over Na₂SO₄ and concentrated. The resulting residue waspurified by flash column chromatography (0-50% EtOAc/heptane gradient)to afford the title compound. MS (ESI+) m/z 646.5 (M+H).

Example 16.5-Ethyl-1-(6-(1-(3-ethyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

LiOH (2.0M in water; 0.18 mL, 0.356 mmol) was added dropwise to asolution of Example 16-A (75 mg, 0.119 mmol) in EtOH (1 mL) and THF (1mL). The mixture was then stirred at 60° C. for 3 h. The pH of themixture was adjusted by addition of 1N aqueous HCl to ˜2. The mixturewas then concentrated. The residue was purified by RP-HPLC (HC-B) toprovide the title compound ¹H NMR (400 MHz, Methanol-d₄) δ 7.97 (s, 1H)7.82-7.89 (m, 1H) 7.67 (dd, J=7.71, 0.76 Hz, 1H) 7.58 (d, J=7.20 Hz, 1H)7.24 (d, J=7.71 Hz, 1H) 7.13-7.17 (m, 1H) 7.06 (d, J=7.96 Hz, 1H) 6.89(d, J=7.71 Hz, 1H) 6.79-6.86 (m, 2H) 4.55 (s, 2H) 3.90 (s, 2H) 3.40-3.43(m, 2H) 3.38 (d, J=7.20 Hz, 2H) 3.04-3.10 (m, 4H) 2.96-3.03 (m, 2H) 2.54(q, J=7.75 Hz, 2H) 2.43-2.49 (m, 1H) 1.71-1.85 (m, 2H) 1.58-1.67 (m, 2H)1.19 (t, J=7.39 Hz, 3H) 1.07 (t, J=7.58 Hz, 3H). HRMS; calcd. forC₃₅H₃₉F₃N₅O₂(M+H) 618.3056, found 618.3049.

Example 17 Example 17-A. Ethyl5-ethyl-1-(6-(3-methyl-1H-indol-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

To a suspension of ethyl1-(6-bromopyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate, Intermediate1-4-2, (0.8 g, 2.27 mmol), bis(pinacolato)diboron (0.63 g, 2.5 mmol),and potassium acetate (0.31 g, 3.2 mmol) in dioxane (10 mL) was addedPd(dppf)Cl₂.CH₂Cl₂ adduct (0.15 g, 0.13 mmol). The mixture was thenstirred for 2 h at 100° C., and then cooled to room temperature. To thereaction mixture were then added 7-bromo-3-methyl-1H-indole(CAS#853355-96-1), Pd(dpp)Cl₂.CH₂Cl₂ adduct (0.15 g, 0.13 mmol), K₃PO₄(1.44 g, 6.8 mmol) and dioxane/H₂O (3 mL/6 mL). The mixture was thenstirred at 100° C. for 2 h, and then diluted with H₂O at roomtemperature. The mixture was then extracted twice with EtOAc. Thecombined organic layers were washed with brine, dried over Na₂SO₄,filtered, and then concentrated. The resulting residue was purified bysilica gel flash column chromatography (0 to 8% EtOAc in hexane) toafford the title compound. MS (ESI+) m/z 375.2 (M+H).

Example 17-B. (±)-Ethyl5-ethyl-1-(6-(3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

A mixture of ethyl5-ethyl-1-(6-(3-methyl-1H-indol-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(0.7 g, 1.87 mmol), triethylsilane (9.0 mL, 56 mmol), and TFA (3.3 mL)was stirred at room temperature for 24 h. The reaction mixture wasrendered basic by satd. aq. NaHCO₃. The mixture was then extracted twicewith EtOAc. The combined organic layers were dried over Na₂SO₄,filtered, and then concentrated. The resulting residue was purified bysilica gel flash column chromatography (0 to 6% EtOAc in hexane) toafford the title compound. MS (ESI+) m/z 377.2 (M+H).

Example 17-C. (±)-Ethyl5-ethyl-1-(6-(3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

A mixture of (±)-ethyl5-ethyl-1-(6-(3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(0.23 g, 0.6 mmol), tert-butyl4-(2-ethyl-4-(hydroxymethyl)phenyl)piperidine-1-carboxylate(Intermediate 5-2) (0.27 g, 0.72 mmol), and K₂CO₃ (0.41 g, 3.0 mmol) inCH₃CN (15 mL) was stirred at 65° C. for 24 h. The reaction mixture wasthen diluted with H₂O. The mixture was then extracted twice with EtOAc.The combined organic layers were washed with brine, dried over Na₂SO₄,filtered, and then concentrated. The resulting residue was purified bysilica gel flash column chromatography (0 to 18% EtOAc in hexane) toafford the title compound. MS (ESI+) m/z 678.5 (M+H).

Example 17-D. (±)-Ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

A mixture of (±)-ethyl5-ethyl-1-(6-(3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(0.54 g, 0.80 mmol) and TFA (1.2 mL) in CH₂Cl₂ (30 mL) was stirred at 0°C. for 3 h. The reaction mixture was rendered basic by satd. aq. NaHCO₃.The mixture was then extracted twice with EtOAc. The combined organiclayers were dried over Na₂SO₄, filtered, and then concentrated tofurnish the title compound. MS (ESI+) m/z 578.4 (M+H).

Example 17-E. a). Ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

To a solution of (±)-ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(as TFA salt, 0.2 g, 0.29 mmol), L-lactic acid (0.03 g, 0.35 mmol) andHATU (0.16 g, 0.43 mmol) in DMF (4 mL) at room temperature was addedDIPEA (0.3 mL, 1.73 mmol). The mixture was stirred at room temperaturefor 5 h. The reaction mixture was then diluted with H₂O. The mixture wasthen extracted twice with EtOAc. The combined organic layers were washedwith brine, dried over Na₂SO₄, filtered, and then concentrated. Theresulting residue was purified by silica gel flash column chromatography(0 to 50% EtOAc in hexane) to afford the title compound. MS (ESI+) m/z650.4 (M+H).

Example 17-E. b). Ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1) (Peak-1) and ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2) (Peak-2)

Resolution of the diastereomers of ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylatewas achieved by chiral SFC using CHIRALPAK® AS-H column with 25%2-propanol in CO₂ to afford ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1) (Peak-1, t_(r)=9.8 min) and ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2) (Peak-2, t_(r)=11.8 min).

Example 17a.5-Ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (Diastereomer-1)

To a solution of ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1) (Peak-1, t_(r)=9.8 min) (51 mg, 0.078 mmol) in MeOH(0.79 mL) and THF (0.79 mL) was added LiOH (1M aq) (0.79 mL, 0.79 mmol).The mixture was then stirred at 40° C. for 3 h, and then cooled to roomtemperature. The reaction mixture at 0° C. was rendered acidic by HCl(aq, 1 M) (0.86 mL, 0.86 mmol), and then extracted with EtOAc. Theaqueous layer was extracted with EtOAc. The combined organic layers wereconcentrated. The resulting residue was triturated with a mixture ofMeOH and DMSO. The resulting solid was collected by filtration to affordthe title compound. ¹H NMR (400 MHz, Methanol-d₄) δ 7.97 (s, 1H), 7.86(t, J=7.9 Hz, 1H), 7.65-7.62 (m, 1H), 7.60-7.56 (m, 1H), 7.24 (d, J=7.7Hz, 1H), 7.15-7.11 (m, 1H), 6.98 (d, J=8.0 Hz, 1H), 6.89-6.81 (m, 3H),4.69-4.54 (m, 2H), 4.16-4.06 (m, 1H), 3.96 (d, J=15.2 Hz, 1H), 3.84 (d,J=15.2 Hz, 1H), 3.59 (t, J=9.5 Hz, 1H), 3.39-3.34 (m, 2H), 3.23-3.14 (m,2H), 3.06-2.93 (m, 2H), 2.75 (t, J=13.2 Hz, 1H), 2.57 (q, J=7.6 Hz, 2H),1.79-1.68 (m, 2H), 1.68-1.52 (m, 2H), 1.39-1.30 (m, 3H), 1.27 (d, J=6.8Hz, 3H), 1.19 (t, J=7.3 Hz, 3H), 1.09 (t, J=7.5 Hz, 3H). HRMS; calcd.for C₃₇H₄₄N₅O₄ (M+H) 622.3393, found 622.3401.

Example 17b.5-Ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (Diastereomer-2)

Saponification of ethyl5-ethyl-1-(6-(1-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2) (Peak-2, t_(r)=11.8 min) by the similar method asdescribed for the synthesis of Example 17a afforded the title compoundafter purification by RP-HPLC (HC-B). ¹H NMR (400 MHz, Methanol-d₄) δ8.05-7.97 (m, 1H), 7.90 (s, 1H), 7.70-7.65 (m, 1H), 7.63 (s, 1H),7.29-7.25 (m, 1H), 7.19-7.14 (m, 1H), 7.00 (s, 1H), 6.87 (d, J=7.6 Hz,3H), 4.73-4.56 (m, 2H), 4.20-4.09 (m, 1H), 4.03-3.96 (m, 1H), 3.92-3.84(m, 1H), 3.67-3.59 (m, 1H), 3.38 (d, J=7.3 Hz, 2H), 3.31-3.13 (m, 2H),3.02 (s, 2H), 2.85-2.73 (m, 1H), 2.61 (d, J=7.6 Hz, 2H), 1.81-1.54 (m,4H), 1.41-1.30 (m, 6H), 1.22 (t, J=7.3 Hz, 3H), 1.12 (t, J=7.5 Hz, 3H).HRMS; calcd. for C₃₇H₄₄N₅O₄ (M+H) 622.3380, found 622.3383.

Example 18.(S)-5-Ethyl-1-(6-(1-(4-(1-(2-hydroxypropanoyl)piperidin-4-yl)-2-methylbenzyl)indolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by the method as outlined in thesynthesis of Example 17 (i.e. 17-A→17-B→17-C→17-D→17-E. a)→17a) butusing 7-bromoindole in the place of 7-bromo-3-methyl-1H-indole in thestep of Example 17-A. ¹H NMR (400 MHz, DMSO-d₆) δ 7.81 (s, 1H), 7.66(dd, J=7.8, 8.0 Hz, 1H), 7.57 (dd, J=0.8, 8.0 Hz, 1H), 7.38 (d, J=7.6Hz, 1H), 7.22 (d, J=7.8 Hz, 1H), 7.17 (d, J=7.2 Hz, 2H), 6.93-7.00 (m,1H), 6.85-6.91 (m, 1H), 6.80 (dd, J=7.3, 7.6 Hz, 1H), 4.39-4.56 (m, 2H),4.01-4.14 (m, 1H), 3.84 (s, 2H), 3.32-3.41 (m, 5H), 2.99-3.10 (m, 2H),2.58-2.73 (m, 2H), 1.86 (s, 3H), 1.68-1.81 (m, 2H), 1.32-1.59 (m, 2H),1.15-1.23 (m, 3H), 1.08 (t, J=7.3 Hz, 3H). HRMS; calcd. for C₃₅H₄₀N₅O₄(M+H) 594.3080, found 594.3068.

Example 19 Example 19-A. (±)-Ethyl1-(6-(3-methyl-1H-indol-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

The title compound was synthesized in fashion analogous to the synthesisof Example 17-A but using ethyl1-(6-bromopyridin-2-yl)-5-(trifliuoromethyl)-1H-pyrazole-4-carboxylate(Intermediate 1-1) instead of Intermediate 1-4-2. MS (ESI+) m/z 415.2(M+H).

Example 19-B. (±)-Ethyl1-(6-(3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

The title compound was synthesized starting from ethyl1-(6-(3-methyl-1H-indol-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylatein fashion analogous to the synthesis of Example 17-B. MS (ESI+) m/z417.0 (M+H).

Example 19-C. a). (±)-Ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

The title compound was synthesized by alkylation of (±)-ethyl1-(6-(3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylatewith(4-(4-(bromomethyl)-2-ethylphenyl)piperidin-1-yl)(cyclopropyl)methanone,Intermediate 5-3, by an analogous method as described in the synthesisof Example 17-C. MS (ESI+) m/z 686.4 (M+H).

Example 19-C. b). Ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(Enantiomer-1) and ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(Enantiomer-2)

Resolution of the enantiomers of (±)-ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylatewas achieved by chiral HPLC using CHIRALPAK® IA column with 70% (0.1%DEA in hexane) in EtOH to afford ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(enantiomer-1, t_(r)=11.6 min) and ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r)=13.3 min).

Example 19a.(+)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

The title compound was saponified starting from ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(enantiomer-1, t_(r)=11.6 min) by the similar method as described forthe synthesis of Example 1. a). ¹H NMR (400 MHz, Methanol-d₄) δ 8.12 (s,1H) 7.85-7.91 (m, 1H) 7.78 (dd, J=7.8, 0.7 Hz, 1H) 7.49 (dd, J=7.8, 0.7Hz, 1H) 7.27 (d, J=7.6 Hz, 1H) 7.14 (d, J=7.3 Hz, 1H) 6.98-7.03 (m, 1H)6.90-6.95 (m, 1H) 6.82-6.88 (m, 2H) 4.61-4.71 (m, 1H) 4.42-4.52 (m, 1H)3.94-4.02 (m, 1H) 3.81-3.89 (m, 1H) 3.60 (t, J=9.5 Hz, 1H) 3.20-3.28 (m,2H) 2.99-3.09 (m, 1H) 2.92-2.99 (m, 1H) 2.70-2.80 (m, 1H) 2.62 (q, J=7.5Hz, 2H) 1.96-2.05 (m, 1H) 1.49-1.85 (m, 4H) 1.27 (d, J=6.8 Hz, 3H) 1.12(t, J=7.6 Hz, 3H) 0.76-0.96 (m, 4H). HRMS; calcd. for C₃₇H₃₉F₃N₅O₃(M+H)658.3005, found 658.2997.

Example 19b.(−)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

Saponification of ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r)=13.3 min) as described for the synthesis ofExample 1. a) afforded the title compound. ¹H NMR and HRMS weresubstantially identical to Example 19a.

Example 20

The following compounds can be synthesized as outlined for thepreparation of Example 19 using the appropriate intermediates delineatedin the table in place of Intermediate 1-1 and Intermediate 5-4respectively. The racemic sample was resolved by the conditionsdescribed in the table.

Chemical name Exam- Intermediate 1 ple Chemical structure Intermediate 5NMR and HRMS Resolution conditions of enantiomers. (+)- and(−)-Carboxylic acids derived from their corresponding resolved esterenantiomers. 20-1

1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid Intermediate 1-4-2 Intermediate 5-3¹H NMR (400 MHz, DMSO-d₆) δ 7.92-7.85 (m, 1H), 7.83 (s, 1H), 7.67-7.62(m, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.23 (d, J = 7.7 Hz, 1H), 7.14 (d, J= 7.1 Hz, 1H), 7.04 (d, J = 7.9 Hz, 1H), 6.92-6.79 (m, 3H), 4.59-4.28(m, 2H), 4.00-3.90 (m ,1H), 3.81-3.77 (m, 1H), 3.56-3.52 (m, 1H),3.46-3.36 (m, 3H), 3.17 (s, 2H), 2.98-2.83 (m, 2H), 2.69-2.52 (m, 3H),2.03-1.94 (m, 1H), 1.73-1.32 (m, 4H), 1.23 (d, J = 6.8 Hz, 3H), 1.13 (t,J = 7.3 Hz, 3H), 1.05 (t, J = 7.5 Hz, 3H), 0.84-0.62 (m, 4H). HRMS;calcd. for C₃₈H₄₄N₅O₃ (M + H) 618.3445, found 618.3298. Resolutionconditions of enantiomers of corresponding esters: Ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate wassubjected to chiral SFC using CHIRALCEL ® OJ-H column with 5% MeOH with0.1% TFA in CO₂ to give (+)-ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(t_(r) = 2.95 min) and (−)-ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(t_(r) = 3.36 min). (+)-20-1:(+)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyraozle-4-carboxylic acidwas derived from saponification of (+)-ethyl1-(6-(1-(4-(1-(cyclopropanecarobnyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(t_(r) = 2.95 min). (−)-20-1:(−)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acidwas derived from saponification of (−)-ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(t_(r) = 3.36 min). 20-2

1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid Intermediate 1-4-2Intermediate 5-6 ¹H NMR (400 MHz, DMSO-d₆) δ 7.94 (s, 1 H) 7.69-7.78 (m,1 H) 7.60 (d, J = 7.5 Hz, 1 H) 7.44 (d, J = 7.6 Hz, 1 H) 7.13-7.24 (m, 3H) 6.96 (d, J = 7.8 Hz, 1 H) 6.90 (s, 1 H) 6.83 (t, J = 7.5 Hz, 1 H)4.45-4.55 (m, 1 H) 4.30-4.40 (m, 1 H) 3.91 (d, J = 15.7 Hz, 1 H) 3.74(d, J = 15.7 Hz, 1 H) 3.46-3.57 (m, 1 H) 3.25-3.29 (m, 3 H) 3.08-3.20(m, 1 H) 2.82-2.93 (m, 1 H) 2.58-2.76 (m, 2 H) 1.94-2.04 (m, 1 H) 1.86(s, 3 H) 1.67-1.83 (m, 2 H) 1.33-1.58 (m, 2 H) 1.29 (d, J = 6.7 Hz, 3 H)1.12 (t, J = 7.3 Hz, 3 H) 0.69 (d, J = 7.8 Hz, 4 H). HRMS; calcd. forC₃₇H₄₂N₅O₃ (M + H) 604.3288, found 604.3242. Resolution conditions ofenantiomers of corresponding esters: (±)-Ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate wassubjected to chiral SFC using CHIRALPAK ® IA column with 30% 2-propanolin CO₂ to give ethyl1-(6-(1-(4-(1-(cyclopropanecarobnyl)piperidin-4-yl)-2-methylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate (enantiomer-1,t_(r) = 7.0 min) and ethyl1-(6-(1-(4-(1-cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r) = 7.8 min) (+)-20-2:(+)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acidwas derived from saponification of ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(enantiomer-1, t_(r) = 7.0 min). (−)-20-2:(−)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acidwas derived from saponification of ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r) = 7.8 min). 20-3

1-(6-(1-(4-(1-(Cyclopropanecarobnyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid Intermediate 1-3 Intermediate 5-3¹H NMR (400 MHz, Methanol-d₄) δ 7.96 (s, 1H), 7.85 (t, J = 7.9 Hz, 1H),7.60 (t, J = 7.3 Hz, 2H), 7.24 (d, J = 7.6 Hz, 1H), 7.13 (d, J = 7.2 Hz,1H), 6.98 (d, J = 8.0 Hz, 1H), 6.90- 6.81 (m, 3H), 4.64 (d, J = 14.2 Hz,1H), 4.45 (d, J = 14.5 Hz, 1H), 3.97 (d, J = 15.3 Hz, 1H), 3.82 (d, J =15.3 Hz, 1H), 3.60 (t, J = 9.5 Hz, 1H), 3.22 (q, J = 7.5 Hz, 1H),3.07-2.91 (m, 3H), 2.79 (s, 3H), 2.73 (t, J = 12.4 Hz, 1H), 2.58 (q, J =7.5 Hz, 2H), 2.04-1.96 (m, 1H), 1.84-1.48 (m, 4H), 1.28 (d, J = 6.8 Hz,3H), 1.10 (t, J = 7.5 Hz, 3H), 0.96-0.75 (m, 4H). HRMS; calcd. forC₃₇H₄₂N₅O₃ (M + H) 604.3288, found 604.3287. Resolution condition ofenantiomers of corresponding esters: (±)-Ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate wassubjected to chiral SFC using CHIRALPAK ® column with 30% 2-propanol inCO₂ to give ethyl 1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (enantiomer-1, t_(r)= 7.9 min) and ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r) = 9.8 min). (+)-20-3:(+)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acidwas derived from saponification of ethyl1-(6-(1-(4-(1-(cyclopropanecarobnyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(enantiomer-1, t_(r) = 7.9 min). (−)-20-3:(−)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acidwas derived from saponification of ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methylindolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r) = 9.8 min).

Example 21

The following compounds can be synthesized as outlined for thepreparation of Example 19, using appropriate materials in the table(Intermediate 1 and Intermediate 5) in place of (Intermediate 1-1 andIntermediate 5-4) respectively.

IUPAC name Exam- Intermediate 1 ple structure Intermediate 5 ¹H NMR andHRMS data 21-1

1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)indolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid Intermediate 1-3 Intermediate 5-6 ¹H NMR(400 MHz, Methanol-d₄) δ 7.93 (s, 1 H) 7.65-7.72 (m, 1 H) 7.52 (dd, J =8.0, 0.8 Hz, 1 H) 7.45 (dd, J = 7.7, 0.8 Hz, 1 H) 7.29 (d, J = 8.0 Hz, 1H) 7.14-7.20 (m, 2 H) 6.92 (d, J = 7.8 Hz, 1 H) 6.84 (s, 1 H) 6.80 (t, J= 7.5 Hz, 1 H) 4.52-4.69 (m, 2 H) 4.44 (d, J = 12.6 Hz, 1 H) 3.87 (s, 2H) 3.37-3.46 (m, 2 H) 3.18-3.26 (m, 1 H) 3.03-3.12 (m, 2 H) 2.76 (s, 3H) 2.66-2.78 (m, 1 H), 1.96-2.04 (m, 1 H) 1.86 (s, 3 H) 1.78-1.94 (m, 1H) 1.45-1.67 (m, 2 H) 1.26-1.34 (m, 1 H) 0.76-0.94 (m, 4 H). HRMS;calcd. for C₃₅H₃₈N₅O₃ (M + H) 576.2975, found 576.2975. 21-2

1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)indolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid Intermediate 1-4-2 Intermediate 5-6 ¹H NMR(400 MHz, Methanol-d₄) δ 7.91 (s, 1 H) 7.58-7.65 (m, 1 H) 7.49-7.40 (2H,m), 7.29 (d, J = 8.1 Hz, 1 H) 7.21 (d, J = 7.8 Hz, 1 H) 7.16 (dd, J =7.1, 1.2 Hz, 1 H) 6.98 (d, J = 7.8 Hz, 1 H) 6.88 (s, 1 H) 6.81 (t, J =7.5 Hz, 1 H) 4.41-4.68 (m, 4 H) 3.89 (s, 2 H) 3.37-3.46 (m, 4 H)3.02-3.11 (m, 2 H) 2.67-2.83 (m, 2 H) 1.97-2.06 (m, 1 H) 1.90 (s, 3 H)1.83 (d, J = 8.6 Hz, 1 H) 1.47-1.70 (m, 2 H) 1.13 (t, J = 7.4 Hz, 3 H)0.78-0.95 (m, 4 H). HRMS; calcd. for C₃₆H₄₀N₅O₃ (M + H) 590.3131, found590.3105.

Example 22 Example 22-A. a). (±)-Ethyl5-ethyl-1-(6-(2-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

The title compound was synthesized in fashion analogous to the synthesisof (±)-ethyl5-ethyl-1-(6-(3-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 17-B) but using 7-bromo-2-methyl-1H-indole (CAS#302912-38-5)instead of 7-bromo-3-methyl-1H-indole. MS (ESI+) m/z 377.2 (M+H).

Example 22-A. b). Ethyl5-ethyl-1-(6-(2-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Enantiomer-1) and ethyl5-ethyl-1-(6-(2-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Enantiomer-2)

Resolution of the enantiomers of (±)-ethyl5-ethyl-1-(6-(2-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylatewas achieved by HPLC using CHIRALPAK® IA column with 90% (0.1% DEA inhexane) in 2-propanol to afford ethyl5-ethyl-1-(6-(2-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(enantiomer-1, t_(r)=6.3 min) and ethyl5-ethyl-1-(6-(2-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r)=9.5 min).

Example 22a.(+)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized starting from ethyl5-ethyl-1-(6-(2-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(enantiomer-1, t_(r)=6.3 min) by a similar method described for thepreparation of Example 19-B. a) and saponified as in the Example 7a. ¹HNMR (400 MHz, Methanol-d₄) δ 8.00 (s, 1H), 7.84 (dd, J=7.8, 8.0 Hz, 1H),7.55-7.62 (m, 2H), 7.18 (d, J=8.0 Hz, 1H), 7.11 (dd, J=1.2, 7.2 Hz, 1H),6.88-6.94 (m, 1H), 6.69-6.82 (m, 3H), 4.58-4.67 (m, 1H), 4.36-4.48 (m,1H), 3.97-4.08 (m, 2H), 3.67-3.78 (m, 1H), 3.33-3.44 (m, 2H), 3.17-3.28(m, 2H), 2.92-3.03 (m, 1H), 2.66-2.77 (m, 1H), 2.47-2.63 (m, 3H),1.94-2.03 (m, 1H), 1.44-1.79 (m, 4H), 1.24-1.31 (m, 3H), 1.20 (t, J=7.27Hz, 3H), 1.00-1.08 (m, 3H), 0.76-0.94 (m, 4H). HRMS: calcd. for:C₃₈H₄₄N₅O₃ (M+H) 618.3444, found 618.3450.

Example 22b.(−)-1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2-methylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized starting from ethyl5-ethyl-1-(6-(2-methylindolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r)=9.5 min) by an analogous method as described forthe synthesis of Example 22a. ¹H NMR and HRMS data were substantiallyidentical to Example 22a.

Example 23 Example 23-A.(4-(4-((7-Bromo-3,3-dimethylindolin-1-yl)methyl)-2-ethylphenyl)piperidin-1-yl)(cyclopropyl)methanone

The title compound was synthesized by reaction of7-bromo-3,3-dimethylindoline (CAS#1260675-93-1) with(4-(4-(bromomethyl)-2-ethylphenyl)piperidin-1-yl)(cyclopropyl)methanone(Intermediate 5-3) by analogous method as described in the synthesis ofExample 17-C. MS (ESI+) m/z 495.4 (M+H).

Example 23.1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3,3-dimethylindolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by reaction of ethyl1-(6-bromopyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate (Intermediate1-4-2) with(4-(4-((7-Bromo-3,3-dimethylindolin-1-yl)methyl)-2-ethylphenyl)piperidin-1-yl)(cyclopropyl)methanoneby the similar method as described for the synthesis of Example 17-A,which was then saponified similarly to Example 7a. ¹H NMR (400 MHz,Methanol-d₄) δ 7.97 (s, 1H), 7.85 (dd, J=7.7, 8.0 Hz, 1H), 7.58 (d,J=7.8 Hz, 2H), 7.21 (dd, J=1.3, 7.7 Hz, 1H), 7.10 (dd, J=1.2, 7.3 Hz,1H), 6.98 (d, J=8.0 Hz, 1H), 6.80-6.88 (m, 3H), 4.64 (d, J=12.1 Hz, 1H),4.45 (br. d, J=12.9 Hz, 1H), 3.92 (s, 2H), 3.32-3.38 (m, 2H), 3.20-3.28(m, 1H), 3.18 (s, 2H), 2.96-3.06 (m, 1H), 2.67-2.79 (m, 1H), 2.57 (q,J=7.5 Hz, 2H), 1.95-2.04 (m, 1H), 1.47-1.82 (m, 4H), 1.29 (s, 6H), 1.20(t, J=7.3 Hz, 3H), 1.09 (t, J=7.5 Hz, 3H), 0.76-0.95 (m, 4H). HRMS;calcd. for C₃₉H₄₆N₅O₃ (M+H) 632.3601, found 632.3595.

Example 24 Example 24-A. Ethyl5-methyl-1-(6-(1-(2-methyl-4-(piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

The title compound was synthesized by the methods as described asoutlined in the preparation of Example 17 (i.e. Example17-A→17-B→17-C→17-D) starting from Intermediate 1-3, 7-bromoindole andIntermediate 5-5. MS (ESI+) m/z 536.5 (M+H).

Example 24-B. Ethyl1-(6-(1-(4-(1-cyclopropylpiperidin-4-yl)-2-methylbenzyl)indolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

To a solution of ethyl5-methyl-1-(6-(1-(2-methyl-4-(piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(130 mg, 0.24 mmol) in EtOH (2 mL) was added1-ethoxycyclopropyl)oxy]-trimethylsilane (CAS#27374-25-0) (0.078 mL,0.39 mmol), followed by AcOH (0.015 mL, 0.27 mmol) and NaCNBH₃ (31 mg,0.49 mmol). The mixture was then stirred at 70° C. for 16 h, and thendiluted with H₂O. The mixture was then extracted with CH₂Cl₂. Theorganic layer was then washed with brine, dried over MgSO₄, filtered andthen concentrated. The resulting residue was purified by silica gelflash column chromatography (isocratic, 40% EtOAc in heptane) to affordthe title compound. MS (ESI+) m/z 576.5 (M+H).

Example 24.1-(6-(1-(4-(1-Cyclopropylpiperidin-4-yl)-2-methylbenzyl)indolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by saponification of ethyl1-(6-(1-(4-(1-cyclopropylpiperidin-4-yl)-2-methylbenzyl)indolin-7-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylateby an analogous method as described for the synthesis of Example 7a. ¹HNMR (400 MHz, DMSO-d₆) δ 7.89 (s, 1H), 7.71 (dd, J=7.8, 8.0 Hz, 1H),7.61 (dd, J=0.8, 8.2 Hz, 1H), 7.39 (dd, J=0.8, 7.5 Hz, 1H), 7.14-7.20(m, 3H), 6.90-6.95 (m, 1H), 6.85 (br. s, 1H), 6.79 (dd, J=7.2, 7.7 Hz,1H), 3.82 (s, 2H), 3.33 (t, J=8.7 Hz, 2H), 2.97-3.07 (m, 4H), 2.78 (s,3H), 2.31-2.41 (m, 1H), 2.17-2.26 (m, 2H), 1.83 (s, 3H), 1.56-1.70 (m,3H), 1.43-1.55 (m, 2H), 0.38-0.44 (m, 2H), 0.26-0.32 (m, 2H). HRMS;calcd. for C₃₄H₃₈N₅O₂ (M+H) 548.3026, found 548.3000.

Example 25 Example 25-A. Ethyl1-(6-(1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

The title compound was synthesized by reaction of ethyl1-(6-(indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(Intermediate 4-1) with tert-butyl6-(bromomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate(CAS#622867-53-2) as outlined in the synthesis of Example 14 (i.e.Example 14-A→14-B). MS (ESI+) m/z 548.4 (M+H).

Example 25-B. Ethyl1-(6-(1-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

To a solution of ethyl1-(6-(1-((1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(90 mg, 0.16 mmol), picolinaldehyde (0.039 mL, 0.41 mmol), and AcOH(0.033 mL, 0.58 mmol) in DCE (2 mL) was added Na(OAc)₃BH (174 mg, 0.82mmol). The mixture was then stirred at room temperature for 16 h. Thereaction was then quenched with sat. aq. NaHCO₃. The mixture was thenextracted with CH₂Cl₂. The organic layer was then washed successivelywith H₂O, and brine, dried over Na₂SO₄, filtered, and then concentratedto furnish the title compound. MS (ESI+) m/z 639.5 (M+H).

Example 25.1-(6-(1-((2-(Pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by saponification of ethyl1-(6-(1-((2-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)methyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylateby an analogous method as described for the synthesis of Example 1. a).¹H NMR (400 MHz, DMSO-d₆) δ 8.48-8.54 (m, 1H), 8.12 (s, 1H), 7.96-8.02(m, 1H), 7.74-7.83 (m, 2H), 7.57-7.62 (m, 1H), 7.48 (d, J=7.8 Hz, 1H),7.25-7.30 (m, 1H), 7.14-7.23 (m, 2H), 6.79-6.91 (m, 4H), 3.82 (s, 2H),3.76 (s, 2H), 3.55 (s, 2H), 3.30 (t, J=8.6 Hz, 2H), 2.98 (t, J=8.6 Hz,2H), 2.66-2.77 (m, 4H). HRMS; calcd. for C₃₄H₃₀F₃N₆O₂(M+H) 609.2177,found 609.2196.

Example 26.1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)benzyl)-1H-indol-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

To a mixture of1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)benzyl)indolin-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid, Example 12, (21 mg, 0.034 mmol) in cyclopentylmethyl ether (1.0mL) was added o-chloranil (20 mg, 0.081 mmol) and the resulting orangemixture was permitted to stir for ca. 20 minutes. The mixture was thendiluted with saturated aqueous Na₂S₂O₃ and MeOH and stirred for ca. 5minutes. The mixture was then further diluted with dichloromethane. Theresulting layers were separated, and the aqueous layer was extracted twoadditional times with CH₂Cl₂. The organic layers were combined, driedover Na₂SO₄, filtered, and concentrated. The resulting residue waspurified by RP-HPLC (HC-A) to afford the title compound. ¹H NMR (400MHz, Methanol-d₄) δ8.11 (s, 1H) 7.75-7.86 (m, 1H) 7.66-7.74 (m, 1H)7.48-7.61 (m, 1H) 7.31 (d, J=3.16 Hz, 1H) 7.20 (d, J=6.95 Hz, 1H)7.09-7.16 (m, 1H) 7.04 (dd, J=7.33, 1.14 Hz, 1H) 6.83 (d, J=8.21 Hz, 2H)6.63 (d, J=3.28 Hz, 1H) 6.29 (d, J=8.08 Hz, 2H) 5.21 (s, 2H) 4.55-4.64(m, 1H) 4.36-4.46 (m, 1H) 2.61-2.74 (m, 2H) 2.27 (t, J=7.45 Hz, 1H)1.93-2.02 (m, 1H) 1.37-1.86 (m, 4H) 0.77-0.94 (m, 4H). HRMS; calcd. forC₃₄H₃₁F₃N₅O₃(M+H) 614.2379, found 614.2372.

Example 27.1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-1H-indol-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

To a mixture of1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)indolin-7-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid (Example 14) (30 mg, 0.05 mmol) in cyclopropylmethyl ether (1.1 mL)was added o-chloranil (28 mg, 0.114 mmol) and the resulting orangemixture was permitted to stir for ca. 20 minutes. The mixture was thendiluted with dichloromethane, saturated aqueous Na₂S₂O₃, and MeOH andstirred for ca. 5 minutes. The mixture was then further diluted withdichloromethane. The resulting layers were separated, and the aqueouslayer was extracted two additional times with dichloromethane. Theorganic layers were dried via passing through a phase separator and thenconcentrated. The resulting residue was purified by RP-HPLC (HC-A) toafford the title compound. ¹H NMR (400 MHz, Methanol-d₄) δ8.04 (s, 1H)7.79-7.88 (m, 1H) 7.72 (td, J=7.15, 0.98 Hz, 2H) 7.34 (d, J=3.18 Hz, 1H)7.19 (dd, J=7.58, 0.61 Hz, 1H) 7.10-7.15 (m, 1H) 7.03-7.07 (m, 1H) 6.75(d, J=7.82 Hz, 1H) 6.65 (d, J=3.18 Hz, 1H) 6.02-6.10 (m, 2H) 5.17 (s,2H) 4.55-4.66 (m, 1H) 4.33-4.44 (m, 1H) 3.10-3.21 (m, 3H) 2.88 (tt,J=11.92, 3.48 Hz, 1H) 2.67 (t, J=12.35 Hz, 1H) 2.41 (q, J=7.58 Hz, 2H)1.92-2.02 (m, 1H) 1.39-1.69 (m, 4H) 1.02 (t, J=7.34 Hz, 3H) 0.95 (t,J=7.52 Hz, 3H) 0.77-0.90 (m, 4H). HRMS; calcd. for C₃₇H₄₀N₅O₃ (M+H)602.3131, found 602.3103.

Example 28 Example 28-A. Ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methyl-1H-indol-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate

To a solution of ethyl1-(6-(3-methyl-1H-indol-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(Example 19-A), (130 mg, 0.314 mmol) in THF (2 mL) at 0° C. was added60% NaH in oil (12 mg, 0.3 mmol). The mixture was permitted to stir for10 minutes, at which time a solution of(4-(4-(bromomethyl)-2-ethylphenyl)piperidin-1-yl)(cyclopropyl)methanone,Intermediate 5-3, (90 mg, 0.26 mmol) in THF (1 mL) was added. After ca.10 minutes the mixture was brought to room temperature and DMF (1 mL)was added. The mixture was then placed at 45° C. for 1.5 h, and then anadditional aliquot of NaH was added (3 mg, 0.075 mmol) and heating at45° C. was continued for another 1.5 h. The mixture was then cooled toroom temperature and quenched with a 3:1 mixture of MeOH:AcOH. Theresulting mixture was diluted with sat aq. NaHCO₃, and further dilutedwith ethyl acetate. The resulting layers were separated, and the aqueouslayer was extracted an additional two times with ethyl acetate. Theorganic layers were combined, dried over Na₂SO₄, filtered andconcentrated. The resulting residue was purified by silica gel flashcolumn chromatograph (heptane/EtOAc=90/10 to 10/90) to afford the titlecompound. MS (ESI+) m/z 684.5 (M+H).

Example 28.1-(6-(1-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methyl-1H-indol-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by saponification of ethyl1-(6-(1-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-3-methyl-1H-indol-7-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylateby the similar method as described for the synthesis of Example 1. a).¹H NMR (400 MHz, Methanol-d₄) δ 8.15 (s, 1H) 7.77 (t, J=7.83 Hz, 1H)7.66 (dd, J=7.83, 1.14 Hz, 1H) 7.48-7.57 (m, 1H) 7.09-7.22 (m, 2H)6.99-7.09 (m, 2H) 6.78 (d, J=8.08 Hz, 1H) 6.08-6.22 (m, 2H) 5.12 (s, 2H)4.57-4.68 (m, 1H) 4.35-4.48 (m, 1H) 2.87-3.00 (m, 1H) 2.64-2.79 (m, 1H)2.45 (q, J=7.58 Hz, 2H) 2.38 (s, 3H) 1.92-2.03 (m, 1H) 1.36-1.79 (m, 5H)0.99 (t, J=7.58 Hz, 3H) 0.77-0.89 (m, 4H). HRMS; calcd. forC₃₇H₃₇F₃N₅O₃(M+H) 656.2849, found 656.2863.

Example 29 Example 29-A. (S)-tert-Butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidine-1-carboxylate

To a suspension of ethyl1-(6-bromopyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate, Intermediate1-4-2, (0.85 g, 2.62 mmol), KOAc (0.4 g, 4.08 mmol), andbis(pinacolato)diboron (0.8 g, 3.15 mmol) in dioxane (10 mL) was addedPd(dppf)Cl₂.CH₂Cl₂ adduct (0.1 g, 0.122 mmol). The mixture was thenstirred at 100° C. for 1 h, and then cooled to room temperature.

To a suspension of (S)-tert-butyl4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidine-1-carboxylate,Intermediate 3-4-5, (0.8 g, 1.6 mmol) and K₃PO₄ (1 g, 4.71 mmol) indioxane/H₂O (5 mL/10 mL) was added the reaction mixture prepared above,followed by Pd(dppf)Cl₂.CH₂Cl₂ adduct (0.1 g, 0.122 mmol). The mixturewas then stirred at 100° C. for 15 h, and then cooled to roomtemperature. The reaction mixture was then diluted with EtOAc. Theorganic phase was washed with H₂O and brine, and then dried over Na₂SO₄.The organic extracts were then filtered through a plug of silica gel,which was rinsed with EtOAc. The filtrate was then concentrated. Theresulting residue was purified by silica gel flash column chromatography(heptane/EtOAc=88/12) to afford the title compound. MS (ESI+) m/z 665.5(M+H).

Example 29-B. (S)-Ethyl5-ethyl-1-(6-(3-(3-ethyl-4-(piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

To a solution of (S)-tert-butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidine-1-carboxylate(720 mg, 1.08 mmol) in CH₂Cl₂ (15 mL) at 0° C. was addeddiisopropylethylamine (840 mg, 6.50 mmol), followed by TMSOTf (481 mg,2.17 mmol). The mixture was stirred at 0° C. for 10 minutes. Thereaction was quenched with addition of satd. aq. NaHCO₃ (15 mL). Thebi-phasic mixture was separated. The organic phase was washed withbrine, dried over Na₂SO₄, filtered, and then concentrated. The resultingresidue was purified by silica gel flash column chromatography(CH₂Cl₂/MeOH=100:0 to 90:10) to afford the title compound. MS (ESI+) m/z565.4 (M+H).

Example 29-C. (S)-Ethyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidine-1-carboxylate

To a solution of (S)-ethyl5-ethyl-1-(6-(3-(3-ethyl-4-(piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(100 mg, 0.177 mmol) in CH₂Cl₂ (1.25 mL) at room temperature were addedtriethylamine (54 mg, 0.531 mmol) and ethyl chloroformate (21 mg, 0.195mmol). The mixture was stirred at room temperature for 1 h, and thendiluted with EtOAc. The mixture was then washed successively with satd.aq. NaHCO₃, and brine, dried over Na₂SO₄, filtered, and thenconcentrated. The resulting residue was purified by silica gel flashcolumn chromatography (heptane/EtOAc=100:0 to 50:50) to afford the titlecompound. MS (ESI+) m/z 637.4 (M+H).

Example 29.(S)-1-(6-(3-(4-(1-(Ethoxycarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by a saponification of (S)-ethyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidine-1-carboxylateby a similar manner as described for the synthesis of Example 7a,followed by RP-HPLC purification (HC-B). ¹H NMR (400 MHz, Methanol-d₄) b7.93 (s, 1H) 7.84-7.90 (m, 1H) 7.70 (dd, J=7.8, 0.7 Hz, 1H) 7.59 (d,J=8.0 Hz, 2H) 7.42-7.49 (m, 2H) 6.97 (d, J=8.6 Hz, 1H) 6.55 (dd, J=8.5,2.7 Hz, 1H) 6.50 (d, J=2.7 Hz, 1H) 6.17 (dd, J=6.2, 2.3 Hz, 1H) 4.25 (d,J=11.7 Hz, 2H) 4.14 (q, J=7.1 Hz, 2H) 3.28-3.37 (m, 2H) 3.21 (dt,J=15.9, 7.8 Hz, 1H) 2.80-3.04 (m, 4H) 2.53-2.62 (m, 2H) 2.38-2.50 (m,1H) 2.17-2.27 (m, 1H) 1.64-1.75 (m, 2H) 1.50-1.63 (m, 2H) 1.28 (t, J=7.1Hz, 3H) 1.09-1.15 (m, 6H). HRMS; calcd. for C₃₆H₄₁N₄O₅ (M+H) 609.3077,found 609.3072.

Example 30 Example 30-A. Ethyl5-ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

To a solution of (S)-ethyl5-ethyl-1-(6-(3-(3-ethyl-4-(piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 29-B) (0.146 g, 0.259 mmol), DIPEA (0.135 mL, 0.776 mmol), andL-(+)-lactic acid (0.047 g, 0.517 mmol) in DMF (1.3 mL) was added HATU(0.123 g, 0.323 mmol). The mixture was then stirred at room temperaturefor 0.5 h, and then diluted with H₂O/brine (ca. 1/1). The mixture wasthen extracted twice with EtOAc. The combined organic layers were washedwith brine, dried over Na₂SO₄, filtered, and then concentrated. Theresulting residue was absorbed onto silica gel, which was purified bysilica gel flash column chromatography (0-60% EtOAc in heptane) toafford the title compound. MS (ESI+) m/z 637.4 (M+H).

Example 30.5-Ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by saponification of ethyl5-ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylateby the similar method for the synthesis of Example 7a, followed byRP-HPLC purification (HC-C). ¹H NMR (400 MHz, DMSO-d₆) δ 7.92-8.00 (m,2H) 7.71-7.77 (m, 1H) 7.68 (dd, J=8.1, 0.6 Hz, 1H) 7.56-7.62 (m, 1H)7.48-7.54 (m, 1H) 7.44-7.48 (m, 1H) 6.97 (d, J=8.3 Hz, 1H) 6.58 (dd,J=8.6, 2.6 Hz, 1H) 6.50 (s, 1H) 6.13 (dd, J=6.0, 2.2 Hz, 1H) 4.80 (br.s., 1H) 4.31-4.59 (m, 2H) 4.06 (d, J=11.0 Hz, 1H) 3.22-3.28 (m, 2H)3.03-3.20 (m, 2H) 2.80-3.00 (m, 2H) 2.59-2.73 (m, 1H) 2.52-2.58 (m, 2H)2.38-2.47 (m, 1H) 2.02-2.18 (m, 1H) 1.64 (d, J=12.10 Hz, 2H) 1.33-1.57(m, 2H) 1.23-1.18 (m, 3H) 1.03-1.14 (m, 6H). HRMS; calcd. for C₃₆H₄₁N₄O₅(M+H) 609.3077, found 609.3077.

Example 31

The following compound can be synthesized by a similar method asoutlined for the synthesis of Example 30 but using the carboxylic acidin the table instead of employing the L-(+)-lactic acid used in Example30-A.

Exam- IUPAC name ple Chemical structure Carboxylic acid ¹H NMR and HRMSdata 31-1

5-Ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenxoy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4- carboxylic acid(S)-2-hydroxypentanoic acid (CAS# 41014-93-1) ¹H NMR (400 MHz, CDCl₃) δ8.05 (d, J = 4.0 Hz, 1 H) 7.66-7.82 (m, 4 H) 7.42-7.53 (m, 2 H)6.96-7.02 (m, 1 H) 6.66 (t, J = 8.1 Hz, 2 H) 5.91-5.84 (m, 1 H) 4.78(br. s., 1 H) 4.43 (br. s., 1 H) 3.85 (d, J = 12.5 Hz, 1 H) 3.37-3.47(m, 2 H) 3.26-3.14 (m, 1H), 3.13- 3.00 (m, 1H), 2.80-2.90 (m, 2 H)2.72-2.80 (m, 1 H) 2.57-2.66 (m, 2 H) 2.35 (d, J = 3.9 Hz, 2 H) 1.83(br. s., 2 H) 1.44-1.71 (m, 6 H) 1.09-1.29 (m, 6 H) 0.79-1.03 (m, 4 H).HRMS; calcd. for C₃₈H₄₅N₄O₅ (M + H) 637.3390, found 637.3379. 31-2

5-Ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid(S)-2-hydroxybutanoic acid (CAS# 3347-90-8) ¹H NMR (400 MHz, DMSO-d₆) δ7.93-8.01 (m, 2 H) 7.72-7.77 (m, 1 H) 7.69 (d, J = 8.1 Hz, 1 H)7.56-7.62 (m, 1 H) 7.49-7.54 (m, 1 H) 7.44-7.48 (m, 1 H) 6.97 (d, J =8.6 Hz, 1 H) 6.59 (dd, J = 8.6, 2.7 Hz, 1 H) 6.50 (br. s., 1 H) 6.13(dd, J = 6.0, 2.2 Hz, 1 H) 4.67 (br. s., 1 H) 4.53 (d, J = 12.2 Hz, 1 H)4.20-4.31 (m, 1 H) 4.06 (d, J = 13.3 Hz, 1 H) 3.22- 3.30 (m, 2 H)3.06-3.18 (m, 2 H) 2.80-3.01 (m, 2 H) 2.62-2.74 (m, 1 H) 2.53-2.59 (m, 2H) 2.44 (dd, J = 14.1, 6.4 Hz, 1 H) 2.01-2.16 (m, 1 H) 1.57-1.73 (m, 3H) 1.32-1.56 (m, 3 H) 1.02-1.17 (m, 6 H) 0.90 (q, J = 7.5 Hz, 3 H).HRMS; calcd. for C₃₇H₄₃N₄O₅ (M + H) 623.3233, found 623.3236. 31-3

5-Ethyl-1-(6-((S)-3-(3-ethyl-4-(1-((S)-3-hydroxy-2-methylpropanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4- carboxylic acid(S)-3-hydroxy-2-methylpropanoic acid (CAS# 26543-05-5) ¹H NMR (400 MHz,DMSO-d₆) δ 7.93-8.00 (m, 2 H) 7.72-7.77 (m, 1 H) 7.69 (dd, J = 8.1, 0.6Hz, 1 H) 7.57-7.62 (m, 1 H) 7.49-7.54 (m, 1 H) 7.44-7.49 (m, 1 H) 6.94-7.02 (m, 1 H) 6.59 (dd, J = 8.6, 2.5 Hz, 1 H) 6.51 (d, J = 2.2 Hz, 1 H)6.11-6.16 (m, 1 H) 4.58 (d, J = 13.0 Hz, 1 H) 4.10 (br. s., 1 H) 3.58(br. s., 1 H) 3.21-3.29 (m, 4 H) 3.07- 3.19 (m, 2 H) 2.83-3.02 (m, 3 H)2.53-2.65 (m, 2 H) 2.44 (dd, J = 14.0, 6.5 Hz, 1 H) 2.07-2.17 (m, 1 H)1.31-1.74 (m, 4 H) 1.13-1.06 (m, 6 H) 1.01-0.95 (m, 3 H). HRMS; calcd.for C₃₇H₄₃N₄O₅ (M + H) 623.3233, found 623.3222 31-4

(S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(1-hydroxycyclobutanecarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole- 4-carboxylic acid1-hydroxycyclobutanecarboxylic acid (CAS# 41248-13-9) ¹H NMR (400 MHz,DMSO-d₆) δ 7.94-8.00 (m, 2 H) 7.75 (dd, J = 7.7, 0.6 Hz, 1 H) 7.69 (dd,J = 8.1, 0.6 Hz, 1 H) 7.56-7.62 (m, 1 H) 7.49-7.54 (m, 1 H) 7.45-7.49(m, 1 H) 6.99 (d, J = 8.6 Hz, 1 H) 6.59 (dd, J = 8.6, 2.7 Hz, 1 H) 6.50(br. s., 1 H) 6.13 (d, J = 4.0 Hz, 1 H) 5.89 br. s., 1 H) 4.51 (d, J =12.5 Hz, 1 H) 4.18 (d, J = 13.1 Hz, 1 H) 3.27 (d, J = 7.6 Hz, 2 H) 3.14(dt, J = 15.9, 7.8 Hz, 1 H) 2.82-3.06 (m, 3 H) 2.53-2.70 (m, 5 H) 2.44(dd, J = 14.5, 6.9 Hz, 1 H) 1.97-2.15 (m, 3 H) 1.69-1.80 (m, 1 H)1.55-1.67 (m, 3 H) 1.51-1.39 (m ,2 H) 1.05-1.24 (m, 6 H). HRMS: calcd.for C₃₈H₄₃N₄O₅ (M + H) 635.3233, found 635.3248.

Example 32 Example 32-A. (±)-Potassium 4-hydroxy-2-methylbutanoate

To a solution of (±)-3-methyldihydrofuran-2(3H)-one (CAS#1679-47-6)(0.95 mL, 10 mmol) in THF (25 mL) and MeOH (25 mL) was added 1M aq. KOH(10.5 mL, 10.5 mmol). The mixture was then stirred at room temperaturefor 3 h, and then concentrated. The resulting residue was trituratedwith acetone, and then the resulting white solid was collected byfiltration to furnish the title compound. ¹H NMR (400 MHz, D₂O) δ 3.58(t, J=7.0 Hz, 2H) 2.24-2.53 (m, 1H) 1.79 (dq, J=14.8, 6.9 Hz, 1H) 1.58(dq, J=13.6, 6.9 Hz, 1H) 1.08 (d, J=7.0 Hz, 3H).

Example 32-B. a). Ethyl5-ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

The title compound was synthesized by reaction of (S)-ethyl5-ethyl-1-(6-(3-(3-ethyl-4-(piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 29-B) with (±)-potassium 4-hydroxy-2-methylbutanoate asdescribed for the synthesis of Example 30-A. MS (ESI+) m/z 665.5 (M+H).

Example 32-B. b). Ethyl5-ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Diastereomer-1) and ethyl5-ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Diastereomer-2)

Resolution of the diastereomers of ethyl5-ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylatewas achieved by chiral SFC using CHIRALPAK® AS-H column with 20% MeOH inCO₂ to give ethyl5-ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1) (t_(r)=3.0 min) and ethyl5-ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2) (t_(r)=4.7 min).

Example 32a.5-Ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicAcid (Diastereomer-1)

The title compound was synthesized by saponification of ethyl5-ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1) (t_(r)=3.0 min) in fashion analogous to Example 7a. ¹HNMR (400 MHz, DMSO-d₆) δ 7.89-8.01 (m, 2H) 7.74 (d, J=7.6 Hz, 1H) 7.68(d, J=8.0 Hz, 1H) 7.56-7.61 (m, 1H) 7.48-7.54 (m, 1H) 7.43-7.48 (m, 1H)6.97 (d, J=8.2 Hz, 1H) 6.58 (d, J=8.6 Hz, 1H) 6.50 (d, J=2.6 Hz, 1H)6.13 (d, J=4.8 Hz, 1H) 4.57 (d, J=11.6 Hz, 1H) 4.09 (d, J=13.0 Hz, 1H)3.36-3.46 (m, 2H) 3.21-3.28 (m, 2H) 3.06-3.19 (m, 2H) 2.82-3.01 (m, 3H)2.52-2.64 (m, 3H) 2.37-2.47 (m, 2H) 2.02-2.17 (m, 1H) 1.58-1.82 (m, 3H)1.30-1.54 (m, 3H) 1.05-1.14 (m, 6H) 1.01 (m, 3H). HRMS; calcd. forC₃₈H₄₅N₄O₅ (M+H) 637.3392, found 637.3390.

Example 32b.5-Ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (Diastereomer-2)

The title compound was synthesized from ethyl5-ethyl-1-(6-((3S)-3-(3-ethyl-4-(1-(4-hydroxy-2-methylbutanoyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2) (t_(r)=4.7 min) by a similar manner to Example 32a. ¹HNMR (400 MHz, DMSO-d₆) δ 7.91-8.01 (m, 2H) 7.74 (d, J=7.3 Hz, 1H) 7.69(d, J=8.0 Hz, 1H) 7.56-7.61 (m, 1H) 7.41-7.55 (m, 2H) 6.97 (d, J=8.4 Hz,1H) 6.58 (d, J=8.4 Hz, 1H) 6.50 (d, J=7.1 Hz, 1H) 6.12 (d, J=4.3 Hz, 1H)4.57 (d, J=12.1 Hz, 1H) 4.43 (br. s., 1H) 4.08 (d, J=11.9 Hz, 1H)3.35-3.47 (m, 2H) 3.26 (d, J=7.5 Hz, 2H) 3.05-3.18 (m, 2H) 2.81-3.01 (m,3H) 2.53-2.63 (m, 3H) 2.38-2.47 (m, 1H) 2.06-2.15 (m, 1H) 1.57-1.85 (m,3H) 1.30-1.55 (m, 3H) 1.13-1.06 (m 6H) 1.04-0.98 (m, 3H). HRMS; calcd.for C₃₈H₄₅N₄O₅ (M+H) 637.3401, found 637.3430.

Example 33 Example 33-A.(S)-1-(6-(3-(4-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

A mixture of (S)-tert-butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidine-1-carboxylate(Example 29-A) (0.204 g, 0.307 mmol) and potassium trimethylsilanolate(0.525 g, 3.68 mmol) in MTBE (1.5 mL) was stirred at 50° C. for 2 h. Thereaction mixture was diluted with H₂O and EtOAc. The pH of the aqueousphase was adjusted around pH 3. The organic layer was then separatedfrom the aqueous layer, dried over Na₂SO₄, filtered and thenconcentrated to furnish the title compound. MS (ESI+) m/z 637.4 (M+H).

Example 33.(S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(1-hydroxycyclopropanecarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

To a solution of(S)-1-(6-(3-(4-(1-(tert-butoxycarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid (0.097 g, 0.15 mmol) and DIPEA (0.080 mL, 0.457 mmol) in CH₂Cl₂(0.6 mL) at 0° C. was added TMSOTf (0.030 mL, 0.168 mmol). The mixturewas then stirred at 0° C. for 0.25 h. To the mixture was then addedadditional DIPEA (0.24 mL, 1.38 mmol), followed by TMSOTf (0.060 mL,0.336 mmol). The mixture was then stirred at 0° C. while in a separateflask, a solution of 1-hydroxycyclopropanecarboxylic acid (0.062 g,0.610 mmol) in DMF (0.6 ml) was charged with DIPEA (0.080 mL, 0.457mmol) and HATU (0.131 g, 0.345 mmol). The mixture was then stirred for 1h at room temperature, and was then added to the reaction mixture aboveat 0° C. The whole mixture was then stirred at room temperature for 0.25h. To this mixture was then added an additional aliquot of a solution of1-hydroxycyclopropanecarboxylic acid (0.062 g, 0.610 mmol) and DIPEA(0.080 mL, 0.457 mmol) and HATU (0.131 g, 0.345 mmol) in DMF (0.6 mL).The combined mixture was then stirred at room temperature for 2 h. Thereaction mixture was then diluted with H₂O, and then the aqueous layerwas brought to ca. pH 3 with 1 N aq. HCl. The organic layer was thendried over Na₂SO₄, filtered, and then concentrated. The resultingresidue was purified by RP-HPLC (HC-C) to afford the title compound. ¹HNMR (400 MHz, CDCl₃) δ 8.05 (s, 1H) 7.79-7.84 (m, 1H) 7.70-7.75 (m, 1H)7.61-7.69 (m, 2H) 7.45-7.50 (m, 1H) 7.40-7.44 (m, 1H) 6.94 (d, J=8.6 Hz,1H) 6.62 (dd, J=8.5, 2.6 Hz, 1H) 6.57 (d, J=2.6 Hz, 1H) 6.10 (d, J=2.7Hz, 1H) 4.71 (d, J=12.5 Hz, 2H) 3.22-3.40 (m, 2H) 2.86-3.12 (m, 3H) 2.60(q, J=7.5 Hz, 2H) 2.27 (d, J=7.3 Hz, 2H) 1.71-1.84 (m, 3H) 1.53-1.70 (m,2H) 1.46 (d, J=6.7 Hz, 2H) 1.09-1.27 (m, 8H) 1.03 (br. s., 2H). HRMS;calcd. for C₃₇H₄₁N₄O₅ (M+H) 621.3077, found 621.3063.

Example 34 Example 34-A. a). (±)-Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

To a solution of ethyl1-(6-bromopyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (Intermediate1-3) (155 mg, 0.50 mmol), bis(pinacolato)diboron (127 mg, 0.50 mmol),KOAc (82 mg, 0.83 mmol) in dioxane (1.1 ml) at room temperature wasadded Pd(dppf)Cl₂.CH₂Cl₂ adduct (24 mg, 0.029 mmol). The mixture wasthen stirred at 90° C. for 2.5 h, and then cooled to room temperature.

Separately, palladium diacetate (4.7 mg, 0.021 mmol) and1,1-bis(di-tert-butylphosphino)ferrocene (CAS#84680-95-5) (9.9 mg, 0.021mmol) were stirred in EtOH (0.56 mL) at 50° C. for 1 h, which was thenadded to the reaction mixture above. To this mixture was then added asolution of(±)-(4-(4-((4-bromo-2,3-dihydrobenzofuran-3-yl)amino)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone(Intermediate 3-9) (190 mg, 0.42 mmol) in dioxane (1.1 ml), followed bypotassium phosphate (2M in water) (0.63 mL, 1.25 mmol). The mixture wasthen stirred at 90° C. for 0.25 h, and then cooled to room temperature.The aqueous phase was removed and the organic phase was concentrated.The resulting residue was purified by silica gel flash chromatography toafford the title compound. MS (ESI+) m/z 606.5 (M+H).

Example 34-A. b). (+)-Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylateand (−)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

Resolution of the enantiomers of (±)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylatewas achieved by chiral SFC using CHIRALPAK® AD-H column with 35% MeOH inCO₂ to give (+)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(t_(r)=4.15 min) and (−)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(t_(r)=5.40 min).

Example 34a.(+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized starting from (+)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(t_(r)=4.15 min) by the similar method as described for the synthesis ofExample 7a. ¹H NMR (400 MHz, Methanol-d₄) δ 7.99 (dd, J=7.8, 8.0 Hz,1H), 7.83-7.91 (m, 2H), 7.55 (dd, J=0.9, 8.0 Hz, 1H), 7.36-7.45 (m, 2H),6.93-7.02 (m, 1H), 6.79 (dd, J=2.1, 8.1 Hz, 1H), 6.71 (d, J=1.7 Hz, 1H),6.41 (d, J=8.3 Hz, 1H), 5.55 (dd, J=3.2, 7.1 Hz, 1H), 4.74-4.80 (m, 1H),4.62 (br. d, J=12.7 Hz, 1H), 4.38-4.48 (m, 2H), 3.18-3.26 (m, 2H),2.58-2.77 (m, 2H), 2.51 (s, 3H), 1.96-2.04 (m, 1H), 1.76-1.95 (m, 2H),1.63 (s, 3H), 1.41-1.61 (m, 2H), 0.76-0.94 (m, 4H). HRMS; calcd. forC₃₄H₃₆N₅O₄ (M+H) 578.2767, found 578.2762.

Example 34b.(−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized starting from (−)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(t_(r)=5.40 min) by saponification using a similar method as describedfor the synthesis of Example 7a. ¹H NMR and HRMS data were substantiallyidentical to Example 34a.

Example 35 Example 35-A. (±)-tert-Butyl4-(4-((4-(6-(4-(ethoxycarbonyl)-5-methyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydrobenzofuran-3-yl)amino)-3-methylphenyl)piperidine-1-carboxylate

To a solution of ethyl1-(6-bromopyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (Intermediate1-3) (0.82 g, 2.65 mmol), bis(pinacolato)diboron (0.74 g, 2.92 mmol),KOAc (0.39 g, 3.98 mmol) in dioxane (20 ml) at room temperature wasadded P Pd(dppf)Cl₂.CH₂Cl₂ adduct (0.13 g, 0.16 mmol). The mixture wasthen stirred at 100° C. for 3 h, and then cooled to room temperature. Tothe reaction mixture were then added a solution of (±)-tert-butyl4-(4-((4-bromo-2,3-dihydrobenzofuran-3-yl)amino)-3-methylphenyl)piperidine-1-carboxylate(Intermediate 3-11) (0.9 g, 1.86 mmol) in dioxane/H₂O (15 mL/15 mL),K₃PO₄ (1.69 g, 7.96 mmol), and Pd(dppf)Cl₂.CH₂Cl₂ adduct (0.22 g, 0.27mmol). The mixture was then stirred at 100° C. for 2 h, and then cooledto room temperature. The reaction mixture was then diluted with EtOAc,and then washed successively with H₂O and brine, dried over Na₂SO₄,filtered, and then concentrated. The resulting residue was purified byflash chromatography (0% to 25% EtOAc in hexanes) to afford the titlecompound. MS (ESI+) m/z 638.4 (M+H).

Example 35-B. (±)-Ethyl5-methyl-1-(6-(3-((2-methyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

The title compound was synthesized by treatment of (±)-tert-butyl4-(4-((4-(6-(4-(ethoxycarbonyl)-5-methyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydrobenzofuran-3-yl)amino)-3-methylphenyl)piperidine-1-carboxylatewith TFA similar to the method described for the synthesis of Example17-D. MS (ESI+) m/z 538.3 (M+H).

Example 35-C. a). Ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

To a solution of (±)-ethyl5-methyl-1-(6-(3-((2-methyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(as TFA salt, 0.9 g, 1.38 mmol), L-lactic acid (0.15 g, 1.66 mmol) andHATU (0.78 g, 2.1 mmol) in DMF (20 mL) at room temperature was addedDIPEA (1.2 mL, 6.9 mmol). The mixture was stirred at room temperaturefor 18 h. The reaction mixture was then diluted with H₂O. The mixturewas then extracted twice with EtOAc. The combined organic layers werewashed with brine, dried over Na₂SO₄, filtered, and then concentrated.The resulting residue was purified by silica gel flash columnchromatography (0% to 4% MeOH in CH₂Cl₂) to afford the title compound.MS (ESI+) m/z 610.3 (M+H).

Example 35-C. b). Ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(diastereomer-1) and ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(diastereomer-2)

Resolution of the diastereomers of ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylatewas achieved by chiral HPLC using CHIRALPAK® IA column with 30% (0.2%Et₃N in EtOH) in hexane to afford ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(diastereomer-1) (t_(r)=9.6 min) and ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(diastereomer-2) (t_(r)=10.9 min).

Example 35a.(+)-1-(6-(3-((4-(1-((S)-2-Hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

A mixture of ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(diastereomer-1) (t_(r)=9.6 min) (65 mg, 0.11 mmol) and LiOH—H₂O (45 mg,1.1 mmol) in THF/MeOH/H₂O (3 mL/3 mL/3 mL) was stirred at 60° C. for 3h, and the cooled to room temperature. The reaction mixture wasneutralized with 1N HCl, and then extracted twice with CH₂Cl₂. Thecombined organic layers were washed with brine, dried over Na₂SO₄,filtered, and then concentrated. The resulting residue was purified bysilica gel flash column chromatography (0% to 10% MeOH in CH₂Cl₂) toafford the title compound. ¹H NMR (400 MHz, Methanol-d₄) δ 7.97-8.03 (m,1H), 7.89 (d, J=7.6 Hz, 1H), 7.85 (s, 1H), 7.55 (dd, J=0.8, 7.9 Hz, 1H),7.38-7.45 (m, 2H), 6.97 (dd, J=2.1, 6.9 Hz, 1H), 6.78 (d, J=8.3 Hz, 1H),6.70 (s, 1H), 6.40 (d, J=8.3 Hz, 1H), 5.52-5.58 (m, 1H), 4.77 (dd,J=7.2, 9.3 Hz, 1H), 4.58-4.66 (m, 2H), 4.44 (dd, J=3.2, 9.3 Hz, 1H),4.04-4.14 (m, 1H), 3.14-3.22 (m, 1H), 2.69-2.79 (m, 1H), 2.57-2.68 (m,1H), 2.50 (d, J=4.4 Hz, 3H), 1.80-1.93 (m, 2H), 1.62 (s, 3H), 1.43-1.60(m, 2H), 1.30-1.39 (m, 3H). HRMS; calcd. for C₃₃H₃₆N₅O₅ (M+H) 582.2716,found 582.2709.

Example 35b.(−)-1-(6-(3-((4-(1-((S)-2-Hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

Saponification of ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(diastereomer-2) (t_(r)=10.9 min) by the similar method as described forthe synthesis of Example 35a afforded the title compound. ¹H NMR (400MHz, Methanol-d₄) δ 7.95-8.02 (m, 1H), 7.82-7.89 (m, 2H), 7.55 (d, J=8.0Hz, 1H), 7.37-7.45 (m, 2H), 6.97 (dd, J=2.0, 6.9 Hz, 1H), 6.76-6.81 (m,1H), 6.70 (br. s, 1H), 6.41 (d, J=8.0 Hz, 1H), 5.56 (dd, J=2.9, 7.1 Hz,1H), 4.73-4.78 (m, 1H), 4.54-4.66 (m, 2H), 4.44 (dd, J=3.2, 9.3 Hz, 1H),4.04-4.14 (m, 1H), 3.15-3.22 (m, 1H), 2.69-2.79 (m, 1H), 2.58-2.68 (m,1H), 2.52 (s, 3H), 1.81-1.92 (m, 2H), 1.63 (s, 3H), 1.44-1.61 (m, 2H),1.27-1.39 (m, 3H). HRMS; calcd. for C₃₃H₃₆N₅O₅ (M+H) 582.2716, found582.2707.

Example 36

The following compounds can be synthesized as outlined for preparationsof Example 35 using appropriate materials in the table (Intermediate 1and Intermediate 3, and carboxylic acid). The racemic sample wasresolved by the conditions described in the table, for those cases ¹HNMR and HRMS data for (+)- and (−)-enantiomers were substantiallyidentical to the racemic sample.

Chemical name Intermediate 1 Exam- Intermediate 3 ple Chemical structureCarboxylic acid ¹H NMR and HRMS Resolution conditions of enantiomers.(+)- and (−)-Carboxylic acids derived from their corresponding resolvedester enantiomers. 36-1

1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole- 4-carboxylic acidIntermediate 1-1 Intermediate 3-10 Cyclopropanecarboxylic acids (CAS#1759-53-1) ¹H NMR (400 MHz, Methanol-d₄) δ 8.00-8.07 (m, 2H), 7.95 (s,1H), 7.53 (dd, J = 2.2, 6.5 Hz, 1H), 7.44-7.49 (m, 1H), 7.36-7.42 (m,1H), 6.97 (dd, J = 0.7, 8.0 Hz, 1H), 6.81 (d, J = 8.9 Hz, 1H), 6.20-6.27(m, 2H), 5.42-5.50 (m, 1H), 4.62-4.70 (m, 1H), 4.59 (dd, J = 6.7, 9.3Hz, 1H), 4.41-4.51 (m, 2H), 3.19-3.29 (m, 1H), 2.88-2.99 (m, 1H), 2.68-2.78 (m, 1H), 2.55 (q, J = 7.5 Hz, 2H), 1.97-2.06 (m, 1H), 1.78-1.87 (m,1H), 1.70-1.77 (m, 1H), 1.47-1.69 (m, 2H), 1.13 (t, J = 7.5 Hz, 3H),0.77-0.96 (m, 4H). HRMS; calcd. for C₃₅H₃₅F₃N₄O₄ (M + H) 646.28641,found 646.2651 Resolution conditions of enantiomers of correspondingesters: Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylatewas subjected to chiral HPLC using CHIRALPAK ® IA column with 60% (0.2%Et3N in hexane) in EtOH to give ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (enantiomer-1, t_(r) = 5.8 min) and ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r) = 6.8 min) (+)-36-1:(+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid was derived from saponification of ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r) = 6.8 min). (−)-36-1:(−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid was derived from saponification of ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(enantiomer-1, t_(r) = 5.8 min) 36-2

1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4- carboxylic acid Intermediate1-4-2 Intermediate 3-10 Cyclopropanecarboxylic acid (CAS# 1759-53-1))36-2 ¹H NMR (400 MHz, Methanol-d₄) δ 7.91-8.01 (m, 3 H) 7.58 (dd, J =7.7, 1.1 Hz, 1 H) 7.36-7.41 (m, 2 H) 6.93-6.99 (m, 1 H) 6.80-6.85 (m, 1H) 6.23-6.29 (m, 2 H) 5.50 (br. s., 1 H) 4.59-4.68 (m, 2 H) 4.40-4.50(m, 2 H) 3.14-3.27 (m, 3 H) 2.87-2.98 (m, 1 H) 2.67-2.78 (m, 1 H) 2.54(q, J = 7.5 Hz, 2 H) 1.95-2.05 (m, 1 H) 1.44-1.84 (m, 4 H) 1.12 (t, J =7.5 Hz, 3 H) 1.05 (t, J = 7.4 Hz, 3 H) 0.76-0.95 (m, 4 H). HRMS; calcd.for C₃₆H₄₀N₅O₄ (M + H) 606.3080, found 606.3066 Resolution conditions ofenantiomers of corresponding esters: Ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylatewas subjected to chiral HPLC using CHIRALPAK ® IA column with 70% (0.2%Et3N in hexane) in EtOH to give ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate (enantiomer-1, t_(r) = 9.6 min) and ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate (enantiomer-2, t_(r)= 13.4 min) (+)-36-2:(+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid was derived from saponification of ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate (enantiomer-1, t_(r)= 9.6 min).. (−)-36-2:(−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid was derived from saponification of ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydrobenzofuran-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate (enantiomer-2, t_(r)= 13.4 min)

Example 37 Example 37-A. a.) (±)-Ethyl1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

To a solution of Intermediate 1-3 (137 mg, 0.44 mmol),bis(pinacolato)diboron (112 mg, 0.44 mmol), and KOAc (80 mg, 0.80 mmol)in dioxane (2.0 mL) was addedchloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)-methyl-t-butylether adduct (CAS #1028206-58-7; 13.5 mg, 0.020 mmol). The mixture wasstirred at 110° C. for 3 h, and then cooled to room temperature.

To a solution of(±)-3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yltrifluoromethanesulfonate (Intermediate 6-1) (209 mg, 0.40 mmol) indioxane (2.0 mL) was added the reaction mixture above, followed by 2Maq. K₃PO₄ (0.4 mL, 0.80 mmol) andchloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)-methyl-t-butylether adduct (CAS #1028206-58-7; 13.5 mg, 0.020 mmol). The mixture wasthen stirred at 100° C. for 15 h, and then cooled to room temperature,and then concentrated with Celite®. The resulting residue was purifiedby silica gel flash chromatography to afford the title compound. MS(ESI+) m/z 603.5 (M+H).

Example 37. a).(±)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

Saponification of (±)-ethyl1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylateusing the similar procedure as described for the synthesis of Example 7aafforded the title compound. ¹H NMR (400 MHz, Methanol-d₄) δ 8.02 (s,1H), 7.92 (t, J=7.9 Hz, 1H), 7.66 (dd, J=8.1, 0.8 Hz, 1H), 7.44 (dd,J=7.7, 0.8 Hz, 1H), 7.36-7.31 (m, 2H), 7.31-7.25 (m, 1H), 6.73-6.67 (m,2H), 6.56 (d, J=7.7 Hz, 1H), 4.60 (d, J=13.5 Hz, 1H), 4.41 (d, J=13.4Hz, 1H), 4.28 (q, J=7.7 Hz, 1H), 3.26-3.07 (m, 2H), 2.94-2.85 (m, 1H),2.84 (s, 3H), 2.71 (d, J=12.9 Hz, 1H), 2.60 (d, J=12.1 Hz, 1H), 2.49(dd, J=13.5, 6.7 Hz, 1H), 2.41 (dd, J=13.6, 9.1 Hz, 1H), 2.17-2.05 (m,1H), 2.03-1.89 (m, 2H), 1.87-1.71 (m, 5H), 1.62-1.38 (m, 2H), 0.90-0.85(m, 2H), 0.84-0.77 (m, 2H). HRMS; calcd. for C₃₆H₃₉N₄O₃ (M+H) 575.3022,found 575.3056.

Example 37. b).(+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid and(−)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

Resolution of the enantiomers of(±)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALCEL® OJ-H column with 25%MeOH in CO₂ to afford(−)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r)=4.7 min) and(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r)=7.2 min). ¹H NMR and HRMS data for (+)- and (−)-enantiomerswere substantially identical to(±)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid.

Example 38

The following compounds can be synthesized as outlined for preparationsof Example 37 using appropriate materials in the table (Intermediate 1and Intermediate 6). The racemic sample was resolved by the conditionsdescribed in the table. ¹H NMR and HRMS data for (+)- and(−)-enantiomers were substantially identical to the racemic form.

Chemical name Exam- Intermediate 1 ple Chemical structure Intermediate 6¹H NMR and HRMS Resolution conditions of enantiomers. 38-1

1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid Intermediate1-4-2 Intermediate 6-2 ¹H NMR (400 MHz, Methanol-d₄) δ 8.09-8.03 (m,2H), 7.71 (d, J = 8.1 Hz, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.45-7.40 (m,1H), 7.31-7.27 (m, 2H), 6.88 (d, J = 8.0 Hz, 1H), 6.58 (d, J = 7.9 Hz,1H), 6.52 (s, 1H), 4.64 (d, J = 11.3 Hz, 1H), 4.49-4.40 (m, 1H),4.24-4.16 (m, 1H), 3.45-3.34 (m, 2H), 3.26-3.20 (m, 1H), 3.03-2.93 (m,1H), 2.93-2.78 (m, 2H), 2.77-2.68 (m, 1H), 2.55-2.44 (m, 3H), 2.30-2.21(m, 1H), 2.13-2.03 (m, 1H), 2.03-1.95 (m, 1H), 1.95-1.86 (m, 1H),1.83-1.45 (m, 4H), 1.17 (t, J = 7.3 Hz, 3H), 1.06 (t, J = 7.5 Hz, 3H),0.94-0.86 (m, 2H), 0.86-0.77 (m, 2H). HRMS; calcd. for C₃₈H₄₃N₄O₃ (M +H) 603.3335, found 603.3345. Resolution of the enantiomers of(±)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC using CHIRALCEL ® OJ-H columnwith 15% MeOH in CO₂ to give(−)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid (t_(r) = 4.50 min) and(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid (t_(r) = 5.25 min). 38-2

1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4- carboxylic acid Intermediate1-3 Intermediate 6-2 ¹H NMR (400 MHz, Methanol-d₄) δ 8.09-8.03 (m, 2H),7.78-7.73 (m, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.47-7.42 (m, 1H), 7.30 (s,1H), 7.29 (s, 1H), 6.86 (d, J = 7.9 Hz, 1H), 6.57 (d, J = 8.0 Hz, 1H),6.53 (s, 1H), 4.64 (d, J = 12.9 Hz, 1H), 4.49-4.40 (m, 1H), 4.26- 4.18(m, 1H), 3.27-3.19 (m, 1H), 3.02-2.89 (m, 2H), 2.88-2.79 (m, 4H), 2.72(t, J = 12.3 Hz, 1H), 2.54-2.46 (m, 3H), 2.28-2.20 (m, 1H), 2.12-1.95(m, 2H), 1.95-1.87 (m, 1H), 1.82-1.46 (m, 4H), 1.05 (t, J = 7.5 Hz, 3H),0.94-0.86 (m, 2H), 0.86-0.78 (m, 2H). HRMS; calcd. for C₃₇H₄₁N₄O₃ (M +H) 589.3179, found 589.3174. Resolution of the enantiomers of(±)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC using CHIRALPAK ® AD-H columnwith 30% MeOH with 5 mM NH₄OH in CO2 to give (−)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid (t_(r) = 3.25min) and (+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid (t_(r) = 4.65min). 38-3

1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid Intermediate 1-4-2Intermediate 6-1 ¹H NMR (400 MHz, Methanol-d₄) δ 8.05 (s, 1H), 7.94 (t,J = 7.9 Hz, 1H), 7.66-7.62 (m, 1H), 7.47 (d, J = 7.1 Hz, 1H), 7.33-7.26(m, 3H), 6.75-6.67 (m, 2H), 6.57 (d, J = 7.8 Hz, 1H), 4.60 (d, J = J =13.0 Hz, 1H), 4.42 (br s, 1H), 4.23 (q, J = 7.7 Hz, 1H), 3.42-3.34 (m,2H), 3.27-3.07 (m, 2H), 2.90 (dd, J = 16.2, 8.0 Hz, 1H), 2.74-2.56 (m,2H), 2.52-2.42 (m, 2H), 2.20-2.04 (m, 1H), 2.04-1.88 (m, 2H), 1.84-1.74(m, 5H), 1.61-1.38 (m, 2H), 1.18 (t, J = 7.3 Hz, 3H), 0.90-0.80 (m, 4H).HRMS; calcd. for C₃₇H₄₁N₄O₃ (M + H) 589.3179, found 589.3193. Resolutionof the enantiomers of(±)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC using CHIRALCEL ® OJ-H columnwith 30% MeOH in CO₂ to give(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ehtyl-1H-pyrazole-4-carboxylic acid (t_(r) = 2.3 min) and(−)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid (t_(r) = 3.5 min).

Example 39 Example 39-A. (±)-tert-Butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)methyl)-2-ethylphenyl)piperidine-1-carboxylate

To a suspension of ethyl1-(6-bromopyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate (Intermediate1-4-2) (448 mg, 1.382 mmol), bis(pinacolato)diboron (383 mg, 1.51 mmol),and KOAc (185 mg, 1.88 mmol) in dioxane (6.3 mL) was addedPd(dppf)Cl₂.CH₂Cl₂ adduct (48 mg, 0.063 mmol). The mixture was thenstirred at 90° C. for 2 h, and then cooled to room temperature. To thereaction mixture was added a solution of (±)-tert-butyl4-(2-ethyl-4-((7-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate(Intermediate 6-3) (713 mg, 1.256 mmol) in dioxane (6.3 mL), followed byK₃PO₄ (2M in water) (1.25 mL, 2.5 mmol) andchloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)-methyl-t-butylether adduct (CAS #1028206-58-7; 48 mg, 0.063 mmol). The mixture wasthen stirred at 90° C. for 0.5 h, and then cooled to room temperature.The mixture was filtered through a plug of Celite®, and then thefiltrate was diluted with EtOAc. The mixture was then washed with H₂O.The organic layer was then passed through an ISOLUTE® Phase Separatorand then concentrated. The resulting residue was purified by silica gelflash column chromatography to afford the title compound. MS (ESI+) m/z663.1 (M+H).

Example 39-B. (±)-Ethyl5-ethyl-1-(6-(3-(3-ethyl-4-(piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

A mixture of (±)-tert-butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)methyl)-2-ethylphenyl)piperidine-1-carboxylate(204 mg, 0.308 mmol) and TFA (240 μL, 3.1 mmol) in CH₂Cl₂ (3.1 mL) wasstirred at room temperature for 5 h, and then concentrated to afford thetitle compound. MS (ESI+) m/z 563.4 (M+H).

Example 39-C. Ethyl5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

To a solution of ethyl5-ethyl-1-(6-(3-(3-ethyl-4-(piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(as TFA salt, 173 mg, 0.31 mmol), DIPEA (160 μL, 0.92 mmol), andL-(+)-lactic acid (28 mg, 0.31 mmol) in DMF (3.1 mL) was added HATU (130mg, 0.338 mmol). The mixture was stirred at room temperature for 2 h,and then diluted with EtOAc. The mixture was then washed with halfsaturated brine. The aqueous layer was extracted with EtOAc. Thecombined organic layers were washed twice with brine, passed through aphase separator, and concentrated. The resulting residue was purified bysilica gel flash column chromatography to afford the title compound. MS(ESI+) m/z 635.4 (M+H).

Example 39. a).5-Ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

To a solution of a diastereomeric mixture of ethyl5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(104 mg, 0.164 mmol) in MeOH (1.6 mL) and THF (1.6 mL) was added LiOH(1M in water) (1.64 mL, 1.64 mmol). The mixture was stirred for 1 h at50° C., and then cooled to room temperature. The reaction was thenquenched with 1N HCl (1.8 mL, 1.8 mmol). The resulting suspension wasextracted with EtOAc. The aqueous layer was extracted with EtOAc. Thecombined organic layers were concentrated to afford the title compound.

Example 39. b).(−)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (diastereomer-1) and(+)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (diastereomer-2)

Resolution of the diastereomers of5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALPAK® AD-H column with 25%IPA in CO₂ to give(−)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (diastereomer-1) (t_(r)=6.95 min) and(+)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (diastereomer-2) (t_(r)=9.75 min).

Analytical data for(−)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (diastereomer-1) (t_(r)=6.95 min): ¹H NMR (400 MHz, Methanol-d₄) δ8.10-8.02 (m, 2H), 7.74-7.66 (m, 2H), 7.45-7.38 (m, 1H), 7.32-7.26 (m,2H), 6.87 (d, J=7.7 Hz, 1H), 6.58 (dd, J=1.7, 8.0 Hz, 1H), 6.52 (s, 1H),4.68-4.55 (m, 2H), 4.24-4.16 (m, 1H), 4.10 (br. d, J=12.7 Hz, 1H),3.47-3.33 (m, 1H), 3.23-3.13 (m, 1H), 3.03-2.69 (m, 4H), 2.55-2.43 (m,3H), 2.31-2.21 (m, 1H), 2.13-2.00 (m, 1H), 1.95-1.84 (m, 1H), 1.77-1.65(m, 2H), 1.64-1.49 (m, 2H), 1.40-1.26 (m, 4H), 1.17 (t, J=7.3 Hz, 3H),1.08-1.02 (m, 3H). HRMS: calcd. for C₃₇H₄₃N₄O₄ (M+H) 607.3284, found607.3276. Analytical data for(+)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (diastereomer-2); ¹H NMR (400 MHz, Methanol-d₄) δ 8.09-8.04 (m,2H), 7.73-7.67 (m, 2H), 7.45-7.39 (m, 1H), 7.32-7.27 (m, 2H), 6.87 (d,J=7.7 Hz, 1H), 6.58 (dd, J=7.9, 1.7 Hz, 1H), 6.52 (s, 1H), 4.68-4.55 (m,2H), 4.24-4.16 (m, 1H), 4.14-4.07 (m, 1H), 3.46-3.34 (m, 2H), 3.22-3.14(m, 1H), 3.03-2.69 (m, 4H), 2.55-2.44 (m, 3H), 2.30-2.21 (m, 1H),2.13-2.00 (m, 1H), 1.95-1.86 (m, 1H), 1.77-1.50 (m, 4H), 1.34 (dd,J=16.9, 6.6 Hz, 3H), 1.17 (t, J=7.4 Hz, 3H), 1.06 (t, J=7.5 Hz, 3H).HRMS; calcd. for C₃₇H₄₃N₄O₄ (M+H) 607.3284, found 607.3276.

Example 40

The following compounds were synthesized as outlined for the preparationof Example 39 using appropriate starting materials in the table(Intermediate 1, Intermediate 6, and carboxylic acid). The racemicsample was resolved by the conditions described in the table.

IUPAC name Intermediate 1 Exam- Intermediate 6 ple Compound structureCarboxylic Acid diastereomer separation condition Analytical data forthe diastereomer-1 (peak-1 in the diastereomer separation) Analyticaldata for the diastereomer-2 (peak-2 in the diastereomer separation) 40-1

5-Ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H- pyrazole-4-carboxylic acidIntermediate 1-4-2 Intermediate 6-3 (S)-2-hydroxypentanoic acid (CAS#41014-93-1) Resolution of the diastereomers of5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC using CHIRALPAK ®AD-H column with 25% IPA with 10 mM NH4OH in CO2 to give(−)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypentaoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (diasteromer-1) (t_(r) = 3.90 min)and (+)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (diastereomer-2)(t_(r) = 5.10 min).(−)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid(diastereomer-1) (t_(r) = 3.90 min): ¹H NMR (400 MHz, Methanol-d₄) δ8.09-8.03 (m, 2H), 7.73-7.66 (m, 2H), 7.44-7.39 (m, 1H), 7.32-7.26 (m,2H), 6.90-6.83 (m, 1H), 6.58 (br. d, J = 7.6 Hz, 1H), 6.52 (br. s., 1H),4.64 (br. d, J = 13.1 Hz, 1H), 4.52-4.43 (m, 1H), 4.24-4.16 (m, 1H),4.13-4.01 (m, 1H), 3.46-3.32 (m, 2H), 3.22-3.14 (m, 1H), 3.03-2.80 (m,3H), 2.80-2.68 (m, 1H), 2.55-2.43 (m, 3H), 2.30-2.20 (m, 1H), 2.13-1.99(m, 1H), 1.95-1.86 (m, 1H), 1.77-1.40 (m, 7H), 1.17 (t, J = 7.3 Hz, 3H),1.05 (t, J = 7.6 Hz, 3H), 1.02-0.93 (m, 3H), 0.93-0.81 (m, 1H). HRMS:calcd. for C₃₉H₄₇N₄O₄ (M + H) 635.3597, found 635.3611.(+)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid(diastereomer-2) (t_(r) = 5.10 min): ¹H NMR (400 MHz, Methanol-d₄) δ8.09-8.03 (m, 2H), 7.71 (d, J = 7.9 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H),7.45-7.39 (m, 1H), 7.32-7.26 (m, 2H), 6.89-6.84 (m, 1H), 6.58 (d, J =7.6 Hz, 1H), 6.52 (s, 1H), 4.64 (d, J = 13.0 Hz, 1H), 4.52-4.43 (m, 1H),4.24- 4.16 (m, 1H), 4.13-4.03 (m, 1H), 3.46-3.33 (m, 2H), 3.22-3.14 (m,1H), 2.97 (t, J = 12.2 Hz, 1H), 2.93-2.80 (m, 2H), 2.75 (t, J = 14.1 Hz,1H), 2.55-2.44 (m, 3H), 2.30-2.21 (m, 1H), 2.13-2.00 (m, 1H), 1.95-1.86(m, 1H), 1.77-1.42 (m, 9H), 1.17 (t, J = 7.3 Hz, 3H), 1.06 (t, J = 7.5Hz, 3H), 1.02-0.94 (m, 3H). HRMS: calcd. for C₃₉H₄₇N₄O₄ (M + H)635.3597, found 635.3618. 40-2

5-Ethyl-1-(6-(3-(4-(1((S)-2- hydroxypropanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid Intermediate 1-4-2Intermediate 6-4 L-(+)-lactic acid Resolution of the diastereomers of5-ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC usingCHIRALCEL ® OJ-H column with 25% MeOH in CO₂ to give(−)-5-ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (diastereomer-1) (t_(r) = 2.6 min)and (+)-5-ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (diastereomer-2)(t_(r) = 4.3 min).(−)-5-ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid(diastereomer-1) (t_(r) = 2.6 min): ¹H NMR (400 MHz, Methanol-d₄) δ 8.04(s, 1H), 7.94 (dd, J = 7.6, 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.47(d, J = 7.7 Hz, 1H), 7.25-7.37 (m, 3H), 6.67-6.74 (m, 2H), 6.54-6.60 (m,1H), 4.55-4.65 (m, 2H), 4.23 (q, J = 7.4 Hz, 1H), 4.07 (br. d. J = 13.0Hz, 1H), 3.25-3.44 (m, 2H), 3.08-3.19 (m, 2H), 2.86-2.95 (m, 1H),2.65-2.76 (m, 1H), 2.55-2.65 (m, 1H), 2.37-2.52 (m, 2H), 2.05-2.18 (m,1H), 1.87-1.97 (m, 1H), 1.71-1.84 (m, 5H), 1.41-1.62 (m, 2H), 1.29-1.38(m, 3H), 1.17 (t, J = 7.3 Hz, 3H). HRMS; calcd. for for C₃₆H₄₁N₄O₄ (M +H) 593.3128, found 593.3115.(+)-5-ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid(diastereomer-2) (t_(r) = 4.3 min): ¹H NMR (400 MHz, Methanol-d₄) δ 8.04(s, 1H), 7.94 (t, J = 7.9 Hz, 1H), 7.64 (d, J = 8.1 Hz, 1H), 7.47 (d, J= 7.7 Hz, 1H), 7.35-7.26 (m, 3H), 6.74-6.66 (m, 2H), 6.57 (d, J = 7.6Hz, 1H), 4.60 (d, J = 10.3 Hz, 2H), 4.23 (q, J = 7.4 Hz, 1H), 4.07 (d, J= 13.0 Hz, 1H), 3.42-3.30 (m, 2H), 3.19-3.07 (m, 2H), 2.90 (dd, J =15.9, 8.4 Hz, 1H), 2.70 (t, J = 13.0 Hz, 1H), 2.60 (t, J = 12.1 Hz, 1H),2.50-2.40 (m, 2H), 2.17-2.05 (m, 1H), 1.92 (dd, J = 12.4, 7.3 Hz, 1H),1.85-1.75 (m, 5H), 1.55-1.45 (m, 2H), 1.33 (dd, J = 11.6, 6.6 Hz, 3H),1.18 (t, J = 7.3 Hz, 3H). HRMS; calcd. for C₃₆H₄₁N₄O (M + H) 593.3128,found 593.3139. 40-3

5-Ethyl-1-(6-(3-(4-(1-((S)-2- hydroxypentanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid Intermediate 1-4-2Intermediate 6-4 (S)-2-hydroxypentanoic acid (CAS# 41014-93-1)Resolution of the diastereomers of (±)-5-ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC usingCHIRALCEL ® OJ-H column with 25% in CO₂ to give(−)-5-ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (diastereomer-1) (t_(r) = 2.4 min) and(+)-5-ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid (diastereomer-2)(t_(r) = 4.6 min).(−)-5-Ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid(diastereomer-1) (t_(r) = 2.4 min): ¹H NMR (400 MHz, Methanol-d₄) δ 8.04(s, 1H), 7.93 (dd, J = 7.8, 8.0 Hz, 1H), 7.64 (dd, J = 0.6, 8.1 Hz, 1H),7.47 (d, J = 7.7 Hz, 1H), 7.36-7.25 (m, 3H), 6.74- 6.66 (m, 2H),6.60-6.54 (m, 1H), 4.65-4.57 (m, 1H), 4.50-4.42 (m, 1H), 4.27-4.19 (m,1H), 4.10-4.00 (m, 1H), 3.44-3.24 (m, 2H), 3.18-3.07 (m, 2H), 2.94-2.85(m, 1H), 2.76-2.66 (m, 1H), 2.65-2.54 (m, 1H), 2.53-2.36 (m, 2H),2.17-2.04 (m, 1H), 1.96-1.88 (m, 1H), 1.84-1.71 (m, 5H), 1.70-1.38 (m,6H), 1.17 (t, J = 7.3 Hz, 3H), 1.01-0.93 (m, 3H). HRMS; calcd. forC₃₈H₄₅N₄O₄ (M + H) 621.3441, found 621.3445.(+)-5-Ethyl-1-(6-(3-(4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid(diastereomer-2) (t_(r) = 4.6 min): ¹H NMR (400 MHz, Methanol-d₄) δ 8.04(s, 1H), 7.93 (t, J = 7.9 Hz, 1H), 7.64 (d, J = 7.5 Hz, 1H), 7.47 (d, J= 7.8 Hz, 1H), 7.33-7.26 (m, 3H), 6.74-6.67 (m, 2H), 6.57 (dd, J = 7.7,3.9 Hz, 1H), 4.60 (d, J = 11.6 Hz, 1H), 4.50-4.40 (m, 1H), 4.23 (q, J =7.8 Hz, 1H), 4.05 (br s, 1H), 3.40-3.30 (m, 2H), 3.20-3.06 (m, 2H), 2.90(dd, J = 15.8, 8.3 Hz, 1H), 2.70 (t, J = 11.3 Hz, 1H), 2.61 (t, J = 12.1Hz, 1H), 2.52-2.39 (m, 2H), 2.18-2.04 (m, 1H), 1.92 (dd, J = 12.2, 7.6Hz, 1H), 1.85-1.76 (m, 5H), 1.70-1.38 (m, 6H), 1.17 (t, J = 7.3 Hz, 3H),1.03-0.93 (m, 3H). HRMS; calcd. for C₃₈H₄₅N₄O₄ (M + H) 621.3441, found621.3446.

Example 41 Example 41. a).(±)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by reaction of (±)-ethyl5-ethyl-1-(6-(3-(3-ethyl-4-(piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 39-B) with methyl chloroformate employing a similar manner asdescribed for the synthesis of Example 29-C, followed by saponificationas described in Example 7a. ¹H NMR (400 MHz, Methanol-d₄) δ 8.09-8.03(m, 2H), 7.71 (dd, J=8.0, 0.7 Hz, 1H), 7.68 (dd, J=7.7, 0.7 Hz, 1H),7.45-7.39 (m, 1H), 7.32-7.26 (m, 2H), 6.87 (d, J=7.9 Hz, 1H), 6.58 (dd,J=7.9, 1.8 Hz, 1H), 6.53-6.50 (m, 1H), 4.26-4.15 (m, 3H), 3.70 (s, 3H),3.45-3.33 (m, 2H), 2.96-2.78 (m, 5H), 2.53-2.44 (m, 3H), 2.30-2.20 (m,1H), 2.12-2.00 (m, 1H), 1.95-1.86 (m, 1H), 1.69-1.48 (m, 4H), 1.17 (t,J=7.4 Hz, 3H), 1.04 (t, J=7.6 Hz, 3H). HRMS; calcd. for C₃₆H₄₁N₄O₄ (M+H)593.3128, found 593.3149.

Example 41. b)(+)-Ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid and(−)-ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Resolution of the enantiomers of(±)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALPAK® AD-H column with 25%IPA in CO₂ to give(−)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (t_(r)=3.5 min) and(+)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (t_(r)=5.1 min). ¹H NMR and HRMS data for (+)- and (−)-enantiomerswere substantially identical to(±)-5-ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid.

Example 42 Example 42. a).(±)-5-Ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

The title compound was synthesized as outlined in the synthesis ofExample 41 but starting from ethyl1-(6-bromopyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate (Intermediate1-4-2) and (±)-tert-butyl4-(3-methyl-4-((7-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydro-1H-inden-1-yl)methyl)phenyl)piperidine-1-carboxylate(Intermediate 6-4) as the starting materials. ¹H NMR (400 MHz,Methanol-d₄) δ 8.04 (s, 1H), 7.93 (t, J=7.9 Hz, 1H), 7.64 (dd, J=8.1,0.7 Hz, 1H), 7.47 (dd, J=7.7, 0.7 Hz, 1H), 7.35-7.25 (m, 3H), 6.73-6.66(m, 2H), 6.56 (d, J=7.7 Hz, 1H), 4.28-4.14 (m, 3H), 3.69 (s, 3H),3.42-3.32 (m, 2H), 3.18-3.07 (m, 1H), 2.95-2.90 (m, 3H), 2.50-2.40 (m,3H), 2.13-2.08 (m, 1H), 1.92 (dd, J=12.5, 7.5 Hz, 1H), 1.79 (s, 3H),1.72 (t, J=12.2 Hz, 2H), 1.55-1.39 (m, 2H), 1.18 (t, J=7.3 Hz, 3H).HRMS; calcd. for C₃₅H₃₉N₄O₄ (M+H) 579.2971, found 579.2971.

Example 42. b).(+)-5-Ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid and(−)-5-ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Resolution of the enantiomers of(±)-5-ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALCEL® OJ-H column with 30%MeOH in CO₂ to give(−)-5-ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (t_(r)=2.3 min) and(+)-5-ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (t_(r)=3.9 min). ¹H NMR and HRMS data for (+)- and (−)-enantiomerswere substantially identical to(±)-5-ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid.

Example 43. (+)- and(−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

The title compounds were isolated via resolution of the enantiomers of(±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (Example 11-1) by chiral SFC using CHIRALCEL® OJ-H column with 5%to 55% MeOH in CO₂ to give(+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (t_(r)=3.23 min) and (−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (t_(r)=4.73 min). ¹H NMR and HRMS data for (+)- and (−)-enantiomerwere substantially identical to Example 11-1.

Example 44. (+)- and(−)-1-(3-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid

The title compounds were isolated via resolution of the enantiomers of(±)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid (Example 11-4) by chiral SFC using CHIRALPAK® AS-H column with5-55% MeOH in CO₂ to give(+)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r)=2.59 min) and(−)-1-(3-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r)=2.81 min). ¹H NMR and HRMS data for (+)- and (−)-enantiomerwere substantially identical to Example 11-4.

Example 45 Example 45-A. tert-Butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-methyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidine-1-carboxylate

TsOH (0.016 g, 0.083 mmol) was added to a solution of Intermediate 3-7(0.3 g, 0.830 mmol) and Intermediate 2-13 (0.24 g, 0.83 mmol) in toluene(8.3 mL), flask was fitted with a Dean-Stark trap and the mixture wasstirred at 130° C. for 17 hours. The mixture was cooled to roomtemperature and then concentrated. The residue was dissolved inanhydrous MeOH (8.3 mL) and cooled to 0° C. Sodium borohydride (0.031 g,0.83 mmol) was added and then the mixture was stirred at roomtemperature for 2 hours. Sodium borohydride (0.031 g, 0.83 mmol) wasadded again and the mixture was stirred for another 16 hours before onemore portion of sodium borohydride (0.031 g, 0.83 mmol) was added. Aftera total of 24 hours of stirring, the reaction was quenched with water,followed by saturated aq. ammonium chloride. The aqueous layer wasextracted with CH₂Cl₂. The organic layers were passed through anISOLUTE® Phase Separator, and then concentrated. The resulting residuewas purified by silica gel flash chromatography to give the titlecompound. MS (ESI+) m/z 636.5 (M+H).

Example 45-B. Ethyl5-methyl-1-(6-(3-((2-methyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

A 4M HCl in dioxane (700 μl, 2.8 mmol) was added to a solution ofExample 45-A (356 mg, 0.560 mmol) in anhydrous MeOH (5.6 mL) at 0° C.The mixture was then stirred at room temperature for 19 hours. Thereaction was quenched with 1M Na₂CO₃ (3 mL), and then extracted twicewith CH₂Cl₂. Combined organic extracts were passed through an ISOLUTE®Phase Separator. The organic layer was concentrated to furnish the titlecompound. MS (ESI+) m/z 536.4 (M+H).

Example 45-C. a) (±)-Ethyl1-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

HATU (94 mg, 0.246 mmol) was added to a solution of (±)-ethyl5-methyl-1-(6-(3-((2-methyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(120 mg, 0.224 mmol), DIPEA (117 μL, 0.672 mmol), andcyclobutanecarboxylic acid (18.32 μL, 0.220 mmol) in DMF (2.2 mL). Themixture was then stirred for 2 h, and then diluted with H₂O/brine (ca.1/1) and EtOAc. The bi-layer was then separated. The aqueous layer wasthen extracted with EtOAc. The combined organic layers were washed withbrine, dried, and concentrated to firnish the title compound. MS (ESI+)m/z 618.5 (M+H).

Example 45-C. b). (+)-Ethyl1-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylateand (−)-ethyl1-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

Resolution of the enantiomers of (±)-ethyl1-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylatewas achieved by chiral SFC using CHIRALPAK® AD-H column with 35% IPA inCO₂ to give (+)-ethyl1-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(t_(r)=4.77 min) and (−)-ethyl1-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(t_(r)=6.13 min).

Example 45a.(+)-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

The title compound was derived from saponification of (+)-ethyl1-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylateas described for the synthesis of Example 7a. ¹H NMR (400 MHz,Methanol-d₄) δ 7.90-7.85 (m, 2H), 7.72 (dd, J=7.8, 0.9 Hz, 1H), 7.56(dd, J=6.4, 2.5 Hz, 1H), 7.53 (dd, J=8.1, 0.8 Hz, 1H), 7.45-7.39 (m,2H), 6.80-6.75 (m, 1H), 6.69-6.66 (m, 1H), 6.54 (d, J=8.2 Hz, 1H),5.35-5.30 (m, 1H), 4.64-4.57 (m, 1H), 3.89 (d, J=13.4 Hz, 1H), 3.45-3.42(m, 1H), 3.24-3.15 (m, 1H), 3.12-3.03 (m, 1H), 2.97 (ddd, J=16.0, 8.7,4.4 Hz, 1H), 2.72-2.63 (m, 1H), 2.62-2.53 (m, 4H), 2.47 (ddt, J=12.9,8.6, 7.1 Hz, 1H), 2.37-2.25 (m, 2H), 2.24-2.16 (m, 2H), 2.13-2.06 (m,1H), 2.06-1.97 (m, 1H), 1.90-1.77 (m, 3H), 1.64 (s, 3H), 1.52-1.39 (m,2H). HRMS; calcd. for C₃₆H₄₀N₅O₃ (M+H) 590.3131, found 590.3106.

Example 45b.(−)-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by saponification of (−)-ethyl1-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylateas described for the synthesis of Example 7a. ¹H NMR and HRMS data weresubstantially identical to Example 45a.

Example 46

The following compounds were synthesized using appropriate materialsdenoted in the table below (Intermediate 3, Intermediate 2 andCarboxylic acid). Ketones as such as those described by Intermediate 3were condensed with anilines described in Intermediate 2 and reduced byanalogous method as described in Example 45-A. The resulting racemicesters were then deprotected (Boc removal) as described in Example 45-B.The resulting piperidine amines were coupled with the appropriateCarboxylic acid denoted in the table below as outlined in Example 45-C.a). The resulting racemic esters were then resolved by the conditionsdescribed in the table. Each enantiomer was independently saponified asdescribed in Example 45a to provide the title compound. ¹H NMR and HRMSdata for (+)- and (−)-enantiomers were substantially identical to theracemic form.

Chemical name Intermediate 3 Exam- Intermediate 2 ple Chemical structureCarboxylic acid ¹H NMR and HRMS Resolution conditions of enantiomers.(+)- and (−)-Carboxylic acids derived from their corresponding resolvedester enantiomers. 46-1

1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methyphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4- carboxylic acid Intermediate3-7 Intermediate 2-13 Isobutyric acid (CAS# 79-31-2) ¹H NMR (400 MHz,Methanol-d₄) δ 7.92-7.85 (m, 2H), 7.73 (dd, J = 7.8, 0.8 Hz, 1H),7.58-7.51 (m, 2H), 7.45-7.39 (m, 2H), 6.78 (dd, J = 8.7, 2.1 Hz, 1H),6.69 (d, J = 2.1 Hz, 1H), 6.55 (d, J = 8.2 Hz, 1H), 5.35-5.30 (m, 1H),4.66 (d, J = 13.0 Hz, 1H), 4.14 (d, J = 13.6 Hz, 1H), 3.25-3.15 (m, 2H),3.03-2.91 (m, 2H), 2.72-2.58 (m, 2H), 2.57 (d, J = 1.1 Hz, 3H),2.53-2.42 (m, 1H), 2.13-2.04 (m, 1H), 1.92-1.79 (m, 2H), 1.64 (s, 3H),1.59-1.40 (m, 2H), 1.12 (dd, J = 14.7, 6.7 Hz, 6H). HRMS; calcd. forC₃₅H₄₀N₅O₃ (M + H) 578.3131, found 578.2963. Resolution of theenantiomers of (±)-ethyl 1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate was achieved by chiral SFC using CHIRALPAK ® AS-H columnwith 5- 55% IPA in CO₂ to give (+)-ethyl1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (t_(r) = 2.70 min) and (−)-ethyl1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (t_(r) = 2.95 min). (+)-46-1:(+)-1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid was derived from saponification of (+)-ethyl1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate. (−)-46-1:(−)-1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid was derived from saponification of (−)-ethyl1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate. 46-2

5-Methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole- 4-carboxylic acidIntermediate 3-7 Intermediate 2-13 Propionic acid (CAS# 79-09-4) ¹H NMR(400 MHz, Methanol-d₄) δ 7.92-7.85 (m, 2H), 7.72 (dd, J = 7.8, 0.9 Hz,1H), 7.58-7.51 (m, 2H), 7.45-7.38 (m, 2H), 6.78 (d, J = 8.1 Hz, 1H),6.69 (d, J = 2.1 Hz, 1H), 6.55 (d, J = 8.3 Hz, 1H), 5.36-5.30 (m, 1H),4.69-4.60 (m, 1H), 4.04 (d, J = 13.8 Hz, 1H), 3.25-3.14 (m, 2H), 2.97(ddd, J = 16.1, 8.8, 4.4 Hz, 1H), 2.72-2.63 (m, 1H), 2.63-2.54 (m, 4H),2.53-2.40 (m, 3H), 2.13-2.03 (m, 1H), 1.90-1.77 (m, 2H), 1.64 (s, 3H),1.60- 1.41 (m, 2H), 1.14 (t, J = 7.5 Hz, 3H). HRMS; calcd. forC₃₄H₃₈N₅O₃ (M + H) 564.2974, found 564.2747. Resolution of theenantiomers of (±)-ethyl 5-methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate was achieved by chiral SFC using CHIRALPAK ® AS-Hcolumn with 5-55% IPA in CO₂ to give (+)-ethyl5-methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate (t_(r) = 3.02 min) and (−)-ethyl5-methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate (t_(r) = 3.20 min). (+)-46-2:(+)-5-Methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acidwas derived from saponification of (+)-ethyl5-methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate.(−)-46-2:(−)-5-Methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acidwas derived from saponification of (+)-ethyl5-methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate.46-3

1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4- carboxylic acid Intermediate3-7 Intermediate 2-13 Cyclopropylacetic acid (CAS# 5239-82-7) ¹H NMR(400 MHz, Methanol-d₄) δ 7.91-7.86 (m, 2H), 7.72 (dd, J = 7.8, 0.9 Hz,1H), 7.56 (dd, J = 6.4, 2.6 Hz, 1H), 7.53 (dd, J = 8.1, 0.8 Hz, 1H),7.45-7.39 (m, 2H), 6.78 (d, J = 8.2 Hz, 1H), 6.70-6.68 (m, 1H), 6.55 (d,J = 8.3 Hz, 1H), 5.35-5.30 (m, 1H), 4.66 (d, J = 12.7 Hz, 1H), 4.05 (d,J = 13.6 Hz, 1H), 3.22-3.15 (m, 2H), 2.97 (ddd, J = 16.0, 8.7, 4.4 Hz,1H), 2.68 (t, J = 12.9 Hz, 1H), 2.64-2.55 (m, 4H), 2.53-2.42 (m, 1H),2.37 (d, J = 6.9 Hz, 2H), 2.13-2.04 (m, 1H), 1.84 (t, J = 14.4 Hz, 2H),1.64 (s, 3H), 1.60-1.42 (m, 2H), 1.07-0.99 (m, 1H), 0.59-0.52 (m, 2H),0.24-0.19 (m, 1H). HRMS; calcd. for C₃₆H₄₀N₅O₃ (M + H) 590.3131, found590.2906. Resolution of the enantiomers of (±)-ethyl 1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate was achieved bychiral SFC using CHIRALPAK ® AS-H column with 5-55% IPA in CO₂ to give(+)-ethyl 1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (t_(r) = 3.28 min)and (−)-ethyl 1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-2-ylmethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (t_(r) =3.53 min). (+)-46-3:(+)-1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid was derived from saponification of (+)-ethyl1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate. (−)-46-3:(−)-1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboyxlicacid was derived from saponification of (−)-ethyl1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate. 46-4

1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-3-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4- carboxylic acidIntermediate 3-7 Intermediate 2-12-1 Cyclopropylacetic acid (CAS#5239-82-7) ¹H NMR (400 MHz, Methanol-d₄) δ 8.13 (t, J = 8.0 Hz, 1H),7.91 (d, J = 7.7 Hz, 1H), 7.76-7.65 (m, 3H), 7.57 (t, J = 7.6 Hz, 1H),7.50 (d, J = 7.6 Hz, 1H), 6.93 (s, 1H), 6.62 (d, J = 8.3 Hz, 1H), 5.48(d, J = 7.6 Hz, 1H), 4.75-4.64 (m, 1H), 4.13-4.02 (m, 1H), 3.27- 3.14(m, 2H), 3.09-2.97 (m, 2H), 2.78-2.66 (m, 4H), 2.51-2.42 (m, 1H), 2.38(t, J = 6.2 Hz, 2H), 2.21-2.12 (m, 1H), 1.94-1.78 (m, 5H), 1.69-1.49 (m,2H), 1.10-0.97 (m, 1H), 0.61-0.50 (m, 2H), 0.22 (t, J = 4.9 Hz, 2H).HRMS; calcd. for C₃₆H₃₉FN₅O₃ (M + H) 608.3037, found 608.2809.Resolution of the enantiomers of (±)-ethyl 1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate was achievedby chiral SFC using CHIRALPAK ® AD-H column with 40% IPA in CO₂ to givea.) ethyl 1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(Peak-1) (t_(r) = 3.01 min) and b.) ethyl1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (Peak-2) (t_(r) = 4.89 min). (+)- or (−)-46-4:1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid was derived from saponification of ethyl1-(-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (Peak-1)(t_(r) = 3.01 min). (−)- or (+)-46-4:1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid was derived from saponification of ethyl1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (Peak-2)(t_(r) = 4.89 min). 46-5

1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-5-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4- carboxylic acidIntermediate 3-7 Intermediate 2-12-2 Cyclopropylacetic acid (CAS#5239-82-7) ¹H NMR (400 MHz, Methanol-d₄) δ 7.93-7.87 (m, 2H), 7.70 (dd,J = 7.7, 0.8 Hz, 1H), 7.58-7.52 (m, 2H), 7.46-7.38 (m, 2H), 6.63 (d, J =8.5 Hz, 1H), 6.24 (dd, J = 13.5, 3.3 Hz, 1H), 5.37-5.31 (m, 1H),4.73-5.62 (m, 1H), 4.05 (t, J = 13.8 Hz, 1H), 3.23-3.14 (m, 2H),3.03-2.93 (m, 1H), 2.93-2.85 (m, 1H), 2.74-2.63 (m, 1H), 2.61 (d, J =1.8 Hz, 3H), 2.57-2.46 (m, 1H), 2.36 (t, J = 6.6 Hz, 2H), 2.08-1.99 (m,1H), 1.90-1.73 (m, 2H), 1.69- 1.46 (m, 5H), 1.08-0.98 (m, 1H), 0.59-0.52(m, 2H), 0.25-0.17 (m, 2H). HRMS; calcd. for C₃₆H₃₉FN₅O₃ (M + H)608.3037, found 608.2852. Resolution of the enantiomers of (±)-ethyl1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-5-fluoro-2-methylpehnyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate was achievedby chiral SFC using CHIRALPAK ® AS-H column with 42% IPA in CO₂ to give(+)-ethyl 1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-5-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(t_(r) = 4.18 min) and (−)-ethyl1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-5-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (t_(r) = 6.45 min). (+)-46-5:(+)-1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-5-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid was derived from saponification of (+)-ethyl1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-5-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate. (−)-46-5:(−)-1-(6-(3-((4-(1-(2-Cyclopropylacetyl)piperidin-4-yl)-5-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid was derived from saponification of (−)-ethyl1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-5-fluoro-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate. 46-6

1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4- carboxylic acid Intermediate3-7 Intermediate 2-10 Cyclopropanecarboxylic acid ¹H NMR (400 MHz,Methanol-d₄) δ 7.95-7.90 (m, 2H), 7.82 (dd, J = 7.8, 0.9 Hz, 1H),7.60-7.56 (m, 2H), 7.44-7.37 (m, 2H), 6.80 (d, J = 8.3 Hz, 1H),6.32-6.27 (m, 2H), 5.26 (dd, J = 6.7, 2.6 Hz, 1H), 4.64 (d, J = 13.2 Hz,1H), 4.45 (d, J = 13.5 Hz, 1H), 3.26-3.14 (m, 2H), 2.97-2.86 (m, 2H),2.77-2.67 (m, 4H), 2.52 (q, J = 7.5 Hz, 2H), 2.39-2.28 (m, 1H),2.17-2.09 (m, 1H), 2.04-1.96 (m, 1H), 1.79 (d, J = 13.3 Hz, 1H), 1.71(d, J = 13.1 Hz, 1H), 1.66-1.44 (m, 2H), 1.11 (t, J = 7.5 Hz, 3H),0.93-0.86 (m, 2H), 0.85-0.78 (m, 2H). HRMS; calcd. for C₃₆H₄₀N₅O₃ (M +H) 590.3131, found 590.3104. Resolution of the enantiomers of (±)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate-was achieved bychiral SFC using CHIRALPAK ® AS-H column with 30% IPA in CO₂ to give(+)-ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (t_(r) = 3.25 min)and (−)-ethyl 1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperdin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (t_(r) =6.25 min). (+)-46-6:(+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid was derived from saponification of (+)-ethyl1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate (t_(r) = 3.25 min).

Example 47 Example 47-A. a). Ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

The title compound was synthesized by reaction of ethyl5-methyl-1-(6-(3-((2-methyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 45-B) with (+)-lactic acid in fashion analogous to thepreparation of Example 45-C. a) MS (ESI+) m/z 608.5 (M+H).

Example 47-A. b). (+)-Ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(Diastereomer-1) and (−)-ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(Diastereomer-2)

Resolution of the diastereomers of ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylatewas achieved by chiral SFC using CHIRALCEL® OJ-H column with 5% to 55%EtOH gradient in CO₂ to give (+)-ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(diastereomer-1) (t_(r)=2.58 min) and (−)-ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(diastereomer-2) (t_(r)=2.99 min).

Example 47a.(+)-1-(6-(3-((4-(1-((S)-2-Hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid (Diastereomer-1)

Saponification of (+)-ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(diastereomer-1) (t_(r)=2.58 min) by the similar method to thepreparation of Example 7a, followed by RP-HPLC (HC-B) purificationafforded the title compound. ¹H NMR (400 MHz, Methanol-d₄) δ 7.91-7.86(m, 2H), 7.72 (dd, J=7.8, 0.9 Hz, 1H), 7.57-7.54 (m, 1H), 7.54-7.51 (m,1H), 7.45-7.38 (m, 2H), 6.78 (d, J=8.0 Hz, 1H), 6.69 (d, J=2.1 Hz, 1H),6.55 (d, J=8.2 Hz, 1H), 5.36-5.30 (m, 1H), 4.65-4.58 (m, 2H), 4.13-4.04(m, 1H), 3.25-3.15 (m, 2H), 3.00-2.93 (m, 1H), 2.78-2.69 (m, 1H),2.67-2.59 (m, 1H), 2.59-2.56 (m, 3H), 2.52-2.42 (m, 1H), 2.13-2.04 (m,1H), 1.91-1.79 (m, 2H), 1.64 (s, 3H), 1.61-1.45 (m, 2H), 1.34 (dd,J=16.0, 6.6 Hz, 3H). HRMS; calcd. for C₃₄H₃₈N₅O₄ (M+H) 580.2924, found580.2697.

Example 47b.(−)-1-(6-(3-((4-(1-((S)-2-Hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid (Diastereomer-2)

(−)-Ethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(diastereomer-2) (t_(r)=2.99 min) was saponified as described in Example7a and purified by reverse phase HPLC (HC-B) to afford the titlecompound. ¹H NMR (400 MHz, Methanol-d₄) δ 7.91-7.84 (m, 2H), 7.71 (dd,J=0.7, 7.8 Hz, 1H), 7.58-7.50 (m, 2H), 7.45-7.38 (m, 2H), 6.82-6.76 (m,1H), 6.70 (d, J=1.7 Hz, 1H), 6.55 (d, J=8.2 Hz, 1H), 5.37-5.31 (m, 1H),4.66-4.53 (m, 2H), 4.15-4.05 (m, 1H), 3.24-3.14 (m, 2H), 3.02-2.92 (m,1H), 2.79-2.68 (m, 1H), 2.67-2.55 (m, 4H), 2.54-2.41 (m, 1H), 2.13-2.03(m, 1H), 1.91-1.79 (m, 2H), 1.64 (s, 3H), 1.61-1.42 (m, 2H), 1.39-1.29(m, 3H). HRMS: calcd. for C₃₄H₃₈N₅O₄ (M+H) 580.2924, found 580.2697.

Example 48 Example 48-A. (±)-Ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

The title compound was synthesized by the similar method to thesynthesis of Example 45-A and then Example 45-B but starting from ethyl1-(6-bromopyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate (Intermediate1-4-2) in the place of Intermediate 1-3 and (±)-tert-butyl4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylateinstead of Intermediate 3-5-C. MS (ESI+) m/z 564.4 (M+H).

Example 48-B. a). Ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

The title compound was synthesized analogously to the preparation ofethyl1-(6-(3-((4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(Example 47-A) but starting with (±)-ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 48-A). MS (ESI+) m/z 636.4 (M+H).

Example 48-B. b). Ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Diastereomer-1) and ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Diastereomer-2)

Resolution of the diastereomers of ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylatewas achieved by chiral HPLC using CHIRALPAK® IA column with 60% hexanewith 0.1% DEA in EtOH to give ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1) (t_(r)=7.6 min) and ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2) (t_(r)=11.3 min).

Example 48a.(+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Saponification of ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2, t_(r)=11.3 min) as described for the synthesis ofExample 7a afforded the title compound. ¹H NMR (600 MHz, Methanol-d₄) δ7.94 (s, 1H), 7.91 (dd, J=7.8, 7.9 Hz, 1H), 7.87 (d, J=7.6 Hz, 1H),7.55-7.59 (m, 2H), 7.37-7.42 (m, 2H), 6.82 (dd, J=4.1, 8.3 Hz, 1H),6.29-6.34 (m, 2H), 5.23 (d, J=6.1 Hz, 1H), 4.58-4.67 (m, 2H), 4.10 (t,J=11.7 Hz, 1H), 3.14-3.25 (m, 3H), 2.88-2.96 (m, 2H), 2.71-2.78 (m, 1H),2.54 (q, J=7.6 Hz, 2H), 2.26-2.34 (m, 1H), 2.12-2.18 (m, 1H), 1.70-1.80(m, 2H), 1.49-1.68 (m, 2H), 1.30-1.39 (m, 4H), 1.08-1.14 (m, 6H). HRMS:calcd. for C₃₆H₄₂N₅O₄ (M+H) 608.3237, found 608.3256.

Example 48b.(−)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1, t_(r)=7.6 min) was saponified as described for thesynthesis of Example 7a to afford the title compound. ¹H NMR (600 MHz,Methanol-d₄) δ 7.94 (s, 1H), 7.91 (dd, J=7.8, 7.9 Hz, 1H), 7.87 (d,J=7.7 Hz, 1H), 7.57 (d, J=7.9 Hz, 2H), 7.38-7.42 (m, 2H), 6.79-6.84 (m,1H), 6.29-6.34 (m, 2H), 5.23 (br. d, J=6.1 Hz, 1H), 4.58-4.67 (m, 2H),4.07-4.14 (m, 1H), 3.13-3.24 (m, 3H), 2.88-2.95 (m, 2H), 2.71-2.78 (m,1H), 2.54 (q, J=7.5 Hz, 2H), 2.26-2.35 (m, 1H), 2.12-2.18 (m, 1H),1.70-1.80 (m, 2H), 1.48-1.67 (m, 2H), 1.31-1.38 (m, 4H), 1.08-1.14 (m,6H). HRMS: calcd. for C₃₆H₄₂N₅O₄ (M+H) 608.3237, found 608.3240.

Example 49 Example 49-A. a). Ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

The title compound was synthesized analogously to the preparation ofethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 48-B. a)) but using (S)-2-hydroxypentanoic acid in the place ofL-(+)-lactic acid. MS (ESI+) m/z 664.4 (M+H).

Example 49-A. b). Ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Diastereomer-1) and ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Diastereomer-2)

Resolution of the diastereomers of ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylatewas achieved by chiral HPLC using CHIRALPAK® IA column with 65% hexanewith 0.1% DEA in EtOH to give ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1) (t_(r)=7.5 min) and ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2) (t_(r)=10.2 min).

Example 49a.(+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Saponification of ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2, t_(r)=10.2 min) as described for the synthesis ofExample 7a afforded the title compound. ¹H NMR (600 MHz, Methanol-d₄) δ7.94 (s, 1H), 7.89-7.93 (m, 1H), 7.85-7.88 (m, 1H), 7.55-7.60 (m, 2H),7.38-7.43 (m, 2H), 6.78-6.84 (m, 1H), 6.29-6.34 (m, 2H), 5.23 (br. d,J=6.4 Hz, 1H), 4.64 (br. d, J=12.4 Hz, 1H), 4.44-4.52 (m, 1H), 4.04-4.13(m, 1H), 3.14-3.27 (m, 4H), 2.88-2.96 (m, 2H), 2.71-2.78 (m, 1H), 2.54(q, J=7.5 Hz, 2H), 2.26-2.35 (m, 1H), 2.12-2.18 (m, 1H), 1.70-1.81 (m,2H), 1.41-1.69 (m, 6H), 1.08-1.16 (m, 6H), 0.94-1.02 (m, 3H). HRMS:calcd. for C₃₈H₄₆N₅O₄ (M+H) 636.3550, found 636.3555.

Example 49b.(−)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypentanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1, t_(r)=7.5 min) was saponified as described for thesynthesis of Example 7a to afford the title compound. ¹H NMR (600 MHz,Methanol-d₄) δ 7.94 (s, 1H), 7.88-7.93 (m, 1H), 7.85-7.88 (m, 1H),7.55-7.59 (m, 2H), 7.37-7.42 (m, 2H), 6.81 (dd, J=8.3, 9.2 Hz, 1H),6.29-6.33 (m, 2H), 5.21-5.26 (m, 1H), 4.62-4.67 (m, 1H), 4.45-4.51 (m,1H), 4.04-4.13 (m, 1H), 3.14-3.28 (m, 4H), 2.88-2.95 (m, 2H), 2.71-2.78(m, 1H), 2.54 (q, J=7.5 Hz, 2H), 2.26-2.35 (m, 1H), 2.11-2.18 (m, 1H),1.71-1.81 (m, 2H), 1.41-1.70 (m, 6H), 1.08-1.16 (m, 6H), 0.94-1.02 (m,3H). HRMS: calcd. for C₃₈H₄₆N₅O₄ (M+H) 636.3550, found 636.3558.

Example 50 Example 50-A. a). Ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

The title compound was synthesized analogously to the preparation ofethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxypropanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 48-B. a)) but using (S)-2-hydroxybutanoic acid in the place ofL-(+)-lactic acid. MS (ESI+) m/z 650.4 (M+H).

Example 50-A. b) Ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Diastereomer-1) and ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Diastereomer-2)

Resolution of the diastereomers of ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylatewas achieved by chiral HPLC using CHIRALPAK® IA column with 60% hexanewith 0.1% DEA in EtOH to give ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1) (t_(r)=7.5 min) and ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2) (t_(r)=10.8 min).

Example 50a.(+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Saponification of ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-2, t_(r)=10.8 min) as described for the synthesis ofExample 7a afforded the title compound. ¹H NMR (400 MHz, Methanol-d₄) δ7.85-7.96 (m, 3H), 7.55-7.60 (m, 2H), 7.37-7.43 (m, 2H), 6.78-6.84 (m,1H), 6.29-6.34 (m, 2H), 5.20-5.25 (m, 1H), 4.61-4.69 (m, 1H), 4.39-4.46(m, 1H), 4.04-4.13 (m, 1H), 3.14-3.28 (m, 3H), 2.87-2.97 (m, 2H),2.70-2.80 (m, 1H), 2.54 (q, J=7.6 Hz, 2H), 2.25-2.36 (m, 1H), 2.10-2.19(m, 1H), 1.48-1.82 (m, 7H), 1.08-1.15 (m, 6H), 0.96-1.05 (m, 3H). HRMS:calcd. for C₃₇H₄₄N₅O₄ (M+H) 622.3393, found 622.3402.

Example 50b.(−)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(1-((S)-2-hydroxybutanoyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(diastereomer-1, t_(r)=7.5 min) was saponified as described for thesynthesis of Example 7a to afford the title compound. ¹H NMR (400 MHz,Methanol-d₄) δ 7.84-7.97 (m, 3H), 7.55-7.60 (m, 2H), 7.37-7.43 (m, 2H),6.78-6.84 (m, 1H), 6.29-6.35 (m, 2H), 5.20-5.27 (m, 1H), 4.61-4.69 (m,1H), 4.38-4.46 (m, 1H), 4.04-4.14 (m, 1H), 3.14-3.29 (m, 3H), 2.87-2.97(m, 2H), 2.70-2.80 (m, 1H), 2.54 (q, J=7.5 Hz, 2H), 2.24-2.37 (m, 1H),2.10-2.19 (m, 1H), 1.45-1.83 (m, 7H), 1.08-1.16 (m, 6H), 0.95-1.05 (m,3H). HRMS: calcd. for C₃₇H₄₄N₅O₄ (M+H) 622.3393, found 622.3413.

Example 51 Example 51-A. a). (±)-Isopropyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate

To a solution of (±)-ethyl5-ethyl-1-(6-(3-((3-ethyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 48-A) (253 mg, 0.449 mmol) in MeOH (2 mL) was added Et₃N (0.188mL, 1.35 mmol), followed by a solution of isopropylchloroformate (0.494mL, 0.494 mmol) in MeOH (0.25 mL) dropwise. The mixture was stirred atthe same temperature for ca. 0.5 h. The reaction mixture was thenconcentrated. The resulting residue was purified by silica gel flashcolumn chromatography (heptane/EtOAc=8/2, isocratic) to afford the titlecompound. MS (ESI+) m/z 650.0 (M+H).

Example 51-A. b). Isopropyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate(Enantiomer-1) and isopropyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate(Enantiomer-2)

Resolution of the enantiomers of (±)-isopropyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylatewas achieved by chiral SFC using CHIRALPAK® AD-H column with 30% IPA inCO₂ to give isopropyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate(enantiomer-1, t_(r)=3.4 min) and Isopropyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate(enantiomer-2, t_(r)=5.3 min).

Example 51a.(+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-(isopropoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Saponification of isopropyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate(enantiomer-1, t_(r)=3.4 min) as described for the synthesis of Example7a afforded the title compound. ¹H NMR (400 MHz, Methanol-d₄) δ 7.96 (s,1H) 7.85-7.94 (m, 2H) 7.55-7.62 (m, 2H) 7.37-7.44 (m, 2H) 6.84 (d, J=8.1Hz, 1H) 6.29-6.37 (m, 2H) 5.24 (dd, J=6.4, 2.2 Hz, 1H) 4.86-4.95 (m, 2H)4.20-4.26 (m, 1H) 3.16-3.29 (m, 3H) 2.75-2.99 (m, 4H) 2.54 (q, J=7.5 Hz,2H) 2.25-2.38 (m, 1H) 2.10-2.22 (m, 1H) 1.68 (br, d, J=15.0 Hz, 2H)1.45-1.63 (m, 2H) 1.28 (d, J=6.2 Hz, 6H) 1.13 (m, 6H). HRMS: calcd. forC₃₇H₄₄N₅O₄ (M+H) 622.3280, found 622.3270.

Example 51b.(−)-Ethyl-1-(6-(3-((3-ethyl-4-(1-(isopropoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Isopropyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate(enantiomer-2, t_(r)=5.3 min) was saponified as described for thesynthesis of Example 7a to afford the title compound. ¹HNMR and HRMSdata were substantially identical to Example 51a.

Example 52

The following compounds in the table below were synthesized in a similarmanner as described for Example 51, employing the appropriate startingmaterials, Example 45-B or Example 48-A, and the appropriatechloroformate as outlined. Saponification of the resulting racemicesters was accomplished via the method described for Example 7a. In someinstances, the racemic esters were first resolved by the conditionsdescribed in the table, and then each resulting enantiomer wasindependently saponified via the method described for Example 7a. ¹H NMRand HRMS data for (−)-enantiomer were substantially identical to(+)-enantiomer.

Chemical name Exam- Example 45-B or Example 48-A ple Chemical structurechloroformate ¹H NMR and HRMS Resolution conditions of enantiomers whenperformed (+)- and (−)-Carboxylic acids derived from their correspondingresolved ester enantiomers. 52-1

1-(6-(3-((4-(1-Ethoxycarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid Example 48-AEthyl chloroformate ¹H NMR (400 MHz, Methanol-d₄) δ 7.94 (s, 1H),7.88-7.67 (m, 2H), 7.60-7.55 (m, 2H), 7.30-7.27 (m, 2H), 6.82 (d, J =8.3 Hz, 1H), 6.33-6.31 (m, 2H), 5.23-5.19 (m, 1H), 4.23 (d, J = 13.3 Hz,2H), 4.14-4.12 (m, 2H), 3.29-3.06 (m, 3H), 3.00-2.69 (m, 4H), 2.53-2.51(m, 2H), 2.32-2.25 (m, 1H), 2.18-2.03 (m, 1H), 1.67-1.65 (m, 2H),1.60-1.48 (m, 2H), 1.27 (m, 3H), 1.15-1.04 (m, 6H). HRMS; calcd. forC₃₆H₄₂N₅O₄ (M + H), 608.3192, found 608.2935 Resolution of theenantiomers of (±)-ethyl 4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate was achieved by chiral SFC using CHIRALPAK ® AD-H columnwith 30% IPA in CO₂ to give ethyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-1, t_(r) = 3.3 min) and ethyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-2, t_(r) = 4.9 min).(−)-52-1:(−)-1-(6-(3-((4-(1-(Ethoxycarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid was derived from saponification of ethyl4-(4-((7-(6-(4-(ethoxycarobnyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-1, t_(r) = 3.3 min). (+)-52-1:(+)-1-(6-(3-((4-(1-(Ethoxycarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyraozle-4-carboxylicacid was derived from saponification of ethyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-2, t_(r) = 4.9 min). 52-2

5-Ethyl-1-(6-(3-((3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H- pyrazole-4-carboxylic acidExample 48-A Methyl chloroformate ¹H NMR (400 MHz, DMSO-d₆) δ 12.47 (s,1H), 8.01-7.90 (m, 3H), 7.72-7.64 (m, 1H), 7.63-7.55 (m, 1H), 7.48-7.37(m, 2H), 6.83 (d, J = 8.2 Hz, 1H), 6.41-6.33 (m, 2H), 5.44 (d, J = 9.1Hz, 1H), 5.30-5.12 (m, 1H), 4.07 (s, 2H), 3.60 (s, 3H), 3.28 (s, 3H),3.20- 3.06 (m ,1H), 2.96-2.78 (m, 3H), 2.77-2.69 (m, 1H), 2.25-2.13 (m,1H), 2.04-1.94 (m, 1H), 1.58 (d, J = 12.1 Hz, 2H), 1.50-1.36 (m, 2H),1.17 (t, J = 7.3 Hz, 3H), 1.07 (t, J = 7.5 Hz, 3H). HRMS; calcd. forC₃₅H₄₀N₅O₄ (M + H) 594.3075, found 594.2903 Resolution of theenantiomers of (±)-methyl 4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-diydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboyxlate was achieved by chiral SFC usingCHIRALPAK ® AD-H column with 30% IPA in CO₂ to give methyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-1, t_(r) = 4.3 min) andmethyl 4-(4-((7-(6-(4-ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-2, t_(r) =7.4 min). (−)-52-2:(−)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid was derived from saponification of methyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-1, t_(r) = 4.3 min).(+)-52-2:(+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid was derived from saponification of methyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-2, t_(r) = 7.4 min).52-3

1-(6-(3-((4-(1-(Allyloxy)carbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid Example 48-AAllyl chloroformate ¹H NMR (400 MHz, DMSO-d₆) δ 12.52 (s, 1H), 8.03-7.89(m, 3H), 7.70-7.64 (m, 1H), 7.63-7.56 (m, 1H), 7.47-7.38 (m, 2H), 6.83(d, J = 8.2 Hz, 1H), 6.45-6.33 (m, 2H), 6.03-5.89 (m, 1H), 5.44 (d, J =9.0 Hz, 1H), 5.35-5.14 (m, 3H), 4.54 (dt, J = 5.2, 1.5 Hz, 2H), 4.11 (d,J = 13.0 Hz, 2H), 3.28 (s, 4H), 3.20-3.08 (m, 1H), 3.00-2.79 (m, 3H),2.79-2.69 (m, 1H), 2.27-2.13 (m, 1H), 2.05-1.92 (m, 1H), 1.67-1.53 (m,2H), 1.53-1.36 (m, 2H), 1.17 (t, J = 7.3 Hz, 3H), 1.07 (t, J = 7.5 Hz,3H). HRMS; calcd. for C₃₇H₄₂N₅O₄ (M + H) 620.323, found 620.3034.Resolution of the enantiomers of (±)-allyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate was achieved by chiral SFC using CHIRALPAK ® AD-H columnwith 35% IPA in CO₂ to give allyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-1, t_(r) = 3.2 min) and allyl4-(4-((7-(6-(4-(ethoxycarobnyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-2, t_(r) = 5.7 min).(−)-52-3:(−)-1-(6-(3-((4-(1-((Allyloxy)carbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid was derived from saponification of allyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-1, t_(r) = 3.2 min). (+)-52-3:(+)-1-(6-(3-((4-(1-((Allyloxy)carbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid was derived from saponification of allyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylphenyl)piperidine-1-carboxylate (enantiomer-2, t_(r) = 5.7 min). 52-4

1-(6-(3-((4-(1-(Ethoxycarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyraozle-4- carboxylic acid Example 45-BEthyl chloroformate ¹H NMR (400 MHz, Methanol-d₄) δ 7.89 (s, 1H), 7.80(t, J = 7.9 Hz, 1H), 7.66-7.55 (m, 1H), 7.54-7.51 (m, 2H), 7.47-7.37 (m,2H), 6.81-6.79 (m, 1H), 6.71 (s, 1H), 6.56-6.55 (d, J = 8.3 Hz, 1H),5.39-5.37 (m, 1H), 4.30-4.15 (m, 2H), 4.11 (t, J = 7.1 Hz, 2H), 3.24-3.08 (m, 1H), 3.05-3.79 (m, 3H), 2.69 (s, 3H), 2.57-2.41 (m, 2H),2.08-2.06 (m, 1H), 1.76 (d, J = 12.2 Hz, 2H), 1.67 (s, 3H), 1.50-1.48(m, 2H), 1.27 (t, J = 7.1 Hz, 3H). HRMS calcd. for C₃₄H₃₈N₅O₄ (M + H),580.2879, found 580.2920. 52-5

1-(6-(3-((4-(1-((2-methoxyethoxy)carbonyl)-piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H- pyrazole-4-carboxylicacid Example 45-B 2-Methoxyethyl carbonochloridate (CAS# 628-12- 6) ¹HNMR (400 MHz, Methanol-d₄) δ 7.90 (s, 1H), 7.88-7.86 (m, 1H), 7.73 (d, J= 7.5 Hz, 1H), 7.58-7.52 (m, 2H), 7.46-7.36 (m, 2H), 6.79-6.76 (m, 1H),6.68 (d, J = 1.7 Hz, 1H), 6.54 (d, J = 8.3 Hz, 1H), 5.32-5.29 (m, 1H),4.27-4.16 (m, 4H), 3.65-3.59 (m, 2H), 3.39 (s, 3H), 3.23-315 (m, 1H),3.03-2.79 (m, 3H), 2.56 (s, 3H), 2.48-2.42 (m, 2H), 2.15- 2.03 (m, 1H),1.77 (d, J = 12.0 Hz, 2H), 1.64 (s, 3H), 1.58-1.45 (m, 2H). HRMS calcd.for C₃₅H₄₀N₅O₅ (M + H), 610.2985, found 610.303. 52-6

5-Methyl-1-(6-(3-((2-methyl-4-(1-((prop-1-en-2-yloxy)carbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole- 4-carboxylic acidExample 45-B Prop-1-en-2-yl carbonochloridate (CAS# 57933- 83-2) ¹H NMR(400 MHz, Methanol-d₄) δ 7.96-7.83 (m, 2H), 7.74-7.72 (m, 1H), 7.54-7.52(m, 2H), 7.49-7.33 (m, 2H), 6.80-6.78 (m, 1H), 6.70-6.68 (m, 1H), 6.55(d, J = 8.3 Hz, 1H), 5.33-5.30 (m, 1H), 4.71-4.56 (m, 2H), 4.22 (d, J =12.3 Hz, 2H), 3.24-3.14 (m, 1H), 3.07-2.81 (m, 3H), 2.64-2.39 (m, 5H),2.12-2.05 (m, 1H), 1.98-1.92 (m, 3H), 1.82-1.79 (m, 2H), 1.71-1.44 (m,5H). HRMS; calcd. for C₃₅H₃₈N₅O₄ (M + H), 592.2871, found 592.2821

Example 53

The following compounds were synthesized using the appropriate materialsdenoted in the table below (Intermediate 3, Intermediate 2, andCarboxylic acid). Ketones of the type represented in Intermediate 3underwent reductive amination with anilines of the type represented inIntermediate 2 by analogous methods described by Example 7-A. a). Theresulting racemic esters can be saponified as described in Example 7a,and the resulting racemic carboxylic acids can be separated by theconditions denoted in the table below to afford each enantiomer.

When the anilines represented by Intermediate 2 contain a Boc protectedpiperidine, the Boc group can be removed after reductive amination asdescribed in Example 35-B, and the resulting amine can be coupled withthe Carboxylic acid denoted in table below as outlined by the procedureused to access Example 35-C. a). The esters of the resulting amides canthen be saponified as in Example 7a to provide the title compound inracemic form. The racemic acids were then resolved by the conditionsdescribed in the table below to afford enantiomerically pure form of thetitle compound. ¹H NMR and HRMS data for (+)- and (−)-enantiomers weresubstantially identical to the racemic form.

Chemical structure Chemical name Intermediate 3 Intermediate 2Carboxylic acid ¹H NMR and HRMS Example Resolution condition forenantiomers 53-1

1-(6-(3-((4-(1- (Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)- 2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl- 1H-pyrazole-4-carboxylic acid Intermediate3-8-1 Intermediate 2-10 Cyclopropanecarboxylic acid (CAS# 1759-53-1) ¹HNMR (400 MHz, Methanol-d₄) δ 7.94 (s, 1H), 7.92-7.87 (m, 1H), 7.87-7.84(m, 1H), 7.60-7.54 (m, 2H), 7.41-7.38 (m, 2H), 6.83 (d, J = 8.5 Hz, 1H),6.35-6.29 (m, 2H), 5.26-5.20 (m, 1H), 4.64 (d, J = 12.8 Hz, 1H), 4.45(d, J = 13.4 Hz, 1H), 3.26-3.15 (m, 4H), 2.97-2.88 (m, 2H), 2.73 (t, J =12.9 Hz, 1H), 2.54 (q, J = 7.5 Hz, 2H), 2.36-2.25 (m, 1H), 2.19-2.11 (m,1H), 2.05-1.96 (m, 1H), 1.79 (d, J = 13.2 Hz, 1H), 1.71 (d, J = 13.0 Hz,1H), 1.65-1.45 (m, 2H), 1.16-1.08 (m, 6H), 0.94-0.77 (m, 4H). HRMS;calcd. for C₃₇H₄₂N₅O₃ (M + H) 604.3288, found 604.3284. Resolution ofthe enantiomers of (±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC using CHIRALPAK ® AD-Hcolumn with 45% IPA in CO₂ to give(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid (t_(r) = 2.02 min) and(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid (t_(r) = 4.12 min). 53-2

1-(6-(3-((4-(1-(2- Cyclopropylacetyl)piperidin-4-yl)-3-ethylphenyl)amino)- 2,3-dihydro-1H-inden-4- yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid Intermediate 3-8-1 Intermediate 2-10Cyclopropylacetic acid (CAS# 5239-82-7) ¹H NMR (400 MHz, Methanol-d₄) δ7.93 (s, 1H), 7.90-7.83 (m, 2H), 7.60-7.53 (m, 2H), 7.41-7.37 (m, 2H),6.83 (d, J = 8.6 Hz, 1H), 6.36-6.30 (m, 2H), 5.26-5.21 (m, 1H), 4.69 (d,J = 13.5 Hz, 1H), 4.06 (d, J = 13.6 Hz, 1H), 3.24-3.15 (m, 4H),2.97-2.85 (m, 2H), 2.74-2.65 (m, 1H), 2.58-2.50 (m, 2H), 2.37 (d, J =6.9 Hz, 2H), 2.34-2.24 (m, 1H), 2.19-2.11 (m, 1H), 1.74 (t, J = 13.9 Hz,2H), 1.67-1.49 (m, 2H), 1.15-1.08 (m, 6H), 1.08-1.00 (m, 1H), 0.59-0.53(m, 2H), 0.23 (dd, J = 5.7, 4.3 Hz, 2H). HRMS; calcd. for C₃₈H₄₄N₅O₃(M + H) 618.3444, found 618.3422. Resolution of the enantiomers of(±)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC using CHIRALCEL ® OJ-Hcolumn with 40% IPA in CO₂ to give(−)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid (t_(r) = 2.80 min) and(+)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid (t_(r) = 6.60 min). 53-3

1-(6-(3-((4-(1-(2- Cyclopropylacetyl)piperidin-4-yl)-2-fluoro-6-methylphenyl) amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)- 5-methyl-1H-pyrazole-4- carboxylic acidIntermediate 3-7 Intermediate 2-12-3 Cyclopropanecarboxylic acid (CAS#1759-53-1) ¹H NMR (400 MHz, Methanol-d₄) δ 8.04-7.98 (m, 1H), 7.84 (t, J= 7.9 Hz, 1H), 7.64 (d, J = 4.0 Hz, 1H), 7.62 (d, J = 3.7 Hz, 1H),7.48-7.42 (m, 1H), 7.42-7.35 (m, 2H), 6.50 (s, 1H), 6.47-6.40 (m, 1H),5.59 (d, J = 6.6 Hz, 1H), 4.64 (d, J = 13.0 Hz, 1H), 4.02 (d, J = 13.9Hz, 1H), 3.19-3.08 (m, 2H), 2.99-2.90 (m, 1H), 2.87 (s, 3H), 2.65 (t, J= 12.8 Hz, 1H), 2.58-2.48 (m, 1H), 2.42-2.30 (m, 3H), 2.16 (dd, J =13.3, 7.4 Hz, 1H), 1.78 (s, 5H), 1.52-1.34 (m, 2H), 1.06-0.99 (m, 1H),0.59-0.52 (m, 2H), 0.24-0.18 (m, 2H). HRMS; calcd. for C₃₆H₃₉FN₅O₃ (M +H) 608.3037, found 608.2897. Resolution of the enantiomers of(±)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-2-fluoro-6-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC usingCHIRALCEL ® OJ-H column with 5-55% MeOH in CO₂ to give(+)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-2-fluoro-6-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid (t_(r) =2.30 min) and (−)-1-(6-(3-((4-(1-(2-cyclopropylacetyl)piperidin-4-yl)-2-fluoro-6-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r) = 2.48 min). 53-4

1-(6-(3-((4-(1- (Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)- 2,3-dihydro-1H-inden- 4-yl)pyridin-2-yl)-5-(difluoromethyl)-1H-pyrazole- 4-carboxylic acid Intermediate 3-8-4Intermediate 2-8 not applicable ¹H NMR (400 MHz, Methanol-d₄) δ7.97-7.91 (m, 2H), 7.82 (d, J = 7.8 Hz, 1H), 7.65- 7.60 (m, 1H), 7.55(d, J = 7.9 Hz, 1H), 7.47-7.40 (m, 2H), 7.38 (t, J = 53.2 Hz, 1H), 6.82-6.77 (m, 1H), 6.74-6.71 (m, 1H), 6.56 (d, J = 8.2 Hz, 1H), 5.26 (dd, J =6.7, 2.7 Hz, 1H), 4.63 (d, J = 12.9 Hz, 1H), 4.44 (d, J = 13.2 Hz, 1H),3.26-3.16 (m, 2H), 2.99-2.90 (m, 1H), 2.78-2.69 (m, 1H), 2.69-2.61 (m,1H), 2.43-2.33 (m, 1H), 2.16-2.08 (m, 1H), 2.04-1.96 (m, 1H), 1.92 (d, J= 13.0 Hz, 1H), 1.84 (d, J = 13.0 Hz, 1H), 1.70 (s, 3H), 1.66-1.42 (m,2H), 0.94-0.86 (m, 2H), 0.86-0.78 (m, 2H). HRMS; calcd. for C₃₅H₃₅F₂N₅O₃C₃₅H₃₆F₂N₅O₃ (M + H) 612.2786, found 612.2514. Resolution of theenantiomers of (±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC usingCHIRALCEL ® OJ-H column with 5% to 55% MeOH in CO₂ to give(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid(t_(r) = 2.53 min) and(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(difluoromethyl)-1H-pyrazole-4-carboxylicacid (t_(r) = 3.25 min).

Example 54 Example 54-A. (±)-Ethyl1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylate

To a suspension of(±)-3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yltrifluoromethanesulfonate (Intermediate 6-1) (250 mg, 0.479 mmol), ethyl5-methyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole-4-carboxylate(Intermediate 1-5) (205 mg, 0.575 mmol) and K₃PO₄ (2M in H₂O) (0.479 mL,0.959 mmol) in dioxane (4 mL) was addedchloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(II)-methyl-t-butylether adduct (CAS #1028206-58-7; 19.6 mg, 0.024 mmol). The mixture wasthen stirred at 100° C. for 2 h, and then cooled to room temperature.The reaction mixture was diluted with EtOAc, and then washedsuccessively with H₂O and brine, dried over Na₂SO₄, filtered, and thenconcentrated. The resulting residue was purified by silica gel flashcolumn chromatography (0-50% EtOAc in heptane) to afford the titlecompound. MS (ESI+) m/z 602.4 (M+H).

Example 54. a).(±)-1-(3-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by saponification of (±)-ethyl1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylateby the similar method as described for the synthesis of Example 7a. ¹HNMR (400 MHz, Methanol-d₄) δ 8.02 (s, 1H), 7.59 (t, J=7.8 Hz, 1H),7.52-7.48 (m, 1H), 7.45 (dt, J=7.9, 1.6 Hz, 1H), 7.39 (s, 1H), 7.30-7.22(m, 2H), 7.08 (d, J=6.8 Hz, 1H), 6.82 (d, J=5.9 Hz, 2H), 6.72 (d, J=8.3Hz, 1H), 4.60 (d, J=12.0 Hz, 1H), 4.41 (d, J=13.6 Hz, 1H), 3.79-3.75 (m,1H), 3.26-3.05 (m, 2H), 2.90 (dd, J=16.1, 7.2 Hz, 1H), 2.66-2.61 (m,2H), 2.58 (s, 3H), 2.48 (dd, J=13.7, 5.2 Hz, 1H), 2.30 (dd, J=13.7, 10.3Hz, 1H), 2.14-1.88 (m, 3H), 1.86-1.78 (m, 5H), 1.65-1.43 (m, 2H),0.94-0.76 (m, 4H). HRMS; calcd. for C₃₇H₄₀N₃O₃ (M+H) 574.3070, found574.3081.

Example 54. b).(+)-1-(3-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid and(−)-1-(3-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid

Resolution of the enantiomers of(±)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALCEL® OJ-H column with 35%IPA in CO₂ to give(−)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r)=3.1 min) and(+)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r)=4.5 min). ¹H NMR and HRMS data for (+)- and (−)-enantiomerswere substantially identical to the racemic form.

Example 55

The following compounds were synthesized using appropriate materials inthe table below (Intermediate 1 and Intermediate 6) by the methodsdescribed above, specifically Example 55-1, was prepared in a fashionsimilar to the procedure described for Example 54, and Example 55-2 wasprepared in a fashion similar to the procedure described for Example 6.In the case of Example 55-1, the racemic form of the title compound wasthen resolved by the conditions described in the table to affordenantiomerically pure form of the title compound. ¹H NMR and HRMS datafor (+)- and (−)-enantiomers were substantially identical to the racemicform.

structure IUPAC name Intermediate 1 Intermediate 6 ¹H NMR and HRMS dataExample enantiomer separation conditions 55-1

1-(3-(3-(4-(1- (Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro- 1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid Intermediate 1-5 Intermediate 6-2¹H NMR (400 MHz, Methanol-d₄) δ 8.02 (s, 1H), 7.68 (t, J = 7.7 Hz, 1H),7.65-7.61 (m, 1H), 7.59 (s, 1H), 7.52-7.48 (m, 1H), 7.28-7.23 (m, 1H),7.21 (d, J = 6.4 Hz, 1H), 7.18- 7.14 (m, 1H), 6.96 (d, J = 7.9 Hz, 1H),6.67 (dd, J = 7.9, 1.6 Hz, 1H), 6.60 (s, 1H), 4.64 (d, J = 12.3 Hz, 1H),4.45 (d, J = 13.2 Hz, 1H), 3.85-3.78 (m, 1H), 3.27-3.20 (m, 1H),3.06-2.96 (m, 1H), 2.87-2.81 (m, 2H), 2.73 (t, J = 12.2 Hz, 1H),2.62-2.57 (m, 2H), 2.56 (s, 3H), 2.44 (dd, J = 13.5, 3.7 Hz, 1H), 2.21(dd, J = 13.5, 9.8 Hz, 1H), 2.13-2.04 (m, 1H), 2.03-1.96 (m, 1H),1.95-1.87 (m, 1H), 1.78 (d, J = 13.5 Hz, 1H), 1.74-1.48 (m, 3H), 1.11(t, J = 7.5 Hz, 3H), 0.93-0.85 (m, 2H), 0.85-0.76 (m, 2H). HRMS; calcd.for C₃₈H₄₂N₃O₃ (M + H) 588.3226, found 588.3224. Resolution of theenantiomers of (±)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid was achieved by chiral SFC using CHIRALCEL ® OJ-H columnwith 15% MeOH in CO2 to give(−)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r) = 5.40 min) and(+)-1-(3-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-methyl-1H-pyrazole-4-carboxylicacid (t_(r) = 7.50 min). 55-2

(+)-1-(3-(3-((4-(1- (Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)- 2,3-dihydro-1H-inden-4-yl)phenyl)-5-(difluoromethyl)- 1H-pyrazole-4- carboxylic acidIntermediate 1-4-5 Intermediate 3-5-A. b) (+) ¹H NMR (400 MHz,Methanol-d₄) δ 7.93 (d, J = 1.0 Hz, 1H), 7.76 (s, 1H), 7.66-7.62 (m,1H), 7.48 (t, J = 52.7 Hz, 1H), 7.44-7.40 (m, 2H), 7.38 (d, J = 7.3 Hz,1H), 7.36-7.34 (m, 1H), 7.31-7.27 (m, 1H), 6.84-6.78 (m, 1H), 6.74 (d, J= 2.1 Hz, 1H), 6.51 (d, J = 8.3 Hz, 1H), 5.11-5.04 (m, 1H), 4.62 (d, J =12.6 Hz, 1H), 4.43 (d, J = 13.3 Hz, 1H), 3.26-3.17 (m, 2H), 3.00-2.88(m, 1H), 2.77-2.56 (m, 2H), 2.45-2.31 (m, 1H), 2.14-2.05 (m, 1H),2.04-1.96 (m, 1H), 1.88 (d, J = 13.3 Hz, 1H), 1.80 (d, J = 13.3 Hz, 1H),1.74 (s, 3H), 1.64-1.41 (m, 2H), 0.93-0.85 (m, 2H), 0.81 (d, J = 7.9 Hz,2H). HRMS; calcd. for C₃₆H₃₇F₂N₄O₃ (M + H) 611.2834, found 611.2808.

Example 56 Example 56-A. a). (±)-tert-Butyl4-(4-((7-(3-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidine-1-carboxylate

The title compound was synthesized by the similar method as describedfor the synthesis of Example 7-A. a) starting from ethyl1-(3-(3-oxo-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate(Intermediate 3-6) and tert-butyl4-(4-amino-3-methylphenyl)piperidine-1-carboxylate (Intermediate 2-13).MS (ESI+) m/z 689.5 (M+H).

Example 56-A. b). (+)-tert-Butyl4-(4-((7-(3-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidine-1-carboxylateand (−)-tert-butyl4-(4-((7-(3-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidine-1-carboxylate

Resolution of the enantiomers of (±)-tert-butyl4-(4-((7-(3-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidine-1-carboxylatewas achieved by chiral SFC using CHIRALPAK® IA column with 25% IPA with10% CH₃CN in CO₂ for the first peak elution, and then 45% IPA with 10%CH₃CN in CO₂ to give (−)-tert-butyl4-(4-((7-(3-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidine-1-carboxylate(t_(r)=2.9 min) and (+)-tert-butyl4-(4-((7-(3-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidine-1-carboxylate(t_(r)=5.2 min).

Example 56.(+)-1-(3-(3-((4-(1-(2-Hydroxyacetyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

The title compound was synthesized starting from (+)-tert-butyl4-(4-((7-(3-(4-(ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidine-1-carboxylate(t_(r)=5.2 min) by the similar method as outlined for the preparation ofExample 51 using 2-chloro-2-oxoethyl acetate (CAS#13831-31-7) instead ofusing isopropyl chloroformate. ¹H NMR (400 MHz, Chloroform-d) δ 7.93 (s,1H), 7.63 (d, J=1.6 Hz, 1H), 7.58 (d, J=8.0 Hz, 1H), 7.20-7.38 (m, 5H),6.77 (d, J=8.2 Hz, 1H), 6.68 (br. s., 1H), 6.46 (d, J=8.2 Hz, 1H),4.85-4.94 (m, 1H), 4.62 (br. d, J=12.7 Hz, 1H), 4.16-4.24 (m, 1H),4.08-4.16 (m, 1H), 3.48-3.60 (m, 1H), 3.06-3.17 (m, 1H), 2.96-3.05 (m,1H), 2.81-2.90 (m, 1H), 2.65-2.74 (m, 1H), 2.50-2.58 (m, 1H), 2.18-2.29(m, 2H), 2.04-2.13 (m, 1H), 1.81 (br. d, J=12.0 Hz, 2H), 1.74 (s, 3H),1.31-1.56 (m, 2H). HRMS; calcd. for C₃₄H₃₄F₃N₄O₄(M+H) 619.2532, found619.2503.

Example 57.(+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by the similar method as describedfor the synthesis of Example 35-A followed by saponification similarlyto the preparation of Example 7a starting with ethyl1-(6-bromopyridin-2-yl)-5-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxylate(Intermediate 1-8) and(+)-(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-3-methylphenyl)piperidin-1-yl)(cyclopropyl)methanone(Intermediate 3-5-A. b) (+), t_(r)=2.93 min). ¹H NMR (400 MHz,Methanol-d₄) δ 7.99 (s, 1H), 7.86 (t, J=7.9 Hz, 1H), 7.73 (dd, J=7.7,0.9 Hz, 1H), 7.66 (dd, J=8.0, 0.8 Hz, 1H), 7.59-7.53 (m, 1H), 7.46-7.40(m, 2H), 6.78 (dd, J=8.3, 2.2 Hz, 1H), 6.71 (d, J=2.1 Hz, 1H), 6.54 (d,J=8.3 Hz, 1H), 5.32 (dd, J=6.8, 3.6 Hz, 1H), 4.74-4.64 (m, 2H),4.64-4.57 (m, 1H), 4.43 (d, J=13.5 Hz, 1H), 3.27-3.15 (m, 2H), 2.97(ddd, J=16.1, 8.7, 4.6 Hz, 1H), 2.72 (t, J=12.7 Hz, 1H), 2.67-2.58 (m,1H), 2.52-2.41 (m, 1H), 2.12-2.03 (m, 1H), 2.03-1.95 (m, 1H), 1.90 (d,J=13.1 Hz, 1H), 1.85-1.77 (m, 1H), 1.65 (s, 3H), 1.62-1.41 (m, 2H),0.92-0.85 (m, 2H), 0.85-0.78 (m, 2H). HRMS; calcd. for C₃₆H₃₇F₃N₅O₃(M+H)644.2848, found 644.2682.

Example 58 Example 58-A. (±)-Ethyl5-methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

DIPEA (62 μl, 0.355 mmol) was added to a solution of (±)-ethyl5-methyl-1-(6-(3-((2-methyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 45-B) (95 mg, 0.177 mmol) and 2-bromo-5-methyl-1,3,4-oxadiazole(CAS#864750-58-3, 29 mg, 0.177 mmol) in EtOH (1.8 mL) and the resultingmixture was stirred at 68° C. 1.5 hour. The reaction mixture was cooledto room temperature and then concentrated. The resulting residue waspurified by silica gel flash chromatography (0-75% EtOAc in heptane then10% MeOH in CH₂Cl₂) to afford the title compound. MS (ESI+) m/z 618.5(M+H).

Example 58. a).(±)-5-Methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by saponification of (±)-ethyl5-methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylateby the method as described for the preparation of Example 7a, followedby RP-HPLC purification (HC-A). ¹H NMR (400 MHz, Methanol-d₄) δ7.92-7.85 (m, 2H), 7.73 (d, J=7.7 Hz, 1H), 7.58-7.50 (m, 2H), 7.46-7.38(m, 2H), 6.80 (d, J=8.0 Hz, 1H), 6.71 (s, 1H), 6.55 (d, J=8.2 Hz, 1H),5.33 (dd, J=6.8, 3.4 Hz, 1H), 4.01 (d, J=12.9 Hz, 2H), 3.25-3.16 (m,3H), 3.01-2.92 (m, 1H), 2.62-2.51 (m, 4H), 2.51-2.42 (m, 1H), 2.39 (s,3H), 2.13-2.04 (m, 1H), 1.86 (d, J=13.6 Hz, 2H), 1.74-1.62 (m, 5H).HRMS; calcd. for C₃₄H₃₆N₇O₃ (M+H) 590.2880, found 590.2786.

Example 58. b).(+)-5-Methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid and(−)-5-Methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

Resolution of the enantiomers of(±)-5-methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALPAK® AD-H column with 5-55%IPA gradient in CO₂ to give(−)-5-methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (t_(r)=3.64 min) and(+)-5-methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid (t_(r)=3.88 min). ¹H NMR and HRMS data for (+)- and (−)-enantiomerswere substantially identical to(±)-5-methyl-1-(6-(3-((2-methyl-4-(1-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid.

Example 59 Example 59-A. (±)-Ethyl5-methyl-1-(6-(3-((2-methyl-4-(1-(pyridin-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate

Chloro-(2-dicyclohexylphosphino-2′6′-diisopropoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II)-methyl-t-butylether adduct (CAS#1028206-60-1, 7.8 mg, 9.5 μmol) was added to asolution of (±)-ethyl5-methyl-1-(6-(3-((2-methyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 45-B) (102 mg, 0.190 mmol), sodium tert-butoxide (CAS#865-48-5,26 mg, 0.267 mmol), and 2-chloropyridine (CAS#109-09-1, 17.7 μl, 0.189mmol) in THF (1.9 mL). The resulting reaction mixture was stirred at 68°C. for 1 hour. The reaction mixture was diluted with EtOAc. The organicphase was then washed successively with water and brine, and thenconcentrated with onto Celite®. The resulting residue was purified bysilica gel flash chromatography (0-50% EtOAc in heptane) to afford thetitle compound. MS (ESI+) m/z 613.6 (M+H).

Example 59.(±)-5-Methyl-1-(6-(3-((2-methyl-4-(1-(pyridin-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid

(±)-Ethyl5-methyl-1-(6-(3-((2-methyl-4-(1-(pyridin-2-yl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylatewas saponified as described for the preparation of Example 1. a) to givethe title compound after RP-HPLC purification (HC-B). ¹H NMR (400 MHz,Methanol-d₄) δ 8.08-8.04 (m, 1H), 7.90 (s, 1H), 7.86 (t, J=7.9 Hz, 1H),7.71 (d, J=7.7 Hz, 1H), 7.59-7.51 (m, 3H), 7.45-7.38 (m, 2H), 6.86 (d,J=8.7 Hz, 1H), 6.81 (d, J=8.5 Hz, 1H), 6.72 (s, 1H), 6.65-6.60 (m, 1H),6.56 (d, J=8.2 Hz, 1H), 5.35 (dd, J=7.1, 3.4 Hz, 1H), 4.34 (d, J=12.5Hz, 2H), 3.24-3.15 (m, 1H), 3.01-2.86 (m, 3H), 2.63 (s, 3H), 2.61-2.53(m, 1H), 2.53-2.41 (m, 1H), 2.14-2.04 (m, 1H), 1.85 (d, J=13.0 Hz, 2H),1.70-1.57 (m, 5H). HRMS; calcd. for C₃₆H₃₇N₆O₂ (M+H) 585.2978, found585.2985.

Example 60 Example 60-A. (±)-Ethyl1-(6-(3-((4-(1-cyclopropylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

(1-Ethoxycyclopropoxy)trimethylsilane (CAS#74-25-0; 35 μl, 0.174 mmol)was added to a solution of (±)-ethyl5-methyl-1-(6-(3-((2-methyl-4-(piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylate(Example 45-B) (95 mg, 0.177 mmol), sodium cyanoborohydride(CAS#25895-60-7, 22.3 mg, 0.355 mmol), and acetic acid (1.0 μl, 0.018mmol) in MeOH (1.8 mL) at room temperature. The resulting reactionmixture was heated to 50° C. for 24 h. The reaction mixture was cooledto room temperature, and then diluted with CH₂Cl₂ and saturated sodiumbicarbonate. The organic layer was passed through an ISOLUTE® PhaseSeparator and the organic layer was concentrated to furnish the titlecompound. MS (ESI+) m/z 576.5 (M+H).

Example 60.(±)-1-(6-(3-((4-(1-Cyclopropylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

(±)-Ethyl1-(6-(3-((4-(1-cyclopropylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylatewas saponified as described for the synthesis of Example 1. a) to givethe title compound, after RP-HPLC purification (HC-C). ¹H NMR (400 MHz,Methanol-d₄) δ 7.90 (t, J=7.9 Hz, 1H), 7.86 (s, 1H), 7.71 (dd, J=7.8,0.9 Hz, 1H), 7.54 (dd, J=6.4, 2.4 Hz, 1H), 7.48 (dd, J=7.9, 0.8 Hz, 1H),7.45-7.38 (m, 2H), 6.77 (dd, J=8.2, 2.2 Hz, 1H), 6.68 (d, J=2.2 Hz, 1H),6.52 (d, J=8.3 Hz, 1H), 5.30 (dd, J=7.0, 3.3 Hz, 1H), 3.44-3.37 (m, 2H),3.24-3.15 (m, 1H), 3.01-2.91 (m, 1H), 2.77 (t, J=12.2 Hz, 2H), 2.57-2.39(m, 5H), 2.23 (s, 1H), 2.12-2.03 (m, 1H), 1.90 (d, J=13.9 Hz, 2H),1.82-1.67 (m, 2H), 1.63 (s, 3H), 0.74 (d, J=7.7 Hz, 4H). HRMS; calcd.for C₃₄H₃₈N₅O₂ (M+H) 548.3026, found 548.3041.

Example 61. a).(±)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by reaction of ethyl1-(6-bromopyridin-2-yl)-5-(trifliuoromethyl)-1H-pyrazole-4-carboxylate(Intermediate 1-1) with(±)-(4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)oxy)-3-(trifluoromethyl)phenyl)piperidin-1-yl)(cyclopropyl)methanone(Intermediate 3-4-6) by the similar method as described for thesynthesis of Example 3. ¹H NMR (400 MHz, Methanol-d₄) δ 7.95 (dd, J=7.8,8.0 Hz, 1H), 7.82-7.89 (m, 2H), 7.68 (d, J=7.5 Hz, 1H), 7.41-7.52 (m,3H), 7.23 (d, J=2.2 Hz, 1H), 7.17 (dd, J=2.2, 8.6 Hz, 1H), 6.94 (d,J=8.6 Hz, 1H), 6.66 (dd, J=2.4, 6.6 Hz, 1H), 4.61-4.71 (m, 1H),4.43-4.53 (m, 1H), 3.14-3.26 (m, 1H), 2.94-3.04 (m, 1H), 2.71-2.85 (m,2H), 2.47-2.58 (m, 1H), 2.06-2.16 (m, 1H), 1.82-2.05 (m, 3H), 1.43-1.70(m, 2H), 0.77-0.95 (m, 4H). HRMS; calcd. C₃₅H₃₁F₆N₄O₄(M+H) 685.2249,found 685.2261.

Example 61. b). (+)- or(−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (enantiomer-1) and (−)- or(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (enantiomer-2)

Resolution of the enantiomers of(±)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid was achieved by chiral SFC using CHIRALPAK® AD-H column with 25%IPA in CO₂ to give (+)- or(−)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (enantiomer-1, t_(r)=2.7 min) and (−)- or(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid (enantiomer-2, t_(r)=3.9 min). ¹H NMR and HRMS were substantiallyidentical to(±)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-(trifluoromethyl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid.

Example 62 Example 62-A. (±)-Ethyl1-(6-(3-((tert-butoxycarbonyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

The title compound was synthesized by an analogous method as thepreparation of Example 35-A but using tert-butyl(7-bromo-2,3-dihydro-1H-inden-1-yl)carbamate (ACS Med. Chem. Lett. 2011,2, 565-570) instead of (±)-tert-butyl4-(4-((4-bromo-2,3-dihydrobenzofuran-3-yl)amino)-3-methylphenyl)piperidine-1-carboxylate(Intermediate 3-11). (ESI+) m/z 463.3 (M+H).

Example 62-B. (±)-Ethyl1-(6-(3-amino-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

The title compound was synthesized by deprotection of (±)-ethyl1-(6-(3-((tert-butoxycarbonyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylateby a similar method as described for the synthesis of Intermediate6-1-E. MS (ESI+) m/z 363.0 (M+H).

Example 62-C. tert-Butyl6-chloro-5-methyl-5′,6′-dihydro-[3,4′-bipyridine]-1′(2′H)-carboxylate

To a suspension of (6-chloro-5-methylpyridin-3-yl)boronic acid(CAS#1003043-40-0, 0.51 g, 2.98 mmol), tert-butyl4-bromo-5,6-dihydropyridine-1(2H)-carboxylate (CAS#159503-91-0, 0.975 g,3.72 mmol) in toluene (7.4 ml) and MeOH (7.4 ml) was added potassiumcarbonate (2M in water; 3.7 ml, 7.4 mmol), followed byPd(dppf)Cl₂.CH₂Cl₂ adduct (0.24 g, 0.3 mmol). The mixture was stirred at90° C. for 0.75 h, and then cooled to room temperature. The reactionmixture was diluted with EtOAc. The mixture was then washed with H₂O,and then passed through an ISOLUTE® Phase Separator and concentrated.The residue was purified by silica gel flash column chromatography(0-50% EtOAc in heptane) to afford the title compound. MS (ESI+) m/z309.2 (M+H).

Example 62-D.(6-Chloro-5-methyl-5′,6′-dihydro-[3,4′-bipyridin]-1′(2′H)-yl)(cyclopropyl)methanone

The title compound was synthesized in an analogous manner to thepreparation of Intermediate 2-3. MS (ESI+) m/z 277.3 (M+H).

Example 62-E. (±)-Ethyl1-(6-(3-((1′-(cyclopropanecarbonyl)-5-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridin]-6-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

To a suspension of ethyl1-(6-(3-amino-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(Example 62-B) (50 mg, 0.138 mmol), sodium tert-butoxide (32 mg, 0.33mmol), and(6-chloro-5-methyl-5′,6′-dihydro-[3,4′-bipyridin]-1′(2′H)-yl)(cyclopropyl)methanone(Example 62-D) (38 mg, 0.138 mmol) in dioxane (1.4 mL) were addedchloro-(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II)-methyl-t-butylether adduct (CAS#1028206-60-1; 5.4 mg, 6.90 μmol) and2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (CAS#564483-18-7.3.3 mg, 6.90 μmol). The mixture was then stirred at 80° C. for 20 h. Thereaction mixture was diluted with EtOAc and filtered through a plug ofCelite®, and then the filtrate was concentrated onto Celite®. Theresidue was purified by silica gel flash column chromatography (0-50%EtOAc in heptane) to afford the title compound. MS (ESI+) m/z 603.2(M+H).

Example 62-F. (±)-Ethyl1-(6-(3-((5-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-methylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate

A mixture of (±)-ethyl1-(6-(3-((1′-(cyclopropanecarbonyl)-5-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridin]-6-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate(30 mg, 0.05 mmol) and Pd/C (10%, 5 mg, 0.05 mmol) in EtOH (0.5 mL) wasstirred under H₂ atmosphere at room temperature for 12 h. The mixturewas filtered through a plug of Celite®, which was rinsed with MeOH. Thefiltrate was concentrated to furnish the title compound. MS (ESI+) m/z605.5 (M+H).

Example 62.(±)-1-(6-(3-((5-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-methylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by saponification of (±)-ethyl1-(6-(3-((5-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-methylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylateby a similar manner as described for the preparation of Example 7a. ¹HNMR (400 MHz, Methanol-d₄) δ 7.87-7.80 (m, 2H), 7.60 (dd, J=7.7, 0.9 Hz,1H), 7.54-7.49 (m, 2H), 7.46-7.39 (m, 2H), 7.34 (d, J=2.3 Hz, 1H),7.16-7.10 (m, 1H), 5.95 (t, J=7.0 Hz, 1H), 4.64 (d, J=13.3 Hz, 1H), 4.47(d, J=13.6 Hz, 1H), 3.27-3.22 (m, 1H), 3.21-3.11 (m, 1H), 3.06-2.94 (m,1H), 2.79-2.60 (m, 6H), 2.06-1.76 (m, 4H), 1.62-1.40 (m, 5H), 0.95-0.86(m, 2H), 0.86-0.78 (m, 2H). HRMS; calcd. for C₃₄H₃₇N₆O₃ (M+H) 577.2927,found 577.2922.

Example 63 Example 63-A. a). (±) Ethyl1-(6-(3-((5-(1-(cyclopropanecarbonyl)piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate

The title compound was synthesized by an analogous method as describedfor the synthesis of (±)-tert-butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-ethyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)methyl)-2-ethylphenyl)piperidine-1-carboxylate(Example 39-A) but starting with ethyl1-(6-bromopyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate (Intermediate1-4-2) and (±)-tert-butyl4-(6-((7-bromo-2,3-dihydro-1H-inden-1-yl)amino)-2-ethylpyridin-3-yl)piperidine-1-carboxylate(Intermediate 3-12). The resulting Boc protected compound can be reactedin accordance with the procedure described as Example 45-B, and theresulting amine can be reacted with cyclopropanecarboxylic acid in afashion similar to the method used for Example 45-C. a). MS (ESI+) m/z633.4 (M+H).

Example 63-A. b). Ethyl1-(6-(3-((5-(1-(cyclopropanecarbonyl)piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(Enantiomer-1) and ethyl1-(6-(3-((5-(1-(cyclopropanecarbonyl)piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(Enantiomer-2)

Resolution of the enantiomers of (±)-ethyl1-(6-(3-((5-(1-(cyclopropanecarbonyl)piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylatewas achieved by chiral SFC using CHIRALPAK® AD-H column with 5% to 55%MeOH gradient in CO₂ to give ethyl1-(6-(3-((5-(1-(cyclopropanecarbonyl)piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(enantiomer-1, t_(r)=6.0 min) and (ethyl1-(6-(3-((5-(1-(cyclopropanecarbonyl)piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r)=10.6 min).

Example 63a. (+)-1-(6-(3-((5-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

Saponification of ethyl1-(6-(3-((5-(1-(cyclopropanecarbonyl)piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(enantiomer-2, t_(r)=3.9 min) similarly to the preparation of Example 7aafforded the title compound. ¹H NMR (400 MHz, Methanol-d₄) δ 7.91 (s,1H) 7.77-7.86 (m, 1H) 7.70 (d, J=7.7 Hz, 1H) 7.54-7.58 (m, 1H) 7.52 (d,J=8.08 Hz, 1H) 7.34-7.43 (m, 2H) 7.19 (d, J=8.97 Hz, 1H) 6.17 (t, J=8.02Hz, 1H) 5.65-5.84 (m, 1H) 4.65 (d, J=13.14 Hz, 1H) 4.47 (d, J=14.02 Hz,1H) 3.33-3.44 (m, 3H) 3.12-3.23 (m, 1H) 2.83-3.03 (m, 2H) 2.67-2.82 (m,1H) 2.55-2.67 (m, 2H) 2.38-2.54 (m, 1H) 1.93-2.12 (m, 2H) 1.67-1.89 (m,2H) 1.40-1.67 (m, 2H) 1.16 (t, J=7.52 Hz, 3H) 1.10 (t, J=7.26 Hz, 3H)0.74-0.98 (m, 4H). HRMS; calcd. for C₃₆H₄₁N₆O₃ (M+H) 605.3235, found605.3184.

Example 63b. (−)-1-(6-(3-((5-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized from ethyl1-(6-(3-((5-(1-(cyclopropanecarbonyl)piperidin-4-yl)-6-ethylpyridin-2-yl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylate(enantiomer-1, t_(r)=3.7 min) by a similar manner as described for thesynthesis of Example 7a. ¹H NMR and HRMS data were substantiallyidentical to Example 63a.

Example 64

The following compounds were synthesized by the similar method asoutlined for the synthesis of Example 29 but using either achloroformate or a sulfonyl chloride as outlined in the table belowinstead of using ethyl chloroformate as in Example 29-C.

Chemical structure IUPAC name chloroformate or sulfonyl chloride Example¹H NMR and HRMS data 64-1

(S)-1-(6-(3-(4-(1-((Benzyloxy) carbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3- dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H- pyrazole-4-carboxylic acid Benzylchloroformate ¹H NMR (400 MHz, Methanol-d₄) δ 7.86-7.95 (m, 2 H) 7.72(dd, J = 7.8, 0.8 Hz, 1 H) 7.57-7.63 (m, 2 H) 7.41-7.51 (m, 2 H)7.36-7.39 (m, 3 H) 7.29-7.36 (m, 1 H) 6.94 (d, J = 8.5 Hz, 1 H) 6.53(dd, J = 8.5, 2.7 Hz, 1 H) 6.48 (d, J = 2.7 Hz, 1 H) 6.17 (dd, J = 6.1,2.5 Hz, 1 H) 5.14 (s, 2 H) 4.27 (d, J = 11.4 Hz, 2 H) 3.12-3.28 (m, 3 H)2.82-3.03 (m, 4 H) 2.52-2.61 (m, 2 H) 2.39-2.50 (m, 1 H) 2.17-2.26 (m, 1H) 1.64-1.73 (m, 2 H) 1.50- 1.63 (m, 2 H) 1.35-1.40 (m, 1 H) 1.08-1.16(m, 6 H). HRMS; calcd. for C₄₁H₄₃N₄O₅ (M + H) 671.3233, found 671.3233.64-2

(S)-5-Ethyl-1-(6- (3-(3-ethyl-4-(1- (isobutoxycarbonyl)piperidin-4-yl)phenoxy)-2,3- dihydro-1H-inden-4-yl) pyridin-2-yl)-1H-pyrazole-4-carboxylic acid isobutyl chloroformate ¹H NMR (400 MHz, Methanol-d₄) δ7.86-7.96 (m, 2 H) 7.72 (dd, J = 7.8, 0.8 Hz, 1 H) 7.57-7.64 (m, 2 H)7.40-7.51 (m, 2 H) 6.95 (d, J = 8.6 Hz, 1 H) 6.53 (dd, J = 8.5, 2.7 Hz,1 H) 6.49 (d, J = 2.7 Hz, 1 H) 6.17 (dd, J = 6.2, 2.4 Hz, 1 H) 4.25 (dd,J = 13.2, 1.7 Hz, 2 H) 3.88 (d, J = 6.6 Hz, 2 H) 3.16-3.28 (m, 3 H)2.82-3.03 (m, 4 H) 2.52-2.62 (m, 2 H) 2.45 (td, J = 14.0, 8.1 Hz, 1 H)2.25-2.18 (m, 1 H) 1.89-2.01 (m, 1 H) 1.65-1.74 (m, 2 H) 1.49-1.64 (m, 2H) 1.12 (t, J = 7.5 Hz, 6 H) 0.94-1.00 (m, 6 H). HRMS; calcd. forC₃₈H₄₅N₄O₅ (M + H) 637.3390, found 637.3389. 64-3

(S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1- (isopropoxycarbonyl)piperidin-4-yl)phenoxy)-2,3- dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole- 4-carboxylic acid isopropyl chloroformate¹H NMR (400 MHz, Methanol-d₄) δ 7.86-7.96 (m, 2 H) 7.72 (dd, J = 7.7 ,0.8 Hz, 1 H) 7.56-7.64 (m, 2 H) 7.40-7.51 (m, 2 H) 6.95 (d, J = 8.6 Hz,1 H) 6.54 (dd, J = 8.5, 2.7 Hz, 1 H) 6.49 (d, J = 2.7 Hz, 1 H) 6.17 (dd,J = 6.1, 2.21 Hz, 1 H) 4.86-4.94 (m, 2 H) 4.24 (d, J = 12.3 Hz, 2 H)3.16-3.26 (m, 2 H) 2.81-3.03 (m, 4 H) 2.53-2.63 (m, 2 H) 2.39-2.51 (m, 1H) 2.16-2.27 (m, 1 H) 1.64-1.73 (m, 2 H) 1.47-1.62 (m, 2 H) 1.24-1.31(m, 6 H) 1.07-1.16 (m, 6 H). HRMS; calcd. for C₃₇H₄₃N₄O₅ (M + H)623.3233, found 623.3240 64-4

(S)-5-Ethyl-1-(6- (3-(3-ethyl-4-(1- (propoxycarbonyl)piperidin-4-yl)phenoxy)-2,3- dihydro-1H-inden-4- yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid propyl chloroformate ¹H NMR (400 MHz, Methanol-d₄) δ7.91 (s, 1 H) 7.81-7.88 (m, 1 H) 7.68 (dd, J = 7.8, 0.8 Hz, 1 H)7.54-7.63 (m, 2 H) 7.45 (dt, J = 14.8, 7.3 Hz, 2 H) 6.98 (d, J = 8.6 Hz,1 H) 6.57 (dd, J = 8.5, 2.6 Hz, 1 H) 6.53 (d, J = 2.7 Hz, 1 H) 6.16 (dd,J = 6.0, 2.1 Hz, 1 H) 4.25 (d, J = 11.4 Hz, 2 H) 4.05 (t, J = 6.6 Hz, 2H) 3.36-3.41 (m, 2 H) 3.21 (dt, J = 16.0, 7.9 Hz, 1 H) 2.81-3.02 (m, 4H) 2.54-2.63 (m, 2 H) 2.36-2.48 (m, 1 H) 2.18-2.29 (m, 1 H) 1.50-1.75(m, 6 H) 1.07-1.17 (m, 6 H) 0.98 (t, J = 7.5 Hz, 3 H). HRMS; calcd. forC₃₇H₄₃N₄O₅ (M + H) 623.3233, found 623.3248 64-5

(S)-1-(6-(3-(4-(1-((Allyloxy) carbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3- dihydro-1H-inden-4- yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylic acid allyl chloroformate ¹H NMR (400 MHz,Methanol-d₄) δ 7.84-7.96 (m, 2 H) 7.72 (dd, J = 7.7, 0.8 Hz, 1 H)7.57-7.63 (m, 2 H) 7.39-7.51 (m, 2 H) 6.96 (d, J = 8.6 Hz, 1 H) 6.54(dd, J = 8.6, 2.78 Hz, 1 H) 6.49 (d, J = 2.7 Hz, 1 H) 6.17 (dd, J = 6.1,2.3 Hz, 1 H) 5.92-6.04 (m, 1 H) 5.29-5.36 (m, 1 H) 5.18-5.25 (m, 1 H)4.60 (dt, J = 5.4, 1.5 Hz, 2 H) 4.26 (d, J = 11.8 Hz, 2 H) 3.16-3.28 (m,2 H) 2.82-3.03 (m, 5 H) 2.57 (dd, J = 7.5, 2.02 Hz, 2 H) 2.45 (d, J =8.6 Hz, 1 H) 2.17-2.27 (m, 1 H) 1.65-1.74 (m, 2 H) 1.57 (d, J = 12.8 Hz,2 H) 1.08- 1.16 (m, 6 H). HRMS; calcd. for C₃₇H₄₁N₄O₅ (M + H) 621.3077,found 621.3074. 64-6

(S)-1-(6-(3-(4-(1- ((Cyclopropylmethoxy) carbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro- 1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole- 4-carboxylic acid Cyclopropylmethylchloroformate ¹H NMR (400 MHz, Methanol-d₄) δ 7.93 (s, 1 H) 7.86-7.91(m, 1 H) 7.71 (dd, J = 7.8, 0.7 Hz, 1 H) 7.60 (dd, J = 8.0, 0.7 Hz, 2 H)7.40-7.51 (m, 2 H) 6.96 (d, J = 8.6 Hz, 1 H) 6.54 (dd, J = 8.6, 2.7 Hz,1 H) 6.50 (d, J = 2.8 Hz, 1 H) 6.17 (dd, J = 6.0, 2.3 Hz, 1 H) 4.26 (d,J = 12.1 Hz, 2 H) 3.93 (d, J = 7.2 Hz, 2 H) 3.15-3.28 (m, 3 H) 2.81-3.03(m, 5 H) 2.54-2.61 (m, 2 H) 2.39-2.49 (m, 1 H) 2.18-2.27 (m, 1 H)1.64-1.74 (m, 2 H) 1.50-1.64 (m, 2 H) 1.12 (td, J = 7.4, 1.5 Hz, 6 H)0.53-0.61 (m, 2 H) 0.27-0.34 (m, 2 H). HRMS; calcd. for C₃₈H₄₃N₄O₅ (M +H) 635.3233, found 635.3216. 64-7

(S)-5-Ethyl-1-(6- (3-(3-ethyl-4-(1- (methoxycarbonyl)piperidin-4-yl)phenoxy)-2,3- dihydro-1H-inden-4- yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid Methyl chloroformate ¹H NMR (400 MHz, Methanol-d₄) δ7.91 (s, 1 H) 7.85 (dd, J = 8.0, 7.7 Hz, 1 H) 7.68 (dd, J = 7.7, 0.7 Hz,1 H) 7.59-7.62 (m, 1 H) 7.57 (dd, J = 8.0, 0.8 Hz, 1 H) 7.44-7.50 (m, 1H) 7.40-7.44 (m, 1 H) 6.98 (d, J = 8.6 Hz, 1 H) 6.55-6.61 (m, 1 H) 6.53(d, J = 2.2 Hz, 1 H) 6.16 (dd, J = 6.0, 2.2 Hz, 1 H) 4.17-4.29 (m, 2 H)3.70 (s, 3 H) 3.34-3.43 (m, 2 H) 3.16-3.26 (m, 1 H) 2.82-3.02 (m, 4 H)2.52-2.63 (m, 2 H) 2.36-2.48 (m, 1 H) 2.19- 2.28 (m, 1 H) 1.65-1.73 (m,2 H) 1.50-1.64 (m, 2 H) 1.08-1.16 (m, 6 H). HRMS: calcd. for C₃₅H₃₉N₄O₅(M + H) 595.2920, found 595.2915. 64-8

(S)-5-Ethyl-1-(6- (3-(3-ethyl-4-(1- (methylsulfonyl)piperidin-4-yl)phenoxy)-2,3- dihydro-1H-inden-4- yl)pyridin-2-yl)-1H-pyrazole-4-carboxylic acid Methanesulfonyl chloride ¹H NMR (400 MHz, Methanol-d₄)δ 7.91 (s, 1 H) 7.85 (dd, J = 8.0, 7.8 Hz, 1 H) 7.67 (dd, J = 7.7, 0.7Hz, 1 H) 7.58-7.63 (m, 1 H) 7.57 (dd, J = 8.0, 0.7 Hz, 1 H) 7.39-7.50(m, 2 H) 7.03 (d, J = 8.6 Hz, 1 H) 6.59 (dd, J = 8.5, 2.8 Hz, 1 H) 6.53(d, J = 2.7 Hz, 1 H) 6.15-6.22 (m, 1 H) 3.78-3.88 (m, 2 H) 3.33-3.44 (m,2 H) 3.16-3.27 (m, 1 H) 2.94-3.04 (m, 1 H) 2.74-2.91 (m, 6 H) 2.51-2.64(m, 2 H) 2.36-2.49 (m, 1 H) 2.17-2.29 (m, 1 H) 1.67-1.87 (m, 4 H)1.05-1.18 (m, 6 H). HRMS; calcd. for C₃₄H₃₉N₄O₅S (M + H) 615.2641, found615.2631

Example 65 Example 65-A. (S)-tert-Butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-isopropyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidine-1-carboxylate

The title compound was synthesized by reaction of ethyl1-(6-bromopyridin-2-yl)-5-isopropyl-1H-pyrazole-4-carboxylate(Intermediate 1-4-7) with (S)-tert-butyl4-(4-((7-bromo-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidine-1-carboxylate(Intermediate 3-4-5) by a similar method as described for the synthesisof Example 29-A. MS (ESI+) m/z 665.5 (M+H).

Example 65-B. (S)-Ethyl1-(6-(3-(3-ethyl-4-(piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-isopropyl-1H-pyrazole-4-carboxylate

The title compound was synthesized by deprotection of (S)-tert-butyl4-(4-((7-(6-(4-(ethoxycarbonyl)-5-isopropyl-1H-pyrazol-1-yl)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)oxy)-2-ethylphenyl)piperidine-1-carboxylateby a similar method as described for the synthesis of Example 29-B. MS(ESI+) m/z 579.5 (M+H).

Example 65-C. (S)-Ethyl1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-isopropyl-1H-pyrazole-4-carboxylate

The title compound was synthesized by reaction of (S)-ethyl1-(6-(3-(3-ethyl-4-(piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-isopropyl-1H-pyrazole-4-carboxylatewith cyclopropanecarboxylic acid by a similar manner as described forthe synthesis of Example 30-A. MS (ESI+) m/z 647.5 (M+H).

Example 65.(S)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-isopropyl-1H-pyrazole-4-carboxylicacid

The title compound was synthesized by saponification of (S)-ethyl1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-isopropyl-1H-pyrazole-4-carboxylateby a similar method as described for the synthesis of Example 7a. ¹H NMR(400 MHz, Methanol-d₄) δ 7.90-7.96 (m, 2H), 7.80 (dd, J=0.7, 7.8 Hz,1H), 7.60 (d, J=7.2 Hz, 1H), 7.41-7.51 (m, 3H), 6.98 (d, J=8.4 Hz, 1H),6.52-6.57 (m, 1H), 6.50 (d, J=2.6 Hz, 1H), 6.22 (d, J=5.6 Hz, 1H),4.61-4.70 (m, 1H), 4.42-4.52 (m, 1H), 3.71 (quin, J=6.9 Hz, 1H),3.15-3.25 (m, 2H), 2.92-3.05 (m, 2H), 2.70-2.81 (m, 1H), 2.53-2.68 (m,2H), 2.37-2.48 (m, 1H), 2.17-2.27 (m, 1H), 1.97-2.05 (m, 1H), 1.50-1.86(m, 4H), 1.26-1.35 (m, 6H), 1.14 (t, J=7.5 Hz, 3H), 0.77-0.95 (m, 4H).HRMS; calcd. for C₃₈H₄₃N₄O₄ (M+H) 619.3284, found 619.3295.

Biological Example 1. CHO Cellular Assay

Chinese hamster ovary (CHO) cells overexpressing soluble guanylatecyclase were generated to test the effect of sGC activators in acellular context. Human cDNAs for GUCYA3 (RefSeq: NM_000856.3) andGUCYB3 (RefSeq: NM_000857.1) were amplified by PCR from a HUVEC (HumanUmbilical Vein Endothelial Cells) cDNA library and cloned into mammalianexpression vectors. CHO K1 cells (ATCC CCL-61) were transfected usingLipofectamine 2000 following manufacturer's instructions and stablyexpressing clones were identified by antibiotic selection. CHO GUCYclone 8E10 was used for subsequent experiments.

Cells were seeded at a density of 3000 cells/well in white 384-wellproxyplates (Perkin Elmer) and incubated overnight, then the medium wasremoved and cells were washed with assay buffer (HBSS, 0.1% BSA, 1 mMIBMX, 20 uM ODQ). sGC activators were serially diluted in DMSO, thendiluted in assay buffer prior to adding to cells (10 ul/well, final DMSOconcentration 0.5%). Cells were incubated with compounds for 1 h roomtemperature, then assayed for cGMP production using Cisbio cGMP HTRF kit(62GM2PEC) according to manufacturer's instructions.

The EC50s are calculated based on the amount of cGMP interpolated fromthe standard curve, using a 4-parameter sigmoidal dose-response.

Compounds of invention are active on sGC activation. Data on Table 1collected using the assay of Biological Example 1. The minimum EC₅₀quantification limit of the assay is 0.5 nM, therefore any compoundlisted as having an EC₅₀ value of 0.5 nM has an EC₅₀ of ≤0.5 nM.

TABLE 1 Example number EC₅₀ (nM) (−)-1. b) 10 (+)-1. b) 0.5 2 1 3a 1 3b6.9 4a 2.4 4b 116 5-1 39 5-2 1 5-3 0.5 5-4 2 5-5 2.4 5-6 0.5 5-7 0.5 5-81 5-9 0.5 6. b). (+) 0.5 6. b). (−) 24 5-10 0.5 7a 0.5 7b 2.4 (−)-8. b)53 (+)-8. b) 0.5 9. b). (−) 184 9. b). (+) 0.5 10a 0.5 10b 49 11-1 111-2 1 11-3 1.4 11-4 0.5 12 1 13 0.5 14 0.5 15 1.5 16 3.5 17a 0.5 17b0.5 18 1.4 19a 0.5 19b 0.5 (+)-20-1 0.5 (−)-20-1 0.5 (+)-20-2 9.9(−)-20-2 1 (+)-20-3 0.5 (−)-20-3 0.5 21-1 0.5 21-2 0.5 22a 1 22b 4.5 232 24 7.9 25 2.4 26 21 27 0.5 28 4.5 29 1 30 0.5 31-1 0.5 31-2 0.5 31-30.5 31-4 0.5 32a 0.5 32b 0.5 33 0.5 34a 0.5 34b 3.9 35a 0.5 35b 17(+)-36-1 0.5 (−)-36-1 20 (+)-36-2 0.5 (−)-36-2 1 37. b). (+) 0.5 37. b).(−) 6.3 38-1 (−) 17 38-1 (+) 0.5 38-2 (−) 9 38-2 (+) 0.5 38-3 (+) 0.538-3 (−) 33 39. b). (−) 1 39. b). (+) 0.5 40-1 (−) 15 40-1 (+) 0.5 40-2(−) 25 40-2 (+) 0.5 40-3 (−) 49 40-3 (+) 0.5 41. b). (−) 18 41. b). (+)0.5 42. b). (−) 93 42. b). (+) 0.5 43 (+) 1 43 (−) 23 44 (+) 0.5 44 (−)9.9 45a 0.5 45b 3.5 (+)-46-1 0.5 (−)-46-1 100 (+)-46-2 1 (−)-46-2 160(+)-46-3 1 (−)-46-3 303 (+) or (−)-46-4 1.4 (−) or (+)-46-4 136 (+)-46-51 (−)-46-5 681 (+)-46-6 0.5 47a 0.5 47b 27 48a 0.5 48b 11 49a 0.5 49b 2050a 0.5 50b 12 51a 0.5 51b 3 (−)-52-1 19 (+)-52-1 0.5 (−)-52-2 1(+)-52-2 0.5 (−)-52-3 3 (+)-52-3 0.5 52-4 0.5 52-5 1 52-6 1.4 (−)-53-121 (+)-53-1 0.5 (−)-53-2 Not determined (+)-53-2 1 (+)-53-3 3.5 (−)-53-359 (+)-53-4 0.5 (−)-53-4 24 54. b). (−) 168 54. b). (+) 1 55-1 (−) 1555-1 (+) 0.5 55-2 0.5 56 1 57 1 58. b). (−) 3.2 58. b). (+) 0.5 59 1 605.3 61. b). (enantiomer-1) 15 61. b). (enantiomer-2) 2 62 6 63a 2 63b 6064-1 2 64-2 3 64-3 1 64-4 0.5 64-5 0.5 64-6 1.4 64-7 0.5 64-8 0.5

What is claimed is:
 1. A compound according to Formula (Ia)

or a pharmaceutically acceptable salt thereof, wherein X is N; Y is CH;A is CH₂, O or N(H); R is hydrogen, C₁-C₄alkyl or trifluoromethyl; R¹ ishydrogen, halogen or C₁-C₄alkyl; R² is piperidinyl which isN-substituted with C₁-C₄alkyl, C₃-C₆cycloalkyl, haloC₁-C₄alkyl,C(O)C₁-C₄alkyl, C(O)C₃-C₆cycloalkyl, C(O)haloC₁-C₄alkyl orC(O)C₁-C₄alkoxy; R³ is hydrogen or C₁-C₄alkyl; R⁴ is hydrogen orC₁-C₄alkyl and R⁵ is hydrogen, halogen, C₁-C₄alkyl or C₃-C₆cycloalkyl.2. The compound of claim 1 which is represented by the formula (Ib):

or a pharmaceutically acceptable salt thereof.
 3. The compound of claim1, wherein Y is CH and A is N(H); or a pharmaceutically acceptable saltthereof.
 4. The compound of claim 1, wherein R² is N-substitutedpiperidin-4-yl wherein the N-substituent is 2,2,2-trifluoroethyl,C(O)cyclopropyl or C(O)C₁-C₄alkyl; or a pharmaceutically acceptable saltthereof.
 5. The compound of claim 1, wherein R¹ is hydrogen or methyl;R³ is hydrogen, methyl or ethyl, wherein at least one of R¹ or R³ ishydrogen; and R⁴ is hydrogen; or a pharmaceutically acceptable saltthereof.
 6. The compound of claim 1, wherein R¹ is methyl; and R³ and R⁴are hydrogen; or a pharmaceutically acceptable salt thereof.
 7. Thecompound of claim 1, wherein R¹ and R⁴ are hydrogen and R³ is ethyl; ora pharmaceutically acceptable salt thereof.
 8. The compound of claim 1,wherein R is trifluoromethyl, methyl or ethyl; or a pharmaceuticallyacceptable salt thereof.
 9. The compound of claim 1, wherein R istrifluoromethyl; or a pharmaceutically acceptable salt thereof.
 10. Thecompound of claim 1, wherein R is methyl or ethyl; or a pharmaceuticallyacceptable salt thereof.
 11. The compound of claim 1, wherein thecompound is a compound according to Formula (II):

Wherein A is O, CH₂ or NH; R is methyl, ethyl or trifluoromethyl; R⁶ is2,2,2-trifluoroethyl, C(O)cyclopropyl or C(O)C₁-C₄alkyl; or apharmaceutically acceptable salt thereof.
 12. The compound of claim 1,wherein the compound is a compound according to Formula (III):

Wherein A is O or NH; R is methyl, ethyl or trifluoromethyl; R⁶ is2,2,2-trifluoroethyl, C(O)cyclopropyl or C(O)C₁-C₄alkyl; or apharmaceutically acceptable salt thereof.
 13. The compound of claim 11,wherein A is NH; R is methyl or ethyl; and R⁶ is C(O)cyclopropyl orC(O)C₁-C₄alkyl; or a pharmaceutically acceptable salt thereof.
 14. Apharmaceutical composition comprising a compound of claim 1, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable excipient.
 15. A compound of claim 1, selected from the groupconsisting of:(−)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(±)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(+)-(S)-1-(6-(3-(2-methyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(+)-(S)-5-ethyl-1-(6-(3-(2-methyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(+)-(S)-1-(6-(3-(4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(±)-5-ethyl-1-(6-(3-((2-methyl-4-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(+)-(S)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(S)-1-(6-(3-(4-(1-(Ethoxycarbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-(4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(+)-Ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(−)-Ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)benzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(+)-5-Ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(−)-5-Ethyl-1-(6-(3-(4-(1-(methoxycarbonyl)piperidin-4-yl)-2-methylbenzyl)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-6-methyl-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(+)-(6-(3-((4-(1-(Cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(−)-(6-(3-((4-(1-(cyclobutanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-((4-(1-isobutyrylpiperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;(+)-5-methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(−)-5-Methyl-1-(6-(3-((2-methyl-4-(1-propionylpiperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-(isopropoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(−)-Ethyl-1-(6-(3-((3-ethyl-4-(1-(isopropoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-((4-(1-(Ethoxycarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-((4-(1-(Ethoxycarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(−)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(+)-5-Ethyl-1-(6-(3-((3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;1-(6-(3-((4-(1-(Ethoxycarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;1-(6-(3-((4-(1-((2-methoxyethoxy)carbonyl)-piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid;5-Methyl-1-(6-(3-((2-methyl-4-(1-((prop-1-en-2-yloxy)carbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(−)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-ethylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid;(S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(isobutoxycarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(isopropoxycarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(propoxycarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid;(S)-1-(6-(3-(4-(1-((Cyclopropylmethoxy)carbonyl)piperidin-4-yl)-3-ethylphenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid and;(S)-5-Ethyl-1-(6-(3-(3-ethyl-4-(1-(methoxycarbonyl)piperidin-4-yl)phenoxy)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-1H-pyrazole-4-carboxylicacid; or pharmaceutically acceptable salts thereof.
 16. A compoundaccording to claim 1, which is(±)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)phenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylicacid, having the formula:

or a pharmaceutically acceptable salt thereof.
 17. A compound accordingto claim 1, which is(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylicacid, having the formula:

or a pharmaceutically acceptable salt thereof.
 18. A compound accordingto claim 1, which is(+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-ethyl-1H-pyrazole-4-carboxylicacid, having the formula:

or a pharmaceutically acceptable salt thereof.